{"PMC7346835": [], "c9cf89e7642b3da75a33d482d26a330212677479": [["IntroductionAutophagy is a lysosomal catabolic process that ensures the degradation and recycling of intra-cytoplasmic components and, therefore, highly contributes to the maintenance of cellular homeostasis.", [["lysosomal", "ANATOMY", 27, 36], ["cellular", "ANATOMY", 187, 195], ["lysosomal", "CELLULAR_COMPONENT", 27, 36], ["cellular", "CELL", 187, 195], ["intra-cytoplasmic components", "PROTEIN", 101, 129], ["a lysosomal catabolic process", "PROBLEM", 25, 54], ["the degradation", "PROBLEM", 68, 83], ["intra-cytoplasmic components", "PROBLEM", 101, 129], ["cellular homeostasis", "PROBLEM", 187, 207], ["lysosomal", "OBSERVATION", 27, 36], ["catabolic process", "OBSERVATION", 37, 54], ["cellular homeostasis", "OBSERVATION", 187, 207]]], ["In order to adapt to various stresses and promote its survival under challenging conditions, the cell also uses autophagy to degrade a broad range of endogenous or exogenous substrates [1] .", [["cell", "ANATOMY", 97, 101], ["cell", "CELL", 97, 101], ["autophagy", "PROBLEM", 112, 121]]], ["The best-studied endogenous substrates of autophagy are mitochondria and protein aggregates [2] [3] [4] .", [["mitochondria", "ANATOMY", 56, 68], ["mitochondria", "CELLULAR_COMPONENT", 56, 68], ["protein aggregates", "TEST", 73, 91]]], ["Defects in the elimination of such substrates are often associated with human pathologies, including neurodegenerative diseases or cancers [5] [6] [7] .IntroductionAutophagy is a very dynamic process and has to be tightly regulated to provide a timed and efficient response to a multitude of signals.", [["cancers", "ANATOMY", 131, 138], ["neurodegenerative diseases", "DISEASE", 101, 127], ["cancers", "DISEASE", 131, 138], ["human", "ORGANISM", 72, 77], ["cancers", "CANCER", 131, 138], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["Defects", "PROBLEM", 0, 7], ["such substrates", "PROBLEM", 30, 45], ["human pathologies", "PROBLEM", 72, 89], ["neurodegenerative diseases", "PROBLEM", 101, 127], ["cancers", "PROBLEM", 131, 138], ["neurodegenerative", "OBSERVATION_MODIFIER", 101, 118]]], ["Posttranslational modifications play a significant role in the induction and regulation of autophagy [8, 9] .", [["Posttranslational modifications", "TREATMENT", 0, 31], ["the induction", "TREATMENT", 59, 72]]], ["Ubiquitination of substrates and protein of the autophagy machinery has notably emerged as a central regulatory mechanism of autophagy acting at various levels to promote autophagy induction or shutdown [10, 11] .IntroductionUbiquitination is a reversible protein modification that consists of the covalent attachment of one or several ubiquitin moieties to protein substrates [12] [13] [14] .", [["[12] [13] [14]", "SIMPLE_CHEMICAL", 377, 391], ["ubiquitin moieties", "PROTEIN", 336, 354], ["Ubiquitination of substrates", "PROBLEM", 0, 28], ["autophagy induction", "TREATMENT", 171, 190], ["IntroductionUbiquitination", "TREATMENT", 213, 239], ["a reversible protein modification", "PROBLEM", 243, 276], ["protein substrates", "TEST", 358, 376], ["reversible", "OBSERVATION_MODIFIER", 245, 255], ["protein modification", "OBSERVATION", 256, 276]]], ["While ubiquitination is achieved by the sequential action of E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase, the removal of ubiquitin from a protein is catalyzed by deubiquitinating enzymes (DUBs) [15] .", [["E2", "CHEMICAL", 93, 95], ["E1 ubiquitin-activating enzyme", "GENE_OR_GENE_PRODUCT", 61, 91], ["E2 ubiquitin-conjugating enzyme", "GENE_OR_GENE_PRODUCT", 93, 124], ["E3", "GENE_OR_GENE_PRODUCT", 133, 135], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 169, 178], ["DUBs", "GENE_OR_GENE_PRODUCT", 236, 240], ["E1 ubiquitin-activating enzyme", "PROTEIN", 61, 91], ["E2 ubiquitin-conjugating enzyme", "PROTEIN", 93, 124], ["E3 ubiquitin ligase", "PROTEIN", 133, 152], ["ubiquitin", "PROTEIN", 169, 178], ["deubiquitinating enzymes", "PROTEIN", 210, 234], ["DUBs", "PROTEIN", 236, 240], ["activating enzyme", "TEST", 74, 91], ["E2 ubiquitin-conjugating enzyme", "TEST", 93, 124], ["an E3 ubiquitin ligase", "TREATMENT", 130, 152], ["the removal of ubiquitin", "TREATMENT", 154, 178], ["ubiquitin ligase", "OBSERVATION", 136, 152]]], ["Ubiquitination can promote or interfere with protein-protein interactions, modifying the The main regulators of autophagy are AMPK (AMP-activated kinase) and mTORC1 (mTOR complex (1) which act as autophagy activator and inhibitor, respectively.", [["AMP", "CHEMICAL", 132, 135], ["AMP", "CHEMICAL", 132, 135], ["AMPK", "GENE_OR_GENE_PRODUCT", 126, 130], ["AMP-activated kinase", "GENE_OR_GENE_PRODUCT", 132, 152], ["mTORC1", "GENE_OR_GENE_PRODUCT", 158, 164], ["mTOR complex (1)", "GENE_OR_GENE_PRODUCT", 166, 182], ["AMPK (AMP-activated kinase", "PROTEIN", 126, 152], ["mTORC1", "PROTEIN", 158, 164], ["mTOR complex", "PROTEIN", 166, 178], ["protein-protein interactions", "TREATMENT", 45, 73], ["AMPK", "TEST", 126, 130], ["AMP", "TEST", 132, 135], ["mTORC1 (mTOR complex", "TREATMENT", 158, 178]]], ["AMPK and mTORC1 regulate the activation of the ULK1 complex which, together with the PI3K-\u0428 complex, initiates the autophagosome formation.", [["autophagosome", "ANATOMY", 115, 128], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["mTORC1", "GENE_OR_GENE_PRODUCT", 9, 15], ["ULK1", "GENE_OR_GENE_PRODUCT", 47, 51], ["PI3K-\u0428 complex", "GENE_OR_GENE_PRODUCT", 85, 99], ["autophagosome", "CELLULAR_COMPONENT", 115, 128], ["AMPK", "PROTEIN", 0, 4], ["mTORC1", "PROTEIN", 9, 15], ["ULK1 complex", "PROTEIN", 47, 59], ["PI3K", "PROTEIN", 85, 89], ["\u0428 complex", "PROTEIN", 90, 99], ["AMPK", "TEST", 0, 4], ["mTORC1", "TREATMENT", 9, 15], ["the ULK1 complex", "PROBLEM", 43, 59], ["the autophagosome formation", "PROBLEM", 111, 138], ["autophagosome formation", "OBSERVATION", 115, 138]]], ["The formation of an autophagosome starts with the generation of a phagophore which elongates into an isolation membrane where the cargos to be degraded are gathered.", [["autophagosome", "ANATOMY", 20, 33], ["membrane", "ANATOMY", 111, 119], ["autophagosome", "CELLULAR_COMPONENT", 20, 33], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["cargos", "CELLULAR_COMPONENT", 130, 136], ["an autophagosome", "PROBLEM", 17, 33], ["a phagophore", "TREATMENT", 64, 76], ["an isolation membrane", "TREATMENT", 98, 119], ["autophagosome", "OBSERVATION", 20, 33], ["isolation membrane", "OBSERVATION", 101, 119]]], ["The enclosure of the isolation membrane forms a double-membraned autophagosome that matures and eventually fuses with the lysosome, forming an autolysosome where lysosomal hydrolases degrade its content.", [["membrane", "ANATOMY", 31, 39], ["autophagosome", "ANATOMY", 65, 78], ["lysosome", "ANATOMY", 122, 130], ["lysosomal", "ANATOMY", 162, 171], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["autophagosome", "CELLULAR_COMPONENT", 65, 78], ["lysosome", "CELLULAR_COMPONENT", 122, 130], ["autolysosome", "CELLULAR_COMPONENT", 143, 155], ["lysosomal hydrolases", "PROTEIN", 162, 182], ["the isolation membrane", "TREATMENT", 17, 39], ["the lysosome", "PROBLEM", 118, 130], ["lysosomal hydrolases", "PROBLEM", 162, 182], ["enclosure", "OBSERVATION_MODIFIER", 4, 13], ["isolation membrane", "OBSERVATION", 21, 39]]], ["The Atg12 and LC3 conjugation systems are essential for the autophagy process and formation of the autophagosome.", [["autophagosome", "ANATOMY", 99, 112], ["Atg12", "GENE_OR_GENE_PRODUCT", 4, 9], ["LC3", "GENE_OR_GENE_PRODUCT", 14, 17], ["autophagosome", "CELLULAR_COMPONENT", 99, 112], ["Atg12", "PROTEIN", 4, 9], ["LC3", "PROTEIN", 14, 17], ["The Atg12 and LC3 conjugation systems", "TEST", 0, 37], ["the autophagy process", "PROBLEM", 56, 77], ["the autophagosome", "PROBLEM", 95, 112]]], ["The Atg12 conjugation system consists in the formation of the Atg12-Atg5-Atg16L1 complex that then promotes the conjugation of LC3; pro-LC3 is cleaved by Atg4 (LC3-I) which is then conjugated with phosphatidylethanolamine (PE) (LC3-II) before being anchored to the nascent autophagosomal membrane.Ubiquitin SystemUbiquitin is a small globular protein with a \uf062-grasp superfold conformation [39, 40] .", [["autophagosomal membrane", "ANATOMY", 273, 296], ["phosphatidylethanolamine", "CHEMICAL", 197, 221], ["PE", "CHEMICAL", 223, 225], ["LC3-II", "CHEMICAL", 228, 234], ["phosphatidylethanolamine", "CHEMICAL", 197, 221], ["Atg12", "GENE_OR_GENE_PRODUCT", 4, 9], ["Atg12", "GENE_OR_GENE_PRODUCT", 62, 67], ["Atg5", "GENE_OR_GENE_PRODUCT", 68, 72], ["Atg16L1", "GENE_OR_GENE_PRODUCT", 73, 80], ["LC3", "GENE_OR_GENE_PRODUCT", 127, 130], ["-LC3", "GENE_OR_GENE_PRODUCT", 135, 139], ["Atg4", "GENE_OR_GENE_PRODUCT", 154, 158], ["LC3-I", "GENE_OR_GENE_PRODUCT", 160, 165], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 197, 221], ["PE", "SIMPLE_CHEMICAL", 223, 225], ["LC3-II", "GENE_OR_GENE_PRODUCT", 228, 234], ["autophagosomal membrane", "CELLULAR_COMPONENT", 273, 296], ["SystemUbiquitin", "GENE_OR_GENE_PRODUCT", 307, 322], ["Atg12", "PROTEIN", 4, 9], ["Atg12", "PROTEIN", 62, 67], ["Atg5", "PROTEIN", 68, 72], ["Atg16L1 complex", "PROTEIN", 73, 88], ["LC3", "PROTEIN", 127, 130], ["pro-LC3", "PROTEIN", 132, 139], ["Atg4", "PROTEIN", 154, 158], ["LC3", "PROTEIN", 160, 163], ["I", "PROTEIN", 164, 165], ["LC3", "PROTEIN", 228, 231], ["SystemUbiquitin", "PROTEIN", 307, 322], ["small globular protein", "PROTEIN", 328, 350], ["The Atg12 conjugation system", "TEST", 0, 28], ["Atg16L1 complex", "TREATMENT", 73, 88], ["phosphatidylethanolamine (PE", "TREATMENT", 197, 225], ["a small globular protein", "PROBLEM", 326, 350], ["PE", "OBSERVATION", 223, 225], ["nascent", "ANATOMY_MODIFIER", 265, 272], ["autophagosomal membrane", "OBSERVATION", 273, 296], ["small", "OBSERVATION_MODIFIER", 328, 333], ["globular protein", "OBSERVATION", 334, 350]]], ["Ubiquitin is covalently conjugated by its terminal glycine (G76) onto a lysine residue of a substrate protein.Ubiquitin SystemProtein ubiquitination is a complex process requiring the successive activity of three types of enzymes: an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligase enzyme.", [["glycine", "CHEMICAL", 51, 58], ["G76", "CHEMICAL", 60, 63], ["lysine", "CHEMICAL", 72, 78], ["E2", "CHEMICAL", 269, 271], ["glycine", "CHEMICAL", 51, 58], ["lysine", "CHEMICAL", 72, 78], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["glycine", "AMINO_ACID", 51, 58], ["G76", "AMINO_ACID", 60, 63], ["SystemProtein", "GENE_OR_GENE_PRODUCT", 120, 133], ["E1", "GENE_OR_GENE_PRODUCT", 234, 236], ["E3", "GENE_OR_GENE_PRODUCT", 309, 311], ["Ubiquitin", "PROTEIN", 0, 9], ["substrate protein", "PROTEIN", 92, 109], ["enzymes", "PROTEIN", 222, 229], ["E1 ubiquitin-activating enzyme", "PROTEIN", 234, 264], ["E2 ubiquitin-conjugating enzyme", "PROTEIN", 269, 300], ["E3 ubiquitin-ligase enzyme", "PROTEIN", 309, 335], ["Ubiquitin", "TREATMENT", 0, 9], ["a lysine residue", "TREATMENT", 70, 86], ["a substrate protein", "TREATMENT", 90, 109], ["a complex process", "PROBLEM", 152, 169], ["enzymes", "TEST", 222, 229], ["an E1 ubiquitin", "TEST", 231, 246], ["activating enzyme", "TEST", 247, 264], ["an E2 ubiquitin", "TEST", 266, 281], ["an E3 ubiquitin", "TEST", 306, 321], ["covalently conjugated", "OBSERVATION", 13, 34], ["SystemProtein ubiquitination", "OBSERVATION", 120, 148]]], ["The ubiquitination process can be broken down in two main steps: (1) The ATP-dependent activation of a ubiquitin molecule by conformational modification of its C-terminus extremity by an E1 enzyme followed by its transfer onto an E2 enzyme, and (2) the conjugation of the activated ubiquitin onto a substrate protein, mediated by an E3 enzyme that bridges the E2 to a The main regulators of autophagy are AMPK (AMP-activated kinase) and mTORC1 (mTOR complex (1) which act as autophagy activator and inhibitor, respectively.", [["ATP", "CHEMICAL", 73, 76], ["E2", "CHEMICAL", 230, 232], ["E2", "CHEMICAL", 360, 362], ["AMP", "CHEMICAL", 411, 414], ["ATP", "CHEMICAL", 73, 76], ["C", "CHEMICAL", 160, 161], ["AMP", "CHEMICAL", 411, 414], ["ATP", "SIMPLE_CHEMICAL", 73, 76], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 282, 291], ["E3", "GENE_OR_GENE_PRODUCT", 333, 335], ["E2", "GENE_OR_GENE_PRODUCT", 360, 362], ["AMPK", "GENE_OR_GENE_PRODUCT", 405, 409], ["AMP-activated kinase", "GENE_OR_GENE_PRODUCT", 411, 431], ["mTORC1", "GENE_OR_GENE_PRODUCT", 437, 443], ["mTOR complex (1)", "GENE_OR_GENE_PRODUCT", 445, 461], ["ubiquitin molecule", "PROTEIN", 103, 121], ["C-terminus", "PROTEIN", 160, 170], ["E1 enzyme", "PROTEIN", 187, 196], ["E2 enzyme", "PROTEIN", 230, 239], ["activated ubiquitin", "PROTEIN", 272, 291], ["substrate protein", "PROTEIN", 299, 316], ["E3 enzyme", "PROTEIN", 333, 342], ["AMPK (AMP-activated kinase", "PROTEIN", 405, 431], ["mTORC1", "PROTEIN", 437, 443], ["mTOR complex", "PROTEIN", 445, 457], ["The ubiquitination process", "PROBLEM", 0, 26], ["The ATP", "PROBLEM", 69, 76], ["a ubiquitin molecule", "TREATMENT", 101, 121], ["its C-terminus extremity", "TREATMENT", 156, 180], ["an E1 enzyme", "TEST", 184, 196], ["an E2 enzyme", "TEST", 227, 239], ["a substrate protein", "TREATMENT", 297, 316], ["an E3 enzyme", "TREATMENT", 330, 342], ["AMPK", "TEST", 405, 409], ["AMP-activated kinase", "TREATMENT", 411, 431], ["mTORC1 (mTOR complex", "TREATMENT", 437, 457], ["ubiquitination process", "OBSERVATION", 4, 26], ["ubiquitin molecule", "OBSERVATION", 103, 121]]], ["AMPK and mTORC1 regulate the activation of the ULK1 complex which, together with the PI3K-III complex, initiates the autophagosome formation.", [["autophagosome", "ANATOMY", 117, 130], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["mTORC1", "GENE_OR_GENE_PRODUCT", 9, 15], ["ULK1", "GENE_OR_GENE_PRODUCT", 47, 51], ["PI3K-III", "GENE_OR_GENE_PRODUCT", 85, 93], ["autophagosome", "CELLULAR_COMPONENT", 117, 130], ["AMPK", "PROTEIN", 0, 4], ["mTORC1", "PROTEIN", 9, 15], ["ULK1 complex", "PROTEIN", 47, 59], ["PI3K-III complex", "PROTEIN", 85, 101], ["AMPK", "TEST", 0, 4], ["mTORC1", "TREATMENT", 9, 15], ["the ULK1 complex", "TEST", 43, 59], ["autophagosome formation", "OBSERVATION", 117, 140]]], ["The formation of an autophagosome starts with the generation of a phagophore which elongates into an isolation membrane where the cargos to be degraded are gathered.", [["autophagosome", "ANATOMY", 20, 33], ["membrane", "ANATOMY", 111, 119], ["autophagosome", "CELLULAR_COMPONENT", 20, 33], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["cargos", "CELLULAR_COMPONENT", 130, 136], ["an autophagosome", "PROBLEM", 17, 33], ["a phagophore", "TREATMENT", 64, 76], ["an isolation membrane", "TREATMENT", 98, 119], ["autophagosome", "OBSERVATION", 20, 33], ["isolation membrane", "OBSERVATION", 101, 119]]], ["The enclosure of the isolation membrane forms a double-membraned autophagosome that matures and eventually fuses with the lysosome, forming an autolysosome where lysosomal hydrolases degrade its content.", [["membrane", "ANATOMY", 31, 39], ["autophagosome", "ANATOMY", 65, 78], ["lysosome", "ANATOMY", 122, 130], ["lysosomal", "ANATOMY", 162, 171], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["autophagosome", "CELLULAR_COMPONENT", 65, 78], ["lysosome", "CELLULAR_COMPONENT", 122, 130], ["autolysosome", "CELLULAR_COMPONENT", 143, 155], ["lysosomal hydrolases", "PROTEIN", 162, 182], ["the isolation membrane", "TREATMENT", 17, 39], ["the lysosome", "PROBLEM", 118, 130], ["lysosomal hydrolases", "PROBLEM", 162, 182], ["enclosure", "OBSERVATION_MODIFIER", 4, 13], ["isolation membrane", "OBSERVATION", 21, 39]]], ["The Atg12 and LC3 conjugation systems are essential for the autophagy process and formation of the autophagosome.", [["autophagosome", "ANATOMY", 99, 112], ["Atg12", "GENE_OR_GENE_PRODUCT", 4, 9], ["LC3", "GENE_OR_GENE_PRODUCT", 14, 17], ["autophagosome", "CELLULAR_COMPONENT", 99, 112], ["Atg12", "PROTEIN", 4, 9], ["LC3", "PROTEIN", 14, 17], ["The Atg12 and LC3 conjugation systems", "TEST", 0, 37], ["the autophagy process", "PROBLEM", 56, 77], ["the autophagosome", "PROBLEM", 95, 112]]], ["The Atg12 conjugation system consists in the formation of the Atg12-Atg5-Atg16L1 complex that then promotes the conjugation of LC3; pro-LC3 is cleaved by Atg4 (LC3-I) which is then conjugated with phosphatidylethanolamine (PE) (LC3-II) before being anchored to the nascent autophagosomal membrane.Ubiquitin SystemUbiquitin is a small globular protein with a \u03b2-grasp superfold conformation [39, 40] .", [["autophagosomal membrane", "ANATOMY", 273, 296], ["phosphatidylethanolamine", "CHEMICAL", 197, 221], ["PE", "CHEMICAL", 223, 225], ["LC3-II", "CHEMICAL", 228, 234], ["phosphatidylethanolamine", "CHEMICAL", 197, 221], ["Atg12", "GENE_OR_GENE_PRODUCT", 4, 9], ["Atg12", "GENE_OR_GENE_PRODUCT", 62, 67], ["Atg5", "GENE_OR_GENE_PRODUCT", 68, 72], ["Atg16L1", "GENE_OR_GENE_PRODUCT", 73, 80], ["LC3", "GENE_OR_GENE_PRODUCT", 127, 130], ["-LC3", "GENE_OR_GENE_PRODUCT", 135, 139], ["Atg4", "GENE_OR_GENE_PRODUCT", 154, 158], ["LC3-I", "GENE_OR_GENE_PRODUCT", 160, 165], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 197, 221], ["PE", "SIMPLE_CHEMICAL", 223, 225], ["LC3-II", "GENE_OR_GENE_PRODUCT", 228, 234], ["autophagosomal membrane", "CELLULAR_COMPONENT", 273, 296], ["SystemUbiquitin", "GENE_OR_GENE_PRODUCT", 307, 322], ["Atg12", "PROTEIN", 4, 9], ["Atg12", "PROTEIN", 62, 67], ["Atg5", "PROTEIN", 68, 72], ["Atg16L1 complex", "PROTEIN", 73, 88], ["LC3", "PROTEIN", 127, 130], ["pro-LC3", "PROTEIN", 132, 139], ["Atg4", "PROTEIN", 154, 158], ["LC3", "PROTEIN", 160, 163], ["I", "PROTEIN", 164, 165], ["LC3", "PROTEIN", 228, 231], ["SystemUbiquitin", "PROTEIN", 307, 322], ["small globular protein", "PROTEIN", 328, 350], ["The Atg12 conjugation system", "TEST", 0, 28], ["Atg16L1 complex", "TREATMENT", 73, 88], ["phosphatidylethanolamine (PE", "TREATMENT", 197, 225], ["a small globular protein", "PROBLEM", 326, 350], ["PE", "OBSERVATION", 223, 225], ["nascent", "ANATOMY_MODIFIER", 265, 272], ["autophagosomal membrane", "OBSERVATION", 273, 296], ["small", "OBSERVATION_MODIFIER", 328, 333], ["globular protein", "OBSERVATION", 334, 350]]], ["Ubiquitin is covalently conjugated by its terminal glycine (G76) onto a lysine residue of a substrate protein.Ubiquitin SystemProtein ubiquitination is a complex process requiring the successive activity of three types of enzymes: an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligase enzyme.", [["glycine", "CHEMICAL", 51, 58], ["G76", "CHEMICAL", 60, 63], ["lysine", "CHEMICAL", 72, 78], ["E2", "CHEMICAL", 269, 271], ["glycine", "CHEMICAL", 51, 58], ["lysine", "CHEMICAL", 72, 78], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["glycine", "AMINO_ACID", 51, 58], ["G76", "AMINO_ACID", 60, 63], ["SystemProtein", "GENE_OR_GENE_PRODUCT", 120, 133], ["E1", "GENE_OR_GENE_PRODUCT", 234, 236], ["E3", "GENE_OR_GENE_PRODUCT", 309, 311], ["Ubiquitin", "PROTEIN", 0, 9], ["substrate protein", "PROTEIN", 92, 109], ["enzymes", "PROTEIN", 222, 229], ["E1 ubiquitin-activating enzyme", "PROTEIN", 234, 264], ["E2 ubiquitin-conjugating enzyme", "PROTEIN", 269, 300], ["E3 ubiquitin-ligase enzyme", "PROTEIN", 309, 335], ["Ubiquitin", "TREATMENT", 0, 9], ["a lysine residue", "TREATMENT", 70, 86], ["a substrate protein", "TREATMENT", 90, 109], ["a complex process", "PROBLEM", 152, 169], ["enzymes", "TEST", 222, 229], ["an E1 ubiquitin", "TEST", 231, 246], ["activating enzyme", "TEST", 247, 264], ["an E2 ubiquitin", "TEST", 266, 281], ["an E3 ubiquitin", "TEST", 306, 321], ["covalently conjugated", "OBSERVATION", 13, 34], ["SystemProtein ubiquitination", "OBSERVATION", 120, 148]]], ["The ubiquitination process can be broken down in two main steps: (1) The ATP-dependent activation of a ubiquitin molecule by conformational modification of its C-terminus extremity by an E1 enzyme followed by its transfer onto an E2 enzyme, and (2) the conjugation of the activated ubiquitin onto a substrate protein, mediated by an E3 enzyme that bridges the E2 to a specific substrate allowing for the subsequent transfer of ubiquitin from the E2 enzyme to the substrate through the formation of an isopeptide bond [41, 42] .", [["ATP", "CHEMICAL", 73, 76], ["E2", "CHEMICAL", 230, 232], ["E2", "CHEMICAL", 360, 362], ["E2", "CHEMICAL", 446, 448], ["ATP", "CHEMICAL", 73, 76], ["C", "CHEMICAL", 160, 161], ["isopeptide", "CHEMICAL", 501, 511], ["ATP", "SIMPLE_CHEMICAL", 73, 76], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 282, 291], ["E3", "GENE_OR_GENE_PRODUCT", 333, 335], ["E2", "GENE_OR_GENE_PRODUCT", 360, 362], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 427, 436], ["E2 enzyme", "GENE_OR_GENE_PRODUCT", 446, 455], ["ubiquitin molecule", "PROTEIN", 103, 121], ["C-terminus", "PROTEIN", 160, 170], ["E1 enzyme", "PROTEIN", 187, 196], ["E2 enzyme", "PROTEIN", 230, 239], ["activated ubiquitin", "PROTEIN", 272, 291], ["substrate protein", "PROTEIN", 299, 316], ["E3 enzyme", "PROTEIN", 333, 342], ["ubiquitin", "PROTEIN", 427, 436], ["E2 enzyme", "PROTEIN", 446, 455], ["The ubiquitination process", "PROBLEM", 0, 26], ["The ATP", "TEST", 69, 76], ["a ubiquitin molecule", "TREATMENT", 101, 121], ["its C-terminus extremity", "TREATMENT", 156, 180], ["an E1 enzyme", "TEST", 184, 196], ["an E2 enzyme", "TEST", 227, 239], ["an E3 enzyme", "TREATMENT", 330, 342], ["ubiquitination process", "OBSERVATION", 4, 26], ["ubiquitin molecule", "OBSERVATION", 103, 121]]], ["Alternatively, E3 ligases of the HECT family possess E2 and E3 activities [43, 44] .", [["E2", "CHEMICAL", 53, 55], ["E3", "GENE_OR_GENE_PRODUCT", 15, 17], ["HECT", "GENE_OR_GENE_PRODUCT", 33, 37], ["E2", "GENE_OR_GENE_PRODUCT", 53, 55], ["E3", "GENE_OR_GENE_PRODUCT", 60, 62], ["E3 ligases", "PROTEIN", 15, 25], ["HECT family", "PROTEIN", 33, 44], ["E3", "PROTEIN", 60, 62]]], ["There is also evidence for the addition of ubiquitin moieties onto non-lysine residues.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 43, 52], ["ubiquitin moieties", "PROTEIN", 43, 61], ["ubiquitin moieties", "TREATMENT", 43, 61], ["non-lysine residues", "TREATMENT", 67, 86], ["ubiquitin moieties", "OBSERVATION", 43, 61]]], ["The ubiquitination of cysteine or serine and threonine residues requires the formation of thiol-or oxy-ester bonds respectively [45] .Ubiquitin SystemUbiquitination was discovered in 1980 and first described for its essential role in targeting proteins to the proteasome for degradation [46] .", [["cysteine", "CHEMICAL", 22, 30], ["threonine", "CHEMICAL", 45, 54], ["thiol", "CHEMICAL", 90, 95], ["oxy-ester", "CHEMICAL", 99, 108], ["cysteine", "CHEMICAL", 22, 30], ["serine", "CHEMICAL", 34, 40], ["threonine", "CHEMICAL", 45, 54], ["thiol", "CHEMICAL", 90, 95], ["oxy-ester", "CHEMICAL", 99, 108], ["cysteine", "AMINO_ACID", 22, 30], ["serine", "AMINO_ACID", 34, 40], ["threonine", "AMINO_ACID", 45, 54], ["residues", "AMINO_ACID", 55, 63], ["thiol", "SIMPLE_CHEMICAL", 90, 95], ["oxy-ester", "SIMPLE_CHEMICAL", 99, 108], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 134, 143], ["proteasome", "PROTEIN", 260, 270], ["The ubiquitination of cysteine", "TREATMENT", 0, 30], ["serine and threonine residues", "TREATMENT", 34, 63]]], ["It is now widely recognized that ubiquitination also acts in other cellular processes.", [["cellular", "ANATOMY", 67, 75], ["cellular", "CELL", 67, 75], ["ubiquitination", "OBSERVATION", 33, 47], ["cellular processes", "OBSERVATION", 67, 85]]], ["Indeed, a broad range of types of ubiquitination have been reported.", [["ubiquitination", "PROBLEM", 34, 48], ["broad", "OBSERVATION_MODIFIER", 10, 15], ["ubiquitination", "OBSERVATION", 34, 48]]], ["Substrates can be modified by the attachment of a single ubiquitin molecule (mono-ubiquitination) or several single ubiquitin molecules on different lysine residues of the substrate (multi-mono-ubiquitination).", [["lysine", "CHEMICAL", 149, 155], ["lysine", "CHEMICAL", 149, 155], ["ubiquitin molecule", "PROTEIN", 57, 75], ["ubiquitin molecules", "PROTEIN", 116, 135], ["a single ubiquitin molecule (mono-ubiquitination", "TREATMENT", 48, 96], ["several single ubiquitin molecules", "PROBLEM", 101, 135], ["different lysine residues", "TREATMENT", 139, 164], ["the substrate", "TEST", 168, 181], ["lysine residues", "OBSERVATION", 149, 164]]], ["Mono-ubiquitination is primarily described for its function in endocytosis of plasma membrane receptors [47] .", [["plasma membrane", "ANATOMY", 78, 93], ["plasma membrane", "CELLULAR_COMPONENT", 78, 93], ["plasma membrane receptors", "PROTEIN", 78, 103], ["Mono-ubiquitination", "TREATMENT", 0, 19], ["plasma membrane receptors", "TEST", 78, 103]]], ["Alternatively, several ubiquitin molecules can be ligated to one another using ubiquitin internal lysine residues, forming chains of ubiquitin moieties that can elongate on the substrate or directly be attached to a target protein (poly-ubiquitination).", [["lysine", "CHEMICAL", 98, 104], ["ubiquitin molecules", "PROTEIN", 23, 42], ["ubiquitin moieties", "PROTEIN", 133, 151], ["target protein", "PROTEIN", 216, 230], ["several ubiquitin molecules", "TREATMENT", 15, 42], ["ubiquitin internal lysine residues", "TREATMENT", 79, 113], ["ubiquitin moieties", "TREATMENT", 133, 151], ["a target protein (poly-ubiquitination", "TREATMENT", 214, 251], ["ubiquitin molecules", "OBSERVATION", 23, 42], ["lysine residues", "OBSERVATION", 98, 113], ["ubiquitin moieties", "OBSERVATION", 133, 151]]], ["Because ubiquitin has seven lysine residues, there can be at least as many types of ubiquitin chains that can be generated (K6, K11, K29, K48, K63-linked ubiquitin chains) [48, 49] .", [["lysine", "CHEMICAL", 28, 34], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 8, 17], ["K6", "GENE_OR_GENE_PRODUCT", 124, 126], ["ubiquitin chains", "PROTEIN", 84, 100], ["K6", "PROTEIN", 124, 126], ["K11", "PROTEIN", 128, 131], ["K29", "PROTEIN", 133, 136], ["K48", "PROTEIN", 138, 141], ["K63", "PROTEIN", 143, 146], ["ubiquitin chains", "PROTEIN", 154, 170], ["seven lysine residues", "PROBLEM", 22, 43], ["ubiquitin chains", "PROBLEM", 84, 100], ["K11", "TEST", 128, 131], ["K29", "TEST", 133, 136], ["K48", "TEST", 138, 141], ["lysine residues", "OBSERVATION", 28, 43], ["ubiquitin chains", "OBSERVATION", 84, 100]]], ["Poly-ubiquitin chains can also be assembled through N-to C-terminal interaction to form linear chains (M1) [50, 51] .", [["Poly", "CHEMICAL", 0, 4], ["N", "CHEMICAL", 52, 53], ["C", "CHEMICAL", 57, 58], ["Poly-ubiquitin chains", "SIMPLE_CHEMICAL", 0, 21], ["Poly-ubiquitin chains", "PROTEIN", 0, 21], ["N-to C", "PROTEIN", 52, 58], ["M1", "PROTEIN", 103, 105], ["Poly-ubiquitin chains", "TREATMENT", 0, 21], ["ubiquitin chains", "OBSERVATION", 5, 21]]], ["The tridimensional structures of ubiquitin chains vary depending on the lysine in the ubiquitin used to generate the chain and affect the function or stability of the substrate.", [["lysine", "CHEMICAL", 72, 78], ["lysine", "CHEMICAL", 72, 78], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 33, 42], ["lysine", "AMINO_ACID", 72, 78], ["ubiquitin chains", "PROTEIN", 33, 49], ["ubiquitin", "PROTEIN", 86, 95], ["ubiquitin chains", "TREATMENT", 33, 49], ["the lysine", "TREATMENT", 68, 78], ["the ubiquitin", "TREATMENT", 82, 95], ["tridimensional", "OBSERVATION_MODIFIER", 4, 18], ["ubiquitin chains", "OBSERVATION", 33, 49], ["stability", "OBSERVATION_MODIFIER", 150, 159]]], ["For instance, K48-linked ubiquitin chains have a compact conformation and target substrates for proteasomal degradation, while K63-linked ubiquitin chains display an open conformation and are mostly described to promote signal transduction through the assembly of large protein complexes [52, 53] .Ubiquitin SystemProtein ubiquitination is a reversible posttranslational modification.", [["proteasomal", "ANATOMY", 96, 107], ["K48", "GENE_OR_GENE_PRODUCT", 14, 17], ["SystemProtein", "GENE_OR_GENE_PRODUCT", 308, 321], ["K48", "PROTEIN", 14, 17], ["ubiquitin chains", "PROTEIN", 25, 41], ["K63", "PROTEIN", 127, 130], ["ubiquitin chains", "PROTEIN", 138, 154], ["protein complexes", "PROTEIN", 270, 287], ["K48-linked ubiquitin chains", "TREATMENT", 14, 41], ["proteasomal degradation", "PROBLEM", 96, 119], ["K63-linked ubiquitin chains", "TREATMENT", 127, 154], ["Ubiquitin SystemProtein ubiquitination", "TREATMENT", 298, 336], ["a reversible posttranslational modification", "PROBLEM", 340, 383], ["ubiquitin chains", "OBSERVATION", 25, 41], ["open conformation", "OBSERVATION", 166, 183], ["SystemProtein ubiquitination", "OBSERVATION", 308, 336], ["reversible", "OBSERVATION_MODIFIER", 342, 352], ["posttranslational modification", "OBSERVATION", 353, 383]]], ["The hydrolysis of ubiquitin linkages is conducted by a specific family of proteases: the DUBs.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 18, 27], ["DUBs", "GENE_OR_GENE_PRODUCT", 89, 93], ["proteases", "PROTEIN", 74, 83], ["DUBs", "PROTEIN", 89, 93], ["The hydrolysis of ubiquitin linkages", "PROBLEM", 0, 36], ["the DUBs", "TEST", 85, 93], ["ubiquitin linkages", "OBSERVATION", 18, 36]]], ["These enzymes can act at different stages of the protein ubiquitination process: (1) At the \"initial\" stage, by cleaving the ubiquitin precursors to supply ubiquitin monomers to the ubiquitination enzymes; (2) at the \"intermediate\" stage, by the regulated removal of ubiquitin moieties from proteins to alter their fate (stabilization, conformational change); and (3) at the \"final\" stage by the removal of ubiquitin chains from substrates addressed to the proteasome to facilitate their degradation and processing into ubiquitin monomers, free to enter a new ubiquitination cycle ( Figure 2 ) [54] [55] [56] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 520, 529], ["enzymes", "PROTEIN", 6, 13], ["ubiquitin precursors", "PROTEIN", 125, 145], ["ubiquitin monomers", "PROTEIN", 156, 174], ["ubiquitination enzymes", "PROTEIN", 182, 204], ["ubiquitin moieties", "PROTEIN", 267, 285], ["ubiquitin chains", "PROTEIN", 407, 423], ["proteasome", "PROTEIN", 457, 467], ["ubiquitin monomers", "PROTEIN", 520, 538], ["These enzymes", "TEST", 0, 13], ["the protein ubiquitination process", "PROBLEM", 45, 79], ["the ubiquitination enzymes", "TEST", 178, 204], ["the regulated removal of ubiquitin moieties", "TREATMENT", 242, 285], ["the removal of ubiquitin chains", "TREATMENT", 392, 423], ["the proteasome", "TREATMENT", 453, 467], ["their degradation", "PROBLEM", 482, 499], ["processing into ubiquitin monomers", "TREATMENT", 504, 538], ["a new ubiquitination cycle", "TREATMENT", 554, 580], ["protein ubiquitination process", "OBSERVATION", 49, 79], ["ubiquitin monomers", "OBSERVATION", 156, 174]]], ["The hydrolysis of K48-linked ubiquitin chains, most well-known to induce the proteasomal degradation, can affect the fate of the protein they are added to either by protecting substrates from degradation or by supporting proteasomal degradation, as the removal of K48-linked ubiquitin chains, mostly by proteasomal DUBs, is also required for protein entry into the proteasome [57, 58] .Ubiquitin SystemThere are approximately 100 DUBs encoded by the human genome [15, 59] , which are divided into two main families: the cysteine proteases and the metalloproteases.", [["proteasomal", "ANATOMY", 77, 88], ["proteasomal", "ANATOMY", 221, 232], ["K48", "CHEMICAL", 18, 21], ["K48", "CHEMICAL", 18, 21], ["cysteine", "CHEMICAL", 520, 528], ["K48", "SIMPLE_CHEMICAL", 18, 21], ["K48", "GENE_OR_GENE_PRODUCT", 264, 267], ["proteasomal DUBs", "GENE_OR_GENE_PRODUCT", 303, 319], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 386, 395], ["human", "ORGANISM", 450, 455], ["K48", "PROTEIN", 18, 21], ["ubiquitin chains", "PROTEIN", 29, 45], ["K48", "PROTEIN", 264, 267], ["ubiquitin chains", "PROTEIN", 275, 291], ["proteasomal DUBs", "PROTEIN", 303, 319], ["proteasome", "PROTEIN", 365, 375], ["DUBs", "PROTEIN", 430, 434], ["human genome", "DNA", 450, 462], ["cysteine proteases", "PROTEIN", 520, 538], ["metalloproteases", "PROTEIN", 547, 563], ["human", "SPECIES", 450, 455], ["human", "SPECIES", 450, 455], ["The hydrolysis", "TEST", 0, 14], ["K48-linked ubiquitin chains", "TREATMENT", 18, 45], ["the proteasomal degradation", "PROBLEM", 73, 100], ["the removal of K48-linked ubiquitin chains", "TREATMENT", 249, 291], ["the cysteine proteases", "TREATMENT", 516, 538], ["the metalloproteases", "TREATMENT", 543, 563], ["ubiquitin chains", "OBSERVATION", 29, 45], ["proteasomal degradation", "OBSERVATION", 77, 100], ["proteasomal degradation", "OBSERVATION", 221, 244], ["ubiquitin chains", "OBSERVATION", 275, 291], ["proteasomal DUBs", "OBSERVATION", 303, 319]]], ["There are 12 DUBs from the metalloprotease family characterized by a JAMM (JAB1/PAB1/MPN domain-containing metalloenzymes) domain that catalyzes the hydrolysis of isopeptide bonds in the presence of Zn 2+ .", [["Zn", "CHEMICAL", 199, 201], ["isopeptide", "CHEMICAL", 163, 173], ["Zn 2+", "CHEMICAL", 199, 204], ["JAMM", "GENE_OR_GENE_PRODUCT", 69, 73], ["JAB1", "GENE_OR_GENE_PRODUCT", 75, 79], ["PAB1", "GENE_OR_GENE_PRODUCT", 80, 84], ["Zn 2+", "SIMPLE_CHEMICAL", 199, 204], ["DUBs", "PROTEIN", 13, 17], ["metalloprotease family", "PROTEIN", 27, 49], ["JAMM", "PROTEIN", 69, 73], ["JAB1", "PROTEIN", 75, 79], ["PAB1", "PROTEIN", 80, 84], ["MPN domain-containing metalloenzymes) domain", "PROTEIN", 85, 129], ["a JAMM (JAB1/PAB1/MPN domain", "TREATMENT", 67, 95], ["metalloenzymes", "TREATMENT", 107, 121], ["the hydrolysis of isopeptide bonds", "PROBLEM", 145, 179], ["12 DUBs", "OBSERVATION_MODIFIER", 10, 17], ["isopeptide bonds", "OBSERVATION", 163, 179]]], ["Cysteine proteases are divided into five sub-families according to the sequence and structure of their catalytic domain: ubiquitin-specific proteases (USPs), ubiquitin C-hydrolases (UCHs), otubain proteases (OTUs), Machado Joseph disease proteases (MJDs), and the most recently identified sub-family MIU-containing novel DUB family (MINDYs).", [["Joseph disease", "DISEASE", 223, 237], ["Cysteine", "CHEMICAL", 0, 8], ["Cysteine", "AMINO_ACID", 0, 8], ["ubiquitin-specific proteases", "GENE_OR_GENE_PRODUCT", 121, 149], ["USPs", "GENE_OR_GENE_PRODUCT", 151, 155], ["ubiquitin C-hydrolases", "GENE_OR_GENE_PRODUCT", 158, 180], ["UCHs", "GENE_OR_GENE_PRODUCT", 182, 186], ["otubain proteases", "GENE_OR_GENE_PRODUCT", 189, 206], ["MJDs", "GENE_OR_GENE_PRODUCT", 249, 253], ["DUB", "GENE_OR_GENE_PRODUCT", 321, 324], ["Cysteine proteases", "PROTEIN", 0, 18], ["catalytic domain", "PROTEIN", 103, 119], ["ubiquitin-specific proteases", "PROTEIN", 121, 149], ["USPs", "PROTEIN", 151, 155], ["ubiquitin C-hydrolases", "PROTEIN", 158, 180], ["UCHs", "PROTEIN", 182, 186], ["otubain proteases", "PROTEIN", 189, 206], ["OTUs", "PROTEIN", 208, 212], ["Machado Joseph disease proteases", "PROTEIN", 215, 247], ["MJDs", "PROTEIN", 249, 253], ["MIU", "PROTEIN", 300, 303], ["DUB family", "PROTEIN", 321, 331], ["MINDYs", "PROTEIN", 333, 339], ["Cysteine proteases", "TREATMENT", 0, 18], ["USPs", "TEST", 151, 155], ["ubiquitin C-hydrolases (UCHs)", "TREATMENT", 158, 187], ["otubain proteases", "TREATMENT", 189, 206], ["Machado Joseph disease proteases", "TREATMENT", 215, 247]]], ["The most abundant sub-family of DUBs is the USPs with over 50 members, come after the OTUs (18 members), UCH, MJDs and MINDYs (each with four members) [15] .Deubiquitinating Enzymes Involved in AutophagyProtein posttranslational modifications are crucial in the dynamic regulation of the autophagy process.", [["DUBs", "GENE_OR_GENE_PRODUCT", 32, 36], ["USPs", "GENE_OR_GENE_PRODUCT", 44, 48], ["DUBs", "PROTEIN", 32, 36], ["USPs", "PROTEIN", 44, 48], ["UCH", "PROTEIN", 105, 108], ["MJDs", "PROTEIN", 110, 114], ["MINDYs", "PROTEIN", 119, 125], ["Deubiquitinating Enzymes", "PROTEIN", 157, 181], ["Protein posttranslational modifications", "PROBLEM", 203, 242], ["Autophagy", "OBSERVATION", 194, 203], ["posttranslational modifications", "OBSERVATION", 211, 242], ["autophagy process", "OBSERVATION", 288, 305]]], ["Modifications of core components of the autophagic machinery are notably essential for the induction of autophagy.", [["autophagic", "ANATOMY", 40, 50], ["core components", "OBSERVATION_MODIFIER", 17, 32], ["autophagic machinery", "OBSERVATION", 40, 60]]], ["Autophagy proteins that are ubiquitinated constitute substrates for DUBs, therefore regulating their function and/or stability [60] .Regulation of the mTOR Complex 1 by OTUB1The mechanistic target of Rapamycin complex 1 (mTORC1) plays a central role in the integration of various environmental signals to regulate cell metabolism, growth, proliferation, and survival.", [["cell", "ANATOMY", 314, 318], ["Rapamycin", "CHEMICAL", 200, 209], ["Rapamycin", "CHEMICAL", 200, 209], ["DUBs", "GENE_OR_GENE_PRODUCT", 68, 72], ["mTOR Complex 1", "GENE_OR_GENE_PRODUCT", 151, 165], ["OTUB1", "GENE_OR_GENE_PRODUCT", 169, 174], ["target of Rapamycin complex 1", "GENE_OR_GENE_PRODUCT", 190, 219], ["mTORC1", "GENE_OR_GENE_PRODUCT", 221, 227], ["cell", "CELL", 314, 318], ["Autophagy proteins", "PROTEIN", 0, 18], ["DUBs", "PROTEIN", 68, 72], ["mTOR Complex 1", "PROTEIN", 151, 165], ["OTUB1", "PROTEIN", 169, 174], ["Rapamycin complex 1", "PROTEIN", 200, 219], ["mTORC1", "PROTEIN", 221, 227], ["Autophagy proteins", "PROBLEM", 0, 18], ["DUBs", "TEST", 68, 72], ["Rapamycin complex 1 (mTORC1)", "TREATMENT", 200, 228], ["cell metabolism", "OBSERVATION", 314, 329]]], ["In nutrient-rich conditions, mTORC1 is active and promotes cell growth while down-regulating autophagy.", [["cell", "ANATOMY", 59, 63], ["mTORC1", "GENE_OR_GENE_PRODUCT", 29, 35], ["cell", "CELL", 59, 63], ["mTORC1", "PROTEIN", 29, 35], ["active", "OBSERVATION_MODIFIER", 39, 45]]], ["Conversely, down-regulation of mTORC1 activity during nutrient deprivation activates autophagy.", [["mTORC1", "GENE_OR_GENE_PRODUCT", 31, 37], ["mTORC1", "PROTEIN", 31, 37], ["mTORC1 activity", "TREATMENT", 31, 46], ["nutrient deprivation", "TREATMENT", 54, 74], ["mTORC1 activity", "OBSERVATION", 31, 46]]], ["The protease OTUB1 was recently reported to inhibit mTORC1 activity by deubiquitinating and stabilizing the inhibitor DEPTOR in response to amino acid deprivation [61] ( Figure 3A ).", [["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 140, 150], ["OTUB1", "GENE_OR_GENE_PRODUCT", 13, 18], ["mTORC1", "GENE_OR_GENE_PRODUCT", 52, 58], ["DEPTOR", "GENE_OR_GENE_PRODUCT", 118, 124], ["amino acid", "AMINO_ACID", 140, 150], ["OTUB1", "PROTEIN", 13, 18], ["mTORC1", "PROTEIN", 52, 58], ["DEPTOR", "PROTEIN", 118, 124], ["The protease OTUB1", "TREATMENT", 0, 18], ["the inhibitor DEPTOR", "TREATMENT", 104, 124], ["amino acid deprivation", "TREATMENT", 140, 162]]], ["DEPTOR stabilization by OTUB1 depends on its catalytic activity as the catalytically inactive mutant OTUB1-C91A fails to both remove ubiquitin moieties from DEPTOR and protect it from proteasomal degradation.", [["proteasomal", "ANATOMY", 184, 195], ["OTUB1", "CHEMICAL", 24, 29], ["DEPTOR", "GENE_OR_GENE_PRODUCT", 0, 6], ["OTUB1", "GENE_OR_GENE_PRODUCT", 24, 29], ["OTUB1-C91A", "GENE_OR_GENE_PRODUCT", 101, 111], ["DEPTOR", "SIMPLE_CHEMICAL", 157, 163], ["DEPTOR", "PROTEIN", 0, 6], ["OTUB1", "PROTEIN", 24, 29], ["OTUB1", "PROTEIN", 101, 106], ["C91A", "PROTEIN", 107, 111], ["ubiquitin moieties", "PROTEIN", 133, 151], ["DEPTOR", "PROTEIN", 157, 163], ["DEPTOR", "TREATMENT", 157, 163], ["proteasomal degradation", "PROBLEM", 184, 207], ["proteasomal degradation", "OBSERVATION", 184, 207]]], ["Consistent with these observations, OTUB1 overexpression induces autophagy while its knockdown represses autophagy induction [61] .Deubiquitinating Enzymes Involved in AutophagyProtein posttranslational modifications are crucial in the dynamic regulation of the autophagy process.", [["OTUB1", "GENE_OR_GENE_PRODUCT", 36, 41], ["OTUB1", "PROTEIN", 36, 41], ["Deubiquitinating Enzymes", "PROTEIN", 131, 155], ["OTUB1 overexpression", "TREATMENT", 36, 56], ["autophagy", "PROBLEM", 65, 74], ["Protein posttranslational modifications", "PROBLEM", 177, 216], ["Autophagy", "OBSERVATION", 168, 177], ["posttranslational modifications", "OBSERVATION", 185, 216], ["autophagy process", "OBSERVATION", 262, 279]]], ["Modifications of core components of the autophagic machinery are notably essential for the induction of autophagy.", [["autophagic", "ANATOMY", 40, 50], ["core components", "OBSERVATION_MODIFIER", 17, 32], ["autophagic machinery", "OBSERVATION", 40, 60]]], ["Autophagy proteins that are ubiquitinated constitute substrates for DUBs, therefore regulating their function and/or stability [60] .Regulation of the mTOR Complex 1 by OTUB1The mechanistic target of Rapamycin complex 1 (mTORC1) plays a central role in the integration of various environmental signals to regulate cell metabolism, growth, proliferation, and survival.", [["cell", "ANATOMY", 314, 318], ["Rapamycin", "CHEMICAL", 200, 209], ["Rapamycin", "CHEMICAL", 200, 209], ["DUBs", "GENE_OR_GENE_PRODUCT", 68, 72], ["mTOR Complex 1", "GENE_OR_GENE_PRODUCT", 151, 165], ["OTUB1", "GENE_OR_GENE_PRODUCT", 169, 174], ["target of Rapamycin complex 1", "GENE_OR_GENE_PRODUCT", 190, 219], ["mTORC1", "GENE_OR_GENE_PRODUCT", 221, 227], ["cell", "CELL", 314, 318], ["Autophagy proteins", "PROTEIN", 0, 18], ["DUBs", "PROTEIN", 68, 72], ["mTOR Complex 1", "PROTEIN", 151, 165], ["OTUB1", "PROTEIN", 169, 174], ["Rapamycin complex 1", "PROTEIN", 200, 219], ["mTORC1", "PROTEIN", 221, 227], ["Autophagy proteins", "PROBLEM", 0, 18], ["DUBs", "TEST", 68, 72], ["Rapamycin complex 1 (mTORC1)", "TREATMENT", 200, 228], ["cell metabolism", "OBSERVATION", 314, 329]]], ["In nutrient-rich conditions, mTORC1 is active and promotes cell growth while down-regulating autophagy.", [["cell", "ANATOMY", 59, 63], ["mTORC1", "GENE_OR_GENE_PRODUCT", 29, 35], ["cell", "CELL", 59, 63], ["mTORC1", "PROTEIN", 29, 35], ["active", "OBSERVATION_MODIFIER", 39, 45]]], ["Conversely, down-regulation of mTORC1 activity during nutrient deprivation activates autophagy.", [["mTORC1", "GENE_OR_GENE_PRODUCT", 31, 37], ["mTORC1", "PROTEIN", 31, 37], ["mTORC1 activity", "TREATMENT", 31, 46], ["nutrient deprivation", "TREATMENT", 54, 74], ["mTORC1 activity", "OBSERVATION", 31, 46]]], ["The protease OTUB1 was recently reported to inhibit mTORC1 activity by deubiquitinating and stabilizing the inhibitor DEPTOR in response to amino acid deprivation [61] ( Figure 3A ).", [["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 140, 150], ["OTUB1", "GENE_OR_GENE_PRODUCT", 13, 18], ["mTORC1", "GENE_OR_GENE_PRODUCT", 52, 58], ["DEPTOR", "GENE_OR_GENE_PRODUCT", 118, 124], ["amino acid", "AMINO_ACID", 140, 150], ["OTUB1", "PROTEIN", 13, 18], ["mTORC1", "PROTEIN", 52, 58], ["DEPTOR", "PROTEIN", 118, 124], ["The protease OTUB1", "TREATMENT", 0, 18], ["the inhibitor DEPTOR", "TREATMENT", 104, 124], ["amino acid deprivation", "TREATMENT", 140, 162]]], ["DEPTOR stabilization by OTUB1 depends on its catalytic activity as the catalytically inactive mutant OTUB1-C91A fails to both remove ubiquitin moieties from DEPTOR and protect it from proteasomal degradation.", [["proteasomal", "ANATOMY", 184, 195], ["OTUB1", "CHEMICAL", 24, 29], ["DEPTOR", "GENE_OR_GENE_PRODUCT", 0, 6], ["OTUB1", "GENE_OR_GENE_PRODUCT", 24, 29], ["OTUB1-C91A", "GENE_OR_GENE_PRODUCT", 101, 111], ["DEPTOR", "SIMPLE_CHEMICAL", 157, 163], ["DEPTOR", "PROTEIN", 0, 6], ["OTUB1", "PROTEIN", 24, 29], ["OTUB1", "PROTEIN", 101, 106], ["C91A", "PROTEIN", 107, 111], ["ubiquitin moieties", "PROTEIN", 133, 151], ["DEPTOR", "PROTEIN", 157, 163], ["DEPTOR", "TREATMENT", 157, 163], ["proteasomal degradation", "PROBLEM", 184, 207], ["proteasomal degradation", "OBSERVATION", 184, 207]]], ["Consistent with these observations, OTUB1 overexpression induces autophagy while its knockdown represses autophagy induction [61] .Regulation of ULK1 by USP20The serine/threonine protein kinase ULK1 (Unc51-like kinase 1) is a critical inducer of autophagy (see above and Figure 1 ).", [["serine", "CHEMICAL", 162, 168], ["threonine", "CHEMICAL", 169, 178], ["OTUB1", "GENE_OR_GENE_PRODUCT", 36, 41], ["ULK1", "GENE_OR_GENE_PRODUCT", 145, 149], ["USP20", "GENE_OR_GENE_PRODUCT", 153, 158], ["serine", "AMINO_ACID", 162, 168], ["ULK1", "GENE_OR_GENE_PRODUCT", 194, 198], ["Unc51-like kinase 1", "GENE_OR_GENE_PRODUCT", 200, 219], ["OTUB1", "PROTEIN", 36, 41], ["ULK1", "PROTEIN", 145, 149], ["USP20", "PROTEIN", 153, 158], ["serine/threonine protein kinase", "PROTEIN", 162, 193], ["ULK1", "PROTEIN", 194, 198], ["Unc51-like kinase 1", "PROTEIN", 200, 219], ["OTUB1 overexpression", "TREATMENT", 36, 56], ["autophagy", "PROBLEM", 65, 74], ["ULK1", "TEST", 145, 149], ["The serine/threonine protein kinase ULK1", "TEST", 158, 198], ["Unc51", "TEST", 200, 205], ["kinase", "TEST", 211, 217], ["a critical inducer of autophagy", "PROBLEM", 224, 255]]], ["Dynamic phosphorylation and polyubiquitination regulate ULK1 activity.", [["ULK1", "GENE_OR_GENE_PRODUCT", 56, 60], ["ULK1", "PROTEIN", 56, 60], ["Dynamic phosphorylation", "TREATMENT", 0, 23], ["polyubiquitination regulate", "OBSERVATION", 28, 55], ["ULK1 activity", "OBSERVATION", 56, 69]]], ["Notably, the ubiquitination of ULK1 with K63-linked ubiquitin chains contributes to its stabilization and activity [38] .", [["ULK1", "GENE_OR_GENE_PRODUCT", 31, 35], ["K63-linked ubiquitin chains", "GENE_OR_GENE_PRODUCT", 41, 68], ["ULK1", "PROTEIN", 31, 35], ["K63", "PROTEIN", 41, 44], ["ubiquitin chains", "PROTEIN", 52, 68], ["the ubiquitination of ULK1", "PROBLEM", 9, 35], ["K63-linked ubiquitin chains", "TREATMENT", 41, 68], ["ubiquitin chains", "OBSERVATION", 52, 68], ["stabilization", "OBSERVATION_MODIFIER", 88, 101]]], ["In contrast, the linkage of K48-linked ubiquitin chains leads to proteasomal degradation of ULK1, resulting in a blockade of starvation-induced autophagy [62, 63] .", [["proteasomal", "ANATOMY", 65, 76], ["K48", "GENE_OR_GENE_PRODUCT", 28, 31], ["ULK1", "GENE_OR_GENE_PRODUCT", 92, 96], ["K48", "PROTEIN", 28, 31], ["ubiquitin chains", "PROTEIN", 39, 55], ["ULK1", "PROTEIN", 92, 96], ["K48-linked ubiquitin chains", "TREATMENT", 28, 55], ["proteasomal degradation of ULK1", "PROBLEM", 65, 96], ["ubiquitin chains", "OBSERVATION", 39, 55], ["proteasomal degradation", "OBSERVATION", 65, 88]]], ["A loss-of-function screen of DUBs in HeLa cells identified USP20 as the first DUB to be involved in regulating ULK1 ubiquitination and stability.", [["HeLa cells", "ANATOMY", 37, 47], ["DUBs", "GENE_OR_GENE_PRODUCT", 29, 33], ["HeLa cells", "CELL", 37, 47], ["USP20", "GENE_OR_GENE_PRODUCT", 59, 64], ["DUB", "GENE_OR_GENE_PRODUCT", 78, 81], ["ULK1", "GENE_OR_GENE_PRODUCT", 111, 115], ["DUBs", "PROTEIN", 29, 33], ["HeLa cells", "CELL_LINE", 37, 47], ["USP20", "PROTEIN", 59, 64], ["DUB", "PROTEIN", 78, 81], ["ULK1", "PROTEIN", 111, 115], ["A loss", "PROBLEM", 0, 6], ["DUBs in HeLa cells", "PROBLEM", 29, 47], ["ULK1 ubiquitination", "OBSERVATION", 111, 130], ["stability", "OBSERVATION_MODIFIER", 135, 144]]], ["USP20 interacts with and deubiquitinates ULK1, thus protecting it from degradation.", [["USP20", "CHEMICAL", 0, 5], ["USP20", "GENE_OR_GENE_PRODUCT", 0, 5], ["ULK1", "GENE_OR_GENE_PRODUCT", 41, 45], ["USP20", "PROTEIN", 0, 5], ["ULK1", "PROTEIN", 41, 45]]], ["The maintenance of basal levels of ULK1 by USP20 contributes to rapid induction of autophagy under stress condition.", [["USP20", "CHEMICAL", 43, 48], ["ULK1", "GENE_OR_GENE_PRODUCT", 35, 39], ["USP20", "GENE_OR_GENE_PRODUCT", 43, 48], ["ULK1", "PROTEIN", 35, 39], ["USP20", "PROTEIN", 43, 48], ["autophagy under stress condition", "PROBLEM", 83, 115], ["basal", "ANATOMY_MODIFIER", 19, 24]]], ["Indeed, silencing of USP20 encoding gene inhibits autophagosomes and autolysosomes formation in response to starvation ( Figure 3B ).", [["autophagosomes", "ANATOMY", 50, 64], ["autolysosomes", "ANATOMY", 69, 82], ["USP20", "GENE_OR_GENE_PRODUCT", 21, 26], ["autophagosomes", "CELLULAR_COMPONENT", 50, 64], ["autolysosomes", "SIMPLE_CHEMICAL", 69, 82], ["USP20 encoding gene", "DNA", 21, 40], ["autophagosomes", "PROBLEM", 50, 64], ["autolysosomes formation", "PROBLEM", 69, 92]]], ["However, the interaction between ULK1 and USP20 is weakened upon prolonged induction of autophagy (4 to 8 h), leading to a reduction of the level of ULK1 protein while its ubiquitinated form accumulates [64] .", [["ULK1", "GENE_OR_GENE_PRODUCT", 33, 37], ["USP20", "GENE_OR_GENE_PRODUCT", 42, 47], ["ULK1", "GENE_OR_GENE_PRODUCT", 149, 153], ["ULK1", "PROTEIN", 33, 37], ["USP20", "PROTEIN", 42, 47], ["ULK1 protein", "PROTEIN", 149, 161], ["ULK1", "TEST", 33, 37], ["autophagy", "TEST", 88, 97], ["ULK1 protein", "TEST", 149, 161]]], ["The molecular mechanisms regulating the dissociation of USP20 and ULK1 are not known yet but could depend on posttranslational or allosteric modifications on USP20 as its stability is not affected by starvation; alternatively, the E3 ubiquitin ligase NEDD4L, may compete with USP20 to interact with ULK1 and promotes its proteasomal degradation [63] .Regulation of the Beclin1 ComplexBeclin1 is a multivalent adaptor protein and forms, with VPS34 and VPS15, the core components of the PI3K-III signaling complex, which is essential for the maturation of the autophagosome (see above and Figure 1 ).", [["proteasomal", "ANATOMY", 321, 332], ["autophagosome", "ANATOMY", 558, 571], ["USP20", "GENE_OR_GENE_PRODUCT", 56, 61], ["ULK1", "GENE_OR_GENE_PRODUCT", 66, 70], ["USP20", "GENE_OR_GENE_PRODUCT", 158, 163], ["E3", "GENE_OR_GENE_PRODUCT", 231, 233], ["NEDD4L", "GENE_OR_GENE_PRODUCT", 251, 257], ["USP20", "GENE_OR_GENE_PRODUCT", 276, 281], ["ULK1", "GENE_OR_GENE_PRODUCT", 299, 303], ["Beclin1", "GENE_OR_GENE_PRODUCT", 369, 376], ["ComplexBeclin1", "GENE_OR_GENE_PRODUCT", 377, 391], ["VPS34", "GENE_OR_GENE_PRODUCT", 441, 446], ["VPS15", "GENE_OR_GENE_PRODUCT", 451, 456], ["PI3K-III", "GENE_OR_GENE_PRODUCT", 485, 493], ["autophagosome", "CELLULAR_COMPONENT", 558, 571], ["USP20", "PROTEIN", 56, 61], ["ULK1", "PROTEIN", 66, 70], ["USP20", "PROTEIN", 158, 163], ["E3 ubiquitin ligase", "PROTEIN", 231, 250], ["NEDD4L", "PROTEIN", 251, 257], ["USP20", "PROTEIN", 276, 281], ["ULK1", "PROTEIN", 299, 303], ["Beclin1", "PROTEIN", 369, 376], ["ComplexBeclin1", "PROTEIN", 377, 391], ["multivalent adaptor protein", "PROTEIN", 397, 424], ["VPS34", "PROTEIN", 441, 446], ["VPS15", "PROTEIN", 451, 456], ["PI3K-III signaling complex", "PROTEIN", 485, 511], ["USP20", "TEST", 56, 61], ["ULK1", "PROBLEM", 66, 70], ["USP20", "TREATMENT", 158, 163], ["the E3 ubiquitin ligase NEDD4L", "TREATMENT", 227, 257], ["ULK1", "TEST", 299, 303], ["VPS34", "TEST", 441, 446], ["VPS15", "TEST", 451, 456], ["Beclin1 ComplexBeclin1", "OBSERVATION", 369, 391]]], ["Beclin1 also interacts transiently with accessory factors, such as ATG14L, AMBRA1, UVRAG or Bcl-2 [65] .", [["Beclin1", "GENE_OR_GENE_PRODUCT", 0, 7], ["ATG14L", "GENE_OR_GENE_PRODUCT", 67, 73], ["AMBRA1", "GENE_OR_GENE_PRODUCT", 75, 81], ["UVRAG", "GENE_OR_GENE_PRODUCT", 83, 88], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["Beclin1", "PROTEIN", 0, 7], ["accessory factors", "PROTEIN", 40, 57], ["ATG14L", "PROTEIN", 67, 73], ["AMBRA1", "PROTEIN", 75, 81], ["UVRAG", "PROTEIN", 83, 88], ["Bcl", "PROTEIN", 92, 95], ["accessory factors", "PROBLEM", 40, 57], ["ATG14L", "TEST", 67, 73], ["AMBRA1", "TEST", 75, 81], ["UVRAG", "TEST", 83, 88], ["Bcl", "TEST", 92, 95]]], ["Moreover, Beclin1 versatile ubiquitination is tightly linked to its function and activation [37] .", [["Beclin1", "GENE_OR_GENE_PRODUCT", 10, 17], ["Beclin1", "PROTEIN", 10, 17]]], ["Different types of ubiquitin chains, including K63-and K48-linked chains, were found on Beclin1, and several DUBs control Beclin1 ubiquitination status and activity ( Figure 3C ).Regulation of the Beclin1 ComplexUSP14 is a ubiquitin-specific protease tightly associated with the proteasome which has been shown to cleave K48-linked ubiquitin chains [66, 67] ; however, other studies have shown that USP14 is also able to cleave K63-linked ubiquitin chains [68, 69] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 19, 28], ["K63", "GENE_OR_GENE_PRODUCT", 47, 50], ["K48", "GENE_OR_GENE_PRODUCT", 55, 58], ["Beclin1", "GENE_OR_GENE_PRODUCT", 88, 95], ["DUBs", "GENE_OR_GENE_PRODUCT", 109, 113], ["Beclin1", "GENE_OR_GENE_PRODUCT", 122, 129], ["Beclin1", "GENE_OR_GENE_PRODUCT", 197, 204], ["ComplexUSP14", "GENE_OR_GENE_PRODUCT", 205, 217], ["K48", "GENE_OR_GENE_PRODUCT", 321, 324], ["USP14", "GENE_OR_GENE_PRODUCT", 399, 404], ["K63", "GENE_OR_GENE_PRODUCT", 428, 431], ["ubiquitin chains", "PROTEIN", 19, 35], ["K63", "PROTEIN", 47, 50], ["K48", "PROTEIN", 55, 58], ["Beclin1", "PROTEIN", 88, 95], ["DUBs", "PROTEIN", 109, 113], ["Beclin1", "PROTEIN", 122, 129], ["Beclin1", "PROTEIN", 197, 204], ["ComplexUSP14", "PROTEIN", 205, 217], ["ubiquitin-specific protease", "PROTEIN", 223, 250], ["proteasome", "PROTEIN", 279, 289], ["K48", "PROTEIN", 321, 324], ["ubiquitin chains", "PROTEIN", 332, 348], ["USP14", "PROTEIN", 399, 404], ["K63", "PROTEIN", 428, 431], ["ubiquitin chains", "PROTEIN", 439, 455], ["ubiquitin chains", "TREATMENT", 19, 35], ["K63", "TEST", 47, 50], ["K48", "TREATMENT", 55, 58], ["Beclin1", "TEST", 88, 95], ["a ubiquitin-specific protease", "TREATMENT", 221, 250], ["the proteasome", "TREATMENT", 275, 289], ["other studies", "TEST", 369, 382], ["K63", "TEST", 428, 431], ["ubiquitin chains", "OBSERVATION", 19, 35], ["Beclin1 ubiquitination", "OBSERVATION", 122, 144], ["Beclin1 ComplexUSP14", "OBSERVATION", 197, 217]]], ["Knockdown of USP14 or its inhibition with the inhibitor IU1 (see below Section 4.1) induces the activation of autophagy, indicating that USP14 is a negative regulator of autophagy in H4 (neuroglioma) cells.", [["H4 (neuroglioma) cells", "ANATOMY", 183, 205], ["USP14", "CHEMICAL", 13, 18], ["USP14", "GENE_OR_GENE_PRODUCT", 13, 18], ["IU1", "GENE_OR_GENE_PRODUCT", 56, 59], ["USP14", "GENE_OR_GENE_PRODUCT", 137, 142], ["H4 (neuroglioma) cells", "CELL", 183, 205], ["USP14", "PROTEIN", 13, 18], ["USP14", "PROTEIN", 137, 142], ["H4 (neuroglioma) cells", "CELL_LINE", 183, 205], ["Knockdown of USP14", "TREATMENT", 0, 18], ["the inhibitor IU1", "TREATMENT", 42, 59], ["the activation of autophagy", "PROBLEM", 92, 119], ["autophagy in H4 (neuroglioma) cells", "PROBLEM", 170, 205]]], ["Because silencing the USP14 encoding gene does not affect the stability of Beclin1 or other components of the complex, this suggests that its ability to regulate autophagy is independent of its proteasomal function in H4 (neuroglioma) cells.", [["proteasomal", "ANATOMY", 194, 205], ["H4 (neuroglioma) cells", "ANATOMY", 218, 240], ["USP14", "GENE_OR_GENE_PRODUCT", 22, 27], ["Beclin1", "GENE_OR_GENE_PRODUCT", 75, 82], ["H4 (neuroglioma) cells", "CELL", 218, 240], ["USP14 encoding gene", "DNA", 22, 41], ["Beclin1", "PROTEIN", 75, 82], ["H4 (neuroglioma) cells", "CELL_LINE", 218, 240], ["Beclin1", "PROBLEM", 75, 82]]], ["According to this observation, it was shown that USP14 suppresses the activity of Beclin1 complex and induction of autophagy by interacting with and controlling K63-rather than K48-linked ubiquitin chains of Beclin1 [70] .Regulation of the Beclin1 ComplexAutophagy is highly interconnected with immune processes and can be triggered by activated TLR4 (Toll-like receptor 4).", [["USP14", "CHEMICAL", 49, 54], ["USP14", "GENE_OR_GENE_PRODUCT", 49, 54], ["Beclin1", "GENE_OR_GENE_PRODUCT", 82, 89], ["K63", "GENE_OR_GENE_PRODUCT", 161, 164], ["K48", "GENE_OR_GENE_PRODUCT", 177, 180], ["Beclin1 [70", "GENE_OR_GENE_PRODUCT", 208, 219], ["Beclin1", "GENE_OR_GENE_PRODUCT", 240, 247], ["TLR4", "GENE_OR_GENE_PRODUCT", 346, 350], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 352, 372], ["USP14", "PROTEIN", 49, 54], ["Beclin1 complex", "PROTEIN", 82, 97], ["K63", "PROTEIN", 161, 164], ["K48", "PROTEIN", 177, 180], ["ubiquitin chains", "PROTEIN", 188, 204], ["Beclin1", "PROTEIN", 208, 215], ["Beclin1", "PROTEIN", 240, 247], ["ComplexAutophagy", "PROTEIN", 248, 264], ["TLR4", "PROTEIN", 346, 350], ["Toll-like receptor 4", "PROTEIN", 352, 372], ["Beclin1 complex", "PROBLEM", 82, 97], ["K63", "TEST", 161, 164], ["K48", "TEST", 177, 180], ["the Beclin1 ComplexAutophagy", "PROBLEM", 236, 264], ["immune processes", "PROBLEM", 295, 311], ["activated TLR4 (Toll-like receptor", "TREATMENT", 336, 370], ["Beclin1 ComplexAutophagy", "OBSERVATION", 240, 264]]], ["Activation of TLR4 by microbial components contributes to the recruitment of adaptor proteins and enzymes required for the signal transduction and induction of the immune response by NF-\u03baB (nuclear factor kappa B) transcription factors, such as the E3 ubiquitin ligase and scaffold protein TRAF6 (TNFR-associated factor 6).", [["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 183, 188], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 190, 212], ["E3", "GENE_OR_GENE_PRODUCT", 249, 251], ["TRAF6", "GENE_OR_GENE_PRODUCT", 290, 295], ["TNFR-associated factor 6", "GENE_OR_GENE_PRODUCT", 297, 321], ["TLR4", "PROTEIN", 14, 18], ["adaptor proteins", "PROTEIN", 77, 93], ["enzymes", "PROTEIN", 98, 105], ["NF-\u03baB", "PROTEIN", 183, 188], ["nuclear factor kappa B", "PROTEIN", 190, 212], ["transcription factors", "PROTEIN", 214, 235], ["E3 ubiquitin ligase", "PROTEIN", 249, 268], ["scaffold protein", "PROTEIN", 273, 289], ["TRAF6", "PROTEIN", 290, 295], ["TNFR-associated factor 6", "PROTEIN", 297, 321], ["adaptor proteins", "TREATMENT", 77, 93], ["enzymes", "TEST", 98, 105], ["the signal transduction", "TREATMENT", 119, 142], ["the immune response", "TEST", 160, 179], ["transcription factors", "PROBLEM", 214, 235], ["the E3 ubiquitin ligase", "TREATMENT", 245, 268], ["scaffold protein TRAF6", "TREATMENT", 273, 295], ["TNFR", "TEST", 297, 301]]], ["TRAF6 is then responsible for the induction of autophagy following the activation of the TLR4 in macrophages through the ubiquitination of Beclin1 with K63-ubiquitin chains in murine macrophages RAW 264.7 [71] .", [["macrophages", "ANATOMY", 97, 108], ["TRAF6", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLR4", "GENE_OR_GENE_PRODUCT", 89, 93], ["macrophages", "CELL", 97, 108], ["Beclin1", "GENE_OR_GENE_PRODUCT", 139, 146], ["K63", "GENE_OR_GENE_PRODUCT", 152, 155], ["murine", "ORGANISM", 176, 182], ["macrophages RAW 264.7 [71]", "CELL", 183, 209], ["TRAF6", "PROTEIN", 0, 5], ["TLR4", "PROTEIN", 89, 93], ["macrophages", "CELL_TYPE", 97, 108], ["Beclin1", "PROTEIN", 139, 146], ["K63", "PROTEIN", 152, 155], ["ubiquitin chains", "PROTEIN", 156, 172], ["murine macrophages", "CELL_TYPE", 176, 194], ["RAW 264.7 [71", "CELL_LINE", 195, 208], ["murine", "SPECIES", 176, 182], ["autophagy", "TREATMENT", 47, 56], ["the TLR4 in macrophages", "TREATMENT", 85, 108], ["Beclin1", "TEST", 139, 146], ["K63-ubiquitin chains", "TREATMENT", 152, 172]]], ["Indeed, ubiquitination of the lysine residue 117 within the BH3 domain of Beclin1 prevents its interaction with the inhibitor Bcl-2 [71, 72] .", [["lysine", "CHEMICAL", 30, 36], ["lysine", "CHEMICAL", 30, 36], ["lysine residue 117", "AMINO_ACID", 30, 48], ["Beclin1", "GENE_OR_GENE_PRODUCT", 74, 81], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 126, 131], ["BH3 domain", "PROTEIN", 60, 70], ["Beclin1", "PROTEIN", 74, 81], ["the lysine residue", "TREATMENT", 26, 44], ["Beclin1", "TREATMENT", 74, 81], ["the inhibitor Bcl", "TEST", 112, 129]]], ["In addition, Min and colleagues showed that TRAF6 and USP14 compete for the interaction with Beclin1 in HEK293T (human embryonic kidney 293T) cells and that USP14 negatively regulates autophagy in THP-1 monocyte cells [73] .", [["HEK293T", "ANATOMY", 104, 111], ["embryonic kidney 293T) cells", "ANATOMY", 119, 147], ["THP-1 monocyte cells", "ANATOMY", 197, 217], ["TRAF6", "GENE_OR_GENE_PRODUCT", 44, 49], ["USP14", "GENE_OR_GENE_PRODUCT", 54, 59], ["Beclin1", "GENE_OR_GENE_PRODUCT", 93, 100], ["HEK293T", "CELL", 104, 111], ["human", "ORGANISM", 113, 118], ["embryonic kidney 293T) cells", "CELL", 119, 147], ["USP14", "GENE_OR_GENE_PRODUCT", 157, 162], ["THP-1 monocyte cells", "CELL", 197, 217], ["TRAF6", "PROTEIN", 44, 49], ["USP14", "PROTEIN", 54, 59], ["Beclin1", "PROTEIN", 93, 100], ["HEK293T (human embryonic kidney 293T) cells", "CELL_LINE", 104, 147], ["USP14", "PROTEIN", 157, 162], ["THP-1 monocyte cells", "CELL_LINE", 197, 217], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["TRAF6", "TEST", 44, 49], ["Beclin1 in HEK293T", "TEST", 93, 111], ["cells", "TEST", 142, 147], ["USP14", "TEST", 157, 162], ["autophagy", "TEST", 184, 193], ["THP", "TEST", 197, 200], ["monocyte cells", "TEST", 203, 217], ["kidney", "ANATOMY", 129, 135]]], ["TRAF6 and Beclin1 interact through their coiled-coil domains in the absence of USP14, whereas the interaction is gradually attenuated when the cells are co-transfected with increasing quantity of USP14.", [["cells", "ANATOMY", 143, 148], ["TRAF6", "GENE_OR_GENE_PRODUCT", 0, 5], ["Beclin1", "GENE_OR_GENE_PRODUCT", 10, 17], ["USP14", "GENE_OR_GENE_PRODUCT", 79, 84], ["cells", "CELL", 143, 148], ["USP14", "GENE_OR_GENE_PRODUCT", 196, 201], ["TRAF6", "PROTEIN", 0, 5], ["Beclin1", "PROTEIN", 10, 17], ["coiled-coil domains", "PROTEIN", 41, 60], ["USP14", "PROTEIN", 79, 84], ["USP14", "PROTEIN", 196, 201], ["TRAF6", "TREATMENT", 0, 5], ["Beclin1", "TREATMENT", 10, 17], ["their coiled-coil domains", "TREATMENT", 35, 60], ["increasing quantity of USP14", "PROBLEM", 173, 201], ["increasing", "OBSERVATION_MODIFIER", 173, 183], ["quantity", "OBSERVATION_MODIFIER", 184, 192]]], ["However, the study does not provide any evidence for the catalytic role of USP14 and instead suggests that the interaction of Beclin1 with USP14 inhibit TRAF6-mediated ubiquitination of Beclin1 [73] .", [["USP14", "CHEMICAL", 139, 144], ["USP14", "GENE_OR_GENE_PRODUCT", 75, 80], ["Beclin1", "GENE_OR_GENE_PRODUCT", 126, 133], ["USP14", "GENE_OR_GENE_PRODUCT", 139, 144], ["TRAF6", "GENE_OR_GENE_PRODUCT", 153, 158], ["Beclin1", "GENE_OR_GENE_PRODUCT", 186, 193], ["USP14", "PROTEIN", 75, 80], ["Beclin1", "PROTEIN", 126, 133], ["USP14", "PROTEIN", 139, 144], ["TRAF6", "PROTEIN", 153, 158], ["Beclin1", "PROTEIN", 186, 193], ["the study", "TEST", 9, 18], ["Beclin1", "TEST", 126, 133], ["TRAF6", "TEST", 153, 158]]], ["Additionally, the DUB A20-a downstream target of NF-\u03baB-is responsible for the catalytic removal of K63-linked ubiquitin chains on the lysine 117 of Beclin1 to limit the induction of autophagy in the murine macrophage cell line RAW 264.7 [71] .", [["macrophage cell line RAW 264.7", "ANATOMY", 206, 236], ["lysine", "CHEMICAL", 134, 140], ["lysine", "CHEMICAL", 134, 140], ["DUB", "GENE_OR_GENE_PRODUCT", 18, 21], ["A20", "GENE_OR_GENE_PRODUCT", 22, 25], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 49, 54], ["K63-linked ubiquitin chains", "SIMPLE_CHEMICAL", 99, 126], ["lysine 117", "AMINO_ACID", 134, 144], ["Beclin1", "GENE_OR_GENE_PRODUCT", 148, 155], ["murine", "ORGANISM", 199, 205], ["macrophage cell line RAW 264.7 [71]", "CELL", 206, 241], ["DUB", "PROTEIN", 18, 21], ["A20", "PROTEIN", 22, 25], ["NF-\u03baB", "PROTEIN", 49, 54], ["K63", "PROTEIN", 99, 102], ["ubiquitin chains", "PROTEIN", 110, 126], ["Beclin1", "PROTEIN", 148, 155], ["murine macrophage cell line", "CELL_LINE", 199, 226], ["RAW 264.7 [71", "CELL_LINE", 227, 240], ["murine", "SPECIES", 199, 205], ["the DUB A20", "TEST", 14, 25], ["NF", "TEST", 49, 51], ["the catalytic removal", "TREATMENT", 74, 95], ["K63", "TEST", 99, 102], ["the lysine", "TREATMENT", 130, 140], ["Beclin1", "TREATMENT", 148, 155], ["DUB", "ANATOMY", 18, 21]]], ["Interestingly, Beclin1 and the Bcl-2 family member, MCL-1, compete for their interaction with USP9X, which contributes to their stabilization by protecting them from proteasomal degradation in HEK293T cells [74] .", [["proteasomal", "ANATOMY", 166, 177], ["HEK293T cells", "ANATOMY", 193, 206], ["Beclin1", "GENE_OR_GENE_PRODUCT", 15, 22], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 31, 36], ["MCL-1", "GENE_OR_GENE_PRODUCT", 52, 57], ["USP9X", "GENE_OR_GENE_PRODUCT", 94, 99], ["HEK293T cells", "CELL", 193, 206], ["Beclin1", "PROTEIN", 15, 22], ["Bcl-2 family member", "PROTEIN", 31, 50], ["MCL-1", "PROTEIN", 52, 57], ["USP9X", "PROTEIN", 94, 99], ["HEK293T cells", "CELL_LINE", 193, 206], ["proteasomal degradation in HEK293T cells", "PROBLEM", 166, 206]]], ["In the same study, it was observed that MCL-1 levels were increased in malignant tissues from melanoma patients while Beclin1 was destabilized, suggesting that USP9X promotes tumor progression.", [["malignant tissues", "ANATOMY", 71, 88], ["melanoma", "ANATOMY", 94, 102], ["tumor", "ANATOMY", 175, 180], ["melanoma", "DISEASE", 94, 102], ["tumor", "DISEASE", 175, 180], ["MCL-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["malignant tissues", "TISSUE", 71, 88], ["melanoma", "CANCER", 94, 102], ["patients", "ORGANISM", 103, 111], ["Beclin1", "GENE_OR_GENE_PRODUCT", 118, 125], ["USP9X", "GENE_OR_GENE_PRODUCT", 160, 165], ["tumor", "CANCER", 175, 180], ["MCL", "PROTEIN", 40, 43], ["Beclin1", "PROTEIN", 118, 125], ["USP9X", "PROTEIN", 160, 165], ["patients", "SPECIES", 103, 111], ["the same study", "TEST", 3, 17], ["MCL-1 levels", "TEST", 40, 52], ["malignant tissues", "PROBLEM", 71, 88], ["melanoma", "PROBLEM", 94, 102], ["Beclin1", "TEST", 118, 125], ["USP9X promotes tumor progression", "PROBLEM", 160, 192], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["malignant tissues", "OBSERVATION", 71, 88], ["melanoma", "OBSERVATION", 94, 102], ["tumor", "OBSERVATION_MODIFIER", 175, 180], ["progression", "OBSERVATION_MODIFIER", 181, 192]]], ["However, USP9X function in tumorigenesis appears to be more complex and context-dependent as independent studies have shown that USP9X can be either a tumor promoter or suppressor depending on the origin of the cells [75, 76] .", [["tumor", "ANATOMY", 151, 156], ["cells", "ANATOMY", 211, 216], ["tumor", "DISEASE", 151, 156], ["USP9X", "GENE_OR_GENE_PRODUCT", 9, 14], ["USP9X", "GENE_OR_GENE_PRODUCT", 129, 134], ["tumor", "CANCER", 151, 156], ["cells", "CELL", 211, 216], ["USP9X", "PROTEIN", 9, 14], ["USP9X", "PROTEIN", 129, 134], ["tumor promoter", "DNA", 151, 165], ["USP9X function", "TEST", 9, 23], ["independent studies", "TEST", 93, 112], ["USP9X", "PROBLEM", 129, 134], ["a tumor promoter", "TREATMENT", 149, 165], ["appears to be", "UNCERTAINTY", 41, 54], ["more complex", "OBSERVATION_MODIFIER", 55, 67], ["tumor", "OBSERVATION", 151, 156]]], ["The addition of K11-linked ubiquitin chains to Beclin1 by the E3 ligase NEDD4 triggers its degradation by the proteasome [77] .", [["K11-linked ubiquitin chains", "GENE_OR_GENE_PRODUCT", 16, 43], ["Beclin1", "GENE_OR_GENE_PRODUCT", 47, 54], ["E3", "GENE_OR_GENE_PRODUCT", 62, 64], ["NEDD4", "GENE_OR_GENE_PRODUCT", 72, 77], ["K11", "PROTEIN", 16, 19], ["ubiquitin chains", "PROTEIN", 27, 43], ["Beclin1", "PROTEIN", 47, 54], ["E3 ligase", "PROTEIN", 62, 71], ["NEDD4", "PROTEIN", 72, 77], ["proteasome", "PROTEIN", 110, 120], ["K11-linked ubiquitin chains", "TREATMENT", 16, 43], ["Beclin1", "TREATMENT", 47, 54], ["the E3 ligase NEDD4", "TREATMENT", 58, 77]]], ["The enzymes USP13 and USP19 are known to process K11-linked ubiquitin chains resulting in the stabilization of Beclin1 in HEK293T cells (for both USP13 and USP19 roles), as well as in MEF, HeLa and Bcap-37 cells (role of USP13) [78, 79] .", [["HEK293T cells", "ANATOMY", 122, 135], ["MEF", "ANATOMY", 184, 187], ["HeLa", "ANATOMY", 189, 193], ["Bcap-37 cells", "ANATOMY", 198, 211], ["USP13", "GENE_OR_GENE_PRODUCT", 12, 17], ["USP19", "GENE_OR_GENE_PRODUCT", 22, 27], ["K11", "GENE_OR_GENE_PRODUCT", 49, 52], ["Beclin1", "GENE_OR_GENE_PRODUCT", 111, 118], ["HEK293T cells", "CELL", 122, 135], ["USP13", "GENE_OR_GENE_PRODUCT", 146, 151], ["USP19", "GENE_OR_GENE_PRODUCT", 156, 161], ["MEF", "CELL", 184, 187], ["HeLa", "CELL", 189, 193], ["Bcap-37 cells", "CELL", 198, 211], ["USP13", "GENE_OR_GENE_PRODUCT", 221, 226], ["USP13", "PROTEIN", 12, 17], ["USP19", "PROTEIN", 22, 27], ["K11", "PROTEIN", 49, 52], ["ubiquitin chains", "PROTEIN", 60, 76], ["Beclin1", "PROTEIN", 111, 118], ["HEK293T cells", "CELL_LINE", 122, 135], ["USP13", "PROTEIN", 146, 151], ["USP19", "PROTEIN", 156, 161], ["MEF", "CELL_LINE", 184, 187], ["HeLa", "CELL_LINE", 189, 193], ["Bcap-37 cells", "CELL_LINE", 198, 211], ["USP13", "PROTEIN", 221, 226], ["The enzymes USP13", "TEST", 0, 17], ["USP19", "TEST", 22, 27], ["K11", "TEST", 49, 52], ["linked ubiquitin chains", "PROBLEM", 53, 76], ["Beclin1 in HEK293T cells", "PROBLEM", 111, 135], ["HeLa", "TEST", 189, 193], ["Bcap", "TEST", 198, 202], ["ubiquitin chains", "OBSERVATION", 60, 76], ["HEK293T cells", "OBSERVATION", 122, 135]]], ["Although several lysine residues in Beclin1 may be ubiquitinated with K11-linked chains, USP19 seems to mainly target ubiquitin moieties bound to the lysine 437 of Beclin1 in HEK293T cells, suggesting that its function may not be redundant, but instead complementary to USP13 [78] .Regulation of the Beclin1 ComplexFinally, the DUB USP33 was found to be a regulator of early steps of starvation-induced autophagy activation by promoting the interaction between Beclin1 and the RAS-like GTPase RALB.", [["HEK293T cells", "ANATOMY", 175, 188], ["lysine", "CHEMICAL", 17, 23], ["USP19", "CHEMICAL", 89, 94], ["lysine", "CHEMICAL", 17, 23], ["lysine", "CHEMICAL", 150, 156], ["Beclin1", "GENE_OR_GENE_PRODUCT", 36, 43], ["USP19", "GENE_OR_GENE_PRODUCT", 89, 94], ["Beclin1", "GENE_OR_GENE_PRODUCT", 164, 171], ["HEK293T cells", "CELL", 175, 188], ["Beclin1", "GENE_OR_GENE_PRODUCT", 300, 307], ["DUB", "GENE_OR_GENE_PRODUCT", 328, 331], ["USP33", "GENE_OR_GENE_PRODUCT", 332, 337], ["Beclin1", "GENE_OR_GENE_PRODUCT", 461, 468], ["RAS-like GTPase RALB", "GENE_OR_GENE_PRODUCT", 477, 497], ["Beclin1", "PROTEIN", 36, 43], ["K11", "PROTEIN", 70, 73], ["USP19", "PROTEIN", 89, 94], ["ubiquitin moieties", "PROTEIN", 118, 136], ["lysine 437", "PROTEIN", 150, 160], ["Beclin1", "PROTEIN", 164, 171], ["HEK293T cells", "CELL_LINE", 175, 188], ["Beclin1", "PROTEIN", 300, 307], ["DUB", "PROTEIN", 328, 331], ["USP33", "PROTEIN", 332, 337], ["Beclin1", "PROTEIN", 461, 468], ["RAS", "PROTEIN", 477, 480], ["GTPase", "PROTEIN", 486, 492], ["RALB", "PROTEIN", 493, 497], ["several lysine residues in Beclin1", "PROBLEM", 9, 43], ["K11", "TEST", 70, 73], ["Beclin1 in HEK293T cells", "TREATMENT", 164, 188], ["the DUB USP33", "TEST", 324, 337], ["the RAS", "TEST", 473, 480], ["several", "OBSERVATION_MODIFIER", 9, 16], ["lysine residues", "OBSERVATION", 17, 32], ["may be", "UNCERTAINTY", 44, 50], ["ubiquitinated", "OBSERVATION_MODIFIER", 51, 64], ["may not be", "UNCERTAINTY", 219, 229]]], ["Indeed, the assembly of the complex RALB-EXO84-Beclin1 is made possible by the deubiquitination of RALB at its lysine residue 47 in HEK293T and HeLa cells [80] .", [["HEK293T", "ANATOMY", 132, 139], ["HeLa cells", "ANATOMY", 144, 154], ["lysine", "CHEMICAL", 111, 117], ["RALB", "GENE_OR_GENE_PRODUCT", 36, 40], ["EXO84", "GENE_OR_GENE_PRODUCT", 41, 46], ["Beclin1", "GENE_OR_GENE_PRODUCT", 47, 54], ["RALB", "GENE_OR_GENE_PRODUCT", 99, 103], ["lysine residue 47", "AMINO_ACID", 111, 128], ["HEK293T", "CELL", 132, 139], ["HeLa cells", "CELL", 144, 154], ["RALB", "PROTEIN", 36, 40], ["EXO84", "PROTEIN", 41, 46], ["Beclin1", "PROTEIN", 47, 54], ["RALB", "PROTEIN", 99, 103], ["HEK293T", "CELL_LINE", 132, 139], ["HeLa cells", "CELL_LINE", 144, 154], ["HeLa cells", "TEST", 144, 154]]], ["The identification of USP33 as indirectly regulating Beclin1 activity through the deubiquitination of one of its partners reinforces the hypothesis that the modification and activation of autophagy machinery components are context-specific.AggrephagyThe formation of protein aggregates is a continuous process in the cell, and their degradation by autophagy, referred to as aggrephagy, is one of the first types of selective autophagy that has been described.", [["cell", "ANATOMY", 317, 321], ["USP33", "GENE_OR_GENE_PRODUCT", 22, 27], ["Beclin1", "GENE_OR_GENE_PRODUCT", 53, 60], ["cell", "CELL", 317, 321], ["USP33", "PROTEIN", 22, 27], ["Beclin1", "PROTEIN", 53, 60], ["USP33", "TREATMENT", 22, 27], ["protein aggregates", "PROBLEM", 267, 285], ["a continuous process in the cell", "PROBLEM", 289, 321], ["selective autophagy", "PROBLEM", 415, 434], ["Beclin1 activity", "OBSERVATION", 53, 69], ["protein aggregates", "OBSERVATION", 267, 285], ["selective", "OBSERVATION_MODIFIER", 415, 424], ["autophagy", "OBSERVATION", 425, 434]]], ["Aggrephagy involves the autophagy receptors p62/SQSTM1 and NBR1 which are recruited to ubiquitinated protein aggregates [81] [82] [83] [84] .AggrephagyThe accumulation of protein aggregates that fail to be degraded in neuronal or glial cells is a hallmark of various neurodegenerative diseases.", [["neuronal", "ANATOMY", 218, 226], ["glial cells", "ANATOMY", 230, 241], ["neurodegenerative diseases", "DISEASE", 267, 293], ["p62", "GENE_OR_GENE_PRODUCT", 44, 47], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 48, 54], ["NBR1", "GENE_OR_GENE_PRODUCT", 59, 63], ["neuronal", "CELL", 218, 226], ["glial cells", "CELL", 230, 241], ["autophagy receptors", "PROTEIN", 24, 43], ["p62", "PROTEIN", 44, 47], ["SQSTM1", "PROTEIN", 48, 54], ["NBR1", "PROTEIN", 59, 63], ["neuronal or glial cells", "CELL_TYPE", 218, 241], ["the autophagy receptors", "TEST", 20, 43], ["NBR1", "TEST", 59, 63], ["Aggrephagy", "TREATMENT", 141, 151], ["The accumulation of protein aggregates", "PROBLEM", 151, 189], ["various neurodegenerative diseases", "PROBLEM", 259, 293], ["accumulation of", "OBSERVATION", 155, 170], ["protein aggregates", "OBSERVATION", 171, 189], ["glial cells", "OBSERVATION", 230, 241], ["hallmark", "OBSERVATION_MODIFIER", 247, 255], ["various", "OBSERVATION_MODIFIER", 259, 266], ["neurodegenerative diseases", "OBSERVATION", 267, 293]]], ["Aggregation of \u03b1-synuclein is characteristic of the pathogenesis of Parkinson's disease in which mono-and poly-ubiquitinated \u03b1-synuclein are major constituents of the Lewy bodies [85, 86] .", [["Parkinson's disease", "DISEASE", 68, 87], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 15, 26], ["Parkinson's disease", "CANCER", 68, 87], ["poly-ubiquitinated \u03b1-synuclein", "SIMPLE_CHEMICAL", 106, 136], ["\u03b1-synuclein", "PROTEIN", 15, 26], ["ubiquitinated \u03b1-synuclein", "PROTEIN", 111, 136], ["Parkinson's disease", "PROBLEM", 68, 87], ["mono", "TEST", 97, 101], ["poly-ubiquitinated \u03b1-synuclein", "TREATMENT", 106, 136], ["Parkinson's disease", "OBSERVATION", 68, 87], ["mono", "OBSERVATION_MODIFIER", 97, 101], ["ubiquitinated \u03b1-synuclein", "OBSERVATION", 111, 136], ["Lewy bodies", "OBSERVATION", 167, 178]]], ["Mono-ubiquitination of \u03b1-synuclein seems to be required for its targeting of proteasomal degradation and thus negatively regulates its autophagic degradation.", [["\u03b1-synuclein", "CHEMICAL", 23, 34], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 23, 34], ["\u03b1-synuclein", "PROTEIN", 23, 34], ["\u03b1-synuclein", "TREATMENT", 23, 34], ["proteasomal degradation", "PROBLEM", 77, 100], ["autophagic degradation", "OBSERVATION", 135, 157]]], ["USP9X interacts with \u03b1-synuclein in vitro and in vivo and contributes to the removal of mono-ubiquitin moieties and favors its targeting for degradation by autophagy rather than the proteasome [87] .", [["mono-ubiquitin", "CHEMICAL", 88, 102], ["USP9X", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 21, 32], ["mono-ubiquitin moieties", "SIMPLE_CHEMICAL", 88, 111], ["USP9X", "PROTEIN", 0, 5], ["\u03b1-synuclein", "PROTEIN", 21, 32], ["mono-ubiquitin moieties", "PROTEIN", 88, 111], ["proteasome", "PROTEIN", 182, 192], ["\u03b1-synuclein in vitro", "TREATMENT", 21, 41], ["the removal of mono-ubiquitin moieties", "TREATMENT", 73, 111]]], ["Conversely, UCH-L1-a DUB associated with Parkinson's disease and whose gene is frequently mutated in familial forms of the pathology [88] -promotes the accumulation of \u03b1-synuclein aggregates in oligodendrocytes [89, 90] .", [["oligodendrocytes", "ANATOMY", 194, 210], ["Parkinson's disease", "DISEASE", 41, 60], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 12, 18], ["DUB", "GENE_OR_GENE_PRODUCT", 21, 24], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 168, 179], ["oligodendrocytes", "CELL", 194, 210], ["UCH", "PROTEIN", 12, 15], ["L1", "PROTEIN", 16, 18], ["DUB", "PROTEIN", 21, 24], ["\u03b1-synuclein", "PROTEIN", 168, 179], ["oligodendrocytes", "CELL_TYPE", 194, 210], ["a DUB", "PROBLEM", 19, 24], ["Parkinson's disease", "PROBLEM", 41, 60], ["the pathology", "TEST", 119, 132], ["\u03b1-synuclein aggregates", "PROBLEM", 168, 190], ["L1", "ANATOMY", 16, 18]]], ["Another independent study also reported that membrane-associated UCH-L1 contributes to \u03b1-synuclein neurotoxicity, possibly by negatively regulating its lysosomal degradation [91] ( Figure 3D ).", [["membrane", "ANATOMY", 45, 53], ["lysosomal", "ANATOMY", 152, 161], ["neurotoxicity", "DISEASE", 99, 112], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 65, 71], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 87, 98], ["lysosomal", "CELLULAR_COMPONENT", 152, 161], ["UCH", "PROTEIN", 65, 68], ["L1", "PROTEIN", 69, 71], ["Another independent study", "TEST", 0, 25], ["\u03b1-synuclein neurotoxicity", "PROBLEM", 87, 112], ["L1", "ANATOMY", 69, 71]]], ["Finally, a recent study demonstrates the prevalence of K63-linked ubiquitin chain conjugates in Lewy bodies, suggesting that their elimination can be primarily ensured by the lysosomal route rather than the 26S proteasome.", [["lysosomal", "ANATOMY", 175, 184], ["K63", "SIMPLE_CHEMICAL", 55, 58], ["ubiquitin chain conjugates", "SIMPLE_CHEMICAL", 66, 92], ["Lewy bodies", "SIMPLE_CHEMICAL", 96, 107], ["26S", "GENE_OR_GENE_PRODUCT", 207, 210], ["K63", "PROTEIN", 55, 58], ["26S proteasome", "PROTEIN", 207, 221], ["a recent study", "TEST", 9, 23], ["K63", "TEST", 55, 58], ["the 26S proteasome", "TREATMENT", 203, 221], ["ubiquitin chain conjugates", "OBSERVATION", 66, 92], ["Lewy bodies", "OBSERVATION", 96, 107]]], ["In addition, this study identifies USP8 as one of the best markers of Lewy bodies in human pigmented neurons in sporadic cases of Parkinson's disease and demonstrates the ability of USP8 to hydrolyze K63-linked ubiquitin chains from \u03b1-synuclein in vitro [92] .", [["Lewy bodies", "ANATOMY", 70, 81], ["pigmented neurons", "ANATOMY", 91, 108], ["Parkinson's disease", "DISEASE", 130, 149], ["USP8", "GENE_OR_GENE_PRODUCT", 35, 39], ["human", "ORGANISM", 85, 90], ["pigmented neurons", "CELL", 91, 108], ["USP8", "GENE_OR_GENE_PRODUCT", 182, 186], ["K63", "SIMPLE_CHEMICAL", 200, 203], ["\u03b1-synuclein", "SIMPLE_CHEMICAL", 233, 244], ["USP8", "PROTEIN", 35, 39], ["human pigmented neurons", "CELL_TYPE", 85, 108], ["USP8", "PROTEIN", 182, 186], ["K63", "PROTEIN", 200, 203], ["ubiquitin chains", "PROTEIN", 211, 227], ["\u03b1-synuclein", "PROTEIN", 233, 244], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["this study", "TEST", 13, 23], ["Lewy bodies", "PROBLEM", 70, 81], ["Parkinson's disease", "PROBLEM", 130, 149], ["hydrolyze K63", "TREATMENT", 190, 203], ["ubiquitin chains", "TREATMENT", 211, 227], ["\u03b1-synuclein in vitro", "TREATMENT", 233, 253], ["Lewy bodies", "OBSERVATION", 70, 81], ["human pigmented", "OBSERVATION_MODIFIER", 85, 100], ["neurons", "ANATOMY", 101, 108], ["Parkinson's disease", "OBSERVATION", 130, 149]]], ["Moreover, Usp8 gene extinction significantly reduces the total level of \u03b1-synuclein both in a Drosophila model of Parkinson's disease and in human embryonic kidney (HEK293T) cultured cells [92] .", [["embryonic kidney", "ANATOMY", 147, 163], ["HEK293T", "ANATOMY", 165, 172], ["cells", "ANATOMY", 183, 188], ["Parkinson's disease", "DISEASE", 114, 133], ["Usp8", "GENE_OR_GENE_PRODUCT", 10, 14], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 72, 83], ["human", "ORGANISM", 141, 146], ["embryonic kidney", "CELL", 147, 163], ["HEK293T", "CELL", 165, 172], ["cells", "CELL", 183, 188], ["Usp8 gene", "DNA", 10, 19], ["\u03b1-synuclein", "PROTEIN", 72, 83], ["human embryonic kidney (HEK293T) cultured cells", "CELL_LINE", 141, 188], ["Drosophila", "SPECIES", 94, 104], ["human", "SPECIES", 141, 146], ["Drosophila", "SPECIES", 94, 104], ["human", "SPECIES", 141, 146], ["Usp8 gene extinction", "PROBLEM", 10, 30], ["\u03b1-synuclein", "TREATMENT", 72, 83], ["Parkinson's disease", "PROBLEM", 114, 133], ["cultured cells", "TEST", 174, 188], ["Parkinson's disease", "OBSERVATION", 114, 133], ["kidney", "ANATOMY", 157, 163]]], ["Thus, the presence of USP8 on endosomal membranes (see below) and in Lewy bodies, as well as its ability to deubiquitinate \u03b1-synuclein, makes it a preferred therapeutic target according to the assumption that inhibition of USP8 could directly promote the elimination of amyloid fibers by the endocytic and lysosomal pathways.AggrephagyIt was recently shown that the selective autophagy receptor p62 binds to protein aggregates modified not only with K63-linked ubiquitin chains but also with K33-linked ubiquitin chains [93, 94] .", [["endosomal membranes", "ANATOMY", 30, 49], ["amyloid fibers", "ANATOMY", 270, 284], ["lysosomal", "ANATOMY", 306, 315], ["USP8", "GENE_OR_GENE_PRODUCT", 22, 26], ["endosomal membranes", "CELLULAR_COMPONENT", 30, 49], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 123, 134], ["USP8", "GENE_OR_GENE_PRODUCT", 223, 227], ["amyloid fibers", "CELLULAR_COMPONENT", 270, 284], ["lysosomal", "CELLULAR_COMPONENT", 306, 315], ["p62", "GENE_OR_GENE_PRODUCT", 395, 398], ["K63", "SIMPLE_CHEMICAL", 450, 453], ["K33", "SIMPLE_CHEMICAL", 492, 495], ["USP8", "PROTEIN", 22, 26], ["\u03b1-synuclein", "PROTEIN", 123, 134], ["USP8", "PROTEIN", 223, 227], ["autophagy receptor", "PROTEIN", 376, 394], ["p62", "PROTEIN", 395, 398], ["K63", "PROTEIN", 450, 453], ["ubiquitin chains", "PROTEIN", 461, 477], ["K33", "PROTEIN", 492, 495], ["ubiquitin chains", "PROTEIN", 503, 519], ["USP8 on endosomal membranes", "PROBLEM", 22, 49], ["USP8", "TREATMENT", 223, 227], ["amyloid fibers", "PROBLEM", 270, 284], ["Aggrephagy", "TREATMENT", 325, 335], ["the selective autophagy receptor p62", "TREATMENT", 362, 398], ["protein aggregates", "TEST", 408, 426], ["K63", "TEST", 450, 453], ["K33", "TEST", 492, 495], ["endosomal membranes", "OBSERVATION", 30, 49], ["Lewy bodies", "OBSERVATION", 69, 80], ["ubiquitin chains", "OBSERVATION", 461, 477]]], ["ZRANB1/TRABID is a K29-and K33-specific DUB [95] .", [["ZRANB1", "GENE_OR_GENE_PRODUCT", 0, 6], ["TRABID", "GENE_OR_GENE_PRODUCT", 7, 13], ["K29", "GENE_OR_GENE_PRODUCT", 19, 22], ["K33", "GENE_OR_GENE_PRODUCT", 27, 30], ["DUB", "GENE_OR_GENE_PRODUCT", 40, 43], ["ZRANB1", "PROTEIN", 0, 6], ["TRABID", "PROTEIN", 7, 13], ["K29", "PROTEIN", 19, 22], ["K33", "PROTEIN", 27, 30], ["DUB", "PROTEIN", 40, 43]]], ["Knockdown of ZRANB1 enhances the recruitment of p62 to K33-associated protein aggregates, suggesting that ZRANB1 is a negative regulator of aggrephagy; yet, the physiological function of K33-linked ubiquitin chains and the role of ZRANB1 are not entirely understood [94] .AggrephagyIn Drosophila, the p62 homolog Ref (2)P is also implicated in the clearance of ubiquitinated protein aggregates [96, 97] .", [["ZRANB1", "GENE_OR_GENE_PRODUCT", 13, 19], ["p62", "GENE_OR_GENE_PRODUCT", 48, 51], ["K33", "GENE_OR_GENE_PRODUCT", 55, 58], ["ZRANB1", "GENE_OR_GENE_PRODUCT", 106, 112], ["K33-linked ubiquitin chains", "GENE_OR_GENE_PRODUCT", 187, 214], ["ZRANB1", "GENE_OR_GENE_PRODUCT", 231, 237], ["AggrephagyIn Drosophila", "ORGANISM", 272, 295], ["p62", "GENE_OR_GENE_PRODUCT", 301, 304], ["Ref (2)P", "GENE_OR_GENE_PRODUCT", 313, 321], ["ZRANB1", "PROTEIN", 13, 19], ["p62", "PROTEIN", 48, 51], ["K33", "PROTEIN", 55, 58], ["ZRANB1", "PROTEIN", 106, 112], ["K33", "PROTEIN", 187, 190], ["ubiquitin chains", "PROTEIN", 198, 214], ["ZRANB1", "PROTEIN", 231, 237], ["p62 homolog Ref (2)P", "PROTEIN", 301, 321], ["Drosophila", "SPECIES", 285, 295], ["Drosophila", "SPECIES", 285, 295], ["K33", "TEST", 55, 58], ["protein aggregates", "PROBLEM", 70, 88], ["ZRANB1", "TREATMENT", 231, 237], ["ubiquitinated protein aggregates", "TEST", 361, 393], ["recruitment", "OBSERVATION_MODIFIER", 33, 44]]], ["However, little is known about the regulation of autophagy-associated ubiquitination processes in flies.", [["ubiquitination processes", "OBSERVATION", 70, 94]]], ["The only DUB known to regulate ubiquitin-dependent autophagy negatively is dUSP36 [98] .", [["DUB", "GENE_OR_GENE_PRODUCT", 9, 12], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 31, 40], ["DUB", "PROTEIN", 9, 12], ["ubiquitin", "PROTEIN", 31, 40], ["dependent autophagy", "PROBLEM", 41, 60], ["DUB", "OBSERVATION", 9, 12]]], ["This protein negatively regulates the formation of ubiquitinated nuclear aggregates, while promoting cell growth.", [["nuclear aggregates", "ANATOMY", 65, 83], ["cell", "ANATOMY", 101, 105], ["nuclear", "CELLULAR_COMPONENT", 65, 72], ["cell", "CELL", 101, 105], ["This protein", "TEST", 0, 12], ["ubiquitinated nuclear aggregates", "PROBLEM", 51, 83], ["ubiquitinated", "OBSERVATION_MODIFIER", 51, 64], ["nuclear aggregates", "OBSERVATION", 65, 83], ["cell growth", "OBSERVATION", 101, 112]]], ["Indeed, deletion of the dUSP36 encoding gene results in the robust accumulation of ubiquitinated protein aggregates, which include the histone protein H2B, and in the activation of autophagy, independently of the TOR pathway [98] (Figure 3D ).AggrephagyProtein aggregates clearance requires the action of selective receptors to be adequately targeted for autophagic degradation [3] .", [["autophagic", "ANATOMY", 355, 365], ["dUSP36", "GENE_OR_GENE_PRODUCT", 24, 30], ["histone protein H2B", "GENE_OR_GENE_PRODUCT", 135, 154], ["TOR", "GENE_OR_GENE_PRODUCT", 213, 216], ["AggrephagyProtein", "GENE_OR_GENE_PRODUCT", 243, 260], ["dUSP36 encoding gene", "DNA", 24, 44], ["ubiquitinated protein aggregates", "PROTEIN", 83, 115], ["histone protein H2B", "PROTEIN", 135, 154], ["TOR", "PROTEIN", 213, 216], ["selective receptors", "PROTEIN", 305, 324], ["ubiquitinated protein aggregates", "PROBLEM", 83, 115], ["the histone protein H2B", "TREATMENT", 131, 154], ["AggrephagyProtein aggregates clearance", "PROBLEM", 243, 281], ["selective receptors", "TREATMENT", 305, 324], ["autophagic degradation", "PROBLEM", 355, 377], ["ubiquitinated protein aggregates", "OBSERVATION", 83, 115]]], ["NDP52 is an autophagy receptor mostly described for its role in addressing ubiquitin-decorated bacteria for degradation by autophagy [99, 100] .", [["NDP52", "GENE_OR_GENE_PRODUCT", 0, 5], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 75, 84], ["NDP52", "PROTEIN", 0, 5], ["autophagy receptor", "PROTEIN", 12, 30], ["ubiquitin", "PROTEIN", 75, 84], ["an autophagy receptor", "PROBLEM", 9, 30], ["decorated bacteria", "PROBLEM", 85, 103], ["autophagy", "TEST", 123, 132]]], ["However, a new role for NDP52 in the formation of TRAF6 aggregates was unveiled [101] .", [["NDP52", "CHEMICAL", 24, 29], ["NDP52", "GENE_OR_GENE_PRODUCT", 24, 29], ["TRAF6", "GENE_OR_GENE_PRODUCT", 50, 55], ["NDP52", "PROTEIN", 24, 29], ["TRAF6", "PROTEIN", 50, 55], ["NDP52", "TREATMENT", 24, 29], ["new", "OBSERVATION_MODIFIER", 11, 14]]], ["Indeed, NDP52 mediates the aggregation and selective autophagic degradation of the TLR adaptor molecule TRIF and the signaling molecule TRAF6 in response to TLR4 stimulation.", [["NDP52", "CHEMICAL", 8, 13], ["NDP52", "GENE_OR_GENE_PRODUCT", 8, 13], ["TLR", "GENE_OR_GENE_PRODUCT", 83, 86], ["TRIF", "GENE_OR_GENE_PRODUCT", 104, 108], ["TRAF6", "GENE_OR_GENE_PRODUCT", 136, 141], ["TLR4", "GENE_OR_GENE_PRODUCT", 157, 161], ["NDP52", "PROTEIN", 8, 13], ["TLR adaptor molecule", "PROTEIN", 83, 103], ["TRIF", "PROTEIN", 104, 108], ["signaling molecule", "PROTEIN", 117, 135], ["TRAF6", "PROTEIN", 136, 141], ["TLR4", "PROTEIN", 157, 161], ["the aggregation", "PROBLEM", 23, 38], ["selective autophagic degradation", "TREATMENT", 43, 75], ["the TLR adaptor molecule TRIF", "TREATMENT", 79, 108], ["the signaling molecule TRAF6", "TREATMENT", 113, 141], ["TLR4 stimulation", "TREATMENT", 157, 173], ["selective", "OBSERVATION_MODIFIER", 43, 52], ["autophagic degradation", "OBSERVATION", 53, 75], ["molecule TRAF6", "OBSERVATION", 127, 141], ["TLR4 stimulation", "OBSERVATION", 157, 173]]], ["Ubiquitination of NDP52, mediated by TRAF6, is necessary for its activity and is counteracted by A20 [101] ( Figure 3D ).AggrephagyWith the variety of proteins prone to aggregations, it is not surprising that different DUBs are involved in the regulation of the formation and degradation of protein aggregates.", [["NDP52", "GENE_OR_GENE_PRODUCT", 18, 23], ["TRAF6", "GENE_OR_GENE_PRODUCT", 37, 42], ["A20", "GENE_OR_GENE_PRODUCT", 97, 100], ["DUBs", "GENE_OR_GENE_PRODUCT", 219, 223], ["NDP52", "PROTEIN", 18, 23], ["TRAF6", "PROTEIN", 37, 42], ["A20", "PROTEIN", 97, 100], ["DUBs", "PROTEIN", 219, 223], ["protein aggregates", "PROBLEM", 291, 309]]], ["Protein aggregation is a hallmark of various pathologies, notably neurodegeneration and infection, and a better understanding of the regulatory mechanisms associated with each pathology will greatly benefit the development of appropriate and targeted treatments.MitophagyMitophagy refers to the clearance of exhausted mitochondria by autophagy.", [["mitochondria", "ANATOMY", 318, 330], ["Protein aggregation", "DISEASE", 0, 19], ["neurodegeneration", "DISEASE", 66, 83], ["infection", "DISEASE", 88, 97], ["mitochondria", "CELLULAR_COMPONENT", 318, 330], ["Protein aggregation", "PROBLEM", 0, 19], ["various pathologies", "PROBLEM", 37, 56], ["neurodegeneration", "PROBLEM", 66, 83], ["infection", "PROBLEM", 88, 97], ["targeted treatments", "TREATMENT", 242, 261], ["MitophagyMitophagy", "PROBLEM", 262, 280], ["exhausted mitochondria", "PROBLEM", 308, 330], ["aggregation", "OBSERVATION", 8, 19], ["various", "OBSERVATION_MODIFIER", 37, 44], ["pathologies", "OBSERVATION", 45, 56], ["neurodegeneration", "OBSERVATION", 66, 83], ["infection", "OBSERVATION", 88, 97]]], ["The mitochondrial kinase Pink1 and the E3-ubiquitin ligase Parkin play a central role in the mitochondrial quality control.", [["mitochondrial", "ANATOMY", 4, 17], ["mitochondrial", "ANATOMY", 93, 106], ["mitochondrial", "CELLULAR_COMPONENT", 4, 17], ["Pink1", "GENE_OR_GENE_PRODUCT", 25, 30], ["E3", "GENE_OR_GENE_PRODUCT", 39, 41], ["Parkin", "GENE_OR_GENE_PRODUCT", 59, 65], ["mitochondrial", "CELLULAR_COMPONENT", 93, 106], ["mitochondrial kinase", "PROTEIN", 4, 24], ["Pink1", "PROTEIN", 25, 30], ["E3", "PROTEIN", 39, 41], ["ubiquitin ligase", "PROTEIN", 42, 58], ["Parkin", "PROTEIN", 59, 65], ["The mitochondrial kinase Pink1", "TEST", 0, 30], ["the E3-ubiquitin ligase Parkin", "TREATMENT", 35, 65], ["the mitochondrial quality control", "TREATMENT", 89, 122], ["mitochondrial", "OBSERVATION", 4, 17], ["kinase Pink1", "OBSERVATION", 18, 30], ["ligase Parkin", "OBSERVATION", 52, 65], ["central", "OBSERVATION_MODIFIER", 73, 80], ["mitochondrial quality", "OBSERVATION", 93, 114]]], ["Upon mitochondria damage and loss of membrane potential, Parkin is translocated to the outer mitochondrial membrane (OMM) and activated by stabilized Pink1 [102] .", [["mitochondria", "ANATOMY", 5, 17], ["membrane", "ANATOMY", 37, 45], ["outer mitochondrial membrane", "ANATOMY", 87, 115], ["OMM", "ANATOMY", 117, 120], ["mitochondria", "CELLULAR_COMPONENT", 5, 17], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["Parkin", "GENE_OR_GENE_PRODUCT", 57, 63], ["outer", "CELLULAR_COMPONENT", 87, 92], ["mitochondrial membrane", "CELLULAR_COMPONENT", 93, 115], ["OMM", "CELLULAR_COMPONENT", 117, 120], ["Parkin", "PROTEIN", 57, 63], ["Pink1", "PROTEIN", 150, 155], ["mitochondria damage", "PROBLEM", 5, 24], ["loss of membrane potential", "PROBLEM", 29, 55], ["mitochondria damage", "OBSERVATION", 5, 24], ["loss", "OBSERVATION_MODIFIER", 29, 33], ["membrane potential", "OBSERVATION_MODIFIER", 37, 55], ["outer", "ANATOMY_MODIFIER", 87, 92], ["mitochondrial membrane", "ANATOMY", 93, 115]]], ["Active Parkin ubiquitinates a myriad of substrates on the OMM that can be recognized by ubiquitin-binding selective autophagy receptors [103, 104] .", [["Parkin", "GENE_OR_GENE_PRODUCT", 7, 13], ["OMM", "CELLULAR_COMPONENT", 58, 61], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 88, 97], ["Parkin", "PROTEIN", 7, 13], ["ubiquitin-binding selective autophagy receptors", "PROTEIN", 88, 135], ["Parkin", "OBSERVATION", 7, 13]]], ["So far, three DUBs-USP30, s-USP35, and USP15-have been reported to counteract Parkin activity following acute mitochondrial depolarization, thus acting as a negative regulator of mitophagy.", [["mitochondrial", "ANATOMY", 110, 123], ["DUBs", "GENE_OR_GENE_PRODUCT", 14, 18], ["USP30", "GENE_OR_GENE_PRODUCT", 19, 24], ["s-", "GENE_OR_GENE_PRODUCT", 26, 28], ["USP35", "GENE_OR_GENE_PRODUCT", 28, 33], ["USP15", "GENE_OR_GENE_PRODUCT", 39, 44], ["Parkin", "GENE_OR_GENE_PRODUCT", 78, 84], ["mitochondrial", "CELLULAR_COMPONENT", 110, 123], ["DUBs", "PROTEIN", 14, 18], ["USP30", "PROTEIN", 19, 24], ["USP35", "PROTEIN", 28, 33], ["USP15", "PROTEIN", 39, 44], ["Parkin", "PROTEIN", 78, 84], ["s-USP35", "TEST", 26, 33], ["USP15", "TEST", 39, 44], ["acute mitochondrial depolarization", "PROBLEM", 104, 138], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["mitochondrial depolarization", "OBSERVATION", 110, 138]]], ["USP8 is the only DUB identified so far as a positive regulator of mitophagy ( Figure 3E ).MitophagyUSP30 is a mitochondrial enzyme, tethered to the outer membrane of the mitochondria with its catalytic domain facing the cytoplasm [105] .", [["mitochondrial", "ANATOMY", 110, 123], ["outer membrane", "ANATOMY", 148, 162], ["mitochondria", "ANATOMY", 170, 182], ["cytoplasm", "ANATOMY", 220, 229], ["MitophagyUSP30", "CHEMICAL", 90, 104], ["USP8", "GENE_OR_GENE_PRODUCT", 0, 4], ["DUB", "GENE_OR_GENE_PRODUCT", 17, 20], ["MitophagyUSP30", "GENE_OR_GENE_PRODUCT", 90, 104], ["mitochondrial", "CELLULAR_COMPONENT", 110, 123], ["outer membrane", "CELLULAR_COMPONENT", 148, 162], ["mitochondria", "CELLULAR_COMPONENT", 170, 182], ["cytoplasm", "ORGANISM_SUBSTANCE", 220, 229], ["USP8", "PROTEIN", 0, 4], ["DUB", "PROTEIN", 17, 20], ["MitophagyUSP30", "PROTEIN", 90, 104], ["mitochondrial enzyme", "PROTEIN", 110, 130], ["catalytic domain", "PROTEIN", 192, 208], ["a mitochondrial enzyme", "TEST", 108, 130], ["DUB", "OBSERVATION", 17, 20]]], ["Several independent studies point out that USP30 is one of the major DUB regulating mitophagy.", [["USP30", "GENE_OR_GENE_PRODUCT", 43, 48], ["DUB", "GENE_OR_GENE_PRODUCT", 69, 72], ["USP30", "PROTEIN", 43, 48], ["DUB", "PROTEIN", 69, 72], ["Several independent studies", "TEST", 0, 27]]], ["Overexpression of USP30 reverses the ubiquitination of Parkin substrates, such as TOM20, and impairs mitophagy [106] [107] [108] [109] .", [["USP30", "CHEMICAL", 18, 23], ["USP30", "GENE_OR_GENE_PRODUCT", 18, 23], ["Parkin", "GENE_OR_GENE_PRODUCT", 55, 61], ["TOM20", "GENE_OR_GENE_PRODUCT", 82, 87], ["USP30", "PROTEIN", 18, 23], ["Parkin substrates", "PROTEIN", 55, 72], ["TOM20", "PROTEIN", 82, 87], ["Parkin substrates", "PROBLEM", 55, 72]]], ["USP30 function in autophagy is dependent on its catalytic activity as a catalytically inactive mutant USP30-C77A is ineffective at inhibiting mitophagy [106] .", [["USP30", "GENE_OR_GENE_PRODUCT", 0, 5], ["USP30", "GENE_OR_GENE_PRODUCT", 102, 107], ["USP30", "PROTEIN", 0, 5], ["USP30", "PROTEIN", 102, 107], ["C77A", "PROTEIN", 108, 112], ["dependent", "OBSERVATION_MODIFIER", 31, 40]]], ["The depletion of USP30 was shown to enhance the degradation of mitochondria in neuronal and HeLa cell cultures [106, 109] .", [["mitochondria", "ANATOMY", 63, 75], ["neuronal", "ANATOMY", 79, 87], ["HeLa cell cultures", "ANATOMY", 92, 110], ["USP30", "CHEMICAL", 17, 22], ["USP30", "GENE_OR_GENE_PRODUCT", 17, 22], ["mitochondria", "CELLULAR_COMPONENT", 63, 75], ["neuronal", "CELL", 79, 87], ["HeLa cell cultures", "CELL", 92, 110], ["USP30", "PROTEIN", 17, 22], ["neuronal and HeLa cell cultures", "CELL_LINE", 79, 110], ["The depletion of USP30", "PROBLEM", 0, 22], ["the degradation of mitochondria", "PROBLEM", 44, 75], ["HeLa cell cultures", "TEST", 92, 110]]], ["USP30 knockdown also increases the ubiquitination level on multiple Parkin substrates, thus confirming that USP30 antagonizes Parkin function.", [["USP30", "CHEMICAL", 0, 5], ["USP30", "GENE_OR_GENE_PRODUCT", 0, 5], ["Parkin", "GENE_OR_GENE_PRODUCT", 68, 74], ["USP30", "GENE_OR_GENE_PRODUCT", 108, 113], ["Parkin", "GENE_OR_GENE_PRODUCT", 126, 132], ["USP30", "PROTEIN", 0, 5], ["Parkin substrates", "PROTEIN", 68, 85], ["USP30", "PROTEIN", 108, 113], ["Parkin", "PROTEIN", 126, 132], ["the ubiquitination level", "PROBLEM", 31, 55], ["multiple Parkin substrates", "TREATMENT", 59, 85], ["increases", "OBSERVATION_MODIFIER", 21, 30], ["ubiquitination", "OBSERVATION_MODIFIER", 35, 49]]], ["USP30 proteolytic activity is more efficient on K6-linked ubiquitin chains, even though it can also process K11, K48 and K63 chains [108, 110] .", [["USP30", "GENE_OR_GENE_PRODUCT", 0, 5], ["K6-linked ubiquitin chains", "GENE_OR_GENE_PRODUCT", 48, 74], ["K11", "GENE_OR_GENE_PRODUCT", 108, 111], ["K48", "GENE_OR_GENE_PRODUCT", 113, 116], ["USP30", "PROTEIN", 0, 5], ["K6", "PROTEIN", 48, 50], ["ubiquitin chains", "PROTEIN", 58, 74], ["K11", "PROTEIN", 108, 111], ["K48", "PROTEIN", 113, 116], ["K63 chains", "PROTEIN", 121, 131], ["K11", "TEST", 108, 111], ["K48", "TEST", 113, 116]]], ["The ubiquitin chains targeted by USP30 are similar to the ones Parkin adds to its substrates, suggesting that these two enzymes act as antagonists on shared substrates.", [["USP30", "GENE_OR_GENE_PRODUCT", 33, 38], ["Parkin", "GENE_OR_GENE_PRODUCT", 63, 69], ["ubiquitin chains", "PROTEIN", 4, 20], ["USP30", "PROTEIN", 33, 38], ["Parkin", "PROTEIN", 63, 69], ["The ubiquitin chains", "TREATMENT", 0, 20], ["these two enzymes", "TEST", 110, 127], ["ubiquitin chains", "OBSERVATION", 4, 20]]], ["The majority of the work carried out on the regulation of mitophagy have relied on cells overexpressing Parkin along with the use of mitochondrial-depolarizing agents.", [["cells", "ANATOMY", 83, 88], ["mitochondrial", "ANATOMY", 133, 146], ["cells", "CELL", 83, 88], ["Parkin", "GENE_OR_GENE_PRODUCT", 104, 110], ["mitochondrial", "CELLULAR_COMPONENT", 133, 146], ["Parkin", "PROTEIN", 104, 110], ["mitophagy", "TREATMENT", 58, 67], ["cells overexpressing Parkin", "PROBLEM", 83, 110], ["mitochondrial-depolarizing agents", "TREATMENT", 133, 166]]], ["Such experiments simulate an extreme scenario of mitochondrial stress and interpretations may not be relevant to basal conditions of mitochondrial clearance [111] .", [["mitochondrial", "ANATOMY", 49, 62], ["mitochondrial", "ANATOMY", 133, 146], ["mitochondrial", "CELLULAR_COMPONENT", 49, 62], ["mitochondrial", "CELLULAR_COMPONENT", 133, 146], ["mitochondrial stress", "PROBLEM", 49, 69], ["mitochondrial clearance", "TEST", 133, 156], ["mitochondrial stress", "OBSERVATION", 49, 69]]], ["However, recently published work by Marcassa and colleagues describes the investigation into the role of USP30 in more physiological conditions [112] .", [["USP30", "CHEMICAL", 105, 110], ["USP30", "GENE_OR_GENE_PRODUCT", 105, 110], ["USP30", "PROTEIN", 105, 110]]], ["The authors propose a new model in which USP30 acts upstream Pink1 as the depletion of Pink1 in cells lacking USP30 abrogated the increased mitophagy induced by USP30 knockdown in U2OS cells [112] .", [["cells", "ANATOMY", 96, 101], ["U2OS cells", "ANATOMY", 180, 190], ["USP30", "CHEMICAL", 161, 166], ["USP30", "GENE_OR_GENE_PRODUCT", 41, 46], ["Pink1", "GENE_OR_GENE_PRODUCT", 61, 66], ["Pink1", "GENE_OR_GENE_PRODUCT", 87, 92], ["cells", "CELL", 96, 101], ["USP30", "GENE_OR_GENE_PRODUCT", 110, 115], ["USP30", "GENE_OR_GENE_PRODUCT", 161, 166], ["U2OS cells", "CELL", 180, 190], ["USP30", "PROTEIN", 41, 46], ["Pink1", "PROTEIN", 61, 66], ["Pink1", "PROTEIN", 87, 92], ["USP30", "PROTEIN", 110, 115], ["USP30", "PROTEIN", 161, 166], ["U2OS cells", "CELL_LINE", 180, 190], ["a new model", "TREATMENT", 20, 31], ["Pink1 in cells", "PROBLEM", 87, 101], ["the increased mitophagy", "PROBLEM", 126, 149], ["U2OS cells", "TEST", 180, 190], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["mitophagy", "OBSERVATION", 140, 149]]], ["In the same study, USP30 is revealed to regulate the degradation of peroxisome by autophagy (pexophagy) in a similar way to its role in mitophagy.", [["peroxisome", "ANATOMY", 68, 78], ["USP30", "CHEMICAL", 19, 24], ["USP30", "GENE_OR_GENE_PRODUCT", 19, 24], ["peroxisome", "CELLULAR_COMPONENT", 68, 78], ["USP30", "PROTEIN", 19, 24], ["the same study", "TEST", 3, 17]]], ["Like mitochondria, peroxisomes are the main source of reactive oxygen species (ROS) that can be damaging to the cells if produced in high quantities [113] .", [["mitochondria", "ANATOMY", 5, 17], ["peroxisomes", "ANATOMY", 19, 30], ["cells", "ANATOMY", 112, 117], ["oxygen", "CHEMICAL", 63, 69], ["ROS", "CHEMICAL", 79, 82], ["oxygen", "CHEMICAL", 63, 69], ["mitochondria", "CELLULAR_COMPONENT", 5, 17], ["peroxisomes", "CELLULAR_COMPONENT", 19, 30], ["reactive oxygen species", "SIMPLE_CHEMICAL", 54, 77], ["ROS", "SIMPLE_CHEMICAL", 79, 82], ["cells", "CELL", 112, 117], ["reactive oxygen species", "PROBLEM", 54, 77], ["main", "OBSERVATION_MODIFIER", 39, 43], ["reactive", "OBSERVATION_MODIFIER", 54, 62], ["oxygen species", "OBSERVATION", 63, 77]]], ["Moreover, contact sites between mitochondria and peroxisomes exist, and mitochondria were shown to play a role in the generation of peroxisomes [114] ; thus reinforcing the hypothesis of an intrinsic relationship between both organelles.", [["mitochondria", "ANATOMY", 32, 44], ["peroxisomes", "ANATOMY", 49, 60], ["mitochondria", "ANATOMY", 72, 84], ["peroxisomes", "ANATOMY", 132, 143], ["organelles", "ANATOMY", 226, 236], ["mitochondria", "CELLULAR_COMPONENT", 32, 44], ["peroxisomes", "CELLULAR_COMPONENT", 49, 60], ["mitochondria", "CELLULAR_COMPONENT", 72, 84], ["peroxisomes", "CELLULAR_COMPONENT", 132, 143], ["organelles", "CELLULAR_COMPONENT", 226, 236]]], ["The depletion of USP30 increases both pexophagy and mitophagy.", [["USP30", "CHEMICAL", 17, 22], ["USP30", "GENE_OR_GENE_PRODUCT", 17, 22], ["pexophagy", "GENE_OR_GENE_PRODUCT", 38, 47], ["USP30", "PROTEIN", 17, 22], ["The depletion of USP30", "TREATMENT", 0, 22], ["mitophagy", "PROBLEM", 52, 61], ["depletion", "OBSERVATION", 4, 13]]], ["However, the localization of USP30 on mitochondria and peroxisomes relies on distinct sequences, suggesting that the role of USP30 in pexophagy is independent to its mitochondrial function [112] .", [["mitochondria", "ANATOMY", 38, 50], ["peroxisomes", "ANATOMY", 55, 66], ["mitochondrial", "ANATOMY", 166, 179], ["USP30", "GENE_OR_GENE_PRODUCT", 29, 34], ["mitochondria", "CELLULAR_COMPONENT", 38, 50], ["peroxisomes", "CELLULAR_COMPONENT", 55, 66], ["USP30", "GENE_OR_GENE_PRODUCT", 125, 130], ["pexophagy", "GENE_OR_GENE_PRODUCT", 134, 143], ["mitochondrial", "CELLULAR_COMPONENT", 166, 179], ["USP30", "PROTEIN", 29, 34], ["USP30", "PROTEIN", 125, 130], ["distinct sequences", "TEST", 77, 95]]], ["It is possible that USP30 acts at different levels during the mitophagy or pexophagy processes depending on the conditions.", [["USP30", "CHEMICAL", 20, 25], ["USP30", "GENE_OR_GENE_PRODUCT", 20, 25], ["USP30", "PROTEIN", 20, 25], ["USP30 acts", "PROBLEM", 20, 30], ["the mitophagy", "TREATMENT", 58, 71], ["pexophagy processes", "PROBLEM", 75, 94]]], ["In basal condition, USP30 could serve as a safety check-point to avoid mitophagy or pexophagy to be triggered inappropriately.MitophagyBesides, other studies identified additional DUBs which may also contribute to the regulation of mitophagy.", [["USP30", "CHEMICAL", 20, 25], ["USP30", "SIMPLE_CHEMICAL", 20, 25], ["DUBs", "GENE_OR_GENE_PRODUCT", 180, 184], ["USP30", "PROTEIN", 20, 25], ["DUBs", "PROTEIN", 180, 184], ["a safety check", "TEST", 41, 55], ["mitophagy", "PROBLEM", 71, 80], ["pexophagy", "TREATMENT", 84, 93], ["other studies", "TEST", 144, 157], ["additional DUBs", "PROBLEM", 169, 184], ["mitophagy", "PROBLEM", 232, 241], ["basal", "ANATOMY_MODIFIER", 3, 8]]], ["USP35 short form (s-USP35) is another DUB that is localized at the mitochondria [109] .", [["mitochondria", "ANATOMY", 67, 79], ["USP35", "GENE_OR_GENE_PRODUCT", 0, 5], ["USP35", "GENE_OR_GENE_PRODUCT", 20, 25], ["DUB", "GENE_OR_GENE_PRODUCT", 38, 41], ["mitochondria", "CELLULAR_COMPONENT", 67, 79], ["USP35", "PROTEIN", 0, 5], ["USP35", "PROTEIN", 20, 25], ["DUB", "PROTEIN", 38, 41], ["another DUB", "PROBLEM", 30, 41], ["DUB", "OBSERVATION", 38, 41]]], ["In a similar manner to USP30, overexpression of s-USP35 impairs mitophagy while s-USP35 knockdown enhances mitochondrial degradation [109] .MitophagyUSP15 is the third DUB identified to antagonize Parkin-mediated mitophagy.", [["mitochondrial", "ANATOMY", 107, 120], ["s-", "CHEMICAL", 80, 82], ["USP30", "GENE_OR_GENE_PRODUCT", 23, 28], ["s-USP35", "GENE_OR_GENE_PRODUCT", 48, 55], ["s-USP35", "GENE_OR_GENE_PRODUCT", 80, 87], ["mitochondrial", "CELLULAR_COMPONENT", 107, 120], ["MitophagyUSP15", "GENE_OR_GENE_PRODUCT", 140, 154], ["DUB", "GENE_OR_GENE_PRODUCT", 168, 171], ["Parkin", "GENE_OR_GENE_PRODUCT", 197, 203], ["USP30", "PROTEIN", 23, 28], ["s-USP35", "PROTEIN", 48, 55], ["USP35", "PROTEIN", 82, 87], ["MitophagyUSP15", "PROTEIN", 140, 154], ["DUB", "PROTEIN", 168, 171], ["Parkin", "PROTEIN", 197, 203], ["mitophagy", "PROBLEM", 64, 73], ["mitochondrial degradation", "PROBLEM", 107, 132], ["the third DUB", "PROBLEM", 158, 171]]], ["Overexpression of USP15 inhibits mitophagy dependently of its catalytic activity, while depletion of USP15 enhances mitophagy.", [["USP15", "CHEMICAL", 18, 23], ["USP15", "GENE_OR_GENE_PRODUCT", 18, 23], ["USP15", "GENE_OR_GENE_PRODUCT", 101, 106], ["USP15", "PROTEIN", 18, 23], ["USP15", "PROTEIN", 101, 106], ["mitophagy dependently", "PROBLEM", 33, 54], ["mitophagy", "PROBLEM", 116, 125], ["dependently", "OBSERVATION_MODIFIER", 43, 54]]], ["Unlike USP30 and s-USP35, USP15 is only rarely localized at the mitochondria [115] .MitophagyOnly one DUB, USP8, may act as a positive regulator of mitophagy through Parkin regulation.", [["mitochondria", "ANATOMY", 64, 76], ["USP30", "GENE_OR_GENE_PRODUCT", 7, 12], ["s-USP35", "GENE_OR_GENE_PRODUCT", 17, 24], ["USP15", "GENE_OR_GENE_PRODUCT", 26, 31], ["mitochondria", "CELLULAR_COMPONENT", 64, 76], ["DUB", "GENE_OR_GENE_PRODUCT", 102, 105], ["USP8", "GENE_OR_GENE_PRODUCT", 107, 111], ["Parkin", "GENE_OR_GENE_PRODUCT", 166, 172], ["USP30", "PROTEIN", 7, 12], ["USP35", "PROTEIN", 19, 24], ["USP15", "PROTEIN", 26, 31], ["DUB", "PROTEIN", 102, 105], ["USP8", "PROTEIN", 107, 111], ["Parkin", "PROTEIN", 166, 172], ["DUB", "OBSERVATION", 102, 105]]], ["Usp8 knockdown impairs Parkin-mediated mitophagy by preventing Parkin recruitment of depolarized mitochondria.", [["mitochondria", "ANATOMY", 97, 109], ["Usp8", "GENE_OR_GENE_PRODUCT", 0, 4], ["Parkin", "GENE_OR_GENE_PRODUCT", 23, 29], ["Parkin", "GENE_OR_GENE_PRODUCT", 63, 69], ["mitochondria", "CELLULAR_COMPONENT", 97, 109], ["Usp8", "PROTEIN", 0, 4], ["Parkin", "PROTEIN", 23, 29], ["Parkin", "PROTEIN", 63, 69], ["Parkin-mediated mitophagy", "TREATMENT", 23, 48], ["depolarized mitochondria", "PROBLEM", 85, 109], ["Parkin recruitment", "OBSERVATION", 63, 81], ["depolarized mitochondria", "OBSERVATION", 85, 109]]], ["In this process, USP8 selectively removes K6-linked ubiquitin chains on Parkin and counteracts Parkin auto-ubiquitination and auto-catalytic activation [116] .MitophagyWhether and how these DUBs act in concert or within different organs or situations remains to be determined to fully understand their specific requirements in physiological or stressed conditions.Targeted Degradation of CargoesProteins can be degraded by autophagy independently of their aggregation in a way that can be either dependent or independent of their ubiquitination state.", [["organs", "ANATOMY", 230, 236], ["USP8", "CHEMICAL", 17, 21], ["USP8", "GENE_OR_GENE_PRODUCT", 17, 21], ["K6", "GENE_OR_GENE_PRODUCT", 42, 44], ["Parkin", "GENE_OR_GENE_PRODUCT", 72, 78], ["Parkin", "GENE_OR_GENE_PRODUCT", 95, 101], ["DUBs", "GENE_OR_GENE_PRODUCT", 190, 194], ["organs", "ORGAN", 230, 236], ["USP8", "PROTEIN", 17, 21], ["K6-linked ubiquitin chains", "PROTEIN", 42, 68], ["Parkin", "PROTEIN", 72, 78], ["Parkin", "PROTEIN", 95, 101], ["DUBs", "PROTEIN", 190, 194], ["auto-catalytic activation", "PROBLEM", 126, 151], ["ubiquitin chains", "OBSERVATION", 52, 68]]], ["To date, only a few substrates, known to be directly targeted for degradation by autophagy in response to ubiquitination, have been shown to be regulated by a specific DUB ( Figure 3F ).Targeted Degradation of CargoesThe Hypoxia-Inducible Factor 1, \u03b1 subunit (HIF-1\u03b1) is a transcription factor essential for cells to adapt rapidly to low oxygen levels (hypoxia).", [["cells", "ANATOMY", 308, 313], ["oxygen", "CHEMICAL", 338, 344], ["hypoxia", "DISEASE", 353, 360], ["oxygen", "CHEMICAL", 338, 344], ["DUB", "GENE_OR_GENE_PRODUCT", 168, 171], ["Figure 3F", "GENE_OR_GENE_PRODUCT", 174, 183], ["Hypoxia-Inducible Factor 1", "GENE_OR_GENE_PRODUCT", 221, 247], ["\u03b1 subunit", "GENE_OR_GENE_PRODUCT", 249, 258], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 260, 266], ["cells", "CELL", 308, 313], ["oxygen", "SIMPLE_CHEMICAL", 338, 344], ["DUB", "PROTEIN", 168, 171], ["Figure 3F", "PROTEIN", 174, 183], ["Hypoxia-Inducible Factor 1", "PROTEIN", 221, 247], ["\u03b1 subunit (HIF-1\u03b1", "PROTEIN", 249, 266], ["transcription factor", "PROTEIN", 273, 293], ["The Hypoxia", "PROBLEM", 217, 228], ["a transcription factor", "PROBLEM", 271, 293], ["cells", "PROBLEM", 308, 313], ["low oxygen levels", "PROBLEM", 334, 351], ["hypoxia", "PROBLEM", 353, 360]]], ["When oxygen is available, HIF-1\u03b1 is polyubiquitinated and rapidly degraded either by the proteasome or directly by the lysosome through chaperone-mediated autophagy [117, 118] .", [["lysosome", "ANATOMY", 119, 127], ["oxygen", "CHEMICAL", 5, 11], ["oxygen", "CHEMICAL", 5, 11], ["oxygen", "SIMPLE_CHEMICAL", 5, 11], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 26, 32], ["lysosome", "CELLULAR_COMPONENT", 119, 127], ["HIF-1\u03b1", "PROTEIN", 26, 32], ["proteasome", "PROTEIN", 89, 99], ["polyubiquitinated", "PROBLEM", 36, 53]]], ["The DUB Cezanne/OTUD7B is itself induced by oxygen deprivation in cultured endothelial cells.", [["endothelial cells", "ANATOMY", 75, 92], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["DUB", "GENE_OR_GENE_PRODUCT", 4, 7], ["OTUD7B", "GENE_OR_GENE_PRODUCT", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["endothelial cells", "CELL", 75, 92], ["DUB", "PROTEIN", 4, 7], ["OTUD7B", "PROTEIN", 16, 22], ["cultured endothelial cells", "CELL_LINE", 66, 92], ["The DUB Cezanne/OTUD7B", "TREATMENT", 0, 22], ["oxygen deprivation", "TREATMENT", 44, 62], ["oxygen deprivation", "OBSERVATION", 44, 62], ["endothelial cells", "OBSERVATION", 75, 92]]], ["Moreover, loss of Cezanne reduces the amount of HIF-1\u03b1 protein while Cezanne overexpression stabilizes HIF-1\u03b1 and protects it from autophagic degradation in a catalytic-dependent manner by specifically processing K11-linked ubiquitin chains [119] .", [["Cezanne", "CHEMICAL", 18, 25], ["Cezanne", "GENE_OR_GENE_PRODUCT", 18, 25], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 48, 54], ["Cezanne", "GENE_OR_GENE_PRODUCT", 69, 76], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 103, 109], ["K11", "GENE_OR_GENE_PRODUCT", 213, 216], ["HIF-1\u03b1 protein", "PROTEIN", 48, 62], ["HIF-1\u03b1", "PROTEIN", 103, 109], ["K11", "PROTEIN", 213, 216], ["ubiquitin chains", "PROTEIN", 224, 240], ["loss of Cezanne", "PROBLEM", 10, 25], ["HIF", "TEST", 48, 51], ["autophagic degradation", "PROBLEM", 131, 153], ["K11", "TEST", 213, 216], ["autophagic degradation", "OBSERVATION", 131, 153]]], ["Mutation of the CMA-targeting motif (KFERQ motif) of HIF-1\u03b1 makes it insensitive to Cezanne knockdown, thus suggesting that Cezanne specifically regulates the degradation of HIF-1\u03b1 mediated by CMA.", [["Cezanne", "CHEMICAL", 124, 131], ["CMA", "CHEMICAL", 193, 196], ["CMA", "GENE_OR_GENE_PRODUCT", 16, 19], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 53, 59], ["Cezanne", "GENE_OR_GENE_PRODUCT", 84, 91], ["Cezanne", "ORGANISM", 124, 131], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 174, 180], ["CMA", "SIMPLE_CHEMICAL", 193, 196], ["CMA-targeting motif", "DNA", 16, 35], ["KFERQ motif", "DNA", 37, 48], ["HIF-1\u03b1", "PROTEIN", 53, 59], ["HIF-1\u03b1", "PROTEIN", 174, 180], ["Mutation of the CMA", "PROBLEM", 0, 19], ["motif (KFERQ motif", "TREATMENT", 30, 48]]], ["Cezanne is not the only DUB to regulate the ubiquitination status of HIF-1\u03b1.", [["Cezanne", "ORGANISM", 0, 7], ["DUB", "GENE_OR_GENE_PRODUCT", 24, 27], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 69, 75], ["DUB", "PROTEIN", 24, 27], ["HIF-1\u03b1", "PROTEIN", 69, 75], ["Cezanne", "TREATMENT", 0, 7]]], ["Indeed, USP8 is essential for the removal of ubiquitin moieties on HIF-1\u03b1 in normoxia, contributing to the maintenance of a basal level of HIF-1\u03b1.", [["USP8", "GENE_OR_GENE_PRODUCT", 8, 12], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 67, 73], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 139, 145], ["USP8", "PROTEIN", 8, 12], ["ubiquitin moieties", "PROTEIN", 45, 63], ["HIF-1\u03b1", "PROTEIN", 67, 73], ["HIF-1\u03b1", "PROTEIN", 139, 145], ["the removal of ubiquitin moieties", "TREATMENT", 30, 63]]], ["In this case, however, USP8 appears to protect HIF-1\u03b1 from proteasomal degradation [120] .", [["proteasomal", "ANATOMY", 59, 70], ["USP8", "CHEMICAL", 23, 27], ["USP8", "GENE_OR_GENE_PRODUCT", 23, 27], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 47, 53], ["USP8", "PROTEIN", 23, 27], ["HIF-1\u03b1", "PROTEIN", 47, 53], ["USP8", "TEST", 23, 27], ["HIF", "TEST", 47, 50], ["proteasomal degradation", "PROBLEM", 59, 82]]], ["These two studies show that different DUBs can regulate the fate of a shared substrate depending on the physiology of the cell.Targeted Degradation of CargoesConnexin-43/Cx43 is a member of the connexin family that forms the gap junction channels between adjacent cells, enabling direct intercellular exchanges between cells, which is another example of a substrate for at least two different degradative pathways.", [["cell", "ANATOMY", 122, 126], ["gap junction", "ANATOMY", 225, 237], ["cells", "ANATOMY", 264, 269], ["intercellular", "ANATOMY", 287, 300], ["cells", "ANATOMY", 319, 324], ["DUBs", "GENE_OR_GENE_PRODUCT", 38, 42], ["cell", "CELL", 122, 126], ["CargoesConnexin-43/Cx43", "GENE_OR_GENE_PRODUCT", 151, 174], ["connexin", "GENE_OR_GENE_PRODUCT", 194, 202], ["gap junction", "CELLULAR_COMPONENT", 225, 237], ["cells", "CELL", 264, 269], ["cells", "CELL", 319, 324], ["DUBs", "PROTEIN", 38, 42], ["CargoesConnexin-43", "PROTEIN", 151, 169], ["/Cx43", "PROTEIN", 169, 174], ["connexin family", "PROTEIN", 194, 209], ["gap junction channels", "PROTEIN", 225, 246], ["adjacent cells", "CELL_TYPE", 255, 269], ["These two studies", "TEST", 0, 17], ["different DUBs", "PROBLEM", 28, 42], ["CargoesConnexin", "TREATMENT", 151, 166], ["direct intercellular exchanges between cells", "PROBLEM", 280, 324], ["different", "OBSERVATION_MODIFIER", 28, 37], ["DUBs", "OBSERVATION", 38, 42]]], ["Indeed, Cx43 polyubiquitination triggers its degradation through either the proteasome or the lysosome via endocytosis and autophagy [121] [122] [123] [124] .", [["lysosome", "ANATOMY", 94, 102], ["Cx43", "GENE_OR_GENE_PRODUCT", 8, 12], ["lysosome", "CELLULAR_COMPONENT", 94, 102], ["Cx43", "PROTEIN", 8, 12], ["proteasome", "PROTEIN", 76, 86], ["Cx43 polyubiquitination", "PROBLEM", 8, 31], ["autophagy", "TEST", 123, 132]]], ["USP8 interacts with and deubiquitinates Cx43, removing monoubiquitin moieties as well as K63-and K48-linked ubiquitin chains.", [["USP8", "GENE_OR_GENE_PRODUCT", 0, 4], ["Cx43", "GENE_OR_GENE_PRODUCT", 40, 44], ["K63", "GENE_OR_GENE_PRODUCT", 89, 92], ["K48", "SIMPLE_CHEMICAL", 97, 100], ["USP8", "PROTEIN", 0, 4], ["Cx43", "PROTEIN", 40, 44], ["monoubiquitin moieties", "PROTEIN", 55, 77], ["K63", "PROTEIN", 89, 92], ["K48", "PROTEIN", 97, 100], ["ubiquitin chains", "PROTEIN", 108, 124], ["monoubiquitin moieties", "TREATMENT", 55, 77], ["K63", "TEST", 89, 92], ["K48-linked ubiquitin chains", "TREATMENT", 97, 124], ["ubiquitin chains", "OBSERVATION", 108, 124]]], ["Cx43 ubiquitination and degradation by autophagy are increased in Usp8 knockdown cells [125] .", [["cells", "ANATOMY", 81, 86], ["Cx43", "GENE_OR_GENE_PRODUCT", 0, 4], ["Usp8", "GENE_OR_GENE_PRODUCT", 66, 70], ["Cx43", "PROTEIN", 0, 4], ["Usp8 knockdown cells", "CELL_LINE", 66, 86], ["Cx43 ubiquitination", "TEST", 0, 19], ["autophagy", "TEST", 39, 48], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["Even though USP8 regulates autophagic degradation of Cx43 in basal condition, one cannot exclude that USP8 may also affect Cx43 through the endolysosomal pathways in different conditions as USP8 is well described for its implication in the endocytosis of various plasma membrane receptors [126] [127] [128] .Targeted Degradation of CargoesThus, there are several cases of proteins being degraded through different processes notably as a result of the linkage of different kinds of ubiquitin moieties and undergoing tight regulation by specific DUBs.Regulation of the Fusion of Endosome to AutophagosomeAutophagy and endocytosis are two conserved and interconnected degradative pathways among eukaryotes.", [["endolysosomal", "ANATOMY", 140, 153], ["plasma membrane", "ANATOMY", 263, 278], ["USP8", "GENE_OR_GENE_PRODUCT", 12, 16], ["Cx43", "GENE_OR_GENE_PRODUCT", 53, 57], ["USP8", "GENE_OR_GENE_PRODUCT", 102, 106], ["Cx43", "GENE_OR_GENE_PRODUCT", 123, 127], ["endolysosomal", "CELLULAR_COMPONENT", 140, 153], ["USP8", "GENE_OR_GENE_PRODUCT", 190, 194], ["plasma membrane", "CELLULAR_COMPONENT", 263, 278], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 481, 490], ["DUBs", "GENE_OR_GENE_PRODUCT", 544, 548], ["Endosome", "GENE_OR_GENE_PRODUCT", 577, 585], ["AutophagosomeAutophagy", "GENE_OR_GENE_PRODUCT", 589, 611], ["USP8", "PROTEIN", 12, 16], ["Cx43", "PROTEIN", 53, 57], ["USP8", "PROTEIN", 102, 106], ["Cx43", "PROTEIN", 123, 127], ["USP8", "PROTEIN", 190, 194], ["plasma membrane receptors", "PROTEIN", 263, 288], ["ubiquitin moieties", "PROTEIN", 481, 499], ["DUBs", "PROTEIN", 544, 548], ["Endosome", "PROTEIN", 577, 585], ["autophagic degradation of Cx43 in basal condition", "PROBLEM", 27, 76], ["various plasma membrane receptors", "TEST", 255, 288], ["proteins", "PROBLEM", 372, 380], ["different kinds of ubiquitin moieties", "PROBLEM", 462, 499], ["endocytosis", "PROBLEM", 616, 627], ["ubiquitin moieties", "OBSERVATION", 481, 499], ["Fusion", "OBSERVATION", 567, 573]]], ["Moreover, fusion events between autophagosomes and endocytic compartments have been observed and investigated [129, 130] .", [["autophagosomes", "ANATOMY", 32, 46], ["endocytic compartments", "ANATOMY", 51, 73], ["autophagosomes", "CELLULAR_COMPONENT", 32, 46], ["endocytic compartments", "CELLULAR_COMPONENT", 51, 73], ["fusion events", "PROBLEM", 10, 23], ["fusion", "OBSERVATION", 10, 16], ["endocytic", "ANATOMY_MODIFIER", 51, 60]]], ["Endocytosis and autophagy converge not only at the level of lysosomes but also at the level of early and late endosomes, forming another type of vesicle called amphisomes.", [["lysosomes", "ANATOMY", 60, 69], ["late endosomes", "ANATOMY", 105, 119], ["vesicle", "ANATOMY", 145, 152], ["amphisomes", "ANATOMY", 160, 170], ["lysosomes", "CELLULAR_COMPONENT", 60, 69], ["late endosomes", "CELLULAR_COMPONENT", 105, 119], ["vesicle", "CELLULAR_COMPONENT", 145, 152], ["amphisomes", "CELLULAR_COMPONENT", 160, 170], ["Endocytosis", "PROBLEM", 0, 11], ["autophagy", "PROBLEM", 16, 25], ["autophagy", "OBSERVATION", 16, 25], ["lysosomes", "OBSERVATION", 60, 69], ["vesicle", "ANATOMY", 145, 152]]], ["Several DUBs, known for their role in endocytosis, also impact directly or indirectly the autophagic flux ( Figure 3G ).Regulation of the Fusion of Endosome to AutophagosomeAMSH is a metalloprotease of the JAMM type involved in the sorting of cell-surface receptors at endosomes [131] [132] [133] [134] .", [["cell", "ANATOMY", 243, 247], ["surface", "ANATOMY", 248, 255], ["endosomes", "ANATOMY", 269, 278], ["DUBs", "GENE_OR_GENE_PRODUCT", 8, 12], ["Endosome", "GENE_OR_GENE_PRODUCT", 148, 156], ["AutophagosomeAMSH", "GENE_OR_GENE_PRODUCT", 160, 177], ["JAMM", "GENE_OR_GENE_PRODUCT", 206, 210], ["cell", "CELL", 243, 247], ["endosomes", "CELLULAR_COMPONENT", 269, 278], ["DUBs", "PROTEIN", 8, 12], ["Endosome", "PROTEIN", 148, 156], ["AutophagosomeAMSH", "PROTEIN", 160, 177], ["metalloprotease", "PROTEIN", 183, 198], ["JAMM type", "PROTEIN", 206, 215], ["cell-surface receptors", "PROTEIN", 243, 265], ["Several DUBs", "PROBLEM", 0, 12], ["DUBs", "OBSERVATION", 8, 12], ["endocytosis", "OBSERVATION", 38, 49], ["autophagic flux", "OBSERVATION", 90, 105], ["Fusion", "OBSERVATION", 138, 144]]], ["AMSH localizes at the endosomes and promotes the recycling of internalized receptors [135, 136] .", [["endosomes", "ANATOMY", 22, 31], ["AMSH", "GENE_OR_GENE_PRODUCT", 0, 4], ["endosomes", "CELLULAR_COMPONENT", 22, 31], ["AMSH", "PROTEIN", 0, 4], ["internalized receptors", "PROTEIN", 62, 84]]], ["Disruption of AMSH in mice results in the loss of neurons in the hippocampus and severe atrophy of the cerebral cortex [137] .", [["neurons", "ANATOMY", 50, 57], ["hippocampus", "ANATOMY", 65, 76], ["cerebral cortex", "ANATOMY", 103, 118], ["loss of neurons", "DISEASE", 42, 57], ["atrophy", "DISEASE", 88, 95], ["AMSH", "GENE_OR_GENE_PRODUCT", 14, 18], ["mice", "ORGANISM", 22, 26], ["neurons", "CELL", 50, 57], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 65, 76], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 103, 118], ["AMSH", "PROTEIN", 14, 18], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["the loss of neurons in the hippocampus", "PROBLEM", 38, 76], ["severe atrophy of the cerebral cortex", "PROBLEM", 81, 118], ["loss", "OBSERVATION_MODIFIER", 42, 46], ["neurons", "ANATOMY", 50, 57], ["hippocampus", "ANATOMY", 65, 76], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["atrophy", "OBSERVATION", 88, 95], ["cerebral cortex", "ANATOMY", 103, 118]]], ["An independent study observed that the loss of AMSH in neurons results in the accumulation of ubiquitinated protein aggregates associated with the autophagy receptor p62, indicating that the autophagy flux is impaired [138] ( Figure 3D) .", [["neurons", "ANATOMY", 55, 62], ["AMSH", "GENE_OR_GENE_PRODUCT", 47, 51], ["neurons", "CELL", 55, 62], ["p62", "GENE_OR_GENE_PRODUCT", 166, 169], ["AMSH", "PROTEIN", 47, 51], ["neurons", "CELL_TYPE", 55, 62], ["autophagy receptor p62", "PROTEIN", 147, 169], ["An independent study", "TEST", 0, 20], ["the loss of AMSH in neurons", "PROBLEM", 35, 62], ["ubiquitinated protein aggregates", "PROBLEM", 94, 126], ["the autophagy receptor p62", "TEST", 143, 169], ["the autophagy flux", "PROBLEM", 187, 205], ["ubiquitinated protein aggregates", "OBSERVATION", 94, 126]]], ["However, at this stage of the study, it is not possible to discriminate whether the blockade of the autophagy flux results from an impairment in the endocytic process or a lack of targeting of cargoes to autophagosome, independently of endocytosis.", [["autophagosome", "ANATOMY", 204, 217], ["autophagosome", "CELLULAR_COMPONENT", 204, 217], ["the study", "TEST", 26, 35], ["the autophagy flux", "PROBLEM", 96, 114], ["an impairment in the endocytic process", "PROBLEM", 128, 166], ["endocytosis", "PROBLEM", 236, 247], ["autophagy flux", "OBSERVATION", 100, 114], ["impairment", "OBSERVATION", 131, 141], ["endocytic process", "OBSERVATION", 149, 166]]], ["In the plant model Arabidopsis thaliana, the ortholog AMSH1 interacts with the ESCRT-III protein VPS2.1 and contributes to autophagic degradation [139] (Figure 3G ).Regulation of the Fusion of Endosome to AutophagosomeUSP8 is a second DUB playing a major role in endocytosis by regulating both the ubiquitination status of cargoes and members of the ESCRT machinery regulating membrane deformation and scission events [126] [127] [128] [140] [141] [142] .", [["autophagic", "ANATOMY", 123, 133], ["membrane", "ANATOMY", 377, 385], ["Arabidopsis thaliana", "ORGANISM", 19, 39], ["AMSH1", "GENE_OR_GENE_PRODUCT", 54, 59], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 79, 88], ["VPS2.1", "GENE_OR_GENE_PRODUCT", 97, 103], ["Endosome", "GENE_OR_GENE_PRODUCT", 193, 201], ["AutophagosomeUSP8", "GENE_OR_GENE_PRODUCT", 205, 222], ["DUB", "GENE_OR_GENE_PRODUCT", 235, 238], ["ESCRT", "GENE_OR_GENE_PRODUCT", 350, 355], ["membrane", "CELLULAR_COMPONENT", 377, 385], ["AMSH1", "PROTEIN", 54, 59], ["ESCRT-III protein", "PROTEIN", 79, 96], ["VPS2.1", "PROTEIN", 97, 103], ["Endosome", "PROTEIN", 193, 201], ["AutophagosomeUSP8", "PROTEIN", 205, 222], ["DUB", "PROTEIN", 235, 238], ["ESCRT", "PROTEIN", 350, 355], ["Arabidopsis thaliana", "SPECIES", 19, 39], ["Arabidopsis thaliana", "SPECIES", 19, 39], ["the ESCRT", "TEST", 75, 84], ["III protein VPS2.1", "TEST", 85, 103], ["autophagic degradation", "PROBLEM", 123, 145], ["a second DUB", "PROBLEM", 226, 238], ["scission events", "PROBLEM", 402, 417], ["Arabidopsis thaliana", "OBSERVATION", 19, 39], ["autophagic degradation", "OBSERVATION", 123, 145], ["Fusion", "OBSERVATION", 183, 189], ["endocytosis", "OBSERVATION", 263, 274], ["membrane deformation", "OBSERVATION", 377, 397]]], ["USP8 has been extensively studied for its role in the regulation of the trafficking and lysosomal degradation of receptors, such as EGFR, through the endocytic process [135, 143] .", [["lysosomal", "ANATOMY", 88, 97], ["USP8", "CHEMICAL", 0, 4], ["USP8", "GENE_OR_GENE_PRODUCT", 0, 4], ["lysosomal", "CELLULAR_COMPONENT", 88, 97], ["EGFR", "GENE_OR_GENE_PRODUCT", 132, 136], ["USP8", "PROTEIN", 0, 4], ["EGFR", "PROTEIN", 132, 136], ["lysosomal degradation of receptors", "PROBLEM", 88, 122], ["EGFR", "TEST", 132, 136]]], ["In addition to its role in endocytosis, loss of dUSP8 in Drosophila blocks the progression of autophagy, resulting in the accumulation of Ref(2)P/p62 and ubiquitinated proteins [144] .", [["dUSP8", "GENE_OR_GENE_PRODUCT", 48, 53], ["Ref(2)P", "GENE_OR_GENE_PRODUCT", 138, 145], ["p62", "GENE_OR_GENE_PRODUCT", 146, 149], ["dUSP8", "PROTEIN", 48, 53], ["Ref(2)P", "PROTEIN", 138, 145], ["p62", "PROTEIN", 146, 149], ["ubiquitinated proteins", "PROTEIN", 154, 176], ["Drosophila", "SPECIES", 57, 67], ["Drosophila", "SPECIES", 57, 67], ["endocytosis", "PROBLEM", 27, 38], ["loss of dUSP8 in Drosophila blocks", "PROBLEM", 40, 74], ["autophagy", "PROBLEM", 94, 103], ["P/p62", "TEST", 144, 149], ["ubiquitinated proteins", "TEST", 154, 176], ["endocytosis", "OBSERVATION", 27, 38], ["progression", "OBSERVATION_MODIFIER", 79, 90], ["autophagy", "OBSERVATION_MODIFIER", 94, 103], ["accumulation", "OBSERVATION_MODIFIER", 122, 134]]], ["As for dUSP8, dUSP12 depletion affects both the autophagic flux and endocytosis process.", [["dUSP12", "CHEMICAL", 14, 20], ["dUSP8", "GENE_OR_GENE_PRODUCT", 7, 12], ["dUSP12", "GENE_OR_GENE_PRODUCT", 14, 20], ["dUSP8", "PROTEIN", 7, 12], ["dUSP12", "PROTEIN", 14, 20], ["dUSP8", "PROBLEM", 7, 12], ["dUSP12 depletion", "PROBLEM", 14, 30], ["the autophagic flux", "PROBLEM", 44, 63], ["endocytosis process", "PROBLEM", 68, 87], ["autophagic flux", "OBSERVATION", 48, 63], ["endocytosis process", "OBSERVATION", 68, 87]]], ["Indeed, silencing dUSP12 encoding gene results in the accumulation of autophagosomes in Drosophila [144] , and USP12 negatively regulates the endocytosis and translocation of the Notch receptor to the lysosomes in both Drosophila and mammalian cells [145] .", [["autophagosomes", "ANATOMY", 70, 84], ["lysosomes", "ANATOMY", 201, 210], ["cells", "ANATOMY", 244, 249], ["dUSP12", "GENE_OR_GENE_PRODUCT", 18, 24], ["autophagosomes", "CELLULAR_COMPONENT", 70, 84], ["USP12", "GENE_OR_GENE_PRODUCT", 111, 116], ["Notch receptor", "GENE_OR_GENE_PRODUCT", 179, 193], ["lysosomes", "CELLULAR_COMPONENT", 201, 210], ["mammalian cells", "CELL", 234, 249], ["dUSP12", "PROTEIN", 18, 24], ["USP12", "PROTEIN", 111, 116], ["Notch receptor", "PROTEIN", 179, 193], ["Drosophila and mammalian cells", "CELL_TYPE", 219, 249], ["Drosophila", "SPECIES", 88, 98], ["Drosophila", "SPECIES", 219, 229], ["Drosophila", "SPECIES", 219, 229], ["the endocytosis", "PROBLEM", 138, 153], ["mammalian cells", "OBSERVATION", 234, 249]]], ["Although these studies cannot exclude a direct role of these DUBs in the regulation of autophagy, they support a close imbrication of endocytosis and autophagy and suggest interdependence of the two processes.", [["DUBs", "GENE_OR_GENE_PRODUCT", 61, 65], ["DUBs", "PROTEIN", 61, 65], ["these studies", "TEST", 9, 22], ["endocytosis", "PROBLEM", 134, 145], ["autophagy", "PROBLEM", 150, 159], ["DUBs", "OBSERVATION", 61, 65]]], ["This hypothesis is reinforced by the fact that disruption of the endocytic process using dominant-negative Rab or by their knockdown also results in impaired autophagy [146] .Regulation of the Fusion of Endosome to AutophagosomeThe particular case of the \u03b22-adrenergic receptors (\u03b22-ARs) also illustrates a reliable interconnection between the endocytic and autophagic processes and their tight regulation by ubiquitination. \u03b22-adrenergic receptors (\u03b22-ARs) availability on the plasma membrane is tightly regulated by balancing their internalization and recycling rates.", [["plasma membrane", "ANATOMY", 478, 493], ["\u03b22-ARs", "CHEMICAL", 450, 456], ["Rab", "GENE_OR_GENE_PRODUCT", 107, 110], ["Endosome", "GENE_OR_GENE_PRODUCT", 203, 211], ["Autophagosome", "GENE_OR_GENE_PRODUCT", 215, 228], ["\u03b22-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 255, 278], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 280, 286], ["\u03b22-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 425, 448], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 450, 456], ["plasma membrane", "CELLULAR_COMPONENT", 478, 493], ["dominant-negative Rab", "PROTEIN", 89, 110], ["Endosome", "PROTEIN", 203, 211], ["\u03b22-adrenergic receptors", "PROTEIN", 255, 278], ["\u03b22-ARs", "PROTEIN", 280, 286], ["\u03b22", "PROTEIN", 425, 427], ["ARs", "PROTEIN", 453, 456], ["impaired autophagy", "PROBLEM", 149, 167], ["the endocytic and autophagic processes", "PROBLEM", 340, 378], ["adrenergic receptors", "TEST", 428, 448], ["the plasma membrane", "TEST", 474, 493], ["Fusion", "OBSERVATION", 193, 199], ["autophagic processes", "OBSERVATION", 358, 378], ["tight", "OBSERVATION_MODIFIER", 389, 394]]], ["Misregulation of \u03b22-ARs trafficking has been associated in various pathologies, including heart failure and asthma [147] . \u03b22-ARs take an unconventional route to the lysosomes; indeed, after their endocytic internalization, ubiquitinated \u03b22-ARs are directed to the autophagosomes rather than the lysosomes [148] .", [["heart", "ANATOMY", 90, 95], ["lysosomes", "ANATOMY", 166, 175], ["autophagosomes", "ANATOMY", 265, 279], ["lysosomes", "ANATOMY", 296, 305], ["heart failure", "DISEASE", 90, 103], ["asthma", "DISEASE", 108, 114], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 17, 23], ["heart", "ORGAN", 90, 95], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 123, 129], ["lysosomes", "CELLULAR_COMPONENT", 166, 175], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 238, 244], ["autophagosomes", "CELLULAR_COMPONENT", 265, 279], ["lysosomes", "CELLULAR_COMPONENT", 296, 305], ["\u03b22", "PROTEIN", 17, 19], ["\u03b22", "PROTEIN", 123, 125], ["\u03b22", "PROTEIN", 238, 240], ["ARs", "PROTEIN", 241, 244], ["various pathologies", "PROBLEM", 59, 78], ["heart failure", "PROBLEM", 90, 103], ["asthma", "PROBLEM", 108, 114], ["various", "OBSERVATION_MODIFIER", 59, 66], ["pathologies", "OBSERVATION", 67, 78], ["heart", "ANATOMY", 90, 95], ["failure", "OBSERVATION", 96, 103], ["asthma", "OBSERVATION", 108, 114]]], ["The post-endocytic sorting of the receptor from the endosomes to the autophagosomes is modulated by the proteases USP20 and USP33 [149] .", [["endosomes", "ANATOMY", 52, 61], ["autophagosomes", "ANATOMY", 69, 83], ["endosomes", "CELLULAR_COMPONENT", 52, 61], ["autophagosomes", "CELLULAR_COMPONENT", 69, 83], ["USP20", "GENE_OR_GENE_PRODUCT", 114, 119], ["proteases", "PROTEIN", 104, 113], ["USP20", "PROTEIN", 114, 119], ["USP33", "PROTEIN", 124, 129], ["the proteases USP20", "TEST", 100, 119], ["USP33", "TEST", 124, 129]]], ["However, solely USP20 was shown to promote the deubiquitination of \u03b22-ARs and their post-endocytic trafficking to autophagosomes.", [["autophagosomes", "ANATOMY", 114, 128], ["USP20", "CHEMICAL", 16, 21], ["USP20", "GENE_OR_GENE_PRODUCT", 16, 21], ["\u03b22-ARs", "GENE_OR_GENE_PRODUCT", 67, 73], ["autophagosomes", "CELLULAR_COMPONENT", 114, 128], ["USP20", "PROTEIN", 16, 21], ["\u03b22", "PROTEIN", 67, 69], ["autophagosomes", "CELL_TYPE", 114, 128]]], ["In this process, phosphorylation of USP20 at serine residue 333 is required for its activity providing an additional level of regulation [148] .Regulation of the Fusion of Endosome to AutophagosomeRecently, the protein CHMP2A of the ESCRT-III complex was identified to be crucial for the closure of the autophagosome [150] .", [["autophagosome", "ANATOMY", 303, 316], ["serine", "CHEMICAL", 45, 51], ["USP20", "GENE_OR_GENE_PRODUCT", 36, 41], ["serine residue 333", "AMINO_ACID", 45, 63], ["Endosome", "GENE_OR_GENE_PRODUCT", 172, 180], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 219, 225], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 233, 242], ["autophagosome", "CELLULAR_COMPONENT", 303, 316], ["USP20", "PROTEIN", 36, 41], ["Endosome", "PROTEIN", 172, 180], ["CHMP2A", "PROTEIN", 219, 225], ["ESCRT-III complex", "PROTEIN", 233, 250], ["phosphorylation of USP20 at serine residue", "TREATMENT", 17, 59], ["the protein CHMP2A", "TEST", 207, 225], ["Fusion", "OBSERVATION", 162, 168], ["closure", "OBSERVATION", 288, 295]]], ["Therefore, endosomes-associated DUBs such as USP8 and AMSH, or other DUBs that remain to be identified, may also play a direct regulatory role in this process through the regulation of ESCRT-III components activity, as recently shown for CHMP1B during endocytosis [140] .Transcriptional Regulation of Autophagy by USP44The expression of a number of genes related to autophagy is activated upon starvation in mammalian cell culture.", [["endosomes", "ANATOMY", 11, 20], ["cell culture", "ANATOMY", 418, 430], ["endosomes", "CELLULAR_COMPONENT", 11, 20], ["DUBs", "GENE_OR_GENE_PRODUCT", 32, 36], ["USP8", "GENE_OR_GENE_PRODUCT", 45, 49], ["AMSH", "GENE_OR_GENE_PRODUCT", 54, 58], ["DUBs", "GENE_OR_GENE_PRODUCT", 69, 73], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 185, 194], ["CHMP1B", "GENE_OR_GENE_PRODUCT", 238, 244], ["USP44", "GENE_OR_GENE_PRODUCT", 314, 319], ["mammalian cell culture", "CELL", 408, 430], ["DUBs", "PROTEIN", 32, 36], ["USP8", "PROTEIN", 45, 49], ["AMSH", "PROTEIN", 54, 58], ["DUBs", "PROTEIN", 69, 73], ["ESCRT-III components", "PROTEIN", 185, 205], ["CHMP1B", "PROTEIN", 238, 244], ["USP44", "PROTEIN", 314, 319], ["mammalian cell culture", "CELL_LINE", 408, 430], ["associated DUBs", "PROBLEM", 21, 36], ["USP8", "TEST", 45, 49], ["AMSH", "PROBLEM", 54, 58], ["other DUBs", "PROBLEM", 63, 73], ["CHMP1B during endocytosis", "PROBLEM", 238, 263], ["autophagy", "PROBLEM", 366, 375], ["mammalian cell culture", "TEST", 408, 430], ["DUBs", "OBSERVATION", 32, 36]]], ["In this process, histone protein H2B monoubiquitination (H2Bub1) is an essential modification for the regulation of gene transcription.", [["histone protein H2B", "GENE_OR_GENE_PRODUCT", 17, 36], ["H2Bub1", "GENE_OR_GENE_PRODUCT", 57, 63], ["histone protein", "PROTEIN", 17, 32], ["H2B", "PROTEIN", 33, 36], ["H2Bub1", "PROTEIN", 57, 63], ["histone protein H2B monoubiquitination (H2Bub1)", "TREATMENT", 17, 64], ["an essential modification", "TREATMENT", 68, 93], ["gene transcription", "TREATMENT", 116, 134], ["H2B monoubiquitination", "OBSERVATION", 33, 55]]], ["The level of H2Bub1 is controlled by the protease USP44 which is upregulated after starvation.", [["H2Bub1", "GENE_OR_GENE_PRODUCT", 13, 19], ["USP44", "GENE_OR_GENE_PRODUCT", 50, 55], ["H2Bub1", "PROTEIN", 13, 19], ["protease USP44", "PROTEIN", 41, 55], ["the protease USP44", "TREATMENT", 37, 55]]], ["Knockdown of Usp44 results in the maintenance of H2Bub1 upon starvation and abolishes the change in expression of starvation-induced autophagy-related genes.", [["Usp44", "GENE_OR_GENE_PRODUCT", 13, 18], ["H2Bub1", "GENE_OR_GENE_PRODUCT", 49, 55], ["Usp44", "PROTEIN", 13, 18], ["H2Bub1", "PROTEIN", 49, 55], ["autophagy-related genes", "DNA", 133, 156], ["H2Bub1 upon starvation", "TREATMENT", 49, 71]]], ["Moreover, downregulation of USP44 encoding gene blocks the induction of autophagy in mESCs (mouse embryonic stem cells) ( Figure 3H ).", [["mESCs", "ANATOMY", 85, 90], ["embryonic stem cells", "ANATOMY", 98, 118], ["USP44", "GENE_OR_GENE_PRODUCT", 28, 33], ["mESCs", "CELL", 85, 90], ["mouse", "ORGANISM", 92, 97], ["embryonic stem cells", "CELL", 98, 118], ["Figure 3H", "CELL", 122, 131], ["USP44", "PROTEIN", 28, 33], ["mESCs", "CELL_TYPE", 85, 90], ["mouse embryonic stem cells", "CELL_LINE", 92, 118], ["mouse", "SPECIES", 92, 97], ["mouse", "SPECIES", 92, 97], ["downregulation of USP44 encoding gene blocks", "TREATMENT", 10, 54], ["autophagy in mESCs (mouse embryonic stem cells", "TREATMENT", 72, 118]]], ["This study thus unveils a new role for DUB in the transcriptional regulation of autophagy through the modulation of H2B monoubiquitination [151] .Regulation of Autophagy by Bacterial and Viral DUB-Like EnzymesUbiquitination of microbial molecular patterns is used by eukaryotic cells to tag invasive pathogens and target them for autophagic degradation.", [["cells", "ANATOMY", 278, 283], ["autophagic", "ANATOMY", 330, 340], ["DUB", "GENE_OR_GENE_PRODUCT", 39, 42], ["H2B", "GENE_OR_GENE_PRODUCT", 116, 119], ["Viral DUB", "ORGANISM", 187, 196], ["eukaryotic cells", "CELL", 267, 283], ["DUB", "PROTEIN", 39, 42], ["H2B", "PROTEIN", 116, 119], ["Bacterial and Viral DUB", "PROTEIN", 173, 196], ["eukaryotic cells", "CELL_TYPE", 267, 283], ["This study", "TEST", 0, 10], ["DUB", "PROBLEM", 39, 42], ["H2B monoubiquitination", "TREATMENT", 116, 138], ["Bacterial", "TEST", 173, 182], ["Viral DUB", "TEST", 187, 196], ["tag invasive pathogens", "PROBLEM", 287, 309], ["autophagic degradation", "PROBLEM", 330, 352], ["H2B monoubiquitination", "OBSERVATION", 116, 138], ["Bacterial", "OBSERVATION_MODIFIER", 173, 182], ["Viral DUB", "OBSERVATION", 187, 196], ["microbial molecular patterns", "OBSERVATION", 227, 255]]], ["This reaction leads to the accumulation of ubiquitinated protein aggregate known as ubiquitinated aggresome-like induced structures (ALIS).", [["ubiquitinated aggresome", "PROTEIN", 84, 107], ["This reaction", "PROBLEM", 0, 13], ["ubiquitinated protein aggregate", "PROBLEM", 43, 74], ["ubiquitinated aggresome", "PROBLEM", 84, 107], ["ubiquitinated protein aggregate", "OBSERVATION", 43, 74], ["ubiquitinated", "OBSERVATION_MODIFIER", 84, 97], ["aggresome", "OBSERVATION", 98, 107]]], ["Such aggregates contribute to the upregulation of autophagy and the removal of intracellular pathogens.", [["intracellular", "ANATOMY", 79, 92], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 92], ["autophagy", "PROBLEM", 50, 59], ["the removal", "TREATMENT", 64, 75], ["intracellular pathogens", "PROBLEM", 79, 102], ["intracellular", "OBSERVATION_MODIFIER", 79, 92], ["pathogens", "OBSERVATION", 93, 102]]], ["In response to this host defense mechanism, intracellular pathogens, such as bacteria or viruses, have developed strategies to hijack the host ubiquitin pathway by expressing DUB-like enzymes able to counteract ubiquitination and permit them to escape their elimination by autophagy.Regulation of Autophagy by Bacterial and Viral DUB-Like EnzymesFor instance, the intracellular pathogenic bacteria Salmonella enterica serovar Typhimurium (S. Typhimurium) counteracts the ALIS-induced autophagy by translocating a DUB-like enzyme, SseL (Salmonella-secreted factor L), into the cytosol.", [["intracellular", "ANATOMY", 44, 57], ["intracellular", "ANATOMY", 364, 377], ["cytosol", "ANATOMY", 576, 583], ["ALIS", "CHEMICAL", 471, 475], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 57], ["DUB", "GENE_OR_GENE_PRODUCT", 175, 178], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 364, 377], ["pathogenic bacteria", "ORGANISM", 378, 397], ["Salmonella enterica serovar Typhimurium", "ORGANISM", 398, 437], ["S. Typhimurium", "ORGANISM", 439, 453], ["ALIS", "GENE_OR_GENE_PRODUCT", 471, 475], ["DUB", "GENE_OR_GENE_PRODUCT", 513, 516], ["SseL", "GENE_OR_GENE_PRODUCT", 530, 534], ["Salmonella-secreted factor L", "GENE_OR_GENE_PRODUCT", 536, 564], ["cytosol", "CELLULAR_COMPONENT", 576, 583], ["DUB-like enzymes", "PROTEIN", 175, 191], ["Bacterial and Viral DUB-Like Enzymes", "PROTEIN", 310, 346], ["DUB-like enzyme", "PROTEIN", 513, 528], ["SseL", "PROTEIN", 530, 534], ["Salmonella-secreted factor L", "PROTEIN", 536, 564], ["Salmonella", "SPECIES", 398, 408], ["enterica serovar Typhimurium", "SPECIES", 409, 437], ["S. Typhimurium", "SPECIES", 439, 453], ["Salmonella enterica serovar Typhimurium", "SPECIES", 398, 437], ["S. Typhimurium", "SPECIES", 439, 453], ["intracellular pathogens", "PROBLEM", 44, 67], ["bacteria", "PROBLEM", 77, 85], ["viruses", "PROBLEM", 89, 96], ["expressing DUB-like enzymes", "PROBLEM", 164, 191], ["Bacterial", "TEST", 310, 319], ["Viral DUB", "TEST", 324, 333], ["Enzymes", "TEST", 339, 346], ["the intracellular pathogenic bacteria", "TEST", 360, 397], ["Salmonella enterica serovar Typhimurium", "TEST", 398, 437], ["the ALIS", "TEST", 467, 475], ["a DUB", "TEST", 511, 516], ["enzyme", "TEST", 522, 528], ["Salmonella", "TEST", 536, 546], ["intracellular", "OBSERVATION_MODIFIER", 44, 57], ["pathogens", "OBSERVATION", 58, 67], ["viruses", "OBSERVATION", 89, 96], ["Viral DUB", "OBSERVATION", 324, 333], ["pathogenic", "OBSERVATION_MODIFIER", 378, 388], ["bacteria", "OBSERVATION_MODIFIER", 389, 397], ["cytosol", "ANATOMY", 576, 583]]], ["Lysates from mouse macrophages infected with \u2206sseL mutant bacteria are enriched in ubiquitinated proteins, and immunofluorescence experiments revealed that these bacteria are more prone to ubiquitination and recognition by autophagy markers such as LC3 or p62 [152, 153] .", [["Lysates", "ANATOMY", 0, 7], ["macrophages", "ANATOMY", 19, 30], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["mouse", "ORGANISM", 13, 18], ["macrophages", "CELL", 19, 30], ["\u2206sseL mutant bacteria", "ORGANISM", 45, 66], ["LC3", "GENE_OR_GENE_PRODUCT", 249, 252], ["p62", "GENE_OR_GENE_PRODUCT", 256, 259], ["mouse macrophages", "CELL_TYPE", 13, 30], ["ubiquitinated proteins", "PROTEIN", 83, 105], ["autophagy markers", "PROTEIN", 223, 240], ["LC3", "PROTEIN", 249, 252], ["p62", "PROTEIN", 256, 259], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["Lysates", "TEST", 0, 7], ["mouse macrophages", "PROBLEM", 13, 30], ["\u2206sseL mutant bacteria", "PROBLEM", 45, 66], ["ubiquitinated proteins", "PROBLEM", 83, 105], ["immunofluorescence experiments", "TEST", 111, 141], ["these bacteria", "PROBLEM", 156, 170], ["autophagy markers", "TEST", 223, 240], ["mouse macrophages", "OBSERVATION", 13, 30], ["bacteria", "OBSERVATION_MODIFIER", 58, 66], ["ubiquitinated proteins", "OBSERVATION", 83, 105]]], ["Secreted SseL deubiquitinates ALIS and the Salmonella-containing vacuoles, reducing the induction of autophagy, further promoting the survival and replication of S. Typhimurium [152] ( Figure 3D ).Regulation of Autophagy by Bacterial and Viral DUB-Like EnzymesLike Salmonella, Legionella is an intracellular bacterium that can establish niches in cytoplasmic vacuoles which allows for the survival and replication of the bacteria.", [["vacuoles", "ANATOMY", 65, 73], ["intracellular bacterium", "ANATOMY", 294, 317], ["cytoplasmic vacuoles", "ANATOMY", 347, 367], ["SseL", "GENE_OR_GENE_PRODUCT", 9, 13], ["ALIS", "GENE_OR_GENE_PRODUCT", 30, 34], ["vacuoles", "CELLULAR_COMPONENT", 65, 73], ["S. Typhimurium", "ORGANISM", 162, 176], ["Viral DUB-Like EnzymesLike Salmonella", "ORGANISM", 238, 275], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 294, 307], ["cytoplasmic vacuoles", "CELLULAR_COMPONENT", 347, 367], ["SseL", "PROTEIN", 9, 13], ["ALIS", "PROTEIN", 30, 34], ["Viral DUB", "PROTEIN", 238, 247], ["S. Typhimurium", "SPECIES", 162, 176], ["S. Typhimurium", "SPECIES", 162, 176], ["the Salmonella", "TREATMENT", 39, 53], ["vacuoles", "TREATMENT", 65, 73], ["autophagy", "TREATMENT", 101, 110], ["Bacterial", "TEST", 224, 233], ["Viral DUB", "TEST", 238, 247], ["EnzymesLike Salmonella", "PROBLEM", 253, 275], ["Legionella", "PROBLEM", 277, 287], ["an intracellular bacterium", "PROBLEM", 291, 317], ["cytoplasmic vacuoles", "TEST", 347, 367], ["the survival", "TREATMENT", 385, 397], ["the bacteria", "PROBLEM", 417, 429], ["Bacterial", "OBSERVATION_MODIFIER", 224, 233], ["Viral DUB", "OBSERVATION", 238, 247], ["intracellular bacterium", "OBSERVATION", 294, 317], ["cytoplasmic vacuoles", "OBSERVATION", 347, 367]]], ["The Legionella pneumophila effector protein RavZ is a secreted cysteine protease that interferes with the autophagy machinery by irreversibly deconjugating LC3 from the autophagosome membrane [154] .", [["autophagosome membrane", "ANATOMY", 169, 191], ["cysteine", "CHEMICAL", 63, 71], ["Legionella pneumophila", "ORGANISM", 4, 26], ["RavZ", "GENE_OR_GENE_PRODUCT", 44, 48], ["LC3", "GENE_OR_GENE_PRODUCT", 156, 159], ["autophagosome membrane", "CELLULAR_COMPONENT", 169, 191], ["Legionella pneumophila effector protein", "PROTEIN", 4, 43], ["RavZ", "PROTEIN", 44, 48], ["secreted cysteine protease", "PROTEIN", 54, 80], ["LC3", "PROTEIN", 156, 159], ["Legionella pneumophila", "SPECIES", 4, 26], ["Legionella pneumophila", "SPECIES", 4, 26], ["The Legionella pneumophila effector", "TEST", 0, 35], ["a secreted cysteine protease", "PROBLEM", 52, 80], ["Legionella", "OBSERVATION_MODIFIER", 4, 14], ["pneumophila effector protein RavZ", "OBSERVATION", 15, 48], ["autophagosome membrane", "OBSERVATION", 169, 191]]], ["LC3 is an autophagy-related ubiquitin-like protein anchored to the autophagosome membrane.", [["autophagosome membrane", "ANATOMY", 67, 89], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["autophagosome membrane", "CELLULAR_COMPONENT", 67, 89], ["LC3", "PROTEIN", 0, 3], ["autophagy-related ubiquitin-like protein", "PROTEIN", 10, 50], ["an autophagy", "PROBLEM", 7, 19], ["autophagy", "OBSERVATION", 10, 19], ["ubiquitin", "OBSERVATION_MODIFIER", 28, 37], ["autophagosome membrane", "OBSERVATION", 67, 89]]], ["The process leading to LC3 lipidation and association to the membrane is similar to the ubiquitination process and requires a ubiquitin-like conjugation system.", [["membrane", "ANATOMY", 61, 69], ["LC3", "GENE_OR_GENE_PRODUCT", 23, 26], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 126, 135], ["LC3", "PROTEIN", 23, 26], ["ubiquitin", "PROTEIN", 126, 135], ["LC3 lipidation", "PROBLEM", 23, 37], ["the ubiquitination process", "PROBLEM", 84, 110], ["a ubiquitin-like conjugation system", "TREATMENT", 124, 159], ["LC3 lipidation", "OBSERVATION", 23, 37], ["ubiquitination process", "OBSERVATION", 88, 110]]], ["RavZ deconjugates LC3 from the autophagosome membrane by hydrolyzing the amide bond between the C-terminal glycine residue and an adjacent aromatic residue; the lack of terminal glycine residue prevents the conjugation of LC3 to the membrane [154, 155] .", [["autophagosome membrane", "ANATOMY", 31, 53], ["membrane", "ANATOMY", 233, 241], ["glycine", "CHEMICAL", 107, 114], ["glycine", "CHEMICAL", 178, 185], ["RavZ", "CHEMICAL", 0, 4], ["amide", "CHEMICAL", 73, 78], ["C", "CHEMICAL", 96, 97], ["glycine", "CHEMICAL", 107, 114], ["glycine", "CHEMICAL", 178, 185], ["RavZ", "GENE_OR_GENE_PRODUCT", 0, 4], ["LC3", "GENE_OR_GENE_PRODUCT", 18, 21], ["autophagosome membrane", "CELLULAR_COMPONENT", 31, 53], ["glycine", "AMINO_ACID", 178, 185], ["LC3", "GENE_OR_GENE_PRODUCT", 222, 225], ["membrane", "CELLULAR_COMPONENT", 233, 241], ["RavZ", "PROTEIN", 0, 4], ["LC3", "PROTEIN", 18, 21], ["LC3", "PROTEIN", 222, 225], ["hydrolyzing the amide bond", "PROBLEM", 57, 83], ["the C-terminal glycine residue", "PROBLEM", 92, 122], ["an adjacent aromatic residue", "PROBLEM", 127, 155], ["terminal glycine residue", "PROBLEM", 169, 193], ["autophagosome membrane", "OBSERVATION", 31, 53], ["terminal", "ANATOMY_MODIFIER", 98, 106], ["glycine residue", "OBSERVATION", 107, 122], ["aromatic residue", "OBSERVATION", 139, 155], ["terminal", "OBSERVATION_MODIFIER", 169, 177], ["glycine residue", "OBSERVATION", 178, 193]]], ["RavZ can also process conventional ubiquitin chains and prevent the targeting of intracellular bacteria for autophagic degradation [156] .", [["intracellular", "ANATOMY", 81, 94], ["autophagic", "ANATOMY", 108, 118], ["RavZ", "CHEMICAL", 0, 4], ["RavZ", "GENE_OR_GENE_PRODUCT", 0, 4], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["RavZ", "PROTEIN", 0, 4], ["ubiquitin chains", "PROTEIN", 35, 51], ["conventional ubiquitin chains", "TREATMENT", 22, 51], ["intracellular bacteria", "PROBLEM", 81, 103], ["autophagic degradation", "PROBLEM", 108, 130], ["ubiquitin chains", "OBSERVATION", 35, 51]]], ["Indeed, using a co-infection system with Salmonella and Legionella, Kubori and colleagues showed that Legionella RavZ protease prevents the recruitment of the autophagy receptors p62 and NDP52 to the Salmonella-containing vacuoles.", [["vacuoles", "ANATOMY", 222, 230], ["Legionella", "ORGANISM", 102, 112], ["RavZ protease", "GENE_OR_GENE_PRODUCT", 113, 126], ["p62", "GENE_OR_GENE_PRODUCT", 179, 182], ["NDP52", "GENE_OR_GENE_PRODUCT", 187, 192], ["vacuoles", "CELLULAR_COMPONENT", 222, 230], ["Legionella RavZ protease", "PROTEIN", 102, 126], ["autophagy receptors", "PROTEIN", 159, 178], ["p62", "PROTEIN", 179, 182], ["NDP52", "PROTEIN", 187, 192], ["Salmonella", "SPECIES", 41, 51], ["a co-infection system", "TEST", 14, 35], ["Salmonella", "PROBLEM", 41, 51], ["Legionella", "PROBLEM", 56, 66], ["Legionella RavZ protease", "TREATMENT", 102, 126], ["the Salmonella", "TEST", 196, 210], ["Legionella RavZ", "OBSERVATION", 102, 117]]], ["The lack of autophagy receptors at the SCVs is due to the removal of ubiquitin moieties from the SCVs by RavZ [156] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 69, 78], ["SCVs", "CELLULAR_COMPONENT", 97, 101], ["autophagy receptors", "PROTEIN", 12, 31], ["ubiquitin moieties", "PROTEIN", 69, 87], ["autophagy receptors", "PROBLEM", 12, 31], ["the removal of ubiquitin moieties", "TREATMENT", 54, 87], ["autophagy receptors", "OBSERVATION", 12, 31], ["ubiquitin moieties", "OBSERVATION", 69, 87]]], ["It was recently shown that RavZ specificity toward LC3 anchored to the autophagosomal membrane depends on its interaction with PI3P [157] ; this observation suggests that RavZ activity as DUB on ubiquitin coats depends on the lipid structure of the nearby vacuole.Regulation of Autophagy by Bacterial and Viral DUB-Like EnzymesAutophagy also targets viruses; yet, many viruses exploit autophagy for their replication [158] .", [["autophagosomal membrane", "ANATOMY", 71, 94], ["vacuole", "ANATOMY", 256, 263], ["RavZ", "GENE_OR_GENE_PRODUCT", 27, 31], ["LC3", "GENE_OR_GENE_PRODUCT", 51, 54], ["autophagosomal membrane", "CELLULAR_COMPONENT", 71, 94], ["PI3P [157]", "GENE_OR_GENE_PRODUCT", 127, 137], ["RavZ", "GENE_OR_GENE_PRODUCT", 171, 175], ["DUB", "GENE_OR_GENE_PRODUCT", 188, 191], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 195, 204], ["vacuole", "CELLULAR_COMPONENT", 256, 263], ["Viral", "ORGANISM", 305, 310], ["DUB", "GENE_OR_GENE_PRODUCT", 311, 314], ["RavZ", "PROTEIN", 27, 31], ["LC3", "PROTEIN", 51, 54], ["RavZ", "PROTEIN", 171, 175], ["DUB", "PROTEIN", 188, 191], ["ubiquitin coats", "PROTEIN", 195, 210], ["Bacterial and Viral DUB-Like EnzymesAutophagy", "PROTEIN", 291, 336], ["LC3", "PROBLEM", 51, 54], ["this observation", "TEST", 140, 156], ["RavZ activity", "PROBLEM", 171, 184], ["DUB on ubiquitin coats", "TREATMENT", 188, 210], ["Bacterial and Viral DUB-Like EnzymesAutophagy", "PROBLEM", 291, 336], ["targets viruses", "PROBLEM", 342, 357], ["autophagosomal membrane", "OBSERVATION", 71, 94], ["RavZ activity", "OBSERVATION", 171, 184], ["ubiquitin coats", "OBSERVATION", 195, 210], ["Bacterial", "OBSERVATION_MODIFIER", 291, 300], ["Viral DUB", "OBSERVATION", 305, 314]]], ["Coronaviruses induce the formation of double-membrane vesicles that allow for their replication and are often decorated with LC3 and cell infection with coronaviruses is often accompanied with induction of autophagy [159] .", [["double-membrane vesicles", "ANATOMY", 38, 62], ["cell", "ANATOMY", 133, 137], ["infection", "DISEASE", 138, 147], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["membrane vesicles", "CELLULAR_COMPONENT", 45, 62], ["LC3", "GENE_OR_GENE_PRODUCT", 125, 128], ["cell", "CELL", 133, 137], ["coronaviruses", "ORGANISM", 153, 166], ["LC3", "PROTEIN", 125, 128], ["Coronaviruses", "PROBLEM", 0, 13], ["double-membrane vesicles", "TREATMENT", 38, 62], ["LC3", "PROBLEM", 125, 128], ["cell infection", "PROBLEM", 133, 147], ["coronaviruses", "PROBLEM", 153, 166], ["autophagy", "PROBLEM", 206, 215], ["double-membrane vesicles", "OBSERVATION", 38, 62], ["cell infection", "OBSERVATION", 133, 147]]], ["The non-structural protein PLP2-TM, which is a transmembrane papain-like protease with deubiquitinating activity [160] , is sufficient for the accumulation of autophagosomes in different cell lines.", [["autophagosomes", "ANATOMY", 159, 173], ["cell lines", "ANATOMY", 187, 197], ["PLP2-TM", "GENE_OR_GENE_PRODUCT", 27, 34], ["autophagosomes", "CELLULAR_COMPONENT", 159, 173], ["cell lines", "CELL", 187, 197], ["non-structural protein", "PROTEIN", 4, 26], ["PLP2", "PROTEIN", 27, 31], ["TM", "PROTEIN", 32, 34], ["transmembrane papain-like protease", "PROTEIN", 47, 81], ["cell lines", "CELL_LINE", 187, 197], ["The non-structural protein PLP2", "TEST", 0, 31], ["a transmembrane papain", "TREATMENT", 45, 67], ["the accumulation of autophagosomes", "PROBLEM", 139, 173], ["non-structural protein", "OBSERVATION", 4, 26], ["different cell lines", "OBSERVATION", 177, 197]]], ["However, its role in the regulation of autophagy is independent of its protease activity [161] .", [["protease", "PROTEIN", 71, 79]]], ["PLP2-TM interacts with LC3 and promotes the accumulation of autophagosomes by blocking their fusion with the lysosomes.", [["autophagosomes", "ANATOMY", 60, 74], ["lysosomes", "ANATOMY", 109, 118], ["PLP2-TM", "GENE_OR_GENE_PRODUCT", 0, 7], ["LC3", "GENE_OR_GENE_PRODUCT", 23, 26], ["autophagosomes", "CELLULAR_COMPONENT", 60, 74], ["lysosomes", "CELLULAR_COMPONENT", 109, 118], ["PLP2", "PROTEIN", 0, 4], ["TM", "PROTEIN", 5, 7], ["LC3", "PROTEIN", 23, 26], ["LC3", "TREATMENT", 23, 26], ["the accumulation of autophagosomes", "TREATMENT", 40, 74], ["blocking their fusion", "TREATMENT", 78, 99]]], ["In their study, Chen and colleagues suggest that PLP2-TM blocks autophagosome-lysosome fusion through its interaction with Beclin1, a prime target for viruses that manipulate the autophagy pathway [162] .", [["autophagosome", "ANATOMY", 64, 77], ["lysosome", "ANATOMY", 78, 86], ["PLP2-TM", "GENE_OR_GENE_PRODUCT", 49, 56], ["autophagosome", "CELLULAR_COMPONENT", 64, 77], ["lysosome", "CELLULAR_COMPONENT", 78, 86], ["Beclin1", "GENE_OR_GENE_PRODUCT", 123, 130], ["PLP2", "PROTEIN", 49, 53], ["TM", "PROTEIN", 54, 56], ["Beclin1", "PROTEIN", 123, 130], ["PLP2", "TEST", 49, 53], ["TM blocks autophagosome", "TREATMENT", 54, 77], ["lysosome fusion", "TREATMENT", 78, 93], ["Beclin1", "TREATMENT", 123, 130], ["viruses", "PROBLEM", 151, 158], ["lysosome fusion", "OBSERVATION", 78, 93]]], ["PLP2-TM also promotes the interaction of STING (stimulator of interferon genes) with Beclin1, possibly to impede the activation of downstream antiviral responses, accentuated by the deubiquitination of components of the signaling cascade such as RIG-1 or TRAF3 [161, 163] .Regulation of Autophagy by Bacterial and Viral DUB-Like EnzymesThese studies provide fascinating examples of possible coevolution and adaptation of the pathogens with their host, where pathogens managed to bypass the host's defense to their own benefit.Targeting Deubiquitinating Enzymes Acting in Autophagy for Therapeutic PurposeUbiquitination regulates major cellular functions by controlling protein stability and activity, and defects in this process contribute to the development of many diseases.", [["cellular", "ANATOMY", 635, 643], ["PLP2-TM", "GENE_OR_GENE_PRODUCT", 0, 7], ["STING", "GENE_OR_GENE_PRODUCT", 41, 46], ["stimulator of interferon", "GENE_OR_GENE_PRODUCT", 48, 72], ["Beclin1", "GENE_OR_GENE_PRODUCT", 85, 92], ["RIG-1", "GENE_OR_GENE_PRODUCT", 246, 251], ["TRAF3", "GENE_OR_GENE_PRODUCT", 255, 260], ["cellular", "CELL", 635, 643], ["PLP2", "PROTEIN", 0, 4], ["TM", "PROTEIN", 5, 7], ["STING", "PROTEIN", 41, 46], ["interferon genes", "DNA", 62, 78], ["Beclin1", "PROTEIN", 85, 92], ["RIG-1", "PROTEIN", 246, 251], ["TRAF3", "PROTEIN", 255, 260], ["Bacterial and Viral DUB-Like Enzymes", "PROTEIN", 300, 336], ["Deubiquitinating Enzymes", "PROTEIN", 536, 560], ["STING (stimulator of interferon genes", "TREATMENT", 41, 78], ["Beclin1", "TREATMENT", 85, 92], ["the signaling cascade", "PROBLEM", 216, 237], ["RIG", "TEST", 246, 249], ["Bacterial", "TEST", 300, 309], ["Viral DUB", "TEST", 314, 323], ["Enzymes", "TEST", 329, 336], ["These studies", "TEST", 336, 349], ["the pathogens", "PROBLEM", 421, 434], ["pathogens", "PROBLEM", 458, 467], ["bypass", "TREATMENT", 479, 485], ["Deubiquitinating Enzymes", "TEST", 536, 560], ["Therapeutic PurposeUbiquitination", "TREATMENT", 585, 618], ["defects in this process", "PROBLEM", 705, 728], ["many diseases", "PROBLEM", 762, 775], ["Viral DUB", "OBSERVATION", 314, 323], ["cellular functions", "OBSERVATION", 635, 653], ["defects", "OBSERVATION", 705, 712], ["many", "OBSERVATION_MODIFIER", 762, 766], ["diseases", "OBSERVATION", 767, 775]]], ["In some cases, ubiquitin-dependent autophagic processes constitute entry points to design new treatments.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 15, 24], ["ubiquitin", "PROTEIN", 15, 24], ["dependent autophagic processes", "PROBLEM", 25, 55], ["new treatments", "TREATMENT", 90, 104]]], ["Depending on the context, however, autophagy can either be beneficial and contribute to survival and recovery or have adverse effects.", [["adverse effects", "PROBLEM", 118, 133]]], ["As such, there is a need for in-depth understanding of autophagy function and regulation in pathological or physiological situations to define in which situation the inhibition of a particular DUB will be beneficial or detrimental.", [["DUB", "GENE_OR_GENE_PRODUCT", 193, 196], ["DUB", "PROTEIN", 193, 196], ["autophagy function", "PROBLEM", 55, 73], ["a particular DUB", "PROBLEM", 180, 196]]], ["Interestingly, the design of chemical tools is also a powerful strategy to probe the effect of DUBs inhibition to help both the understanding of their role in the regulation of autophagy and the design of future treatments to modulate autophagy in the corresponding pathologies.The Challenge of Developing Drugs Targeting DUBsEfficiency and usability of an inhibitor depends on its specificity.", [["DUBs", "GENE_OR_GENE_PRODUCT", 95, 99], ["DUBs", "PROTEIN", 95, 99], ["DUBs", "PROTEIN", 322, 326], ["DUBs inhibition", "TREATMENT", 95, 110], ["future treatments", "TREATMENT", 205, 222], ["Developing Drugs", "TREATMENT", 295, 311], ["DUBsEfficiency", "TREATMENT", 322, 336], ["an inhibitor", "TREATMENT", 354, 366], ["DUBsEfficiency", "OBSERVATION", 322, 336]]], ["As such, the discovery of DUB-focused drugs has been challenging [20] .", [["DUB", "GENE_OR_GENE_PRODUCT", 26, 29], ["DUB", "PROTEIN", 26, 29], ["DUB-focused drugs", "TREATMENT", 26, 43]]], ["Indeed, although DUBs have a catalytic pocket that is suitable for drug development, their sequence and structure are very similar.", [["DUBs", "GENE_OR_GENE_PRODUCT", 17, 21], ["DUBs", "PROTEIN", 17, 21], ["a catalytic pocket", "PROBLEM", 27, 45], ["their sequence", "TEST", 85, 99], ["catalytic pocket", "OBSERVATION", 29, 45], ["very", "OBSERVATION_MODIFIER", 118, 122], ["similar", "OBSERVATION_MODIFIER", 123, 130]]], ["Moreover, DUBs are flexible enzymes, and the regulation of their activity can involve allosteric effects as described for several DUBs that alternate between active and inactive conformations [164] [165] [166] [167] [168] [169] .", [["DUBs", "GENE_OR_GENE_PRODUCT", 10, 14], ["DUBs", "GENE_OR_GENE_PRODUCT", 130, 134], ["DUBs", "PROTEIN", 10, 14], ["DUBs", "PROTEIN", 130, 134], ["flexible enzymes", "TEST", 19, 35], ["several DUBs", "PROBLEM", 122, 134]]], ["For instance, the free catalytic domain of USP7 undergoes significant structural modifications when it is complexed to Ubal (ubiquitin aldehyde, an irreversible DUB inhibitor) [164, 170] .", [["Ubal", "CHEMICAL", 119, 123], ["ubiquitin aldehyde", "CHEMICAL", 125, 143], ["Ubal", "CHEMICAL", 119, 123], ["aldehyde", "CHEMICAL", 135, 143], ["USP7", "GENE_OR_GENE_PRODUCT", 43, 47], ["Ubal", "SIMPLE_CHEMICAL", 119, 123], ["ubiquitin aldehyde", "SIMPLE_CHEMICAL", 125, 143], ["DUB", "GENE_OR_GENE_PRODUCT", 161, 164], ["catalytic domain", "PROTEIN", 23, 39], ["USP7", "PROTEIN", 43, 47], ["the free catalytic domain of USP7", "PROBLEM", 14, 47], ["significant structural modifications", "PROBLEM", 58, 94], ["an irreversible DUB inhibitor", "TREATMENT", 145, 174], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["structural modifications", "OBSERVATION", 70, 94]]], ["Recent publications of the dynamic interaction of USP7 with specific small-molecule inhibitors demonstrated that the binding of the molecules into the active site of USP7 modifies the catalytic residue C223.", [["USP7", "GENE_OR_GENE_PRODUCT", 50, 54], ["USP7", "GENE_OR_GENE_PRODUCT", 166, 170], ["USP7", "PROTEIN", 50, 54], ["USP7", "PROTEIN", 166, 170], ["catalytic residue C223", "PROTEIN", 184, 206], ["USP7", "TEST", 50, 54], ["specific small-molecule inhibitors", "TREATMENT", 60, 94], ["the catalytic residue C223", "PROBLEM", 180, 206], ["active", "OBSERVATION_MODIFIER", 151, 157], ["catalytic residue", "OBSERVATION", 184, 201]]], ["This modification of the active site of USP7 results in its inability to change conformation and perform the cleavage of ubiquitin chains.", [["USP7", "GENE_OR_GENE_PRODUCT", 40, 44], ["USP7", "PROTEIN", 40, 44], ["ubiquitin chains", "PROTEIN", 121, 137], ["USP7", "PROBLEM", 40, 44], ["the cleavage of ubiquitin chains", "TREATMENT", 105, 137], ["active", "OBSERVATION_MODIFIER", 25, 31], ["ubiquitin chains", "OBSERVATION", 121, 137]]], ["These studies show that the development of specific inhibitors binding to the active site of DUBs is a realistic approach, opening new avenues in the field [171, 172] .", [["DUBs", "GENE_OR_GENE_PRODUCT", 93, 97], ["DUBs", "PROTEIN", 93, 97], ["These studies", "TEST", 0, 13], ["specific inhibitors binding", "PROBLEM", 43, 70], ["DUBs", "OBSERVATION", 93, 97]]], ["In addition to intrinsic modulation of their activity and substrate specificity, some DUBs require cofactors.", [["DUBs", "GENE_OR_GENE_PRODUCT", 86, 90], ["DUBs", "PROTEIN", 86, 90], ["intrinsic modulation", "OBSERVATION", 15, 35]]], ["For instance, the full activation of USP19 requires its interaction with Hsp90, which promotes the binding of ubiquitin to the catalytic domain of USP19 [173] .", [["USP19", "GENE_OR_GENE_PRODUCT", 37, 42], ["Hsp90", "GENE_OR_GENE_PRODUCT", 73, 78], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 110, 119], ["USP19", "PROTEIN", 37, 42], ["Hsp90", "PROTEIN", 73, 78], ["ubiquitin", "PROTEIN", 110, 119], ["catalytic domain", "PROTEIN", 127, 143], ["USP19", "PROTEIN", 147, 152], ["Hsp90", "TEST", 73, 78]]], ["Another example is the proteasome-associated enzyme USP14, whose activity is strongly enhanced when in association with the proteasome [66] .The Challenge of Developing Drugs Targeting DUBsDespite the complexity of the regulation of DUBs activity, much effort has been placed in the identification and development of small-molecule regulating DUBs catalytic activity.", [["USP14", "GENE_OR_GENE_PRODUCT", 52, 57], ["DUBs", "GENE_OR_GENE_PRODUCT", 233, 237], ["DUBs", "GENE_OR_GENE_PRODUCT", 343, 347], ["proteasome-associated enzyme", "PROTEIN", 23, 51], ["USP14", "PROTEIN", 52, 57], ["proteasome", "PROTEIN", 124, 134], ["DUBs", "PROTEIN", 185, 189], ["DUBs", "PROTEIN", 233, 237], ["DUBs", "PROTEIN", 343, 347], ["the proteasome", "TEST", 19, 33], ["Developing Drugs", "TREATMENT", 158, 174], ["DUBs activity", "TREATMENT", 233, 246], ["small-molecule regulating DUBs catalytic activity", "PROBLEM", 317, 366], ["DUBs activity", "OBSERVATION", 233, 246], ["small", "OBSERVATION_MODIFIER", 317, 322], ["DUBs catalytic activity", "OBSERVATION", 343, 366]]], ["Some of the most successful small-molecules affecting autophagy the process, through the inhibition of the activity of autophagy-associated DUBs, are shortly introduced hereafter.Characterised Inhibitors of DUBs Acting in AutophagyScreens for inhibitors of DUBs sought to identify new small-molecules with potential in two main therapeutic fields, for cancer treatment and neurodegeneration (reviewed in [20] ).", [["cancer", "ANATOMY", 352, 358], ["cancer", "DISEASE", 352, 358], ["neurodegeneration", "DISEASE", 373, 390], ["DUBs", "GENE_OR_GENE_PRODUCT", 140, 144], ["DUBs", "GENE_OR_GENE_PRODUCT", 207, 211], ["DUBs", "GENE_OR_GENE_PRODUCT", 257, 261], ["cancer", "CANCER", 352, 358], ["DUBs", "PROTEIN", 140, 144], ["DUBs", "PROTEIN", 207, 211], ["DUBs", "PROTEIN", 257, 261], ["inhibitors of DUBs", "TREATMENT", 243, 261], ["new small-molecules", "PROBLEM", 281, 300], ["cancer treatment", "TREATMENT", 352, 368], ["neurodegeneration", "PROBLEM", 373, 390], ["most", "OBSERVATION_MODIFIER", 12, 16], ["successful", "OBSERVATION_MODIFIER", 17, 27], ["small", "OBSERVATION_MODIFIER", 28, 33], ["-molecules", "OBSERVATION_MODIFIER", 33, 43], ["DUBs", "OBSERVATION", 140, 144], ["cancer", "OBSERVATION", 352, 358]]], ["In both fields, some of the inhibitors' targets play a role in the regulation of autophagy that possibly contributes to pathogenesis.Characterised Inhibitors of DUBs Acting in AutophagyUSP14 is an enzyme associated with the proteasome, which plays an essential role in the regulation of protein turnover.", [["DUBs", "GENE_OR_GENE_PRODUCT", 161, 165], ["AutophagyUSP14", "GENE_OR_GENE_PRODUCT", 176, 190], ["DUBs", "PROTEIN", 161, 165], ["AutophagyUSP14", "PROTEIN", 176, 190], ["proteasome", "PROTEIN", 224, 234], ["the inhibitors", "TREATMENT", 24, 38], ["autophagy", "PROBLEM", 81, 90], ["pathogenesis", "PROBLEM", 120, 132], ["an enzyme", "TEST", 194, 203], ["the proteasome", "TREATMENT", 220, 234], ["both", "ANATOMY_MODIFIER", 3, 7], ["fields", "ANATOMY_MODIFIER", 8, 14], ["possibly contributes to", "UNCERTAINTY", 96, 119]]], ["The role of USP14 is particularly important in neurons to maintain synaptic functions and constitutes an appealing target for drug development in order to modulate the activity of the proteasome [174] .", [["neurons", "ANATOMY", 47, 54], ["synaptic", "ANATOMY", 67, 75], ["USP14", "CHEMICAL", 12, 17], ["USP14", "GENE_OR_GENE_PRODUCT", 12, 17], ["neurons", "CELL", 47, 54], ["USP14", "PROTEIN", 12, 17], ["proteasome", "PROTEIN", 184, 194], ["drug development", "TREATMENT", 126, 142]]], ["A screen of 63,052 compounds using proteasome reconstituted with USP14, led to the identification of the first inhibitor of USP14.", [["USP14", "CHEMICAL", 65, 70], ["USP14", "GENE_OR_GENE_PRODUCT", 65, 70], ["USP14", "GENE_OR_GENE_PRODUCT", 124, 129], ["proteasome", "PROTEIN", 35, 45], ["USP14", "PROTEIN", 65, 70], ["USP14", "PROTEIN", 124, 129], ["A screen", "TEST", 0, 8], ["proteasome", "TREATMENT", 35, 45], ["USP14", "TREATMENT", 65, 70], ["the first inhibitor of USP14", "TREATMENT", 101, 129]]], ["The small-molecule IU1 inhibits specifically USP14 with an IC 50 of 4-5 \u00b5M [66] .", [["IU1", "SIMPLE_CHEMICAL", 19, 22], ["USP14", "SIMPLE_CHEMICAL", 45, 50], ["USP14", "PROTEIN", 45, 50], ["an IC", "TEST", 56, 61], ["small", "OBSERVATION_MODIFIER", 4, 9], ["-molecule", "OBSERVATION_MODIFIER", 9, 18]]], ["The inhibitor IU1 blocks the activity of USP14 only in the presence of the proteasome, suggesting that it binds only to the activated enzyme.", [["IU1", "CHEMICAL", 14, 17], ["IU1", "SIMPLE_CHEMICAL", 14, 17], ["USP14", "GENE_OR_GENE_PRODUCT", 41, 46], ["USP14", "PROTEIN", 41, 46], ["proteasome", "PROTEIN", 75, 85], ["activated enzyme", "PROTEIN", 124, 140], ["The inhibitor IU1 blocks", "TREATMENT", 0, 24], ["the proteasome", "TREATMENT", 71, 85], ["the activated enzyme", "TEST", 120, 140]]], ["Moreover, the compound IU1 abrogates the catalytic activity of USP14 without affecting its noncatalytic regulatory function [66] .", [["IU1", "CHEMICAL", 23, 26], ["USP14", "CHEMICAL", 63, 68], ["IU1", "SIMPLE_CHEMICAL", 23, 26], ["USP14", "GENE_OR_GENE_PRODUCT", 63, 68], ["USP14", "PROTEIN", 63, 68]]], ["However, with the growing number of USP14 substrates identified, there was a need for the development of IU1 analogs with improved selectivity over the USP14-substrate complexes.", [["IU1", "CHEMICAL", 105, 108], ["USP14", "GENE_OR_GENE_PRODUCT", 36, 41], ["IU1 analogs", "SIMPLE_CHEMICAL", 105, 116], ["USP14", "SIMPLE_CHEMICAL", 152, 157], ["USP14 substrates", "PROTEIN", 36, 52], ["USP14", "PROTEIN", 152, 157], ["substrate complexes", "PROTEIN", 158, 177], ["USP14 substrates", "PROBLEM", 36, 52], ["IU1 analogs", "PROBLEM", 105, 116], ["growing", "OBSERVATION_MODIFIER", 18, 25]]], ["A curated screen of 87 variants of IU1 led to the identification of IU1-47 as a new potent inhibitor of USP14.", [["IU1-47", "CHEMICAL", 68, 74], ["IU1-47", "CHEMICAL", 68, 74], ["IU1", "GENE_OR_GENE_PRODUCT", 35, 38], ["IU1-47", "GENE_OR_GENE_PRODUCT", 68, 74], ["USP14", "GENE_OR_GENE_PRODUCT", 104, 109], ["IU1", "DNA", 35, 38], ["USP14", "PROTEIN", 104, 109], ["A curated screen", "TEST", 0, 16], ["IU1", "TEST", 68, 71], ["a new potent inhibitor of USP14", "TREATMENT", 78, 109]]], ["IU1-47 treatment of murine primary neuron cultures and in neurons derived from human-induced pluripotent stem cells (iPSC) accelerates the degradation of the microtubule-associated protein Tau, which is implicated in many neurodegenerative diseases.", [["primary neuron cultures", "ANATOMY", 27, 50], ["neurons", "ANATOMY", 58, 65], ["pluripotent stem cells", "ANATOMY", 93, 115], ["iPSC", "ANATOMY", 117, 121], ["microtubule", "ANATOMY", 158, 169], ["IU1-47", "CHEMICAL", 0, 6], ["neurodegenerative diseases", "DISEASE", 222, 248], ["IU1-47", "CHEMICAL", 0, 6], ["IU1-47", "SIMPLE_CHEMICAL", 0, 6], ["murine", "ORGANISM", 20, 26], ["primary neuron cultures", "CELL", 27, 50], ["neurons", "CELL", 58, 65], ["human", "ORGANISM", 79, 84], ["pluripotent stem cells", "CELL", 93, 115], ["iPSC", "CELL", 117, 121], ["microtubule", "CELLULAR_COMPONENT", 158, 169], ["Tau", "GENE_OR_GENE_PRODUCT", 189, 192], ["murine primary neuron cultures", "CELL_LINE", 20, 50], ["human-induced pluripotent stem cells", "CELL_LINE", 79, 115], ["iPSC", "CELL_LINE", 117, 121], ["microtubule", "PROTEIN", 158, 169], ["Tau", "PROTEIN", 189, 192], ["murine", "SPECIES", 20, 26], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["IU1", "TEST", 0, 3], ["murine primary neuron cultures", "TEST", 20, 50], ["human-induced pluripotent stem cells", "TREATMENT", 79, 115], ["the degradation", "PROBLEM", 135, 150], ["associated protein Tau", "PROBLEM", 170, 192], ["many neurodegenerative diseases", "PROBLEM", 217, 248], ["pluripotent stem cells", "OBSERVATION", 93, 115], ["protein Tau", "OBSERVATION", 181, 192], ["many", "OBSERVATION_MODIFIER", 217, 221], ["neurodegenerative diseases", "OBSERVATION", 222, 248]]], ["Besides, the inhibition of USP14 by IU1-47 induced an increase of the autophagy flux, consistent with the increased degradation rate of Tau [175] .Characterised Inhibitors of DUBs Acting in AutophagyAs mentioned above, UCH-L1 is a negative regulator of autophagy widely studied for its implication in Parkinson's disease and its contribution to the aggregation of \u03b1-synuclein as a result of autophagy blockade [86, 89] .", [["USP14", "CHEMICAL", 27, 32], ["IU1-47", "CHEMICAL", 36, 42], ["Parkinson's disease", "DISEASE", 301, 320], ["IU1-47", "CHEMICAL", 36, 42], ["USP14", "GENE_OR_GENE_PRODUCT", 27, 32], ["IU1-47", "SIMPLE_CHEMICAL", 36, 42], ["Tau [175]", "GENE_OR_GENE_PRODUCT", 136, 145], ["DUBs", "GENE_OR_GENE_PRODUCT", 175, 179], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 219, 225], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 364, 375], ["USP14", "PROTEIN", 27, 32], ["Tau", "PROTEIN", 136, 139], ["DUBs", "PROTEIN", 175, 179], ["UCH", "PROTEIN", 219, 222], ["L1", "PROTEIN", 223, 225], ["\u03b1-synuclein", "PROTEIN", 364, 375], ["USP14", "TEST", 27, 32], ["IU1", "TEST", 36, 39], ["the autophagy flux", "PROBLEM", 66, 84], ["the increased degradation rate of Tau", "PROBLEM", 102, 139], ["Parkinson's disease", "PROBLEM", 301, 320], ["\u03b1-synuclein", "TREATMENT", 364, 375], ["autophagy blockade", "TREATMENT", 391, 409], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["autophagy flux", "OBSERVATION", 70, 84], ["consistent with", "UNCERTAINTY", 86, 101], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["L1", "ANATOMY", 223, 225]]], ["UCH-L1 is also expressed in various primary lung tumors while not detectable in normal, healthy lung tissue, suggesting a possible contribution to cancer [176] .", [["primary lung tumors", "ANATOMY", 36, 55], ["lung tissue", "ANATOMY", 96, 107], ["cancer", "ANATOMY", 147, 153], ["primary lung tumors", "DISEASE", 36, 55], ["cancer", "DISEASE", 147, 153], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 0, 6], ["lung tumors", "CANCER", 44, 55], ["lung tissue", "TISSUE", 96, 107], ["cancer", "CANCER", 147, 153], ["UCH", "PROTEIN", 0, 3], ["L1", "PROTEIN", 4, 6], ["various primary lung tumors", "PROBLEM", 28, 55], ["cancer", "PROBLEM", 147, 153], ["L1", "ANATOMY", 4, 6], ["various", "OBSERVATION_MODIFIER", 28, 35], ["primary", "OBSERVATION_MODIFIER", 36, 43], ["lung", "ANATOMY", 44, 48], ["tumors", "OBSERVATION", 49, 55], ["normal", "OBSERVATION", 80, 86], ["lung", "ANATOMY", 96, 100], ["tissue", "OBSERVATION", 101, 107], ["suggesting a possible", "UNCERTAINTY", 109, 130], ["cancer", "OBSERVATION", 147, 153]]], ["Because of the correlation between UCH-L1 and tumor progression, as well as its implication in neurodegenerative disease, UCH-L1 is a recognized target for the development of therapeutic inhibitors.", [["tumor", "ANATOMY", 46, 51], ["tumor", "DISEASE", 46, 51], ["neurodegenerative disease", "DISEASE", 95, 120], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 35, 41], ["tumor", "CANCER", 46, 51], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 122, 128], ["UCH", "PROTEIN", 35, 38], ["UCH", "PROTEIN", 122, 125], ["L1", "DNA", 126, 128], ["tumor progression", "PROBLEM", 46, 63], ["neurodegenerative disease", "PROBLEM", 95, 120], ["therapeutic inhibitors", "TREATMENT", 175, 197], ["L1", "ANATOMY", 39, 41], ["tumor", "OBSERVATION", 46, 51], ["neurodegenerative", "OBSERVATION_MODIFIER", 95, 112], ["disease", "OBSERVATION", 113, 120], ["L1", "ANATOMY", 126, 128]]], ["As such, the compound LDN-57444 was identified in a high throughput drug screening as a specific UCH-L1 inhibitor.", [["LDN-57444", "CHEMICAL", 22, 31], ["LDN-57444", "CHEMICAL", 22, 31], ["LDN-57444", "SIMPLE_CHEMICAL", 22, 31], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 97, 103], ["UCH", "PROTEIN", 97, 100], ["the compound LDN", "TEST", 9, 25], ["drug screening", "TEST", 68, 82], ["a specific UCH-L1 inhibitor", "TREATMENT", 86, 113]]], ["Treating H1299 lung cancer cell line with this compound significantly reduces the cell proliferation rate [177] .", [["H1299 lung cancer cell line", "ANATOMY", 9, 36], ["cell", "ANATOMY", 82, 86], ["lung cancer", "DISEASE", 15, 26], ["H1299 lung cancer cell line", "CELL", 9, 36], ["cell", "CELL", 82, 86], ["H1299 lung cancer cell line", "CELL_LINE", 9, 36], ["H1299 lung cancer cell line", "PROBLEM", 9, 36], ["this compound", "PROBLEM", 42, 55], ["the cell proliferation rate", "TEST", 78, 105], ["lung", "ANATOMY", 15, 19], ["cancer", "OBSERVATION", 20, 26], ["cell line", "OBSERVATION", 27, 36], ["significantly", "OBSERVATION_MODIFIER", 56, 69], ["cell proliferation", "OBSERVATION", 82, 100]]], ["NSC632839 is another inhibitor that affects UCH-L1 activity.", [["NSC632839", "CHEMICAL", 0, 9], ["NSC632839", "CHEMICAL", 0, 9], ["NSC632839", "SIMPLE_CHEMICAL", 0, 9], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 44, 50], ["UCH", "PROTEIN", 44, 47], ["another inhibitor", "TREATMENT", 13, 30], ["L1", "ANATOMY", 48, 50]]], ["However, NSC632839 activity is not specific to UCH-L1, and it is already known to inhibit USP2 and USP7 [178, 179] .", [["NSC632839", "CHEMICAL", 9, 18], ["NSC632839", "GENE_OR_GENE_PRODUCT", 9, 18], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 47, 53], ["USP2", "GENE_OR_GENE_PRODUCT", 90, 94], ["USP7", "GENE_OR_GENE_PRODUCT", 99, 103], ["NSC632839", "PROTEIN", 9, 18], ["UCH", "PROTEIN", 47, 50], ["USP2", "PROTEIN", 90, 94], ["USP7", "PROTEIN", 99, 103], ["USP2", "TEST", 90, 94], ["USP7", "TEST", 99, 103], ["L1", "ANATOMY", 51, 53]]], ["The amount of p62 in cells is reduced after treatment with both LDN-57444 and NCS632839, suggesting that these drugs could prevent the accumulation of protein aggregates [178] .", [["cells", "ANATOMY", 21, 26], ["LDN-57444", "CHEMICAL", 64, 73], ["NCS632839", "CHEMICAL", 78, 87], ["LDN-57444", "CHEMICAL", 64, 73], ["NCS632839", "CHEMICAL", 78, 87], ["p62", "GENE_OR_GENE_PRODUCT", 14, 17], ["cells", "CELL", 21, 26], ["LDN-57444", "SIMPLE_CHEMICAL", 64, 73], ["NCS632839", "SIMPLE_CHEMICAL", 78, 87], ["p62", "PROTEIN", 14, 17], ["p62 in cells", "PROBLEM", 14, 26], ["treatment", "TREATMENT", 44, 53], ["these drugs", "TREATMENT", 105, 116], ["the accumulation of protein aggregates", "PROBLEM", 131, 169], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["p62", "OBSERVATION", 14, 17], ["reduced", "OBSERVATION_MODIFIER", 30, 37]]], ["Therefore, these inhibitors may constitute new tools to investigate further the implication of UCH-L1 in Parkinson's disease and evaluate whether UCH-L1 inhibition favors the clearance of \u03b1-synuclein aggregates in neurons.Characterised Inhibitors of DUBs Acting in AutophagyInhibition of early regulators is another strategy to inhibit autophagy in some situations.", [["neurons", "ANATOMY", 214, 221], ["Parkinson's disease", "DISEASE", 105, 124], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 95, 101], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 146, 152], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 188, 199], ["neurons", "CELL", 214, 221], ["DUBs", "GENE_OR_GENE_PRODUCT", 250, 254], ["UCH", "PROTEIN", 95, 98], ["UCH", "PROTEIN", 146, 149], ["neurons", "CELL_TYPE", 214, 221], ["DUBs", "PROTEIN", 250, 254], ["these inhibitors", "TREATMENT", 11, 27], ["UCH", "TEST", 95, 98], ["Parkinson's disease", "PROBLEM", 105, 124], ["UCH", "TEST", 146, 149], ["\u03b1-synuclein aggregates in neurons", "PROBLEM", 188, 221], ["L1", "ANATOMY", 99, 101]]], ["The inhibitor WP1130, which targets USP9X, was reported to lead to an increase in ULK1 ubiquitination, inducing its transfer to the aggresomes and its inhibition, further resulting in the blockade of autophagy in several cultured cell lines, including the bone osteosarcoma U2OS cell line [180] .", [["aggresomes", "ANATOMY", 132, 142], ["cell lines", "ANATOMY", 230, 240], ["bone osteosarcoma U2OS cell line", "ANATOMY", 256, 288], ["WP1130", "CHEMICAL", 14, 20], ["osteosarcoma", "DISEASE", 261, 273], ["WP1130", "CHEMICAL", 14, 20], ["WP1130", "SIMPLE_CHEMICAL", 14, 20], ["USP9X", "GENE_OR_GENE_PRODUCT", 36, 41], ["ULK1", "GENE_OR_GENE_PRODUCT", 82, 86], ["cell lines", "CELL", 230, 240], ["bone osteosarcoma U2OS cell line [180]", "CELL", 256, 294], ["USP9X", "PROTEIN", 36, 41], ["ULK1", "PROTEIN", 82, 86], ["cultured cell lines", "CELL_LINE", 221, 240], ["bone osteosarcoma U2OS cell line", "CELL_LINE", 256, 288], ["The inhibitor", "TREATMENT", 0, 13], ["USP9X", "TEST", 36, 41], ["an increase in ULK1 ubiquitination", "PROBLEM", 67, 101], ["autophagy", "PROBLEM", 200, 209], ["several cultured cell lines", "TREATMENT", 213, 240], ["the bone osteosarcoma", "PROBLEM", 252, 273], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["ULK1 ubiquitination", "OBSERVATION", 82, 101], ["cultured cell lines", "OBSERVATION", 221, 240], ["bone", "ANATOMY", 256, 260], ["osteosarcoma U2OS cell line", "OBSERVATION", 261, 288]]], ["It was speculated that the inhibition of USP9X could be responsible for the accumulation and subsequent aggregation of ubiquitinated ULK1.", [["USP9X", "CHEMICAL", 41, 46], ["USP9X", "GENE_OR_GENE_PRODUCT", 41, 46], ["ULK1", "GENE_OR_GENE_PRODUCT", 133, 137], ["USP9X", "PROTEIN", 41, 46], ["ULK1", "PROTEIN", 133, 137], ["the inhibition of USP9X", "PROBLEM", 23, 46], ["the accumulation", "PROBLEM", 72, 88], ["subsequent aggregation of ubiquitinated ULK1", "PROBLEM", 93, 137], ["could be responsible for", "UNCERTAINTY", 47, 71], ["aggregation", "OBSERVATION_MODIFIER", 104, 115], ["ubiquitinated ULK1", "OBSERVATION", 119, 137]]], ["However, silencing Usp9X did not result in changes in ULK1 expression level when cells were treated with WP1130.", [["cells", "ANATOMY", 81, 86], ["WP1130", "CHEMICAL", 105, 111], ["WP1130", "CHEMICAL", 105, 111], ["Usp9X", "GENE_OR_GENE_PRODUCT", 19, 24], ["ULK1", "GENE_OR_GENE_PRODUCT", 54, 58], ["cells", "CELL", 81, 86], ["Usp9X", "PROTEIN", 19, 24], ["ULK1", "PROTEIN", 54, 58], ["silencing Usp9X", "PROBLEM", 9, 24], ["changes in ULK1 expression level", "PROBLEM", 43, 75]]], ["This could be because WP1130 is only partially specific and could have other targets in vivo that remain to be discovered [180, 181] .Characterised Inhibitors of DUBs Acting in AutophagyIn order to screen and select new small-molecules interfering with autophagy in mammalian cells, an imaging-based assay has been optimized by Liu and colleagues that makes use of cells expressing the autophagy marker GFP-LC3 to quantify the accumulation of autophagosomes [79] .", [["mammalian cells", "ANATOMY", 266, 281], ["cells", "ANATOMY", 365, 370], ["autophagosomes", "ANATOMY", 443, 457], ["WP1130", "CHEMICAL", 22, 28], ["WP1130", "SIMPLE_CHEMICAL", 22, 28], ["DUBs", "GENE_OR_GENE_PRODUCT", 162, 166], ["mammalian cells", "CELL", 266, 281], ["cells", "CELL", 365, 370], ["GFP-LC3", "GENE_OR_GENE_PRODUCT", 403, 410], ["autophagosomes", "CELLULAR_COMPONENT", 443, 457], ["WP1130", "PROTEIN", 22, 28], ["DUBs", "PROTEIN", 162, 166], ["mammalian cells", "CELL_TYPE", 266, 281], ["GFP", "PROTEIN", 403, 406], ["LC3", "PROTEIN", 407, 410], ["new small-molecules", "PROBLEM", 216, 235], ["autophagy in mammalian cells", "PROBLEM", 253, 281], ["an imaging", "TEST", 283, 293], ["the accumulation of autophagosomes", "PROBLEM", 423, 457]]], ["Using this assay, they screened the ICCB known bioactives library, a collection of 472 compounds, and they identified the inhibitor spautin-1 (specific and potent autophagy inhibitor 1).", [["spautin-1", "GENE_OR_GENE_PRODUCT", 132, 141], ["ICCB known bioactives library", "DNA", 36, 65], ["this assay", "TEST", 6, 16], ["a collection", "TEST", 67, 79], ["the inhibitor spautin", "TREATMENT", 118, 139], ["potent autophagy inhibitor", "TREATMENT", 156, 182], ["bioactives library", "OBSERVATION", 47, 65]]], ["Spautin-1 inhibits the catalytic activity of both USP10 and USP13 with an IC 50 of~0.6-0.7 \u00b5M.", [["Spautin-1", "CHEMICAL", 0, 9], ["Spautin-1", "CHEMICAL", 0, 9], ["USP10", "CHEMICAL", 50, 55], ["USP13", "CHEMICAL", 60, 65], ["Spautin-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["USP10", "SIMPLE_CHEMICAL", 50, 55], ["USP13", "SIMPLE_CHEMICAL", 60, 65], ["Spautin", "TEST", 0, 7], ["an IC", "TEST", 71, 76]]], ["These two DUBs are involved in the regulation of Beclin1 ubiquitination in the Vps34 complex and, therefore, constitute an entry point to modulate the initiation of autophagy.", [["DUBs", "GENE_OR_GENE_PRODUCT", 10, 14], ["Beclin1", "GENE_OR_GENE_PRODUCT", 49, 56], ["Vps34", "GENE_OR_GENE_PRODUCT", 79, 84], ["DUBs", "PROTEIN", 10, 14], ["Beclin1", "PROTEIN", 49, 56], ["Vps34 complex", "PROTEIN", 79, 92], ["Beclin1 ubiquitination", "TREATMENT", 49, 71], ["autophagy", "PROBLEM", 165, 174], ["DUBs", "OBSERVATION", 10, 14], ["Beclin1 ubiquitination", "OBSERVATION", 49, 71], ["Vps34 complex", "OBSERVATION", 79, 92]]], ["Cancer cell lines treated with spautin-1 demonstrated an increased cell death rate under starvation conditions.", [["Cancer cell lines", "ANATOMY", 0, 17], ["cell", "ANATOMY", 67, 71], ["Cancer", "DISEASE", 0, 6], ["death", "DISEASE", 72, 77], ["spautin-1", "CHEMICAL", 31, 40], ["Cancer cell lines", "CELL", 0, 17], ["spautin-1", "GENE_OR_GENE_PRODUCT", 31, 40], ["cell", "CELL", 67, 71], ["Cancer cell lines", "CELL_LINE", 0, 17], ["Cancer cell lines", "TREATMENT", 0, 17], ["an increased cell death rate under starvation conditions", "PROBLEM", 54, 110], ["cell lines", "OBSERVATION", 7, 17], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["cell death", "OBSERVATION", 67, 77]]], ["As such, spautin-1 constitutes a potential lead for the development of autophagy inhibitors for anti-cancer therapies [79] .Characterised Inhibitors of DUBs Acting in AutophagyBecause of its essential function in mitophagy, which is crucial to clear damaged mitochondria notably in neuronal cells, several small-molecule inhibitors of USP30 have been developed in the past few years.", [["mitochondria", "ANATOMY", 258, 270], ["neuronal cells", "ANATOMY", 282, 296], ["USP30", "CHEMICAL", 335, 340], ["spautin-1", "CHEMICAL", 9, 18], ["spautin-1", "GENE_OR_GENE_PRODUCT", 9, 18], ["anti-cancer", "CANCER", 96, 107], ["DUBs", "GENE_OR_GENE_PRODUCT", 152, 156], ["mitochondria", "CELLULAR_COMPONENT", 258, 270], ["neuronal cells", "CELL", 282, 296], ["USP30", "GENE_OR_GENE_PRODUCT", 335, 340], ["DUBs", "PROTEIN", 152, 156], ["neuronal cells", "CELL_TYPE", 282, 296], ["USP30", "PROTEIN", 335, 340], ["autophagy inhibitors", "TREATMENT", 71, 91], ["anti-cancer therapies", "TREATMENT", 96, 117], ["DUBs", "PROBLEM", 152, 156], ["several small-molecule inhibitors of USP30", "PROBLEM", 298, 340], ["neuronal cells", "OBSERVATION", 282, 296], ["small", "OBSERVATION_MODIFIER", 306, 311]]], ["For example, based on a phenotypic screening, it was shown that the inhibition of USP30 by the compound 15-oxospiramilactone enhances the activity of USP30's targets Mfn1 and Mfn2-two GTPases anchored at the OMM and essential for tethering adjacent mitochondria-and promotes mitochondrial fusion, thus contributing to the restoration of the mitochondria network [182] .", [["OMM", "ANATOMY", 208, 211], ["mitochondria", "ANATOMY", 249, 261], ["mitochondrial", "ANATOMY", 275, 288], ["mitochondria", "ANATOMY", 341, 353], ["USP30", "CHEMICAL", 82, 87], ["15-oxospiramilactone", "CHEMICAL", 104, 124], ["15-oxospiramilactone", "CHEMICAL", 104, 124], ["USP30", "GENE_OR_GENE_PRODUCT", 82, 87], ["15-oxospiramilactone", "SIMPLE_CHEMICAL", 104, 124], ["USP30", "GENE_OR_GENE_PRODUCT", 150, 155], ["Mfn1", "GENE_OR_GENE_PRODUCT", 166, 170], ["Mfn2", "GENE_OR_GENE_PRODUCT", 175, 179], ["GTPases", "GENE_OR_GENE_PRODUCT", 184, 191], ["OMM", "CELLULAR_COMPONENT", 208, 211], ["mitochondria", "CELLULAR_COMPONENT", 249, 261], ["mitochondrial", "CELLULAR_COMPONENT", 275, 288], ["mitochondria", "CELLULAR_COMPONENT", 341, 353], ["USP30", "PROTEIN", 82, 87], ["USP30", "PROTEIN", 150, 155], ["Mfn1", "PROTEIN", 166, 170], ["Mfn2", "PROTEIN", 175, 179], ["GTPases", "PROTEIN", 184, 191], ["a phenotypic screening", "TEST", 22, 44], ["USP30", "TEST", 82, 87], ["Mfn1", "TREATMENT", 166, 170], ["Mfn2", "TEST", 175, 179], ["tethering adjacent mitochondria", "PROBLEM", 230, 261], ["mitochondrial fusion", "TREATMENT", 275, 295], ["mitochondrial fusion", "OBSERVATION", 275, 295]]], ["More recently, an in vitro study identified a new small-molecule MF-094, as a potent and selective inhibitor of USP30.", [["MF-094", "CHEMICAL", 65, 71], ["MF-094", "CHEMICAL", 65, 71], ["MF-094", "SIMPLE_CHEMICAL", 65, 71], ["USP30", "GENE_OR_GENE_PRODUCT", 112, 117], ["USP30", "PROTEIN", 112, 117], ["an in vitro study", "TEST", 15, 32], ["a new small-molecule MF", "PROBLEM", 44, 67], ["selective inhibitor of USP30", "TREATMENT", 89, 117], ["new", "OBSERVATION_MODIFIER", 46, 49], ["small", "OBSERVATION_MODIFIER", 50, 55]]], ["This compound has the opposite effect of 15-oxospiramilactone, as MF-094-mediated inhibition of USP30 accelerates mitophagy [183] .", [["15-oxospiramilactone", "CHEMICAL", 41, 61], ["MF-094", "CHEMICAL", 66, 72], ["USP30", "CHEMICAL", 96, 101], ["15-oxospiramilactone", "CHEMICAL", 41, 61], ["MF-094", "CHEMICAL", 66, 72], ["15-oxospiramilactone", "SIMPLE_CHEMICAL", 41, 61], ["MF-094", "SIMPLE_CHEMICAL", 66, 72], ["USP30", "GENE_OR_GENE_PRODUCT", 96, 101], ["USP30", "PROTEIN", 96, 101]]], ["These two studies highlight the fact that the same DUBs can be involved in different processes, dependent on the signal they may receive and the interaction within different protein complexes.Characterised Inhibitors of DUBs Acting in AutophagyThere is no doubt that new inhibitors of DUBs will arise with problems related to the existence of several substrates or to poor selectivity, requiring in-depth analysis of the selected compounds in different cell types and stress situations before any preclinical assays.", [["cell", "ANATOMY", 453, 457], ["DUBs", "GENE_OR_GENE_PRODUCT", 51, 55], ["DUBs", "GENE_OR_GENE_PRODUCT", 220, 224], ["DUBs", "GENE_OR_GENE_PRODUCT", 285, 289], ["cell", "CELL", 453, 457], ["DUBs", "PROTEIN", 51, 55], ["protein complexes", "PROTEIN", 174, 191], ["DUBs", "PROTEIN", 220, 224], ["DUBs", "PROTEIN", 285, 289], ["These two studies", "TEST", 0, 17], ["the same DUBs", "PROBLEM", 42, 55], ["new inhibitors of DUBs", "PROBLEM", 267, 289], ["problems", "PROBLEM", 306, 314], ["poor selectivity", "PROBLEM", 368, 384], ["depth analysis", "TEST", 399, 413], ["stress situations", "PROBLEM", 468, 485], ["any preclinical assays", "TEST", 493, 515], ["no doubt", "UNCERTAINTY", 253, 261], ["new", "OBSERVATION_MODIFIER", 267, 270], ["different cell types", "OBSERVATION", 443, 463]]], ["Interestingly, these investigations may tell a lot about how DUBs regulate autophagy and other cell processes, and may be used as molecular tools to unveil regulatory mechanisms.ConclusionsProtein ubiquitination is an essential, reversible, posttranslational modification involved in virtually every cellular process.", [["cell", "ANATOMY", 95, 99], ["cellular", "ANATOMY", 300, 308], ["DUBs", "GENE_OR_GENE_PRODUCT", 61, 65], ["cell", "CELL", 95, 99], ["cellular", "CELL", 300, 308], ["DUBs", "PROTEIN", 61, 65], ["these investigations", "TEST", 15, 35], ["Protein ubiquitination", "TEST", 189, 211], ["posttranslational modification", "PROBLEM", 241, 271], ["Protein ubiquitination", "OBSERVATION", 189, 211], ["reversible", "OBSERVATION_MODIFIER", 229, 239], ["posttranslational modification", "OBSERVATION", 241, 271], ["cellular process", "OBSERVATION", 300, 316]]], ["The past decades have seen remarkable progress in the understanding of the function of DUBs, their mechanism of action and regulation.", [["DUBs", "GENE_OR_GENE_PRODUCT", 87, 91], ["DUBs", "PROTEIN", 87, 91]]], ["Recently, there has been an increasing body of evidence that ubiquitination plays a crucial role in regulating autophagy, and DUBs intervene at multiple steps in autophagy.", [["DUBs", "GENE_OR_GENE_PRODUCT", 126, 130], ["DUBs", "PROTEIN", 126, 130], ["DUBs", "TREATMENT", 126, 130], ["increasing", "OBSERVATION_MODIFIER", 28, 38], ["ubiquitination", "OBSERVATION", 61, 75]]], ["Deregulation in both autophagy and ubiquitination/deubiquitination processes have been linked to many pathologies such as neurodegenerative diseases, cancer onset and progression, and different kinds of viral or bacterial infections.", [["cancer", "ANATOMY", 150, 156], ["neurodegenerative diseases", "DISEASE", 122, 148], ["cancer", "DISEASE", 150, 156], ["viral or bacterial infections", "DISEASE", 203, 232], ["cancer", "CANCER", 150, 156], ["Deregulation in both autophagy", "PROBLEM", 0, 30], ["ubiquitination/deubiquitination processes", "PROBLEM", 35, 76], ["many pathologies", "PROBLEM", 97, 113], ["neurodegenerative diseases", "PROBLEM", 122, 148], ["cancer onset", "PROBLEM", 150, 162], ["progression", "PROBLEM", 167, 178], ["viral or bacterial infections", "PROBLEM", 203, 232], ["deubiquitination processes", "OBSERVATION", 50, 76], ["neurodegenerative", "OBSERVATION_MODIFIER", 122, 139], ["diseases", "OBSERVATION", 140, 148], ["cancer", "OBSERVATION", 150, 156], ["progression", "OBSERVATION_MODIFIER", 167, 178], ["different kinds", "OBSERVATION_MODIFIER", 184, 199], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["bacterial", "OBSERVATION_MODIFIER", 212, 221], ["infections", "OBSERVATION", 222, 232]]], ["Also, considerable effort was placed on the development and optimization of small-molecules acting as DUBs inhibitors.", [["DUBs", "GENE_OR_GENE_PRODUCT", 102, 106], ["DUBs", "PROTEIN", 102, 106], ["small-molecules", "PROBLEM", 76, 91], ["DUBs inhibitors", "TREATMENT", 102, 117], ["considerable", "OBSERVATION_MODIFIER", 6, 18], ["effort", "OBSERVATION", 19, 25], ["small", "OBSERVATION_MODIFIER", 76, 81]]], ["Such molecules can serve not only as leads for the development of drug-like molecules but also as tremendous useful tools to investigate the molecular mechanism of autophagy and its regulation by the ubiquitin system.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 200, 209], ["drug-like molecules", "PROBLEM", 66, 85]]], ["By the development of molecules targeting protein-protein interaction instead of the catalytic activity, it could be possible to manipulate and orientate precisely the function of a DUB towards a given process and/or target to avoid pleiotropic effects.", [["DUB", "GENE_OR_GENE_PRODUCT", 182, 185], ["DUB", "PROTEIN", 182, 185], ["protein-protein interaction", "TREATMENT", 42, 69], ["pleiotropic effects", "PROBLEM", 233, 252]]]], "a01fad236c84911b2ba7e7ba3aeb4a3b0b77436f": [["1 However, its significance as an issue of public policy has perhaps never been higher.", [["higher", "OBSERVATION_MODIFIER", 80, 86]]], ["The threat of bioterrorism and the emergence of new forms of infectious disease have prompted international organizations and governments to review the state of public health laws to facilitate a swift response to health emergencies.", [["infectious disease", "DISEASE", 61, 79], ["bioterrorism", "PROBLEM", 14, 26], ["infectious disease", "PROBLEM", 61, 79], ["threat", "OBSERVATION_MODIFIER", 4, 10], ["bioterrorism", "OBSERVATION", 14, 26], ["infectious", "OBSERVATION", 61, 71]]], ["Relatedly, there is an emerging acknowledgement that existing legislation on public health is based upon outdated assumptions regarding both the causes and spread of disease and societal arrangements.", [["disease", "PROBLEM", 166, 173], ["societal arrangements", "TREATMENT", 178, 199]]], ["Furthermore, so-called 'lifestyle' diseases such as obesity and smoking-related illnesses are increasingly regarded as proper subjects for governmental attention -not least because of the pressure which they may place upon finite resources for health care -and legal intervention of various types represents one strategy for addressing the root causes of such conditions.", [["root", "ANATOMY", 340, 344], ["obesity", "DISEASE", 52, 59], ["smoking", "CHEMICAL", 64, 71], ["so-called 'lifestyle' diseases", "PROBLEM", 13, 43], ["obesity", "PROBLEM", 52, 59], ["health care", "TREATMENT", 244, 255], ["legal intervention", "TREATMENT", 261, 279], ["such conditions", "PROBLEM", 355, 370]]], ["Finally, and perhaps least tangibly, academic work which postulates that modern governments should be centrally concerned with the management of risk has prompted re-evaluation of the potential of legal mechanisms to provide a framework for the assessment of, and responses to, new forms of risk arising in the public health context.", [["the assessment", "TEST", 241, 255]]], ["Although this task is not wholly straightforward, given both practical and intellectual obstacles, it is the authors' belief that the topicality of the subject matter and the pedagogical benefits which it may yield significantly outweigh the obstacles which stand in the way of its acceptance within the academy.Defining 'public health law'It is perhaps trite to observe that the starting point for any field of study must be to offer a definition of its subject matter and scope.", [["any field of study", "TEST", 399, 417]]], ["2 Even if agreement can be reached upon this matter, definitions of the field of study will continue to vary across jurisdictions in response to the characteristics of the domestic legal framework.", [["the field of study", "TEST", 68, 86]]], ["The most comprehensive definition is that offered by Gostin, developed in an American context:Defining 'public health law''Public health law is the study of the legal powers and duties of the state, in collaboration with its partners (e.g. health care, business, the community, the media, and academe) to assure the conditions for people to be healthy (e.g. to identify, prevent, and ameliorate risks to health in the population) and the limitations on the power of the state to constrain the autonomy, privacy, liberty, proprietary, or other legally protected interests of individuals for the common good.", [["people", "ORGANISM", 331, 337], ["people", "SPECIES", 331, 337]]], ["3 This might be compared with an Australian definition, which identifies public health law as 'any area of legal regulation which affects the maintenance and improvement of the health of individuals in a community', 4 and with that of Martin, writing from a UK perspective, who has defined the field as 'that body of law which can be used as a tool in the provision, protection and promotion of the health rights of the population'.", [["legal", "OBSERVATION", 107, 112], ["improvement", "OBSERVATION_MODIFIER", 158, 169]]], ["5 The differences between these definitions reflect the nature of the legal framework in differing jurisdictions: in some instances, public health law will primarily take the form of legislative intervention, while in others (such as England and Wales), a patchwork of legislation dealing with public health sits alongside regulation through the common law, which enables individuals to bring actions in public or private law to protect their public health 'rights'.", [["legislative intervention", "TREATMENT", 183, 207]]], ["Common to each, however, is a perception of the facilitative role which may be played by law: that, as Gostin has written, it can function as an 'essential tool for creating the conditions that enable people to lead healthier and safer lives'.", [["people", "ORGANISM", 201, 207], ["people", "SPECIES", 201, 207]]], ["3, 5 In contrast to the above, medical law concerns itself primarily with the individual, not the collective, with the physician-patient nexus being central.", [["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136]]], ["As Kennedy and Grubb note, it 'is essentially concerned with the relationship between health care professionals (particularly doctors and to a lesser extent hospitals or other institutions) and patients'.", [["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202]]], ["6 It emphasizes internal, rather than external, causes of disease and ill health, and its orientation is towards the remedying of error, not the management and reduction of risks to health.", [["disease", "PROBLEM", 58, 65], ["the management", "TREATMENT", 141, 155], ["internal", "OBSERVATION_MODIFIER", 16, 24], ["disease", "OBSERVATION", 58, 65]]], ["Notwithstanding that there has been a recent emergence of courses in healthcare law, which seek to move beyond the clinical relationship to explore broader legal issues in the organization and delivery of health services, 7 public health remains, at best, a subsidiary concern as the focus remains upon care of the sick as distinct from promotion of the health of the population.The low profile of public health lawPublic health law remains substantially neglected as a subject of academic study.", [["academic study", "TEST", 481, 495], ["low profile", "OBSERVATION_MODIFIER", 383, 394]]], ["Taking the UK as an illustration, the syllabus for examinations for membership of the Faculty of Public Health makes no specific reference to awareness of the legal framework, focusing instead upon 'candidates' knowledge and understanding of the scientific basis of public health, and their ability to apply their knowledge and skills to the practice of public health'.", [["examinations", "TEST", 51, 63]]], ["8,a Likewise, of the 17 universities offering the degree of Master of Public Health in the UK, only one (Nottingham) currently offers an optional module specifically dedicated to the study of public health law, b albeit that legal issues will necessarily arise in the context of other modules, such as those addressing communicable diseases or ethical issues.The low profile of public health lawA similar gap exists for those who approach the practice of public health from a legal background.", [["communicable diseases", "PROBLEM", 319, 340], ["ethical issues", "PROBLEM", 344, 358], ["low profile", "OBSERVATION_MODIFIER", 363, 374]]], ["Again using the UK as an illustration, of the taught Masters level degree programmes in medical/health law or cognate disciplines which are currently provided by law departments in 17 universities, only that offered by Keele includes an optional module in public health law. c Notwithstanding that topics properly situated within the field of public health law may receive attention within the context of other modules, this would appear to be a surprisingly low number in view of the increasing salience of the subject matter to contemporary health policy and practice.The low profile of public health lawThis pattern is not restricted to the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 644, 646], ["low profile", "OBSERVATION_MODIFIER", 574, 585]]], ["Even in the USA, where academic interest in public health law is most widespread, in part as a response to the highly influential work of Gostin, 3 and in part as a result of growing awareness of infectious threats and bioterrorism in the light of severe acute respiratory syndrome (SARS) and the September 11 2001 attacks, it has been commented that 'the omission of public health from the legal curriculum is almost complete and ubiquitous'.", [["acute respiratory syndrome", "DISEASE", 255, 281], ["SARS", "DISEASE", 283, 287], ["infectious threats", "PROBLEM", 196, 214], ["bioterrorism", "PROBLEM", 219, 231], ["severe acute respiratory syndrome", "PROBLEM", 248, 281], ["widespread", "OBSERVATION_MODIFIER", 70, 80], ["infectious", "OBSERVATION_MODIFIER", 196, 206], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["acute", "OBSERVATION_MODIFIER", 255, 260], ["respiratory syndrome", "OBSERVATION", 261, 281]]], ["1,10d A disjuncture between law and public health?The low profile of public health lawWhat might explain this state of relative academic inattention?", [["inattention", "DISEASE", 137, 148], ["relative academic inattention", "PROBLEM", 119, 148], ["low profile", "OBSERVATION_MODIFIER", 54, 65]]], ["12 Perhaps the most potent explanation for such distrust derives from the differentiation between the collective orientation of public health and the individualist inclinations of medicine.", [["medicine", "TREATMENT", 180, 188], ["most potent", "OBSERVATION_MODIFIER", 15, 26]]], ["Law is much more clearly aligned with the goals of the latter.", [["much more clearly aligned", "OBSERVATION_MODIFIER", 7, 32]]], ["13 The Enlightenment notion of the individual body as the subject matter for medical intervention and the site of disease was paralleled by the evolution, within legal theory, of a conceptualization of rights, duties and responsibilities which accrued to the individual.", [["body", "ANATOMY", 46, 50], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["medical intervention", "TREATMENT", 77, 97], ["disease", "PROBLEM", 114, 121], ["disease", "OBSERVATION", 114, 121]]], ["There was, therefore, a detachment of the individual from the collectivity -and a prioritization of the formerwithin both medicine and law, with the consequence that when the two disciplines coincided, the focus lay upon the individualized physician-patient relationship.", [["patient", "ORGANISM", 250, 257], ["patient", "SPECIES", 250, 257], ["a detachment", "PROBLEM", 22, 34], ["detachment", "OBSERVATION", 24, 34]]], ["A significant consequence of this has been the existence within the public health literature of an a The second part of the examination, which must also be passed for full membership of the Faculty to be awarded, consists of a series of scenarios in which candidates demonstrate their ability to apply relevant knowledge, skills and attitudes to the practice of public health.", [["the examination", "TEST", 120, 135], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["Again, no specific legal knowledge is demanded. b The authors understand that the London School of Hygiene and Tropical Medicine is, as this article goes to press, in the process of validating such a module. c ongoing debate regarding whether public health goals are consonant with the individualistic inclination of human rights law.", [["human", "ORGANISM", 317, 322], ["human", "SPECIES", 317, 322], ["human", "SPECIES", 317, 322], ["Tropical Medicine", "TREATMENT", 111, 128], ["no", "UNCERTAINTY", 7, 9]]], ["3, 14 Concurrently, the sphere of public (collective) health has shifted to the domain of politics and economics, albeit that within that arena, costly interventions for the improvement of public health have frequently been eschewed by government, rendering public health legislation unattractive territory for policy makers.", [["costly interventions", "TREATMENT", 145, 165], ["sphere", "OBSERVATION_MODIFIER", 24, 30]]], ["Although, by definition, public health interventions impact broadly across the population, neglect of such concerns may be justifiable as reflective of a desire to avoid infringement upon individual autonomy and the free market.", [["public health interventions", "TREATMENT", 25, 52], ["free market", "OBSERVATION", 216, 227]]], ["Such a strategy is, therefore, likely to prove especially attractive to governments of a conservative or neoliberal persuasion.The low profile of public health lawThe 'lack of fit' between law and public health is exacerbated by further characteristics of the legal system which are especially apparent in 'common law' jurisdictions such as England, Australia and the USA.", [["a conservative or neoliberal persuasion", "TREATMENT", 87, 126], ["neoliberal persuasion", "OBSERVATION", 105, 126], ["low profile", "OBSERVATION_MODIFIER", 131, 142]]], ["To posit an obvious illustration of this point, English tort law has largely been bereft of effective mechanisms for responding to harms caused to large numbers of people, in the form of the group action (for the continuing problems with such actions, see Gibbons 15 ).", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["such actions", "TREATMENT", 238, 250]]], ["Lawyers undertaking challenging group actions are few and far between, with those UK law firms which undertake health law tending to focus on claims of negligence, contested consent, requests for assisted suicide, or employment and financial issues within the National Health Service (NHS).The low profile of public health lawAs Brownsword concedes, 16 common law principles may, on occasion, further the goals of public health; most notably, in cases involving the tort of nuisance.", [["low profile", "OBSERVATION_MODIFIER", 294, 305]]], ["Nonetheless, such an outcome is perhaps best viewed as a mere by-product of legal doctrine which is oriented towards individual rather than collective interests.", [["legal doctrine", "TREATMENT", 76, 90]]], ["Brownsword's view is, therefore, that the population-wide, policybased goals of public health are better regarded as the stuff of public, not private, law. e However this, too, is not unproblematic.", [["Brownsword's view", "TEST", 0, 17], ["unproblematic", "PROBLEM", 184, 197]]], ["In common law jurisdictions (as distinct from their 'civil law' counterparts, e.g. in continental Europe), public law has -at least until relatively recently -lacked a distinct identity and institutional structure.", [["law jurisdictions", "OBSERVATION", 10, 27]]], ["Coupled with the hegemony of 'Diceyan' readings of the function which law might fulfil vis-\u00e0 -vis the state (namely, that its role is to restrain the exercise of governmental power in order to safeguard the sphere of individual autonomy), 20 this has meant that the facilitative capabilities of public law mechanisms -that which Harlow and Rawlings term the 'green light' or functionalist approach to law 21 -have largely been overlooked in the public health context.The low profile of public health lawIf the individualistic orientation of law and its consequent congruence with the medical model affords an obvious basis for the marginalization of public health law both within the curriculum and practice of public health, other pertinent causative factors may also be identified.", [["low profile", "OBSERVATION_MODIFIER", 471, 482]]], ["Thus, Martin and Coker have pointed to the 20th Century faith in scientific solutions as a means of eradicating or controlling communicable disease; efforts therefore focused upon biomedicine, coupled with strategies to alleviate socio-economic deprivation.", [["communicable disease", "DISEASE", 127, 147], ["controlling communicable disease", "PROBLEM", 115, 147], ["strategies", "TREATMENT", 206, 216], ["socio-economic deprivation", "PROBLEM", 230, 256]]], ["The ready assumption that these avenues would prove successful led to the neglect of law as a tool for ensuring public health:The low profile of public health law'For a long time, the poor state of our public health law failed to trouble us because of the belief that advances in antibiotic medicines and vaccines, and health benefits that accrue from improved social conditions, would be sufficient to control infectious disease, making law practically redundant'.", [["infectious disease", "DISEASE", 411, 429], ["antibiotic medicines", "TREATMENT", 280, 300], ["vaccines", "TREATMENT", 305, 313], ["infectious disease", "PROBLEM", 411, 429]]], ["22 The consequence of this inattention to the legal framework was that -notably in the UK, but also elsewhere -public health law tended to remain rooted in a 19th Century model, based upon the containment of diseases caused by particular physical sources of nuisance or activities, and did not develop in accordance with new understandings of the social and economic determinants of health.", [["inattention", "DISEASE", 27, 38], ["this inattention", "PROBLEM", 22, 38], ["diseases", "PROBLEM", 208, 216], ["diseases", "OBSERVATION", 208, 216]]], ["This very anachronism meant that policy makers tended to ignore the opportunities offered by legal tools; rather than seeking to reform the law in pursuance of these new understandings, they preferred to sideline it and to trust, instead, to science.The low profile of public health lawHere, therefore, is another factor which has hindered the growth of the study and practice of public health law.", [["the study", "TEST", 354, 363], ["low profile", "OBSERVATION_MODIFIER", 254, 265]]], ["The problem of scope, and its implications for the teaching and study of this subject, will be addressed further below.Law as a public health toolThe severance between law and public health has thus given rise to a state of, at best, 'mutual ignorance' between the two disciplines.", [["the teaching and study", "TEST", 47, 69], ["severance", "OBSERVATION_MODIFIER", 150, 159]]], ["12 Fiscal intervention can be deployed to encourage individuals to refrain from or limit risky behaviour, such as smoking and drinking.", [["smoking", "CHEMICAL", 114, 121], ["Fiscal intervention", "TREATMENT", 3, 22]]], ["Laws can regulate the availability of information, for example by restricting the advertising of unhealthy products (such as tobacco and alcohol) or requiring provision of facts to consumers (e.g. nutritional information on food labels). f Persons, professionals and businesses can be regulated directly (e.g. licensing of care homes or laws requiring the wearing of motorcycle helmets) or indirectly through the tort system (e.g. actions in respect of environmental damage, exposure to toxic substances etc.).", [["alcohol", "CHEMICAL", 137, 144], ["alcohol", "CHEMICAL", 137, 144], ["tobacco", "ORGANISM", 125, 132], ["alcohol", "SIMPLE_CHEMICAL", 137, 144], ["Persons", "SPECIES", 240, 247], ["tobacco", "SPECIES", 125, 132], ["motorcycle helmets", "TREATMENT", 367, 385], ["environmental damage", "PROBLEM", 453, 473]]], ["Legal measures may be implemented to bring about environmental change to reduce risks to health (e.g. improvement of sanitation or health and safety in the workplace), or to bring about broader socio-economic change (legislative measures to alleviate poverty should assist in enhancing overall population health).", [["poverty", "DISEASE", 251, 258], ["Legal measures", "TREATMENT", 0, 14], ["legislative measures", "TREATMENT", 217, 237]]], ["Also, on occasion, deregulation may be necessary to achieve public health objectives; for example (and, needless to say, controversially), declassification of certain categories of drug, or decriminalization of prostitution may be said to enhance public health, particularly e In this context, one might note that a successful challenge by an individual in a judicial review case may yield collective health benefits to a wider population.", [["drug", "TREATMENT", 181, 185]]], ["For example, it was reported that the consequence of the decision of the Court of Appeal in R (Rogers) v Swindon PCT NHS Trust [2006] 1 WLR 2649 was that 'hundreds of women' would receive Herceptin for the treatment of early stage breast cancer, 17 and that eventual approval of the drug for use on the NHS by the National Institute for Health and Clinical Excellence (NICE) was, as a result of the case, a 'foregone conclusion'.", [["breast cancer", "ANATOMY", 231, 244], ["WLR 2649", "CHEMICAL", 136, 144], ["Herceptin", "CHEMICAL", 188, 197], ["breast cancer", "DISEASE", 231, 244], ["women", "ORGANISM", 167, 172], ["Herceptin", "SIMPLE_CHEMICAL", 188, 197], ["breast cancer", "CANCER", 231, 244], ["women", "SPECIES", 167, 172], ["Herceptin", "TREATMENT", 188, 197], ["the treatment", "TREATMENT", 202, 215], ["early stage breast cancer", "PROBLEM", 219, 244], ["breast", "ANATOMY", 231, 237], ["cancer", "OBSERVATION", 238, 244]]], ["19 f For example, Regulation 1924/2006/EC restricts the marketing of products by means of certain terms (e.g. 'superfood'), unless accompanied by a specific authorised health claim which explains to consumers the manner in which the product is beneficial to health.Law as a public health toolwhen implemented in conjunction with other measures, such as provision of drug rehabilitation facilities or increased availability of information on sexual health.Law as a public health toolFrom this perspective, law and public health are more properly regarded as complementary and interconnected.", [["EC", "CELL", 39, 41], ["EC", "CELL_TYPE", 39, 41], ["drug rehabilitation facilities", "TREATMENT", 366, 396]]], ["A straightforward, but topical, example of the 'fit' between legal mechanisms and public health goals is afforded by action on smoking.", [["smoking", "CHEMICAL", 127, 134], ["topical", "TREATMENT", 23, 30]]], ["Epidemiology -the core biomedical science of public health -offers evidence that smoking presents a risk to an individual's (and, by extension, to a population's) health.", [["smoking", "CHEMICAL", 81, 88]]], ["A public health practitioner, seeking to move beyond medicine's focus upon diseases caused by behaviour (emphysema, lung cancer etc.), will seek to identify external factors which may stimulate such behaviour, such as parental and peer influences or socio-economic background.", [["lung cancer", "ANATOMY", 116, 127], ["emphysema", "DISEASE", 105, 114], ["lung cancer", "DISEASE", 116, 127], ["lung cancer", "CANCER", 116, 127], ["diseases", "PROBLEM", 75, 83], ["emphysema", "PROBLEM", 105, 114], ["lung cancer", "PROBLEM", 116, 127], ["external factors", "PROBLEM", 157, 173], ["emphysema", "OBSERVATION", 105, 114], ["lung", "ANATOMY", 116, 120], ["cancer", "OBSERVATION", 121, 127]]], ["Legal measures can regulate where and to whom tobacco can be sold, where it can be consumed, how it is marketed and/or displayed, the information which is provided upon the packaging and the extent to which it is taxed.", [["tobacco", "ORGANISM", 46, 53], ["tobacco", "SPECIES", 46, 53], ["the packaging", "TREATMENT", 169, 182]]], ["In addition, law furnishes the basis for state intervention to address causative socio-economic factors in the form of action to address deprivation; for example, through improvement of housing conditions, availability of benefit or minimum wages, enhancement of educational and employment opportunities etc.Law as a public health toolFurthermore, the value of law as a mechanism for securing improvement in public health is increasingly recognized by policy makers.", [["state intervention", "TREATMENT", 41, 59]]], ["The apparently fatal undermining of the assumed superiority of biomedical solutions to public health concerns -evident both in the resurgence over recent decades of communicable diseases such as human immunodeficiency virus/acquired immunodeficiency syndrome, SARS, avian influenza and tuberculosis, and the 'emergence' of non-communicable conditions such as obesity or new threats such as bioterrorism -has been paralleled by a re-awakening of interest in legal and regulatory strategies.", [["communicable diseases", "DISEASE", 165, 186], ["human immunodeficiency virus/acquired immunodeficiency syndrome", "DISEASE", 195, 258], ["SARS", "DISEASE", 260, 264], ["avian influenza", "DISEASE", 266, 281], ["tuberculosis", "DISEASE", 286, 298], ["obesity", "DISEASE", 359, 366], ["human immunodeficiency virus", "ORGANISM", 195, 223], ["avian influenza", "ORGANISM", 266, 281], ["human immunodeficiency virus", "SPECIES", 195, 223], ["avian influenza", "SPECIES", 266, 281], ["human immunodeficiency virus", "SPECIES", 195, 223], ["biomedical solutions", "TREATMENT", 63, 83], ["communicable diseases", "PROBLEM", 165, 186], ["human immunodeficiency virus", "PROBLEM", 195, 223], ["acquired immunodeficiency syndrome", "PROBLEM", 224, 258], ["SARS", "PROBLEM", 260, 264], ["influenza", "PROBLEM", 272, 281], ["tuberculosis", "PROBLEM", 286, 298], ["non-communicable conditions", "PROBLEM", 323, 350], ["obesity", "PROBLEM", 359, 366], ["fatal", "OBSERVATION_MODIFIER", 15, 20], ["immunodeficiency syndrome", "OBSERVATION", 233, 258], ["tuberculosis", "OBSERVATION", 286, 298]]], ["1, 23 The legal instruments thus employed may take differing forms.", [["The legal instruments", "TREATMENT", 6, 27]]], ["Thus, they may be 'hard' or 'soft' in character; for example, contrast the legislation banning smoking in enclosed and substantially enclosed public places and shared workplaces in England and Wales g with non-binding guidance to the NHS on public health interventions and programmes produced by the National Institute for Health and Clinical Excellence (NICE).", [["smoking", "CHEMICAL", 95, 102], ["'hard' or 'soft' in character", "PROBLEM", 18, 47], ["public health interventions", "TREATMENT", 241, 268]]], ["Rather, as Martin has written, 'law has enormous potential to be used for the benefit of public health', in the context both of communicable disease control and, increasingly, in respect of non-communicable diseases.", [["communicable disease control", "PROBLEM", 128, 156], ["non-communicable diseases", "PROBLEM", 190, 215], ["disease", "OBSERVATION", 141, 148], ["non-communicable diseases", "OBSERVATION", 190, 215]]], ["25 A central pedagogical goal of a course in public health law will therefore be to fully explicate the facilitative capabilities of law in this field, while not being neglectful of the tensions to which it may give rise, particularly those which arise from the need to reconcile notions of the public good with culturally valued principles of individual autonomy and human rights.", [["human", "ORGANISM", 368, 373], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 368, 373], ["central", "OBSERVATION_MODIFIER", 5, 12]]], ["But perhaps that is not enough.", [["not enough", "UNCERTAINTY", 20, 30]]], ["26 This line of reasoning would point to the availability of a module in public health law as an optional subject of study on a Master of Public Health degree programme or a law degree syllabus, probably at postgraduate level (since it is those who study at postgraduate level who are most likely to enter into practice in a given field).Law as a public health toolVocational value, however, may be insufficient to justify the incorporation of public health law into an academic curriculum.", [["law degree", "OBSERVATION_MODIFIER", 174, 184]]], ["On this analysis, subjects should be taught not solely for their vocational utility, but for their capacity to 'allow [students] to understand the structures and values that permeate and underpin law. to introduce students to the wide variety of conversations that is going on within law at any one moment, so that they can explore law from a range of different stances'.", [["this analysis", "TEST", 3, 16]]], ["28 A liberal curriculum is thus characterized by pluralism and variety such that those who have benefited from study upon it may be capable of providing 'explicit or implicit personal and individual answers to questions about how the world is ordered and connected and how we value and evaluate these connections'.", [["A liberal curriculum", "TREATMENT", 3, 23], ["pluralism", "PROBLEM", 49, 58], ["liberal curriculum", "OBSERVATION", 5, 23], ["pluralism", "OBSERVATION", 49, 58], ["variety", "OBSERVATION_MODIFIER", 63, 70]]], ["28 A related liberal pedagogical goal which can be pursued through the teaching of public health law arises from its population perspective.", [["A related liberal pedagogical goal", "TREATMENT", 3, 37]]], ["26 Moreover, the population-based approach adopted in this context represents a 'transferable skill' which can assist in enhancing comprehension of law's function in other fields.", [["enhancing", "OBSERVATION_MODIFIER", 121, 130]]], ["For example, it facilitates a reading of criminal behaviour not as an instance of individual delinquency, but rather as activity which may be socially or economically conditioned.", [["delinquency", "DISEASE", 93, 104], ["individual delinquency", "PROBLEM", 82, 104]]], ["This, in turn, prompts questions regarding the legitimacy and efficacy of those legal sanctions which attach to such behaviour.", [["those legal sanctions", "TREATMENT", 74, 95]]], ["These are precisely the types of inquiry about the values inherent within law which Bradney has identified as fundamental to a liberal pedagogy.Law as a public health toolIn addition to its value across the disciplinary boundaries, public health law will also benefit the student of law, given its 'tight intertwining. with existing core courses' in that field of study.", [["existing core courses", "TREATMENT", 324, 345], ["that field of study", "TEST", 350, 369]]], ["29 Understanding of key principles and concepts in numerous subjects, such as administrative law, criminal law, environmental law, European Community law, housing law, human rights law, international law, medical law and tort law, can be enhanced if they are viewed through a public health 'prism', that is:Law as a public health tool'to understand not only public health, but the law, students should grasp the public health context in which key legal doctrines have developed.", [["human", "ORGANISM", 168, 173], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173]]], ["30 Similarly, the common law of nuisance is also interwoven with public health concerns, 5 and the doctrine of nuisance was employed as the legal mechanism for control of disease in public health legislation, much of which, in turn, has been largely subsumed within modern environmental law.", [["disease", "PROBLEM", 171, 178]]], ["9Law as a public health toolCaveat magister: the problems of teaching public health lawLaw as a public health toolThe vocational and liberal pedagogical benefits of public health law are therefore significant, but there are nonetheless a number of inherent obstacles which may give those considering the introduction of a module in the area some pause for thought.Law as a public health toolAt first sight, there would not appear to be any difficulty arising from the novelty of the subject matter.", [["significant", "OBSERVATION_MODIFIER", 197, 208], ["difficulty", "OBSERVATION", 440, 450]]], ["For example, Martin notes that governmental intervention to control public health dangers in the UK dates back to the 13th Century, 5 with Acts dealing with the repair of sewers 31 and control of nuisances, 32 and Regulations of the City of London ordering removal of pigsties from streets. h In this regard, therefore, issues of public health were among the earliest subjects of legal regulation by the state, i and 'the importance of law as a tool for the protection of the public health in England was recognised well before the practice of medicine engaged with systemic approaches to illness and disease'.", [["illness", "DISEASE", 589, 596], ["governmental intervention", "TREATMENT", 31, 56], ["the repair of sewers", "TREATMENT", 157, 177], ["disease", "PROBLEM", 601, 608], ["repair", "OBSERVATION", 161, 167]]], ["1 That said, the epistemological hegemony of the medical approach to ill health coupled with the confidence in scientific solutions has tended, as noted above, to render public health law marginalized.", [["ill", "DISEASE", 69, 72]]], ["While the field may, therefore, not be new, it has been largely dormant for the best part of a century, owing its resurgence to a concatenation of contemporary developments including the emergence of new forms of infectious disease, the threat of bioterrorism, and the growing desire of the state to intervene to regulate personal behaviour which may cause ill health and thereby place pressure on finite healthcare resources. j Although the contemporary relevance of the subject matter may serve to enhance the learning experience as students are presented with topical illustrations of the principles which they are studying, it presents a significant challenge for academics who must keep pace with a rapidly changing environment of law and policy.", [["infectious disease", "DISEASE", 213, 231], ["infectious disease", "PROBLEM", 213, 231], ["new", "OBSERVATION_MODIFIER", 39, 42], ["largely", "OBSERVATION_MODIFIER", 56, 63], ["dormant", "OBSERVATION", 64, 71], ["infectious", "OBSERVATION", 213, 223]]], ["In short, the subject is in a state of transition from a 19th Century model to one which is fit for the 21st Century and, while this presents exciting academic opportunities, it renders it less straightforward to teach than a field in which the legal rules are relatively settled. k A second difficulty arises from the broad scope of the subject matter.", [["A second difficulty", "PROBLEM", 283, 302], ["short", "OBSERVATION_MODIFIER", 3, 8], ["broad", "OBSERVATION_MODIFIER", 319, 324]]], ["Categorising that body of law which regulates public health is therefore as difficult as the task of defining public health'.", [["body", "ANATOMY", 18, 22]]], ["5 In the preceding section, the 'intertwining' of public health law with various other subjects of study, especially within the legal syllabus, was presented as pedagogically beneficial.", [["study", "TEST", 99, 104], ["legal syllabus", "ANATOMY", 128, 142]]], ["33 i Beyond the UK, the origins of public health law can be traced back still further. of whom are likely to have developed specialisms in a relatively small number of fields.", [["specialisms", "PROBLEM", 124, 135], ["likely to", "UNCERTAINTY", 99, 108], ["specialisms", "OBSERVATION", 124, 135], ["relatively", "OBSERVATION_MODIFIER", 141, 151], ["small", "OBSERVATION_MODIFIER", 152, 157], ["number", "OBSERVATION_MODIFIER", 158, 164]]], ["The teaching of public health law demands a degree of polymathism -both within the discipline of law and external to it (given the multidisciplinary character of public health) -which may prove unduly daunting to individuals in an increasingly time-pressed academic environment.", [["polymathism", "PROBLEM", 54, 65], ["polymathism", "OBSERVATION", 54, 65]]], ["This is undoubtedly a significant obstacle, but it is not one which is unprecedented.", [["significant", "OBSERVATION_MODIFIER", 22, 33], ["obstacle", "OBSERVATION", 34, 42]]], ["Prominent amongst these are likely to be the development of forms of intramural and extramural collaboration or networking, which facilitate the sharing of expertise and the pooling of knowledge among scholars with particular disciplinary specialisms.", [["intramural and extramural collaboration", "PROBLEM", 69, 108], ["particular disciplinary specialisms", "PROBLEM", 215, 250], ["likely to be", "UNCERTAINTY", 28, 40], ["intramural", "OBSERVATION_MODIFIER", 69, 79], ["extramural", "OBSERVATION_MODIFIER", 84, 94], ["collaboration", "OBSERVATION", 95, 108]]], ["36 More broadly, the Centers for Law and the Public's Health, which are World Health Organization (WHO) collaborating centres in public health law and human rights (and of which Gostin is a director), seek to serve 'as a primary resource on public health law for public health practitioners, lawyers, legislators, policy-makers, advocates, and the public' and to 'develop core legal competencies in public health law and corresponding curricula, as well as new training materials as needed'.", [["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["new training materials", "TREATMENT", 457, 479]]], ["39 Hence, although further work remains to be done in this area (notably, in respect of the availability of 'standard' pedagogical resources such as textbooks relating to particular jurisdictions), l those contemplating the development of courses in public health law need not feel isolated but can draw upon an evolving community of expertise, information and contacts in order to supplement their existing knowledge.Syllabus design and contentThe all-embracing nature of public health presents a further pedagogical challenge in terms of curriculum design; specifically, which topics to include and which to exclude given the necessarily limited coverage possible in any taught module.", [["'standard' pedagogical resources", "TREATMENT", 108, 140], ["a further pedagogical challenge", "TREATMENT", 496, 527]]], ["The difficulty arises because, as Gostin observes, 'almost everything human beings undertake impacts the population's health'.", [["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75]]], ["It may be argued that precisely because 'public health. can be everything', 40 academics have free rein to select topics of study in which they have particular research interests (thus facilitating research-led teaching), which are of contemporary relevance (thus underlining the contextual dimension of the field), and/or which correspond to their existing expertise (thereby minimizing the need for polymathism).", [["polymathism)", "TREATMENT", 401, 413]]], ["41 However, Gostin is surely correct to caution that the field of public health law becomes 'less credible if it over-reaches', 2,36 and it is, of course, pedagogically important to design coherent courses with academic integrity which contribute to the realization of specified aims and objectives.", [["academic integrity", "TREATMENT", 211, 229]]], ["For this reason, as well as for pragmatic purposes, it is necessary to separate out issues of core and peripheral importance when undertaking the task of syllabus design.", [["pragmatic purposes", "TEST", 32, 50]]], ["This entails identification of an 'inner group' of laws which indisputably concern public health, and an 'outer group' of legal rules which, while they may impact upon the health of the community, are more properly regarded as falling within the remit of other subjects of legal study, such as domestic violence, road safety or urban planning.", [["domestic violence", "DISEASE", 294, 311], ["legal study", "TEST", 273, 284], ["urban planning", "TREATMENT", 328, 342]]], ["42 The task of classification will therefore require engagement both with the compass and meaning of 'health' -which 'perplexing and ambiguous' term 43 will necessarily form the central organizing concept of a course in this field -and with the appropriate topics for, and sources of, legal intervention on public health grounds. m This is an admittedly difficult exercise given that debates regarding the proper scope of such intervention sit at the very heart of this subject, n although some assistance may be provided by the syllabi of public health law courses available on the Internet, 10 in addition to the discussion below.", [["heart", "ANATOMY", 456, 461], ["heart", "ORGAN", 456, 461], ["such intervention", "TREATMENT", 422, 439], ["heart", "ANATOMY", 456, 461]]], ["However, it is precisely the existence and contemporary relevance of such debates which warrants extended academic analysis, which the teaching of this subject can only serve to stimulate.Syllabus design and contentIn structuring such a course, attention should be given both to general questions of public health law (such as its meaning, underlying themes and foundational sources), and to specific issues of public health in respect of which the law operates or has the potential to do so.", [["extended academic analysis", "TEST", 97, 123]]], ["The latter allows the flexibility to tackle emerging issues of importance, such as avian influenza or biosecurity and bioterrorism.", [["influenza", "DISEASE", 89, 98], ["influenza", "PROBLEM", 89, 98], ["bioterrorism", "PROBLEM", 118, 130]]], ["5 This book -which is in fact a collection of essays as distinct from a standard textbook -is now out of print.", [["distinct", "OBSERVATION_MODIFIER", 56, 64]]], ["Does it leave people alone or change them for their own good?", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["Does it aggressively tax and regulate or nurture free enterprise?' 45 conventional source materials -and serves to underline the centrality of the subject matter within the contemporary sociopolitical environment.", [["tax", "PROTEIN", 21, 24]]], ["With no intention of being prescriptive, the following is the syllabus for the authors' LLM unit, with the listed topics being taught across 10 2-hour seminars.Syllabus design and contentPursuing public health and public health law Three preliminary issues are examined in this part of the unit: defining 'public health' and 'public health law'; tracking threads, themes and tensions; and foundations of public health law.Syllabus design and contentAs observed previously, the definitional task is complex, offering the opportunity for extensive and illuminating classroom debate, particularly with regard to the sociopolitical role of law and its capacity to act in a facilitative manner in this field. o The choice of underlying threads, themes and tensions will, to some extent, be a matter for personal choice, although, as noted, 'health' must act as a central organizing concept.", [["no", "UNCERTAINTY", 5, 7]]], ["As in other fields of law, the latter is at the heart of the most important and interesting tensions in public health decision making; the issues of who decides, on what basis and how such decisions are challengeable are fertile ground for academic analysis.", [["heart", "ANATOMY", 48, 53], ["heart", "ORGAN", 48, 53], ["academic analysis", "TEST", 240, 257], ["heart", "ANATOMY", 48, 53]]], ["However, such powers are increasingly dispersed across a number of strataregional, national, supranational and international.", [["increasingly", "OBSERVATION_MODIFIER", 25, 37], ["dispersed", "OBSERVATION_MODIFIER", 38, 47]]], ["Students will therefore be exposed to multiple sources of law and institutions of governance, and will develop an understanding of the impact which one has upon another, for example in setting the parameters of national policy space. p This fuses into an exploration of the foundations of public health law, entailing analysis of the sources of law and regulation, methods of legal intervention, governmental duties and powers at various levels (including an examination of key players such as WHO) and, more broadly, development of an understanding of the policy environment in which public health law operates.Syllabus design and contentA more ambitious goal here is to consider both the feasibility of evolving, and the possible shape of, a 'constitutional settlement for public health', which might establish the scope of legitimate state intervention on public health grounds and the most appropriate modes by which this might be achieved.", [["an exploration", "TEST", 252, 266], ["legal intervention", "TREATMENT", 376, 394], ["an examination", "TEST", 456, 470]]], ["16Infectious diseasesMeasures imposed by the state to control the spread of communicable disease represent the classic territory of public health law.", [["communicable disease", "DISEASE", 76, 96], ["16Infectious diseases", "PROBLEM", 0, 21], ["communicable disease", "PROBLEM", 76, 96], ["diseases", "OBSERVATION", 13, 21]]], ["However, as noted previously, while this form of intervention is of venerable heritage, it is of considerable -indeed growing -contemporary significance.", [["intervention", "TREATMENT", 49, 61]]], ["WHO confirms that infectious diseases are on the increase and that urgent action is required; 48 a conclusion supported by Baker who, in his highly readable account of the history of such diseases, laments the fact that a golden age of protection has slipped away, and cautions that we continue to be 'stalked by the quiet killers'.", [["infectious diseases", "DISEASE", 18, 37], ["infectious diseases", "PROBLEM", 18, 37], ["such diseases", "PROBLEM", 183, 196], ["infectious", "OBSERVATION", 18, 28]]], ["49 This topic naturally lends itself to exposition by means of case study analysis, entailing exploration of the legal mechanisms for and implications of control of one or more infectious diseases of modern-day importance, such as SARS, tuberculosis, pandemic influenza and/or sexually transmitted infections.", [["SARS", "DISEASE", 231, 235], ["tuberculosis", "DISEASE", 237, 249], ["influenza", "DISEASE", 260, 269], ["sexually transmitted infections", "DISEASE", 277, 308], ["pandemic influenza", "SPECIES", 251, 269], ["case study analysis", "TEST", 63, 82], ["exploration", "TEST", 94, 105], ["more infectious diseases", "PROBLEM", 172, 196], ["SARS", "PROBLEM", 231, 235], ["tuberculosis", "PROBLEM", 237, 249], ["pandemic influenza", "PROBLEM", 251, 269], ["sexually transmitted infections", "PROBLEM", 277, 308], ["infectious", "OBSERVATION_MODIFIER", 177, 187], ["tuberculosis", "OBSERVATION", 237, 249]]], ["A particular focus -and the central concern of much of the US literature on public health law 3 -will be upon the compatibility of control measures such as surveillance, screening, immunization and confinement with principles of human rights.", [["human", "ORGANISM", 229, 234], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 229, 234], ["control measures", "TREATMENT", 131, 147], ["surveillance, screening", "TEST", 156, 179], ["immunization", "TREATMENT", 181, 193]]], ["In addition, the topic offers the opportunity to expose students to the inter-relationship between multiple levels of governance and their legal outputs, given the contribution of international, supranational, national, regional and local agencies to the realization of the objective of control of such diseases.Non-communicable diseasesWHO has estimated that non-communicable diseases will account for 75% of all deaths globally by 2030.", [["non-communicable diseases", "DISEASE", 360, 385], ["deaths", "DISEASE", 414, 420], ["such diseases", "PROBLEM", 298, 311], ["Non-communicable diseasesWHO", "PROBLEM", 312, 340], ["non-communicable diseases", "PROBLEM", 360, 385], ["non-communicable", "OBSERVATION_MODIFIER", 360, 376], ["diseases", "OBSERVATION", 377, 385]]], ["Interesting and controversial debates open up around the so-called lifestyle conditions caused by tobacco, alcohol and food, revolving around the key tension between individual freedom and state responsibility; for example, as to the ethics and legality of existing screening programmes for breast and cervical cancer, and the case for introducing new programmes such as those for heart disease.Non-communicable diseasesIn view of the fact that 'tobacco use is the single largest cause of preventable death in the world today', 50 it is imperative for any course in this field to examine the role of law in controlling such use, exploring the largely failed attempts of tort law and the opportunities afforded by other methods of regulating the consumption and marketing of tobacco.", [["breast", "ANATOMY", 291, 297], ["cervical cancer", "ANATOMY", 302, 317], ["heart", "ANATOMY", 381, 386], ["alcohol", "CHEMICAL", 107, 114], ["breast and cervical cancer", "DISEASE", 291, 317], ["heart disease", "DISEASE", 381, 394], ["Non-communicable diseases", "DISEASE", 395, 420], ["death", "DISEASE", 501, 506], ["alcohol", "CHEMICAL", 107, 114], ["tobacco", "ORGANISM", 98, 105], ["alcohol", "SIMPLE_CHEMICAL", 107, 114], ["breast", "CANCER", 291, 297], ["cervical cancer", "CANCER", 302, 317], ["heart", "ORGAN", 381, 386], ["tobacco", "ORGANISM", 446, 453], ["tobacco", "ORGANISM", 774, 781], ["tobacco", "SPECIES", 98, 105], ["tobacco", "SPECIES", 446, 453], ["tobacco", "SPECIES", 774, 781], ["existing screening programmes", "TREATMENT", 257, 286], ["breast and cervical cancer", "PROBLEM", 291, 317], ["introducing new programmes", "TREATMENT", 336, 362], ["heart disease", "PROBLEM", 381, 394], ["Non-communicable diseases", "PROBLEM", 395, 420], ["preventable death", "PROBLEM", 489, 506], ["breast", "ANATOMY", 291, 297], ["cervical", "ANATOMY", 302, 310], ["cancer", "OBSERVATION", 311, 317], ["heart", "ANATOMY", 381, 386], ["disease", "OBSERVATION", 387, 394], ["diseases", "OBSERVATION", 412, 420]]], ["51 Equally important issues arise in respect of legal measures to control food consumption and obesity.", [["obesity", "DISEASE", 95, 102], ["food", "ORGANISM_SUBDIVISION", 74, 78], ["legal measures", "TREATMENT", 48, 62], ["obesity", "PROBLEM", 95, 102], ["obesity", "OBSERVATION", 95, 102]]], ["Insufficient food used to be (and in some places still is) a major threat to public health; the irony of the 21st Century is that excessive or harmful foodstuffs/ingredients are a leading cause of chronic disease.", [["chronic disease", "PROBLEM", 197, 212], ["chronic", "OBSERVATION_MODIFIER", 197, 204], ["disease", "OBSERVATION", 205, 212]]], ["This is compounded by the further irony that chronic conditions which were thought to be characteristic of higher income nations (caused as they are by excess food, alcohol and tobacco) now result in more deaths than communicable diseases in many low-income nations.", [["alcohol", "CHEMICAL", 165, 172], ["deaths", "DISEASE", 205, 211], ["communicable diseases", "DISEASE", 217, 238], ["alcohol", "CHEMICAL", 165, 172], ["alcohol", "SIMPLE_CHEMICAL", 165, 172], ["tobacco", "ORGANISM", 177, 184], ["tobacco", "SPECIES", 177, 184], ["chronic conditions", "PROBLEM", 45, 63], ["communicable diseases", "PROBLEM", 217, 238], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["thought to be", "UNCERTAINTY", 75, 88]]], ["For example, experiences and outcomes of litigation in the so-called 'tobacco wars' across different legal systems might be analysed.", [["tobacco", "ORGANISM", 70, 77], ["tobacco", "SPECIES", 70, 77]]], ["Similarly, the variety of forms of legislative prohibition on smoking in public places can be compared and contrasted.Patient safetySafety in health care has become a key public health issue, not to mention one of professional and political importance.", [["smoking", "CHEMICAL", 62, 69], ["Patient", "SPECIES", 118, 125], ["variety", "OBSERVATION_MODIFIER", 15, 22], ["legislative prohibition", "OBSERVATION", 35, 58]]], ["It is striking (and encouraging) that attention has moved beyond the classic individualistic medical negligence action, towards searching examinations of policies and processes which offer a more sophisticated understanding of why things go wrong and how patients can be harmed by the very systems which are designed to help.", [["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["searching examinations", "TEST", 128, 150]]], ["When viewed in this way, various forms of what is generically termed 'iatrogenic' or 'comiogenic' harm 53 themselves can play in this regard), drawing upon research into provision of safer health care and efforts to introduce a 'learning culture' to reduce the rate of error in medicine.", [["a 'learning culture'", "TREATMENT", 226, 246]]], ["Recent revelations about the problems of controlling methicillin-resistant Staphylococcus aureus and Clostridium difficile infections, and the methods used to contain and reduce infection rates provide a focus for discussion.", [["methicillin", "CHEMICAL", 53, 64], ["Staphylococcus aureus", "DISEASE", 75, 96], ["Clostridium difficile infections", "DISEASE", 101, 133], ["infection", "DISEASE", 178, 187], ["methicillin", "CHEMICAL", 53, 64], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 53, 96], ["Clostridium difficile", "ORGANISM", 101, 122], ["Staphylococcus aureus", "SPECIES", 75, 96], ["Clostridium difficile", "SPECIES", 101, 122], ["Staphylococcus aureus", "SPECIES", 75, 96], ["Clostridium difficile", "SPECIES", 101, 122], ["Recent revelations", "PROBLEM", 0, 18], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 53, 96], ["Clostridium difficile infections", "PROBLEM", 101, 133], ["the methods", "TREATMENT", 139, 150], ["infection rates", "PROBLEM", 178, 193], ["Staphylococcus aureus", "OBSERVATION", 75, 96], ["Clostridium difficile", "OBSERVATION", 101, 122], ["infection", "OBSERVATION", 178, 187]]], ["There is also scope for detailed analysis of the role of key actors, such as the WHO World Alliance for Patient Safety, and comparison of different methods of regulation and approaches to policy making.Controlling the informational environmentThe use and abuse of information is one of the most pressing issues in contemporary public health.", [["Patient", "SPECIES", 104, 111], ["detailed analysis", "TEST", 24, 41]]], ["In a post-industrial 'knowledge economy', the creation, distribution, diffusion, use and manipulation of information is a significant economic, political and cultural activity.", [["distribution", "OBSERVATION_MODIFIER", 56, 68]]], ["Scientific and social scientific knowledge -in the form of evidencebased medicine and related methodologies such as health technology assessment -increasingly forms the basis for policy decisions within health systems, thus connecting information to the notion of power which was identified above.", [["health technology assessment", "TEST", 116, 144]]], ["54 The mass media possesses the capacity to help or hinder public health objectives by encouraging healthy lifestyles and by running 'scare stories' which might adversely affect behaviour to the detriment of the health of the population. q Particularly important in this regard is health information on the Internet, which can mislead but also empower individuals to take charge of their health status, 56 and can serve to exacerbate existing inequalities in a manner which runs counter to public health goals and values.", [["The mass media", "PROBLEM", 3, 17], ["mass", "OBSERVATION", 7, 11]]], ["57 The issue of the accuracy and presentation of information is also pertinent in terms of nutritional information about food products, both in terms of concealing potentially harmful ingredients and also exaggerating potential benefits without adequate evidence (such as organic food and socalled 'super foods').Controlling the informational environmentThis part of the course offers a valuable pedagogical opportunity to expand student awareness and critical analysis of the range of regulatory tools beyond formal legal rules.", [["critical analysis", "TEST", 452, 469]]], ["For example, 'soft law' mechanisms operate to provide a degree of control of the quality of health information on the Internet. rPaying for public healthOne of the most difficult problems facing health systems (both publicly funded and market based) is management of the mismatch between potentially infinite demand and finite resources.", [["soft law", "OBSERVATION_MODIFIER", 14, 22]]], ["59 Public health is no exception to this; indeed, the population-based dimension of public health measures serves particularly to highlight the underlying ethical dilemmas which exist in this context, especially the potential incommensurability of individual and communitarian approaches to the allocation of healthcare resources.", [["the underlying ethical dilemmas", "PROBLEM", 140, 171], ["no exception", "UNCERTAINTY", 20, 32], ["dilemmas", "OBSERVATION", 163, 171]]], ["This part of the course thus addresses issues of priority setting in a public health context, focusing especially on allocative decision making in a public health emergency situation, such as provision of ventilators following an outbreak of pandemic influenza.", [["influenza", "DISEASE", 251, 260], ["ventilators", "TREATMENT", 205, 216], ["pandemic influenza", "PROBLEM", 242, 260]]], ["Given the likelihood that external assessments of research achievement and attendant funding consequences will continue to shape the teaching environment, it is vital to remember the benefits of both teaching one's research and researching one's teaching.", [["external assessments", "TEST", 26, 46]]], ["It is hoped that by explicitly involving students in helping to shape the textbook, they will become more active partners in the learning process which will enhance the overall teaching and learning experience.Paying for public healthWith regard to assessment, law has long lagged behind other disciplines with reference to innovation and imagination, all too often 'playing safe' with standard unseen examinations and coursework essays.", [["standard unseen examinations", "TEST", 386, 414]]], ["61 Happily, the study of public health law lends itself to the utilization of different and, hopefully, more stimulating forms of assessment for students and teachers alike.", [["the study", "TEST", 12, 21], ["assessment", "TEST", 130, 140]]], ["In particular, the use of disease scenarios and incident responses affords the opportunity to stretch student understanding of a range of relevant issues.", [["disease scenarios", "PROBLEM", 26, 43]]], ["For example, students could be required to draft a document providing legal and ethical guidance to public health practitioners tasked with managing an outbreak of an infectious disease.", [["infectious disease", "DISEASE", 167, 185], ["an infectious disease", "PROBLEM", 164, 185], ["infectious", "OBSERVATION", 167, 177]]], ["Here, inspiration might be drawn from the assessments designed for membership of the Faculty of Public Health, whose Part B examinations, while carrying no direct legal content themselves, are scenario based, and include examples such as 'contact investigations for tuberculosis'.", [["tuberculosis", "DISEASE", 266, 278], ["the assessments", "TEST", 38, 53], ["Part B examinations", "TEST", 117, 136], ["tuberculosis'", "PROBLEM", 266, 279]]], ["63 More conventional options are offered by the critical evaluation of existing or proposed public health measures from a legal perspective; for example, the UK and European Union pandemic influenza preparedness plans or the International Health Regulations.", [["influenza", "DISEASE", 189, 198], ["the critical evaluation", "TEST", 44, 67], ["European Union pandemic influenza preparedness", "TREATMENT", 165, 211]]], ["Ample scope also exists for students to compare the legal q Such as uptake of immunization programmes.", [["immunization programmes", "TREATMENT", 78, 101]]], ["1 This is particularly necessary given the evolution of new public health threats.", [["new", "OBSERVATION_MODIFIER", 56, 59]]], ["It is the authors' ambition to address this deficiency and thereby to contribute, in some small way, to the process of updating and reform of the legal framework.ConclusionAs this article has sought to demonstrate, there are considerable challenges in terms of delivery of units in public health law, not least those occasioned by the need to engage with its multidisciplinary nature and to fix upon an appropriate and coherent syllabus design.", [["this deficiency", "PROBLEM", 39, 54], ["considerable", "OBSERVATION_MODIFIER", 225, 237], ["challenges", "OBSERVATION", 238, 248]]], ["However, there are also clear and numerous pedagogical benefits which may be reaped, and the authors would accordingly urge their colleagues not to be overly daunted by the undoubted obstacles which they will confront.", [["clear", "OBSERVATION_MODIFIER", 24, 29], ["numerous", "OBSERVATION_MODIFIER", 34, 42], ["pedagogical benefits", "OBSERVATION", 43, 63], ["may be", "UNCERTAINTY", 70, 76]]], ["Establishing public health law as a recognized subject of study is essential in seeking to generate a critical mass of students and scholars in this important, yet hitherto largely neglected, area.", [["mass", "OBSERVATION", 111, 115]]]], "PMC7302840": [], "PMC7375285": [["It is well documented that nutrition, food, herbals, nutrients, and supplements, including various combinations and compositions, support metabolism and physiology required for health [7,8].", [["herbals", "TREATMENT", 44, 51], ["nutrients", "TREATMENT", 53, 62], ["supplements", "TREATMENT", 68, 79], ["various combinations", "TREATMENT", 91, 111]]], ["Table 1shows the nutrients and herbals that complement the immune system and control inflammation to promote cell-associated antibody production and cell-mediated immunity [9].", [["immune system", "ANATOMY", 59, 72], ["cell", "ANATOMY", 109, 113], ["cell", "ANATOMY", 149, 153], ["inflammation", "DISEASE", 85, 97], ["herbals", "SIMPLE_CHEMICAL", 31, 38], ["cell", "CELL", 109, 113], ["cell", "CELL", 149, 153], ["herbals", "TREATMENT", 31, 38], ["the immune system", "TREATMENT", 55, 72], ["control inflammation", "PROBLEM", 77, 97], ["associated antibody production", "PROBLEM", 114, 144]]], ["A balanced diet, with the myriad of nutrients vital to health, supports normal B and T cell functions for optimal disease-reducing immunity [10].", [["B", "ANATOMY", 79, 80], ["T cell", "ANATOMY", 85, 91], ["B", "CELL", 79, 80], ["T cell", "CELL", 85, 91]]], ["In the case of COVID-19, the goal of nutrition is to reduce infection and disease progression while improving recovery during the course of the disease (Table 1).", [["infection", "DISEASE", 60, 69], ["COVID", "TEST", 15, 20], ["nutrition", "TREATMENT", 37, 46], ["infection", "PROBLEM", 60, 69], ["disease progression", "PROBLEM", 74, 93], ["infection", "OBSERVATION", 60, 69]]], ["Therefore, it is critical that the medical community and supporting healthcare professionals understand the role of nutrition for maintaining health and reducing disease risk.", [["reducing disease risk", "PROBLEM", 153, 174]]], ["In light of improving nutrition to avert or control COVID-19 infections, healthcare providers must support proper nutrition, and specifically, the nutrition necessary to protect those in high risk groups such as the elderly.", [["infections", "DISEASE", 61, 71]]], ["Many elderly individuals suffer from poor nutrition because of marginal intakes of critical vitamins, minerals, and essential amino acids necessary for a robust immune system.", [["immune system", "ANATOMY", 161, 174], ["amino acids", "CHEMICAL", 126, 137], ["vitamins", "CHEMICAL", 92, 100], ["amino acids", "CHEMICAL", 126, 137], ["individuals", "ORGANISM", 13, 24], ["vitamins", "SIMPLE_CHEMICAL", 92, 100], ["minerals", "SIMPLE_CHEMICAL", 102, 110], ["amino acids", "AMINO_ACID", 126, 137], ["critical vitamins", "TREATMENT", 83, 100], ["minerals", "TREATMENT", 102, 110], ["essential amino acids", "TREATMENT", 116, 137]]], ["This situation is further exacerbated by the declining gastrointestinal uptake of micronutrients and macronutrients that occurs with advanced age [11].", [["gastrointestinal", "ANATOMY", 55, 71], ["gastrointestinal", "ORGAN", 55, 71], ["the declining gastrointestinal uptake of micronutrients", "PROBLEM", 41, 96]]]], "0016a5c32e9cea6002cf6f352ecdb5231c7e3194": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Hubei Province, China, in December 2019 for the first time and the World Health Organization (WHO) warned about a coronavirus disease 2019 (COVID-19) pandemic eventually (1, 2) .IntroductionCOVID-19 patients are asymptomatic or present with flu-like symptoms.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 205, 224], ["flu-like symptoms", "DISEASE", 332, 349], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["a coronavirus disease", "PROBLEM", 203, 224], ["COVID", "TEST", 231, 236], ["pandemic", "PROBLEM", 241, 249], ["IntroductionCOVID", "TEST", 269, 286], ["asymptomatic", "PROBLEM", 303, 315], ["flu-like symptoms", "PROBLEM", 332, 349], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["The patient can only experience mild symptoms such as fever, dry cough, shortness of breath, fatigue, slight dyspnea, sore throat, headache, conjunctivitis, and gastrointestinal symptoms.", [["gastrointestinal", "ANATOMY", 161, 177], ["fever", "DISEASE", 54, 59], ["dry cough", "DISEASE", 61, 70], ["shortness of breath", "DISEASE", 72, 91], ["fatigue", "DISEASE", 93, 100], ["dyspnea", "DISEASE", 109, 116], ["sore throat", "DISEASE", 118, 129], ["headache", "DISEASE", 131, 139], ["conjunctivitis", "DISEASE", 141, 155], ["gastrointestinal symptoms", "DISEASE", 161, 186], ["patient", "ORGANISM", 4, 11], ["gastrointestinal", "ORGANISM_SUBDIVISION", 161, 177], ["patient", "SPECIES", 4, 11], ["mild symptoms", "PROBLEM", 32, 45], ["fever", "PROBLEM", 54, 59], ["dry cough", "PROBLEM", 61, 70], ["shortness of breath", "PROBLEM", 72, 91], ["fatigue", "PROBLEM", 93, 100], ["slight dyspnea", "PROBLEM", 102, 116], ["sore throat", "PROBLEM", 118, 129], ["headache", "PROBLEM", 131, 139], ["conjunctivitis", "PROBLEM", 141, 155], ["gastrointestinal symptoms", "PROBLEM", 161, 186], ["slight", "OBSERVATION_MODIFIER", 102, 108], ["dyspnea", "OBSERVATION", 109, 116], ["sore throat", "ANATOMY", 118, 129], ["headache", "OBSERVATION", 131, 139], ["conjunctivitis", "OBSERVATION", 141, 155], ["gastrointestinal", "ANATOMY", 161, 177]]], ["However, some high-risk individuals can develop rapidly progressive acute respiratory distress syndrome (ARDS) (3, 4) .IntroductionSARS-CoV-2 is highly transmissible and can be easily passed from human to human through droplets, 314 Naso-Oropharyngeal sampling for Detection of COVID-19IntroductionVol.", [["respiratory", "ANATOMY", 74, 85], ["acute respiratory distress syndrome", "DISEASE", 68, 103], ["ARDS", "DISEASE", 105, 109], ["individuals", "ORGANISM", 24, 35], ["human", "ORGANISM", 196, 201], ["human", "ORGANISM", 205, 210], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 205, 210], ["rapidly progressive acute respiratory distress syndrome", "PROBLEM", 48, 103], ["ARDS", "PROBLEM", 105, 109], ["IntroductionSARS", "TEST", 119, 135], ["COVID", "TEST", 278, 283], ["rapidly", "OBSERVATION_MODIFIER", 48, 55], ["progressive", "OBSERVATION_MODIFIER", 56, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory distress syndrome", "OBSERVATION", 74, 103], ["ARDS", "OBSERVATION", 105, 109]]], ["15 No. 4 Fall 2020 IRANIAN JOURNAL OF PATHOLOGY contact, and fomites and indirectly by contact with contaminated environmental surfaces followed by selfinoculation of ocular, nasal or oral mucosa (4) .", [["ocular", "ANATOMY", 167, 173], ["nasal", "ANATOMY", 175, 180], ["oral mucosa", "ANATOMY", 184, 195], ["ocular", "ORGAN", 167, 173], ["nasal", "MULTI-TISSUE_STRUCTURE", 175, 180], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 184, 195], ["ocular, nasal or oral mucosa", "PROBLEM", 167, 195], ["ocular", "ANATOMY", 167, 173], ["nasal", "ANATOMY", 175, 180], ["oral mucosa", "ANATOMY", 184, 195]]], ["COVID-19 can spread rapidly amongpatients and healthcare workers in healthcare settings and may have serious and severe complications in high-risk populations, particularly in the elderly, the critically ill, and the immunocompromised patients and young children (5) .IntroductionA simple approach to prevent close contact in healthcare settings during the recent COVID-19 outbreak is to train patients to collect their own nasopharyngeal and oropharyngeal swabs and deliver them to medical laboratories to have them processed.IntroductionThere are several benefits to a home-testing sample collection method, including wider availability with lower costs and decreased risk of exposure to the virus.", [["nasopharyngeal", "ANATOMY", 424, 438], ["oropharyngeal swabs", "ANATOMY", 443, 462], ["COVID-19", "CHEMICAL", 0, 8], ["critically ill", "DISEASE", 193, 207], ["patients", "ORGANISM", 235, 243], ["children", "ORGANISM", 254, 262], ["patients", "ORGANISM", 394, 402], ["nasopharyngeal", "CANCER", 424, 438], ["oropharyngeal swabs", "ORGANISM_SUBDIVISION", 443, 462], ["patients", "SPECIES", 235, 243], ["children", "SPECIES", 254, 262], ["patients", "SPECIES", 394, 402], ["severe complications", "PROBLEM", 113, 133], ["high-risk populations", "PROBLEM", 137, 158], ["IntroductionA simple approach", "TREATMENT", 268, 297], ["a home-testing sample collection method", "TREATMENT", 569, 608], ["the virus", "PROBLEM", 690, 699], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["complications", "OBSERVATION", 120, 133], ["oropharyngeal", "ANATOMY", 443, 456]]], ["Home testing would also decentralize care and provide a wider area of coverage, particularly for older adults who have been identified as high-risk individuals due to a higher mortality rate in adults over 50 years of age (6) .IntroductionThe aim of our study was to determine the degree of concordance between naso-and oropharyngeal samples collected by the patient and a lab technician, using a realtime reverse transcription-polymerase chain reaction (rRT-PCR) assay for SARS-CoV-2.Materials and MethodsThe patients who participated in this study were selected from adults who had been referred to Imam Khomeini Hospital Complex (IKHC), Tehran, Iran, from February 28 to April 27 of 2020 with flu-like symptoms.", [["oropharyngeal samples", "ANATOMY", 320, 341], ["flu-like symptoms", "DISEASE", 696, 713], ["oropharyngeal samples", "CANCER", 320, 341], ["patient", "ORGANISM", 359, 366], ["patients", "ORGANISM", 510, 518], ["adults", "ORGANISM", 569, 575], ["patient", "SPECIES", 359, 366], ["patients", "SPECIES", 510, 518], ["SARS-CoV", "SPECIES", 474, 482], ["Home testing", "TEST", 0, 12], ["a wider area of coverage", "TREATMENT", 54, 78], ["our study", "TEST", 250, 259], ["naso", "TEST", 311, 315], ["a realtime reverse transcription-polymerase chain reaction", "TREATMENT", 395, 453], ["rRT", "TEST", 455, 458], ["SARS", "TEST", 474, 478], ["CoV", "TEST", 479, 482], ["Methods", "TREATMENT", 499, 506], ["this study", "TEST", 539, 549], ["flu-like symptoms", "PROBLEM", 696, 713], ["oropharyngeal", "ANATOMY", 320, 333]]], ["According to the Center for Disease Control and Prevention (CDC), the flu-like symptoms are defined as cough and shortness of breath or difficulty in breathing accompanied by other symptoms such as fever, chills, muscle pain, sore throat, or new loss of taste or smell (7) .", [["muscle", "ANATOMY", 213, 219], ["flu", "DISEASE", 70, 73], ["cough", "DISEASE", 103, 108], ["shortness of breath", "DISEASE", 113, 132], ["fever", "DISEASE", 198, 203], ["chills", "DISEASE", 205, 211], ["muscle pain", "DISEASE", 213, 224], ["sore throat", "DISEASE", 226, 237], ["loss of taste or smell", "DISEASE", 246, 268], ["muscle", "ORGAN", 213, 219], ["Disease Control", "TREATMENT", 28, 43], ["the flu-like symptoms", "PROBLEM", 66, 87], ["cough", "PROBLEM", 103, 108], ["shortness of breath", "PROBLEM", 113, 132], ["difficulty in breathing", "PROBLEM", 136, 159], ["other symptoms", "PROBLEM", 175, 189], ["fever", "PROBLEM", 198, 203], ["chills", "PROBLEM", 205, 211], ["muscle pain", "PROBLEM", 213, 224], ["sore throat", "PROBLEM", 226, 237], ["new loss of taste or smell", "PROBLEM", 242, 268], ["muscle", "ANATOMY", 213, 219], ["sore throat", "ANATOMY", 226, 237]]], ["We recruited all the patients who had undergone chest CT-Scan and had demonstrated radiographic features of atypical pneumonia (highly suggestive of COVID-19).", [["pneumonia", "DISEASE", 117, 126], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["chest CT-Scan", "TEST", 48, 61], ["atypical pneumonia", "PROBLEM", 108, 126], ["COVID", "TEST", 149, 154], ["chest", "ANATOMY", 48, 53], ["atypical", "OBSERVATION_MODIFIER", 108, 116], ["pneumonia", "OBSERVATION", 117, 126]]], ["All the patients were admitted to the infectious diseases ward of IKHC.", [["infectious diseases", "DISEASE", 38, 57], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["IKHC", "TREATMENT", 66, 70], ["infectious", "OBSERVATION", 38, 48]]], ["Written instructions on how to collect the two required specimens were provided for the patients who participated in this study.", [["specimens", "ANATOMY", 56, 65], ["specimens", "CANCER", 56, 65], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["this study", "TEST", 117, 127]]], ["The first two naso-and oropharyngeal samples were collected by the patients (after reading the instructions) and sent immediately to a clinical laboratory.", [["oropharyngeal samples", "ANATOMY", 23, 44], ["oropharyngeal samples", "CANCER", 23, 44], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["oropharyngeal", "ANATOMY", 23, 36]]], ["The following two naso-and oropharyngeal samples were collected (the nasopharyngeal specimen was taken from the opposite nostril) by the lab technician.", [["oropharyngeal samples", "ANATOMY", 27, 48], ["nasopharyngeal specimen", "ANATOMY", 69, 92], ["nostril", "ANATOMY", 121, 128], ["oropharyngeal samples", "CANCER", 27, 48], ["nasopharyngeal specimen", "MULTI-TISSUE_STRUCTURE", 69, 92], ["nostril", "ORGAN", 121, 128], ["the nasopharyngeal specimen", "TEST", 65, 92], ["oropharyngeal", "ANATOMY", 27, 40]]], ["Specimens were obtained by a sterile Dacron swab with a plastic handle and soon after collection, each swab was placed into a separate container containing viral transport medium (VTM).", [["Specimens", "ANATOMY", 0, 9], ["swab", "ANATOMY", 103, 107], ["Specimens", "TEST", 0, 9], ["a sterile Dacron swab", "TREATMENT", 27, 48], ["a plastic handle", "TREATMENT", 54, 70], ["each swab", "TREATMENT", 98, 107], ["viral transport medium", "TREATMENT", 156, 178], ["viral", "OBSERVATION", 156, 161], ["transport medium", "OBSERVATION", 162, 178]]], ["The specimens were transported to a clinical laboratory within 30 minutes of collection and were processed soon after delivery.", [["specimens", "ANATOMY", 4, 13], ["delivery", "TREATMENT", 118, 126]]], ["Patients' demographic data and their clinical history were collected from their files.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Patients' demographic data", "TEST", 0, 26]]], ["None of the patients had a history of having an occupation as a healthcare worker.COVID-19 Rapid Real-Time PCR Total RNA ExtractionIn the present study, RNA extraction was performed using the Viral Nucleic Acid Extraction kit (Cat.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 82, 87], ["the present study", "TEST", 134, 151], ["RNA extraction", "TREATMENT", 153, 167], ["the Viral Nucleic Acid Extraction", "TREATMENT", 188, 221]]], ["YVN50/YVN100) provided by RBC Bioscience, Taipei, Taiwan.", [["YVN50", "PROTEIN", 0, 5], ["YVN100", "PROTEIN", 6, 12], ["RBC", "CELL_TYPE", 26, 29]]], ["The process was initiated by transferring 200\u00b5L of the sample into a microcentrifuge tube.", [["sample", "ANATOMY", 55, 61], ["tube", "TISSUE", 85, 89], ["a microcentrifuge tube", "TREATMENT", 67, 89], ["tube", "OBSERVATION", 85, 89]]], ["Then, 400\u00b5L of VB buffer in addition to 10\u00b5L of Proteinase K were added to the tube and the tube was incubated at 65\u00b0C for 10 minutes.", [["tube", "ANATOMY", 79, 83], ["tube", "ANATOMY", 92, 96], ["Proteinase K", "CHEMICAL", 48, 60], ["Proteinase K", "SIMPLE_CHEMICAL", 48, 60], ["tube", "TISSUE", 79, 83], ["tube", "TISSUE", 92, 96], ["VB buffer", "TREATMENT", 15, 24], ["Proteinase K", "TREATMENT", 48, 60], ["the tube", "TREATMENT", 75, 83], ["the tube", "TREATMENT", 88, 96], ["tube", "OBSERVATION", 79, 83], ["tube", "OBSERVATION", 92, 96]]], ["By adding 500 \u00b5L of 95% ethanol and multiple rounds of washing, using W1 buffer and R-Wash buffer, centrifugation, and following use of 50\u00b5L RNase-free water and another round of centrifugation, eluted nucleic acid was extracted.COVID-19 Rapid Real-Time PCR Total RNA ExtractionRapid real-time PCR This step was performed using the Novel Coronavirus (2019-nCOV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing) of Sansure Biotech (S3102E) (Changsha, China) and a thermal cycler specified for CFX96\u2122 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) by adding 30 \u00b5L PCR-Mastermix (including 2019-nCoV-PCR Mix and 2019-nCoV-PCR-Enzyme Mix, containing premiers, probes, dNTPs, MgCl2, Rnasin and PCR buffer for the 2019-nCoV-PCR Mix and RT enzyme and Taq enzyme for the 2019-nCoV-PCR-Enzyme Mix) into PCR reaction tube with 20 \u00b5L of the extracted RNA sample.", [["ethanol", "CHEMICAL", 24, 31], ["nucleic acid", "CHEMICAL", 202, 214], ["CFX96", "CHEMICAL", 498, 503], ["dNTPs", "CHEMICAL", 683, 688], ["MgCl2", "CHEMICAL", 690, 695], ["ethanol", "CHEMICAL", 24, 31], ["MgCl2", "CHEMICAL", 690, 695], ["ethanol", "SIMPLE_CHEMICAL", 24, 31], ["nucleic acid", "SIMPLE_CHEMICAL", 202, 214], ["dNTPs", "SIMPLE_CHEMICAL", 683, 688], ["MgCl2", "SIMPLE_CHEMICAL", 690, 695], ["Rnasin", "SIMPLE_CHEMICAL", 697, 703], ["Taq enzyme", "GENE_OR_GENE_PRODUCT", 763, 773], ["RNase", "PROTEIN", 141, 146], ["CFX96", "PROTEIN", 498, 503], ["2019-nCoV-PCR Mix and 2019-nCoV-PCR-Enzyme Mix", "DNA", 606, 652], ["Rnasin", "DNA", 697, 703], ["2019", "DNA", 727, 731], ["nCoV", "DNA", 732, 736], ["PCR Mix", "DNA", 737, 744], ["RT enzyme", "DNA", 749, 758], ["Taq enzyme", "PROTEIN", 763, 773], ["nCoV", "DNA", 787, 791], ["washing", "TREATMENT", 55, 62], ["W1 buffer", "TREATMENT", 70, 79], ["R-Wash buffer", "TREATMENT", 84, 97], ["centrifugation", "TREATMENT", 99, 113], ["RNase", "TREATMENT", 141, 146], ["centrifugation", "TREATMENT", 179, 193], ["eluted nucleic acid", "TREATMENT", 195, 214], ["COVID", "TEST", 229, 234], ["Rapid Real", "TEST", 238, 248], ["Time PCR", "TEST", 249, 257], ["Total RNA", "TEST", 258, 267], ["ExtractionRapid", "TEST", 268, 283], ["time PCR", "TEST", 289, 297], ["the Novel Coronavirus", "TREATMENT", 328, 349], ["Nucleic Acid", "TEST", 362, 374], ["PCR", "TEST", 391, 394], ["a thermal cycler", "TREATMENT", 467, 483], ["PCR", "TEST", 581, 584], ["Mastermix", "TEST", 585, 594], ["nCoV", "TEST", 611, 615], ["Mix", "TEST", 620, 623], ["nCoV", "TEST", 633, 637], ["PCR", "TEST", 638, 641], ["Enzyme Mix", "TREATMENT", 642, 652], ["dNTPs", "TREATMENT", 683, 688], ["MgCl2", "TREATMENT", 690, 695], ["Rnasin", "TREATMENT", 697, 703], ["PCR buffer", "TREATMENT", 708, 718], ["nCoV", "TEST", 732, 736], ["PCR Mix", "TEST", 737, 744], ["RT enzyme", "TEST", 749, 758], ["Taq enzyme", "TEST", 763, 773], ["nCoV", "TEST", 787, 791], ["PCR", "TEST", 792, 795], ["Enzyme Mix", "TREATMENT", 796, 806], ["PCR reaction tube", "TREATMENT", 813, 830], ["tube", "OBSERVATION", 826, 830]]], ["Then, the specimen, 2019-nCOV-PCR positive control, and 2019-nCOV-PCR negative control were placed into the specimen wells of the amplification equipment.", [["specimen", "ANATOMY", 10, 18], ["the specimen", "TEST", 6, 18], ["nCOV", "TEST", 25, 29], ["PCR", "TEST", 30, 33], ["PCR", "TEST", 66, 69], ["the amplification equipment", "TREATMENT", 126, 153]]], ["The first two steps \"reverse transcription\" and \"cDNA predenaturation\" were performed at 50\u00b0C (30 min) and 95\u00b0C (1 min), each with a single cycle, respectively.", [["cDNA", "DNA", 49, 53]]], ["Then, the device cooled down to 25\u00b0C for 10 seconds to finalize the process.", [["the device", "TREATMENT", 6, 16]]], ["The device's software was used for calculation of the cycle threshold (Ct) values.", [["The device's software", "TREATMENT", 0, 21], ["the cycle threshold", "TEST", 50, 69], ["Ct) values", "TEST", 71, 81]]], ["For 2019-nCoV-PCR negative control Ct value > 40 and for positive control Ct value No\u2264 35 were defined based on each kit's instructions.", [["PCR", "TEST", 14, 17], ["Ct value", "TEST", 35, 43], ["Ct value", "TEST", 74, 82]]], ["The RT-PCR results were reported as positive or negative.", [["The RT-PCR", "TEST", 0, 10], ["negative", "OBSERVATION", 48, 56]]], ["The whole PCR testing was done by technicians who were blind to the type of the collected specimen.COVID-19 Rapid Real-Time PCR Total RNA ExtractionThe research protocol was confirmed by the Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.MEDICINE.REC.1399.048).Statistical Analyses:To identify the presence of a systematic difference between lab technician-and patient-collected sample results we used McNemar Chi-Square test and for assessing the concordance between test results we calculated Cohen's kappa value.", [["specimen", "ANATOMY", 90, 98], ["TUMS", "DISEASE", 253, 257], ["patient", "ORGANISM", 381, 388], ["patient", "SPECIES", 381, 388], ["The whole PCR testing", "TEST", 0, 21], ["COVID", "TEST", 99, 104], ["Rapid Real", "TEST", 108, 118], ["Total RNA Extraction", "TREATMENT", 128, 148], ["TUMS", "TREATMENT", 253, 257], ["McNemar Chi-Square test", "TEST", 422, 445]]], ["A P-value of less than 0.05 was considered as statistically significant.", [["A P-value", "TEST", 0, 9]]], ["The data were analyzed using SPSS 25 (SPSS Inc., Chicago, IL, USA).Population Demographical Data:Fifty patients with clinical and radiologic evidence of viral pneumonia were entered into the study.", [["viral pneumonia", "DISEASE", 153, 168], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["The data", "TEST", 0, 8], ["SPSS", "TEST", 29, 33], ["viral pneumonia", "PROBLEM", 153, 168], ["the study", "TEST", 187, 196], ["viral", "OBSERVATION_MODIFIER", 153, 158], ["pneumonia", "OBSERVATION", 159, 168]]], ["All patients were admitted to the infectious diseases ward of IKHC.", [["infectious diseases", "DISEASE", 34, 53], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["IKHC", "TREATMENT", 62, 66], ["infectious", "OBSERVATION", 34, 44]]], ["Thirty-two (64%) patients were male and 18 (36%) were female.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["The median age of participants was 56 years, ranging from 24 to 86 years.", [["participants", "ORGANISM", 18, 30], ["participants", "SPECIES", 18, 30]]], ["Among patients, fever (68%), muscle pain, and cough (60% each) were the most common chief complaints.", [["muscle", "ANATOMY", 29, 35], ["fever", "DISEASE", 16, 21], ["muscle pain", "DISEASE", 29, 40], ["cough", "DISEASE", 46, 51], ["patients", "ORGANISM", 6, 14], ["muscle", "ORGAN", 29, 35], ["patients", "SPECIES", 6, 14], ["fever", "PROBLEM", 16, 21], ["muscle pain", "PROBLEM", 29, 40], ["cough", "PROBLEM", 46, 51], ["muscle", "ANATOMY", 29, 35], ["pain", "OBSERVATION", 36, 40]]], ["The other symptoms are sorted in Table 1 .", [["The other symptoms", "PROBLEM", 0, 18]]], ["Hypertension (9 out of 50 patients), cardiovascular diseases, diabetes mellitus, and respiratory illnesses (each 6 out of 50 patients) were the most notable underlying diseases (Table 2) .", [["cardiovascular", "ANATOMY", 37, 51], ["respiratory", "ANATOMY", 85, 96], ["Hypertension", "DISEASE", 0, 12], ["cardiovascular diseases", "DISEASE", 37, 60], ["diabetes mellitus", "DISEASE", 62, 79], ["respiratory illnesses", "DISEASE", 85, 106], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 125, 133], ["Hypertension", "PROBLEM", 0, 12], ["cardiovascular diseases", "PROBLEM", 37, 60], ["diabetes mellitus", "PROBLEM", 62, 79], ["respiratory illnesses", "PROBLEM", 85, 106], ["underlying diseases", "PROBLEM", 157, 176], ["cardiovascular", "ANATOMY", 37, 51], ["diseases", "OBSERVATION", 52, 60], ["diabetes mellitus", "OBSERVATION", 62, 79], ["respiratory", "ANATOMY", 85, 96], ["illnesses", "OBSERVATION", 97, 106], ["diseases", "OBSERVATION", 168, 176]]], ["Four patients had a history of antibiotic therapy (two with Azithromycin alone, one with Ciprofloxacin and Azithromycin and one patient did not remember the name of antibiotic used).", [["Azithromycin", "CHEMICAL", 60, 72], ["Ciprofloxacin", "CHEMICAL", 89, 102], ["Azithromycin", "CHEMICAL", 107, 119], ["Azithromycin", "CHEMICAL", 60, 72], ["Ciprofloxacin", "CHEMICAL", 89, 102], ["Azithromycin", "CHEMICAL", 107, 119], ["patients", "ORGANISM", 5, 13], ["Azithromycin", "SIMPLE_CHEMICAL", 60, 72], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 89, 102], ["Azithromycin", "SIMPLE_CHEMICAL", 107, 119], ["patient", "ORGANISM", 128, 135], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 128, 135], ["antibiotic therapy", "TREATMENT", 31, 49], ["Azithromycin", "TREATMENT", 60, 72], ["Ciprofloxacin", "TREATMENT", 89, 102], ["Azithromycin", "TREATMENT", 107, 119], ["antibiotic", "TREATMENT", 165, 175]]], ["The patients had neither a history of prior hospital admission nor a history of PCR testing for their current disease.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["PCR testing", "TEST", 80, 91], ["their current disease", "PROBLEM", 96, 117]]], ["O2 saturation levels which were measured by pulse oximeter were \u226593% in 30% of patients and <93% for 70% of the patients when coming to the hospital for the first time.", [["O2", "CHEMICAL", 0, 2], ["O2", "SIMPLE_CHEMICAL", 0, 2], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 112, 120], ["O2 saturation levels", "TEST", 0, 20], ["pulse oximeter", "TEST", 44, 58]]], ["In this study, each patient had two sets of collected samples from nasopharyngeal and oropharyngeal swabs, one of each taken by patients their own and the other by a lab technician.", [["samples", "ANATOMY", 54, 61], ["nasopharyngeal", "ANATOMY", 67, 81], ["oropharyngeal swabs", "ANATOMY", 86, 105], ["patient", "ORGANISM", 20, 27], ["nasopharyngeal", "CANCER", 67, 81], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 86, 105], ["patients", "ORGANISM", 128, 136], ["patient", "SPECIES", 20, 27], ["patients", "SPECIES", 128, 136], ["this study", "TEST", 3, 13], ["collected samples", "TEST", 44, 61], ["nasopharyngeal and oropharyngeal swabs", "TEST", 67, 105], ["nasopharyngeal", "ANATOMY", 67, 81], ["oropharyngeal swabs", "ANATOMY", 86, 105]]], ["Assuming patients with at least one swab showing a positive result as being infected with SARS-CoV-2, 26 out of 50 patients were infected.", [["SARS", "DISEASE", 90, 94], ["patients", "ORGANISM", 9, 17], ["SARS-CoV-2", "ORGANISM", 90, 100], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 90, 98], ["one swab", "TEST", 32, 40], ["a positive result", "PROBLEM", 49, 66], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["infected", "OBSERVATION", 76, 84], ["infected", "OBSERVATION", 129, 137]]], ["All patients with a double negative result for lab techniciancollected samples showed a double negative result in patient-collected samples, too.", [["samples", "ANATOMY", 71, 78], ["samples", "ANATOMY", 132, 139], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 114, 121], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 114, 121], ["lab techniciancollected samples", "TEST", 47, 78], ["collected samples", "TEST", 122, 139]]], ["The Chi-Square Tests table showed a McNemar P-value of 0.039 for nasopharyngeal samples and 0.77 for oropharyngeal samples ( Table 3 ).", [["nasopharyngeal samples", "ANATOMY", 65, 87], ["oropharyngeal samples", "ANATOMY", 101, 122], ["nasopharyngeal samples", "CANCER", 65, 87], ["The Chi-Square Tests table", "TEST", 0, 26], ["nasopharyngeal samples", "TEST", 65, 87], ["oropharyngeal samples", "TEST", 101, 122]]], ["The overall percentage of agreement among nasopharyngeal swabs taken by a lab technician and patients was 76% with a kappa value of 0.49 (P<0.001, 95% CI: 0.26-0.72) and the overall percentage of agreement among oropharyngeal swabs taken by a lab technician and patients was 76% with a kappa value of 0.49 (P=0.001, 95% CI: 0.24-0.74), after taking chance agreement into account (Table 4 ).", [["nasopharyngeal swabs", "ANATOMY", 42, 62], ["oropharyngeal swabs", "ANATOMY", 212, 231], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 42, 62], ["patients", "ORGANISM", 93, 101], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 212, 231], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 262, 270], ["nasopharyngeal swabs", "TEST", 42, 62], ["a kappa value", "TEST", 115, 128], ["P", "TEST", 138, 139], ["CI", "TEST", 151, 153], ["oropharyngeal swabs", "TEST", 212, 231], ["a kappa value", "TEST", 284, 297], ["P", "TEST", 307, 308], ["CI", "TEST", 320, 322]]], ["Seven out of 50 patients had four positive PCR results for COVID-19 and 24 patients had four negative PCR results.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 75, 83], ["COVID", "TEST", 59, 64]]], ["Twelve patients were positive for both nasopharyngeal samples (taken by the patient and lab technician) and thirteen were positive for both oropharyngeal samples.", [["nasopharyngeal samples", "ANATOMY", 39, 61], ["oropharyngeal samples", "ANATOMY", 140, 161], ["patients", "ORGANISM", 7, 15], ["nasopharyngeal samples", "CANCER", 39, 61], ["patient", "ORGANISM", 76, 83], ["oropharyngeal samples", "CANCER", 140, 161], ["patients", "SPECIES", 7, 15], ["patient", "SPECIES", 76, 83], ["both nasopharyngeal samples", "PROBLEM", 34, 61], ["both oropharyngeal samples", "PROBLEM", 135, 161], ["nasopharyngeal", "ANATOMY", 39, 53], ["oropharyngeal", "ANATOMY", 140, 153]]], ["Double negative nasopharyngeal PCR results (taken by patient and lab technician) were observed in 26 patients and double negative oropharyngeal PCR results were seen in 25 patients.", [["nasopharyngeal", "ANATOMY", 16, 30], ["oropharyngeal", "ANATOMY", 130, 143], ["patient", "ORGANISM", 53, 60], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 172, 180], ["patient", "SPECIES", 53, 60], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 172, 180], ["nasopharyngeal PCR", "TEST", 16, 34], ["oropharyngeal PCR", "TEST", 130, 147], ["nasopharyngeal", "ANATOMY", 16, 30], ["oropharyngeal", "ANATOMY", 130, 143]]], ["Of remaining, ten patients had positive nasopharyngeal samples collected by the lab technician while their self-collected samples showed negative results and two patients had positive results for their selfcollected nasopharyngeal specimen whereas the lab technician-collected specimen was negative for PCR testing.", [["nasopharyngeal samples", "ANATOMY", 40, 62], ["samples", "ANATOMY", 122, 129], ["nasopharyngeal specimen", "ANATOMY", 216, 239], ["specimen", "ANATOMY", 277, 285], ["patients", "ORGANISM", 18, 26], ["nasopharyngeal samples", "CANCER", 40, 62], ["samples", "CANCER", 122, 129], ["patients", "ORGANISM", 162, 170], ["nasopharyngeal specimen", "CANCER", 216, 239], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 162, 170], ["positive nasopharyngeal samples", "PROBLEM", 31, 62], ["their selfcollected nasopharyngeal specimen", "PROBLEM", 196, 239], ["PCR testing", "TEST", 303, 314], ["nasopharyngeal", "ANATOMY", 40, 54]]], ["For oropharyngeal specimens, this discordance also existed.", [["oropharyngeal specimens", "ANATOMY", 4, 27], ["oropharyngeal specimens", "CANCER", 4, 27], ["oropharyngeal specimens", "TEST", 4, 27]]], ["Five oropharyngial samples, taken by the lab technician had positive PCR results while their selfcollected samples were negative and seven self-collected oropharyngeal specimens were positive for COVID-19 PCR with negative results for lab technician-collected specimens.", [["oropharyngial samples", "ANATOMY", 5, 26], ["samples", "ANATOMY", 107, 114], ["oropharyngeal specimens", "ANATOMY", 154, 177], ["specimens", "ANATOMY", 260, 269], ["oropharyngial samples", "CANCER", 5, 26], ["samples", "CANCER", 107, 114], ["oropharyngeal specimens", "CANCER", 154, 177], ["Five oropharyngial samples", "TEST", 0, 26], ["positive PCR", "PROBLEM", 60, 72], ["their selfcollected samples", "TEST", 87, 114], ["oropharyngeal specimens", "TEST", 154, 177], ["COVID", "TEST", 196, 201], ["collected specimens", "TEST", 250, 269]]], ["In four patients, lab technician-collected samples were positive (two for both samples and two for one of naso-or oropharyngeal samples) whereas their self-collected samples showed negative PCR results.DiscussionThe aim of our study was to determine whether the rRT-PCR results were influenced if the nasopharyngeal and oropharyngeal samples were collected by lab technicians or patients.", [["samples", "ANATOMY", 43, 50], ["samples", "ANATOMY", 79, 86], ["oropharyngeal samples", "ANATOMY", 114, 135], ["samples", "ANATOMY", 166, 173], ["nasopharyngeal", "ANATOMY", 301, 315], ["oropharyngeal samples", "ANATOMY", 320, 341], ["patients", "ORGANISM", 8, 16], ["samples", "CANCER", 43, 50], ["oropharyngeal samples", "CANCER", 114, 135], ["nasopharyngeal", "CANCER", 301, 315], ["oropharyngeal samples", "CANCER", 320, 341], ["patients", "ORGANISM", 379, 387], ["rRT", "DNA", 262, 265], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 379, 387], ["naso", "TEST", 106, 110], ["oropharyngeal samples", "TEST", 114, 135], ["our study", "TEST", 223, 232], ["the rRT-PCR", "TEST", 258, 269], ["the nasopharyngeal and oropharyngeal samples", "TEST", 297, 341], ["oropharyngeal", "ANATOMY", 114, 127], ["nasopharyngeal", "ANATOMY", 301, 315], ["oropharyngeal", "ANATOMY", 320, 333]]], ["Our findings about the nasopharyngeal samples showed a systematic difference as well as a moderate agreement between the two.", [["nasopharyngeal samples", "ANATOMY", 23, 45], ["nasopharyngeal samples", "CANCER", 23, 45], ["the nasopharyngeal samples", "TEST", 19, 45], ["a systematic difference", "PROBLEM", 53, 76], ["nasopharyngeal", "ANATOMY", 23, 37], ["systematic difference", "OBSERVATION", 55, 76], ["moderate", "OBSERVATION_MODIFIER", 90, 98]]], ["In case of the oropharyngeal samples, although there is no systematic difference between these two collection methods, a moderate agreement (kappa value = 049) was observed between them.", [["oropharyngeal samples", "ANATOMY", 15, 36], ["oropharyngeal samples", "CANCER", 15, 36], ["the oropharyngeal samples", "TEST", 11, 36], ["systematic difference", "PROBLEM", 59, 80], ["kappa value", "TEST", 141, 152], ["oropharyngeal", "ANATOMY", 15, 28], ["no", "UNCERTAINTY", 56, 58], ["moderate", "OBSERVATION_MODIFIER", 121, 129]]], ["Accordingly, in neither of these cases, patient-collected samples can replace the samples collected by lab technicians.", [["samples", "ANATOMY", 58, 65], ["samples", "ANATOMY", 82, 89], ["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["the samples", "TEST", 78, 89]]], ["The positive tests were more observed in lab technician-collected samples and discordant results between naso-and oropharyngeal samples were more found in self-collected samples (12 patients for self-collected samples versus 10 for lab technician-collected samples).", [["samples", "ANATOMY", 66, 73], ["oropharyngeal samples", "ANATOMY", 114, 135], ["samples", "ANATOMY", 170, 177], ["samples", "ANATOMY", 210, 217], ["samples", "ANATOMY", 257, 264], ["oropharyngeal samples", "CANCER", 114, 135], ["patients", "ORGANISM", 182, 190], ["samples", "CANCER", 257, 264], ["patients", "SPECIES", 182, 190], ["The positive tests", "TEST", 0, 18], ["naso", "TEST", 105, 109], ["oropharyngeal samples", "TEST", 114, 135], ["oropharyngeal", "ANATOMY", 114, 127]]], ["COVID-19 is a new disease and research and experience about self-collected nasal swabs are limited (7-10).", [["nasal swabs", "ANATOMY", 75, 86], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 75, 86], ["a new disease", "PROBLEM", 12, 25], ["self-collected nasal swabs", "TEST", 60, 86], ["new", "OBSERVATION_MODIFIER", 14, 17], ["disease", "OBSERVATION", 18, 25]]], ["However, several studies in pediatrics' field have shown that parental-collected midturbinate, nasopharyngeal, and/or throat specimens for detecting viruses such as human meta pneumovirus, influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza viruses, and adenoviruses is an efficient and acceptable method (11) (12) .DiscussionNeelam Dhiman et al. demonstrated that health care worker (HCW)-and patient-collected nasal swabs, using flocked nasal midturbinate swab, were suitable alternatives for the detection of influenza A and B using rRT-PCR test.", [["midturbinate", "ANATOMY", 81, 93], ["nasopharyngeal", "ANATOMY", 95, 109], ["throat specimens", "ANATOMY", 118, 134], ["nasal swabs", "ANATOMY", 441, 452], ["nasal midturbinate swab", "ANATOMY", 468, 491], ["influenza A", "DISEASE", 189, 200], ["influenza B", "DISEASE", 208, 219], ["respiratory syncytial virus", "DISEASE", 227, 254], ["parainfluenza viruses", "DISEASE", 256, 277], ["nasopharyngeal", "CANCER", 95, 109], ["human meta pneumovirus", "ORGANISM", 165, 187], ["influenza A virus", "ORGANISM", 189, 206], ["influenza B virus", "ORGANISM", 208, 225], ["respiratory syncytial virus", "ORGANISM", 227, 254], ["parainfluenza viruses", "ORGANISM", 256, 277], ["adenoviruses", "ORGANISM", 283, 295], ["patient", "ORGANISM", 423, 430], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 441, 452], ["B", "CELL", 557, 558], ["human", "SPECIES", 165, 170], ["influenza A virus", "SPECIES", 189, 206], ["influenza B virus", "SPECIES", 208, 225], ["respiratory syncytial virus", "SPECIES", 227, 254], ["parainfluenza", "SPECIES", 256, 269], ["patient", "SPECIES", 423, 430], ["human meta pneumovirus", "SPECIES", 165, 187], ["influenza A virus", "SPECIES", 189, 206], ["influenza B virus", "SPECIES", 208, 225], ["respiratory syncytial virus", "SPECIES", 227, 254], ["several studies in pediatrics' field", "TEST", 9, 45], ["parental-collected midturbinate, nasopharyngeal, and/or throat specimens", "TEST", 62, 134], ["viruses", "PROBLEM", 149, 156], ["human meta pneumovirus", "PROBLEM", 165, 187], ["influenza A virus", "PROBLEM", 189, 206], ["influenza B virus", "PROBLEM", 208, 225], ["respiratory syncytial virus", "PROBLEM", 227, 254], ["parainfluenza viruses", "PROBLEM", 256, 277], ["adenoviruses", "PROBLEM", 283, 295], ["nasal swabs", "TEST", 441, 452], ["flocked nasal midturbinate swab", "TREATMENT", 460, 491], ["the detection", "TEST", 524, 537], ["influenza", "PROBLEM", 541, 550], ["rRT", "TEST", 565, 568], ["PCR test", "TEST", 569, 577], ["nasopharyngeal", "ANATOMY", 95, 109], ["throat", "ANATOMY", 118, 124], ["respiratory syncytial", "ANATOMY", 227, 248], ["parainfluenza viruses", "OBSERVATION", 256, 277], ["nasal", "ANATOMY", 441, 446]]], ["There was no significant difference in the overall positivity rate by either collection methods, and self-collection method was well accepted by patients.", [["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["significant difference", "PROBLEM", 13, 35], ["collection methods", "TEST", 77, 95], ["self-collection method", "TREATMENT", 101, 123], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Of the 72 paired specimens analyzed, 34.7% were positive for influenza A or B RNA by at least one of the collection methods.", [["specimens", "ANATOMY", 17, 26], ["specimens", "CANCER", 17, 26], ["B", "GENE_OR_GENE_PRODUCT", 76, 77], ["influenza A or B RNA", "RNA", 61, 81], ["the 72 paired specimens", "TEST", 3, 26], ["influenza A or B RNA", "PROBLEM", 61, 81]]], ["When the 14 patients who had prior health care training were excluded, the qualitative agreement between collection methods was 94.8% (55 of 58).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["prior health care training", "TREATMENT", 29, 55], ["collection methods", "TEST", 105, 123]]], ["A total of 53.4% of patients (31 of 58) preferred the self-collection method over the HCW collection, and 25.9% (15 of 58) had no preference (5).DiscussionEsposito et al. directly compared parent-collected midturbinate nasal swabs with pediatrician-collected swabs for influenza detection by rRT-PCR and demonstrated moderately high sensitivity (89.3%) and specificity (97.7%) for the parental collection technique.", [["nasal swabs", "ANATOMY", 219, 230], ["swabs", "ANATOMY", 259, 264], ["patients", "ORGANISM", 20, 28], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 219, 230], ["patients", "SPECIES", 20, 28], ["the HCW collection", "TEST", 82, 100], ["influenza detection", "TEST", 269, 288], ["rRT", "TEST", 292, 295], ["PCR", "TEST", 296, 299], ["moderately high sensitivity", "PROBLEM", 317, 344], ["specificity", "TEST", 357, 368], ["the parental collection technique", "TEST", 381, 414], ["total", "OBSERVATION_MODIFIER", 2, 7], ["moderately", "OBSERVATION_MODIFIER", 317, 327]]], ["They also demonstrated that the direct involvement of parents in the collection process increased the child's acceptance of the sample collection (10) .DiscussionIn a study by Christopher P. Seaman, it was suggested that self-collection is highly comparable to professionalcollection for diagnosis of influenza in symptomatic individuals, and they have demonstrated that findings from studies using self-collection are probably only minimally affected by measurement errors.", [["influenza", "DISEASE", 301, 310], ["the sample collection", "TREATMENT", 124, 145], ["self-collection", "PROBLEM", 221, 236], ["influenza", "PROBLEM", 301, 310], ["symptomatic individuals", "PROBLEM", 314, 337], ["studies", "TEST", 385, 392], ["self-collection", "PROBLEM", 399, 414], ["influenza", "OBSERVATION", 301, 310], ["probably only", "UNCERTAINTY", 419, 432], ["minimally", "OBSERVATION_MODIFIER", 433, 442]]], ["They identified 14 studies that compared the diagnostic accuracy of self-collected to professional-collected swabs in symptomatic infected individuals by influenza.", [["swabs", "ANATOMY", 109, 114], ["influenza", "DISEASE", 154, 163], ["individuals", "ORGANISM", 139, 150], ["14 studies", "TEST", 16, 26], ["collected swabs", "TEST", 99, 114], ["symptomatic infected individuals", "PROBLEM", 118, 150], ["influenza", "PROBLEM", 154, 163], ["symptomatic", "OBSERVATION_MODIFIER", 118, 129], ["infected", "OBSERVATION", 130, 138], ["influenza", "OBSERVATION", 154, 163]]], ["Selfcollected swabs were found to be highly acceptable, simple, and comfortable to use.", [["swabs", "ANATOMY", 14, 19], ["Selfcollected swabs", "TEST", 0, 19]]], ["Data from nine studies were meta-analyzed.", [["Data from nine studies", "TEST", 0, 22]]], ["Pooled sensitivity was 87% (95% CI: 80%-92%) and specificity was 99% (95% CI: 98%-100%), compared to professional-collected swabs in the diagnosis of influenza.", [["swabs", "ANATOMY", 124, 129], ["influenza", "DISEASE", 150, 159], ["Pooled sensitivity", "TEST", 0, 18], ["CI", "TEST", 32, 34], ["specificity", "TEST", 49, 60], ["CI", "TEST", 74, 76], ["professional", "TEST", 101, 113], ["collected swabs", "TEST", 114, 129], ["influenza", "PROBLEM", 150, 159], ["influenza", "OBSERVATION", 150, 159]]], ["Pooled sensitivity and specificity estimates were used to assess the potential bias that would be introduced in studies that used the self-collected samples rather than professional collected ones.", [["Pooled sensitivity", "TEST", 0, 18], ["specificity estimates", "TEST", 23, 44]]], ["While self-collected swabbing should not replace the role of clinical testing, findings support the use of self-collected swabs for influenza research and surveillance (11) .DiscussionIn Michael L Jackson's study, a self-collected nasal swab for respiratory virus surveillance was evaluated.", [["nasal swab", "ANATOMY", 231, 241], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 231, 241], ["clinical testing", "TEST", 61, 77], ["influenza research", "TEST", 132, 150], ["surveillance", "TEST", 155, 167], ["a self-collected nasal swab", "TEST", 214, 241], ["respiratory virus surveillance", "TEST", 246, 276]]], ["They tested 135 patients with acute respiratory illness (ARI) who could self-collect nasal swab specimens and send them for laboratory testing.", [["respiratory", "ANATOMY", 36, 47], ["nasal swab specimens", "ANATOMY", 85, 105], ["acute respiratory illness", "DISEASE", 30, 55], ["ARI", "DISEASE", 57, 60], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["acute respiratory illness", "PROBLEM", 30, 55], ["ARI", "PROBLEM", 57, 60], ["nasal swab specimens", "TEST", 85, 105], ["laboratory testing", "TEST", 124, 142], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory", "ANATOMY", 36, 47], ["illness", "OBSERVATION", 48, 55]]], ["Most patients (78.2%) collected and shipped their specimens without errors.", [["specimens", "ANATOMY", 50, 59], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["These results support the use of self-collected nasal swabs in community-based respiratory virus studies.", [["nasal swabs", "ANATOMY", 48, 59], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 48, 59], ["self-collected nasal swabs", "TREATMENT", 33, 59], ["respiratory virus studies", "TEST", 79, 104], ["respiratory virus", "OBSERVATION", 79, 96]]], ["In this study, subjects with ARI were enrolled by phone, with no opportunity for in-person training in the study procedures.", [["ARI", "DISEASE", 29, 32], ["this study", "TEST", 3, 13], ["ARI", "PROBLEM", 29, 32], ["the study procedures", "TEST", 103, 123]]], ["The similar prevalence of viruses in the self-collected specimens versus clinical specimens from the same period suggests that sensitivity is sufficiently high for most research purposes (11) .DiscussionNasal swab testing for COVID19 has recently been assessed with emerging data on the performance of the available RT-PCR tests (13) .", [["specimens", "ANATOMY", 56, 65], ["specimens", "ANATOMY", 82, 91], ["Nasal swab", "ANATOMY", 203, 213], ["COVID19", "CHEMICAL", 226, 233], ["specimens", "CELL", 56, 65], ["COVID19", "GENE_OR_GENE_PRODUCT", 226, 233], ["COVID19", "DNA", 226, 233], ["viruses", "PROBLEM", 26, 33], ["clinical specimens", "TEST", 73, 91], ["sensitivity", "TEST", 127, 138], ["Nasal swab testing", "TEST", 203, 221], ["the available RT-PCR tests", "TEST", 302, 328], ["viruses", "OBSERVATION", 26, 33]]], ["Self-testing for viral respiratory illnesses itself is not new and has been described in influenza, where there is much more experience (14) (15) (16) (17) .DiscussionIn another study, participants were asked to selfcollect swabs in an emergency department.", [["respiratory", "ANATOMY", 23, 34], ["viral respiratory illnesses", "DISEASE", 17, 44], ["influenza", "DISEASE", 89, 98], ["participants", "SPECIES", 185, 197], ["Self-testing", "TEST", 0, 12], ["viral respiratory illnesses", "PROBLEM", 17, 44], ["influenza", "PROBLEM", 89, 98], ["respiratory", "ANATOMY", 23, 34], ["illnesses", "OBSERVATION", 35, 44], ["new", "OBSERVATION_MODIFIER", 59, 62]]], ["Those swabs were compared with swabs collected by health care professionals in the opposite nostril.", [["swabs", "ANATOMY", 6, 11], ["nostril", "ORGANISM_SUBDIVISION", 92, 99], ["Those swabs", "TEST", 0, 11], ["swabs", "TEST", 31, 36]]], ["Results were comparable; 90% of participants found self-collection to be easy or very easy, and only 21% preferred health care professional collection versus self-collection.", [["participants", "ORGANISM", 32, 44], ["participants", "SPECIES", 32, 44], ["self-collection", "PROBLEM", 51, 66], ["self-collection", "PROBLEM", 158, 173]]], ["Notably, a self-testing strategy would be offered only at the direction of a clinician with an understanding that no test is perfect, much like many of our available tests for other illnesses (5) .DiscussionShantanu Nudy et al. suggested that expanding access to a self-service diagnostic pathway for COVID19 would be beneficial, by utilizing at-home nasopharyngeal swab collections and telemedicine services, with the help of a qualified clinician who would triage the patients and determine whether testing is appropriate or not, based on the latest CDC guidelines.", [["nasopharyngeal swab", "ANATOMY", 351, 370], ["COVID19", "CHEMICAL", 301, 308], ["COVID19", "SIMPLE_CHEMICAL", 301, 308], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 351, 370], ["patients", "ORGANISM", 470, 478], ["patients", "SPECIES", 470, 478], ["a self-testing strategy", "TREATMENT", 9, 32], ["our available tests", "TEST", 152, 171], ["other illnesses", "PROBLEM", 176, 191], ["COVID19", "TREATMENT", 301, 308]]], ["Individuals who are able to be safely tested at home would receive a test kit through home delivery from a local distribution site; a pickup at a local clinic, pharmacy, or public health center; or by mail; and then swab their nasopharynx themselves or with the help of caregivers (6) .DiscussionAlthough due to these studies self-collection is assumed to be an efficient and useful method of sample collection for viral diseases such as influenza A, influenza B, RSV, and adenovirus, for the new pathogen COVID-19 the same may not be true.", [["nasopharynx", "ANATOMY", 227, 238], ["sample", "ANATOMY", 393, 399], ["viral diseases", "DISEASE", 415, 429], ["influenza A", "DISEASE", 438, 449], ["influenza B", "DISEASE", 451, 462], ["nasopharynx", "ORGAN", 227, 238], ["influenza A", "ORGANISM", 438, 449], ["influenza B", "ORGANISM", 451, 462], ["RSV", "ORGANISM", 464, 467], ["adenovirus", "ORGANISM", 473, 483], ["RSV", "SPECIES", 464, 467], ["adenovirus", "SPECIES", 473, 483], ["a test kit", "TREATMENT", 67, 77], ["home delivery", "TREATMENT", 86, 99], ["these studies", "TEST", 312, 325], ["sample collection", "TEST", 393, 410], ["viral diseases", "PROBLEM", 415, 429], ["influenza", "PROBLEM", 438, 447], ["influenza B", "PROBLEM", 451, 462], ["RSV", "PROBLEM", 464, 467], ["adenovirus", "PROBLEM", 473, 483], ["the new pathogen COVID", "TEST", 489, 511]]], ["Much less is known about its pathogenesis and its probable behavioral changes are under study.", [["its pathogenesis", "PROBLEM", 25, 41], ["behavioral changes", "PROBLEM", 59, 77], ["probable", "UNCERTAINTY", 50, 58]]], ["Therefore, according to our study, selfcollection methods cannot be simply applied for COVID-19 patients.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["our study", "TEST", 24, 33], ["selfcollection methods", "TREATMENT", 35, 57], ["COVID", "TEST", 87, 92]]], ["In our study, 50 patients of a wide age range, some of whom had underlying diseases, participated in the research.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["our study", "TEST", 3, 12], ["underlying diseases", "PROBLEM", 64, 83], ["diseases", "OBSERVATION", 75, 83]]], ["The small sample size may be considered as a limitation of our study.", [["The small sample size", "PROBLEM", 0, 21], ["our study", "TEST", 59, 68], ["small", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 17, 21], ["may be considered", "UNCERTAINTY", 22, 39]]], ["Other factors such as a wide age range and present comorbidities may also affect the results.", [["present comorbidities", "PROBLEM", 43, 64]]], ["Hence studies with a larger sample size that take the age group and associated diseases into account could alter the final results.DiscussionThe inclusion of a written instruction for participants about sample collection could enhance their technique and ability of proper sampling.", [["sample", "ANATOMY", 203, 209], ["participants", "SPECIES", 184, 196], ["Hence studies", "TEST", 0, 13], ["a larger sample size", "PROBLEM", 19, 39], ["associated diseases", "PROBLEM", 68, 87], ["sample collection", "PROBLEM", 203, 220], ["their technique", "TEST", 235, 250], ["size", "OBSERVATION_MODIFIER", 35, 39], ["diseases", "OBSERVATION", 79, 87]]], ["In our study, of four patients with at least one positive lab techniciancollected sample who showed negative result in both self-collected ones, three of them were 60-year-old or more, so it seems that more attention and caution are necessitated for older age groups and additional teaching and practicing should be dedicated to them for more accurate results.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["our study", "TEST", 3, 12]]], ["In this age group, eleven patients had a history of underlying diseases such as diabetes, hypertension, ischemic heart disease, and respiratory problems.", [["heart", "ANATOMY", 113, 118], ["respiratory", "ANATOMY", 132, 143], ["diabetes", "DISEASE", 80, 88], ["hypertension", "DISEASE", 90, 102], ["ischemic heart disease", "DISEASE", 104, 126], ["respiratory problems", "DISEASE", 132, 152], ["patients", "ORGANISM", 26, 34], ["heart", "ORGAN", 113, 118], ["patients", "SPECIES", 26, 34], ["underlying diseases", "PROBLEM", 52, 71], ["diabetes", "PROBLEM", 80, 88], ["hypertension", "PROBLEM", 90, 102], ["ischemic heart disease", "PROBLEM", 104, 126], ["respiratory problems", "PROBLEM", 132, 152], ["diseases", "OBSERVATION", 63, 71], ["diabetes", "OBSERVATION", 80, 88], ["hypertension", "OBSERVATION", 90, 102], ["ischemic", "OBSERVATION_MODIFIER", 104, 112], ["heart", "ANATOMY", 113, 118], ["disease", "OBSERVATION", 119, 126], ["respiratory problems", "OBSERVATION", 132, 152]]], ["Nine out of the eleven patients had O2 saturation levels of less than 93%.", [["O2", "CHEMICAL", 36, 38], ["O2", "CHEMICAL", 36, 38], ["patients", "ORGANISM", 23, 31], ["O2", "SIMPLE_CHEMICAL", 36, 38], ["patients", "SPECIES", 23, 31], ["O2 saturation levels", "TEST", 36, 56]]], ["Thus, self-collection sampling is not recommended for these patients with severe medical conditions and serious medical treatment and care should be initiated immediately even if the laboratory results are negative.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["self-collection sampling", "TEST", 6, 30], ["severe medical conditions", "PROBLEM", 74, 99], ["serious medical treatment", "TREATMENT", 104, 129]]], ["So as Neelam Dhiman's study explained, \"personalized patient care\" is the preferred measure (5) .DiscussionPrior antibiotic therapy is also an important issue (18) .", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["Dhiman's study", "TEST", 13, 27], ["DiscussionPrior antibiotic therapy", "TREATMENT", 97, 131]]], ["In our study three out of four patients with a history of antibiotic therapy showed four negative PCR results.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["our study", "TEST", 3, 12], ["antibiotic therapy", "TREATMENT", 58, 76]]], ["Thus, it seems to be crucial to separate patients with a history of antibiotic therapy and to study them as a distinct patient group.DiscussionCurrently, CDC recommends PCR testing for the detection of COVID-19.", [["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 119, 126], ["COVID-19", "DNA", 202, 210], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 119, 126], ["antibiotic therapy", "TREATMENT", 68, 86], ["PCR testing", "TEST", 169, 180], ["the detection", "TEST", 185, 198], ["COVID", "TEST", 202, 207]]], ["In a study by Chunqin Long et al., sensitivity of CT scan and rRT-PCR were compared.", [["a study", "TEST", 3, 10], ["CT scan", "TEST", 50, 57], ["rRT-PCR", "TEST", 62, 69]]], ["Based on their study, a CT scan had a sensitivity of 97.2%, whereas the sensitivity of initial rRT-PCR was only 83.3% (14) .", [["their study", "TEST", 9, 20], ["a CT scan", "TEST", 22, 31], ["a sensitivity", "TEST", 36, 49], ["initial rRT-PCR", "TEST", 87, 102]]], ["CT Scan has a higher sensitivity and a lower false negative rate compared to PCR (15) .", [["CT Scan", "TEST", 0, 7], ["a higher sensitivity", "PROBLEM", 12, 32], ["a lower false negative rate", "PROBLEM", 37, 64], ["PCR", "TEST", 77, 80], ["negative", "OBSERVATION", 51, 59]]], ["In our study, 24 out of 50 (48%) patients with clinical and radiological evidence of COVID-19 had four negative PCR results.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["our study", "TEST", 3, 12], ["COVID", "TEST", 85, 90]]], ["So as stated above, PCR testing alone can lead to false negative results and is not able to detect COVID-19 (16, (19) (20) (21) (22) .", [["COVID-19", "CHEMICAL", 99, 107], ["PCR testing", "TEST", 20, 31], ["COVID", "TEST", 99, 104]]], ["CDC proposes the superiority of PCR testing in the first week after infection because it takes 1-3 weeks for the body to make antibodies and after that period, serologic tests are preferred (23) (24) (25) (26) .", [["body", "ANATOMY", 113, 117], ["infection", "DISEASE", 68, 77], ["body", "ORGANISM_SUBDIVISION", 113, 117], ["antibodies", "PROTEIN", 126, 136], ["PCR testing", "TEST", 32, 43], ["infection", "PROBLEM", 68, 77], ["antibodies", "TREATMENT", 126, 136], ["serologic tests", "TEST", 160, 175], ["infection", "OBSERVATION", 68, 77]]], ["Therefore, a combination of PCR and serologic tests are the best laboratory diagnostic approach to detection of COVID-19 (27) (28) (29) .", [["COVID-19 (27) (28)", "CHEMICAL", 112, 130], ["PCR", "TEST", 28, 31], ["serologic tests", "TEST", 36, 51], ["COVID", "TEST", 112, 117]]], ["Special attention should be paid to the clinical course and the radiological examination of all suspected cases as soon as possible.DiscussionIn specimens obtained from clinically and radiologically infected patients, 22 nasopharyngeal lab technician-collected samples showed positive results, whereas only 14 self-collected samples were positive and 20 oropharyngeal lab technician-collected sample were positive compared to 18 positive results in patientcollected ones.", [["specimens", "ANATOMY", 145, 154], ["samples", "ANATOMY", 261, 268], ["samples", "ANATOMY", 325, 332], ["sample", "ANATOMY", 393, 399], ["patients", "ORGANISM", 208, 216], ["samples", "CANCER", 261, 268], ["samples", "CANCER", 325, 332], ["patients", "SPECIES", 208, 216], ["the radiological examination", "TEST", 60, 88], ["DiscussionIn specimens", "TEST", 132, 154], ["collected samples", "TEST", 251, 268], ["oropharyngeal lab technician", "TEST", 354, 382], ["oropharyngeal", "ANATOMY", 354, 367]]], ["This demonstrates a better sampling technique by lab technicians more obviously in nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 83, 102], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 83, 102], ["nasopharyngeal swab", "TEST", 83, 102], ["nasopharyngeal swab", "ANATOMY", 83, 102]]], ["Overall, considering positive results for lab technician and self-collected samples for both naso-and oropharyngeal specimens, lab technicians showed a better performance in sample collection.ConclusionOur study showed a moderate agreement between the specimens collected by the patients and those collected by the lab technicians in both nasopharyngeal and oropharyngeal samples therefore, in COVID-19 cases, sample collection by lab technicians as the IRANIAN JOURNAL OF PATHOLOGY reference method has priority over sample collection by patients and should not be replaced by the latter.", [["samples", "ANATOMY", 76, 83], ["oropharyngeal specimens", "ANATOMY", 102, 125], ["sample", "ANATOMY", 174, 180], ["specimens", "ANATOMY", 252, 261], ["nasopharyngeal", "ANATOMY", 339, 353], ["oropharyngeal samples", "ANATOMY", 358, 379], ["oropharyngeal specimens", "MULTI-TISSUE_STRUCTURE", 102, 125], ["patients", "ORGANISM", 279, 287], ["nasopharyngeal", "CANCER", 339, 353], ["oropharyngeal samples", "CANCER", 358, 379], ["patients", "ORGANISM", 539, 547], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 539, 547], ["both naso-and oropharyngeal specimens", "TEST", 88, 125], ["ConclusionOur study", "TEST", 192, 211], ["a moderate agreement between the specimens", "PROBLEM", 219, 261], ["oropharyngeal", "ANATOMY", 102, 115], ["moderate", "OBSERVATION_MODIFIER", 221, 229], ["nasopharyngeal", "ANATOMY", 339, 353], ["oropharyngeal samples", "ANATOMY", 358, 379]]]], "b704192a38b5463a3d5e931f42369e94e926294e": [["Long-term care institutions as a high-risk environment for older adults during the COVID-19 outbreak During the COVID-19 outbreak, the infection rate and death rate of long-term care (LTC) residents have been unprecedented (Arons et al., 2020; McMichael, 2020) .", [["infection", "DISEASE", 135, 144], ["death", "DISEASE", 154, 159], ["Long-term care institutions", "TREATMENT", 0, 27], ["the COVID", "TEST", 79, 88], ["the COVID", "TEST", 108, 117], ["the infection rate", "PROBLEM", 131, 149], ["long-term care", "TREATMENT", 168, 182], ["infection", "OBSERVATION", 135, 144]]], ["Recent estimates of the Centre for Disease Control suggest that LTC residents constitute about 27% of all COVID-19 deaths in the United States (https://www.kff.org/medicaid/ issue-brief/state-reporting-of-cases-and-deaths-dueto-covid-19-in-long-term-care-facilities/).", [["deaths", "DISEASE", 115, 121], ["Disease Control", "TREATMENT", 35, 50]]], ["In Europe, deaths of LTC residents constitute 50% of all COVID-19 deaths (https://www.businessinsider .com/half-europes-covid-19-deaths-in-long-termcare-facilities-2020-4).", [["deaths", "DISEASE", 11, 17], ["deaths", "DISEASE", 66, 72]]], ["A recent estimate in Quebec, Canada, suggests that LTC residents constitute as many as 88% of COVID-19 deaths (https://ltccovid. org/wp-content/uploads/2020/06/LTCcovid-country-reports_Canada_June-4-2020.pdf or https://www. thestar.com/politics/federal/2020/05/07/82-ofcanadas-covid-19-deaths-have-been-in-long-termcare.html).", [["deaths", "DISEASE", 103, 109], ["COVID", "TEST", 94, 99]]], ["These statistics likely represent an underestimation, given the fact that not all countries administer post-mortem testing to verify the cause of death.", [["death", "DISEASE", 146, 151], ["post-mortem testing", "TEST", 103, 122], ["death", "PROBLEM", 146, 151], ["likely represent", "UNCERTAINTY", 17, 33], ["underestimation", "OBSERVATION", 37, 52]]], ["Moreover, sporadic reports about hidden corpses may imply a tendency to under-report COVID-19 deaths in LTCS (https://www.nytimes. com/2020/04/15/nyregion/coronavirus-nj-andovernursing-home-deaths.html).", [["deaths", "DISEASE", 94, 100], ["LTCS", "DISEASE", 104, 108], ["coronavirus", "ORGANISM", 155, 166], ["coronavirus", "SPECIES", 155, 166], ["com/2020/04/15/nyregion/coronavirus", "SPECIES", 131, 166], ["hidden corpses", "PROBLEM", 33, 47]]]], "36c903ff54f8ff265cdea664def32855f41ba242": [["IntroductionInoculation of the neurotropic JHMV strain of mouse hepatitis virus (a positive-strand RNA virus and a member of the Coronaviridae family) into the CNS of susceptible strains of mice results in an acute encephalomyelitis.", [["CNS", "ANATOMY", 160, 163], ["hepatitis virus", "DISEASE", 64, 79], ["encephalomyelitis", "DISEASE", 215, 232], ["neurotropic", "ORGANISM", 31, 42], ["JHMV strain", "ORGANISM", 43, 54], ["mouse hepatitis virus", "ORGANISM", 58, 79], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 129, 142], ["CNS", "ANATOMICAL_SYSTEM", 160, 163], ["mice", "ORGANISM", 190, 194], ["Coronaviridae family", "PROTEIN", 129, 149], ["mouse", "SPECIES", 58, 63], ["hepatitis virus", "SPECIES", 64, 79], ["mice", "SPECIES", 190, 194], ["mouse hepatitis virus", "SPECIES", 58, 79], ["mice", "SPECIES", 190, 194], ["mouse hepatitis virus", "PROBLEM", 58, 79], ["a positive-strand RNA virus", "PROBLEM", 81, 108], ["an acute encephalomyelitis", "PROBLEM", 206, 232], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["encephalomyelitis", "OBSERVATION", 215, 232]]], ["The resulting infection is characterized by widespread viral replication in astrocytes, microglia, and oligodendrocytes with relatively few infected neurons Knobler et al., 1981; Parra et al., 1999; Perlmane et al., 1999) .", [["astrocytes", "ANATOMY", 76, 86], ["microglia", "ANATOMY", 88, 97], ["oligodendrocytes", "ANATOMY", 103, 119], ["neurons", "ANATOMY", 149, 156], ["infection", "DISEASE", 14, 23], ["astrocytes", "CELL", 76, 86], ["microglia", "CELL", 88, 97], ["oligodendrocytes", "CELL", 103, 119], ["neurons", "CELL", 149, 156], ["astrocytes", "CELL_TYPE", 76, 86], ["microglia", "CELL_TYPE", 88, 97], ["oligodendrocytes", "CELL_TYPE", 103, 119], ["The resulting infection", "PROBLEM", 0, 23], ["widespread viral replication in astrocytes", "PROBLEM", 44, 86], ["microglia", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 14, 23], ["widespread", "OBSERVATION_MODIFIER", 44, 54], ["viral replication", "OBSERVATION", 55, 72], ["astrocytes", "ANATOMY", 76, 86], ["few", "OBSERVATION_MODIFIER", 136, 139]]], ["JHMV infection of the CNS induces localized expression of pro-inflammatory factors that precedes and accompanies the activation and recruitment of immune cells into the CNS.", [["CNS", "ANATOMY", 22, 25], ["immune cells", "ANATOMY", 147, 159], ["CNS", "ANATOMY", 169, 172], ["infection", "DISEASE", 5, 14], ["CNS", "ANATOMICAL_SYSTEM", 22, 25], ["immune cells", "CELL", 147, 159], ["CNS", "ANATOMICAL_SYSTEM", 169, 172], ["pro-inflammatory factors", "PROTEIN", 58, 82], ["immune cells", "CELL_TYPE", 147, 159], ["JHMV", "SPECIES", 0, 4], ["JHMV infection", "PROBLEM", 0, 14], ["the CNS", "PROBLEM", 18, 25], ["pro-inflammatory factors", "PROBLEM", 58, 82], ["immune cells", "TREATMENT", 147, 159], ["infection", "OBSERVATION", 5, 14], ["CNS", "ANATOMY", 22, 25], ["pro-inflammatory factors", "OBSERVATION", 58, 82], ["immune cells", "OBSERVATION", 147, 159], ["CNS", "ANATOMY", 169, 172]]], ["During the acute disease phase, infiltrating virus-specific CD8 + T cells control viral replication by two different effector mechanisms: IFN-\u03b3 secretion controls viral replication in oligodendrocytes, while a perforin-dependent mechanism promotes viral clearance from astrocytes and microglia (Lin et al., 1997; Parra et al., 1999) .", [["CD8 + T cells", "ANATOMY", 60, 73], ["oligodendrocytes", "ANATOMY", 184, 200], ["astrocytes", "ANATOMY", 269, 279], ["microglia", "ANATOMY", 284, 293], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 138, 143], ["oligodendrocytes", "CELL", 184, 200], ["perforin", "GENE_OR_GENE_PRODUCT", 210, 218], ["astrocytes", "CELL", 269, 279], ["microglia", "CELL", 284, 293], ["CD8 + T cells", "CELL_TYPE", 60, 73], ["IFN", "PROTEIN", 138, 141], ["\u03b3", "PROTEIN", 142, 143], ["oligodendrocytes", "CELL_TYPE", 184, 200], ["perforin", "PROTEIN", 210, 218], ["astrocytes", "CELL_TYPE", 269, 279], ["microglia", "CELL_TYPE", 284, 293], ["the acute disease phase", "PROBLEM", 7, 30], ["infiltrating virus", "PROBLEM", 32, 50], ["specific CD8 + T cells", "TREATMENT", 51, 73], ["viral replication", "TREATMENT", 82, 99], ["IFN", "TREATMENT", 138, 141], ["secretion controls viral replication in oligodendrocytes", "PROBLEM", 144, 200], ["a perforin-dependent mechanism", "TREATMENT", 208, 238], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["disease", "OBSERVATION", 17, 24], ["infiltrating virus", "OBSERVATION", 32, 50], ["viral clearance", "OBSERVATION", 248, 263]]], ["While a robust and effective cell-mediated immune response is generated in response to JHMV infection, virus persists within the CNS and is associated with the development of an immune-mediated demyelinating disease similar to the human demyelinating disease MS. During this stage, both T cells and macrophages are important in amplifying disease severity by contributing to myelin damage (Cheever et al., 1949; Perlman et al., 1999) .IntroductionStem cells and neural precursors represent attractive sources for the generation of remyelination-competent cells since they can readily amplify and differentiate into oligodendrocyte committed cells (Ben-Hur et al., 1998; Brustle et al., 1999) .", [["cell", "ANATOMY", 29, 33], ["CNS", "ANATOMY", 129, 132], ["T cells", "ANATOMY", 287, 294], ["macrophages", "ANATOMY", 299, 310], ["myelin", "ANATOMY", 375, 381], ["IntroductionStem cells", "ANATOMY", 435, 457], ["neural precursors", "ANATOMY", 462, 479], ["cells", "ANATOMY", 555, 560], ["oligodendrocyte", "ANATOMY", 615, 630], ["cells", "ANATOMY", 641, 646], ["infection", "DISEASE", 92, 101], ["demyelinating disease", "DISEASE", 194, 215], ["demyelinating disease", "DISEASE", 237, 258], ["MS", "DISEASE", 259, 261], ["myelin damage", "DISEASE", 375, 388], ["cell", "CELL", 29, 33], ["JHMV", "GENE_OR_GENE_PRODUCT", 87, 91], ["CNS", "ANATOMICAL_SYSTEM", 129, 132], ["human", "ORGANISM", 231, 236], ["T cells", "CELL", 287, 294], ["macrophages", "CELL", 299, 310], ["myelin", "TISSUE", 375, 381], ["IntroductionStem cells", "CELL", 435, 457], ["neural precursors", "CELL", 462, 479], ["cells", "CELL", 555, 560], ["oligodendrocyte", "CELL", 615, 630], ["cells", "CELL", 641, 646], ["T cells", "CELL_TYPE", 287, 294], ["macrophages", "CELL_TYPE", 299, 310], ["IntroductionStem cells", "CELL_TYPE", 435, 457], ["neural precursors", "CELL_TYPE", 462, 479], ["remyelination-competent cells", "CELL_TYPE", 531, 560], ["oligodendrocyte committed cells", "CELL_TYPE", 615, 646], ["human", "SPECIES", 231, 236], ["JHMV", "SPECIES", 87, 91], ["human", "SPECIES", 231, 236], ["JHMV infection", "PROBLEM", 87, 101], ["virus", "PROBLEM", 103, 108], ["an immune-mediated demyelinating disease", "PROBLEM", 175, 215], ["the human demyelinating disease MS", "PROBLEM", 227, 261], ["macrophages", "PROBLEM", 299, 310], ["amplifying disease severity", "PROBLEM", 328, 355], ["myelin damage", "PROBLEM", 375, 388], ["IntroductionStem cells", "TREATMENT", 435, 457], ["neural precursors", "TREATMENT", 462, 479], ["remyelination-competent cells", "PROBLEM", 531, 560], ["infection", "OBSERVATION", 92, 101], ["CNS", "ANATOMY", 129, 132], ["demyelinating disease", "OBSERVATION", 194, 215], ["demyelinating", "OBSERVATION_MODIFIER", 237, 250], ["disease", "OBSERVATION", 251, 258], ["macrophages", "ANATOMY", 299, 310]]], ["Stem cell-derived glial precursors have been shown to myelinate following transplantation into the myelin-deficient rat (Brustle et al., 1999) , and neural precursor-derived glial-committed progenitors (Ben-Hur et al., 1998; Keirstead et al., 1999) have been shown to remyelinate following transplantation into regions of acute experimental demyelination (Keirstead et al., 1999) .", [["Stem cell", "ANATOMY", 0, 9], ["glial precursors", "ANATOMY", 18, 34], ["neural precursor", "ANATOMY", 149, 165], ["glial-committed progenitors", "ANATOMY", 174, 201], ["demyelination", "DISEASE", 341, 354], ["Stem cell", "CELL", 0, 9], ["glial precursors", "CELL", 18, 34], ["myelin", "GENE_OR_GENE_PRODUCT", 99, 105], ["rat", "ORGANISM", 116, 119], ["neural precursor-derived glial-committed progenitors", "CELL", 149, 201], ["glial precursors", "CELL_TYPE", 18, 34], ["neural precursor-derived glial-committed progenitors", "CELL_TYPE", 149, 201], ["rat", "SPECIES", 116, 119], ["Stem cell", "TEST", 0, 9], ["transplantation", "TREATMENT", 74, 89], ["transplantation", "TREATMENT", 290, 305], ["acute experimental demyelination", "PROBLEM", 322, 354], ["glial precursors", "OBSERVATION", 18, 34], ["acute", "OBSERVATION_MODIFIER", 322, 327], ["experimental demyelination", "OBSERVATION", 328, 354]]], ["More recently, intracerebroventricular or intrathecal implantation of neural precursors into rodents with EAE, an autoimmune model of demyelination, resulted in the migration of transplanted cells into white matter and improved clinical outcome (Ben-Hur et al., 2003; Pluchino et al., 2003) .IntroductionWhile implantation of myelin-competent cells has shown to be effective in promoting remyelination in animal models of demyelination initiated by either infiltration of autoreactive lymphocytes or injury, there is limited information available with regards to the ability of these cells to enhance demyelination resulting from viral infection.", [["neural precursors", "ANATOMY", 70, 87], ["cells", "ANATOMY", 191, 196], ["white matter", "ANATOMY", 202, 214], ["myelin-competent cells", "ANATOMY", 326, 348], ["lymphocytes", "ANATOMY", 485, 496], ["cells", "ANATOMY", 584, 589], ["EAE", "DISEASE", 106, 109], ["demyelination", "DISEASE", 134, 147], ["demyelination", "DISEASE", 422, 435], ["demyelination", "DISEASE", 601, 614], ["viral infection", "DISEASE", 630, 645], ["intracerebroventricular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 38], ["neural precursors", "MULTI-TISSUE_STRUCTURE", 70, 87], ["cells", "CELL", 191, 196], ["myelin", "GENE_OR_GENE_PRODUCT", 326, 332], ["cells", "CELL", 343, 348], ["lymphocytes", "CELL", 485, 496], ["cells", "CELL", 584, 589], ["neural precursors", "CELL_TYPE", 70, 87], ["transplanted cells", "CELL_TYPE", 178, 196], ["myelin-competent cells", "CELL_TYPE", 326, 348], ["autoreactive lymphocytes", "CELL_TYPE", 472, 496], ["intracerebroventricular or intrathecal implantation", "TREATMENT", 15, 66], ["EAE", "PROBLEM", 106, 109], ["an autoimmune model of demyelination", "PROBLEM", 111, 147], ["the migration of transplanted cells into white matter", "PROBLEM", 161, 214], ["Introduction", "TREATMENT", 292, 304], ["myelin-competent cells", "PROBLEM", 326, 348], ["demyelination", "PROBLEM", 422, 435], ["autoreactive lymphocytes", "PROBLEM", 472, 496], ["injury", "PROBLEM", 500, 506], ["these cells", "PROBLEM", 578, 589], ["demyelination", "PROBLEM", 601, 614], ["viral infection", "PROBLEM", 630, 645], ["intrathecal implantation", "OBSERVATION", 42, 66], ["neural precursors", "OBSERVATION", 70, 87], ["autoimmune", "OBSERVATION", 114, 124], ["demyelination", "OBSERVATION", 134, 147], ["migration", "OBSERVATION_MODIFIER", 165, 174], ["transplanted cells", "OBSERVATION", 178, 196], ["white matter", "OBSERVATION_MODIFIER", 202, 214], ["improved", "OBSERVATION_MODIFIER", 219, 227], ["remyelination", "OBSERVATION", 388, 401], ["demyelination", "OBSERVATION", 422, 435], ["autoreactive lymphocytes", "OBSERVATION", 472, 496], ["demyelination", "OBSERVATION", 601, 614], ["viral", "OBSERVATION_MODIFIER", 630, 635], ["infection", "OBSERVATION", 636, 645]]], ["We believe this is an important and clinically relevant question as the etiology of MS remains enigmatic although viruses have long been considered potential triggering agents for initiating disease (Gilden, 2005; Olson et al., 2005) .", [["MS", "DISEASE", 84, 86], ["MS", "PROBLEM", 84, 86], ["viruses", "PROBLEM", 114, 121], ["disease", "PROBLEM", 191, 198]]], ["Therefore, evaluating potential cellreplacement strategies for inducing remyelination in viral models of neurologic disease may yield insight into whether this method of (Totoiu et al., 2004) .", [["neurologic", "ANATOMY", 105, 115], ["remyelination", "DISEASE", 72, 85], ["neurologic disease", "DISEASE", 105, 123], ["potential cellreplacement strategies", "TREATMENT", 22, 58], ["inducing remyelination", "PROBLEM", 63, 85], ["neurologic disease", "PROBLEM", 105, 123]]], ["Moreover, remyelination was not associated with dampened T cell infiltration into the CNS as has recently been reported following NSC transplantation in mice with EAE (Aharonowiz et al., 2008; Einstein et al., 2006; Hardison et al., 2006) .", [["T cell", "ANATOMY", 57, 63], ["CNS", "ANATOMY", 86, 89], ["NSC", "ANATOMY", 130, 133], ["EAE", "DISEASE", 163, 166], ["T cell", "CELL", 57, 63], ["CNS", "ANATOMICAL_SYSTEM", 86, 89], ["NSC", "CELL", 130, 133], ["mice", "ORGANISM", 153, 157], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["remyelination", "PROBLEM", 10, 23], ["dampened T cell infiltration", "PROBLEM", 48, 76], ["NSC transplantation", "TREATMENT", 130, 149], ["not associated with", "UNCERTAINTY", 28, 47], ["cell infiltration", "OBSERVATION", 59, 76], ["CNS", "ANATOMY", 86, 89]]], ["Having demonstrated that engraftment of glial cells promotes remyelination following JHMV-induced demyelination, we next were interested in addressing several interrelated issues including i) if glial cells derived from neural precursor cells were susceptible to infection and ii) how infection may be controlled within this population of cells.", [["glial cells", "ANATOMY", 40, 51], ["glial cells", "ANATOMY", 195, 206], ["neural precursor cells", "ANATOMY", 220, 242], ["cells", "ANATOMY", 339, 344], ["JHMV", "CHEMICAL", 85, 89], ["demyelination", "DISEASE", 98, 111], ["infection", "DISEASE", 263, 272], ["infection", "DISEASE", 285, 294], ["glial cells", "CELL", 40, 51], ["glial cells", "CELL", 195, 206], ["neural precursor cells", "CELL", 220, 242], ["cells", "CELL", 339, 344], ["glial cells", "CELL_TYPE", 40, 51], ["glial cells", "CELL_TYPE", 195, 206], ["neural precursor cells", "CELL_TYPE", 220, 242], ["engraftment of glial cells", "TREATMENT", 25, 51], ["demyelination", "PROBLEM", 98, 111], ["glial cells", "PROBLEM", 195, 206], ["neural precursor cells", "PROBLEM", 220, 242], ["infection", "PROBLEM", 263, 272], ["how infection", "PROBLEM", 281, 294], ["glial cells", "OBSERVATION", 40, 51]]], ["We believe these are relevant questions within the context of studying animal models of viral-induced demyelination as cells are being transplanted into the CNS in which a persistent virus is present.", [["cells", "ANATOMY", 119, 124], ["CNS", "ANATOMY", 157, 160], ["demyelination", "DISEASE", 102, 115], ["cells", "CELL", 119, 124], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["viral-induced demyelination as cells", "PROBLEM", 88, 124], ["a persistent virus", "PROBLEM", 170, 188], ["viral", "OBSERVATION", 88, 93], ["demyelination", "OBSERVATION", 102, 115], ["CNS", "ANATOMY", 157, 160], ["persistent", "OBSERVATION_MODIFIER", 172, 182], ["virus", "OBSERVATION", 183, 188]]], ["Therefore, analyzing the susceptibility of cellular progeny derived from neural precursor cells to viral infection is important in that these cells may represent important viral reservoirs in the face of persistent infection.", [["cellular progeny", "ANATOMY", 43, 59], ["neural precursor cells", "ANATOMY", 73, 95], ["cells", "ANATOMY", 142, 147], ["viral infection", "DISEASE", 99, 114], ["infection", "DISEASE", 215, 224], ["cellular progeny", "CELL", 43, 59], ["neural precursor cells", "CELL", 73, 95], ["cells", "CELL", 142, 147], ["neural precursor cells", "CELL_TYPE", 73, 95], ["neural precursor cells", "TREATMENT", 73, 95], ["viral infection", "PROBLEM", 99, 114], ["important viral reservoirs", "PROBLEM", 162, 188], ["persistent infection", "PROBLEM", 204, 224], ["precursor cells", "OBSERVATION", 80, 95], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infection", "OBSERVATION", 105, 114], ["viral reservoirs", "OBSERVATION", 172, 188], ["persistent", "OBSERVATION_MODIFIER", 204, 214], ["infection", "OBSERVATION", 215, 224]]], ["Understanding consequences of infection and how replication may be controlled within these cells will provide insight into understanding host defense mechanisms of implanted cells as well as potential relevance to disease outcome.", [["cells", "ANATOMY", 91, 96], ["cells", "ANATOMY", 174, 179], ["infection", "DISEASE", 30, 39], ["cells", "CELL", 91, 96], ["cells", "CELL", 174, 179], ["implanted cells", "CELL_TYPE", 164, 179], ["infection", "PROBLEM", 30, 39], ["implanted cells", "PROBLEM", 164, 179], ["infection", "OBSERVATION", 30, 39], ["implanted cells", "OBSERVATION", 164, 179]]], ["The relevance of this is further highlighted by the fact that while previous studies have demonstrated that JHMV is able to infect and replicate within glial cells (Dubois-Dalcq et al., 1982; Lavi et al., 1987; Rempel et al., 2005) , the fate of neural progenitor cells as well as cells derived from this population to viral infection is not well characterized.IntroductionIn the present study, we demonstrate that primary cultures of glia derived from neural progenitor cells are susceptible to JHMV infection and support viral replication.", [["glial cells", "ANATOMY", 152, 163], ["neural progenitor cells", "ANATOMY", 246, 269], ["cells", "ANATOMY", 281, 286], ["primary cultures", "ANATOMY", 415, 431], ["glia", "ANATOMY", 435, 439], ["neural progenitor cells", "ANATOMY", 453, 476], ["viral infection", "DISEASE", 319, 334], ["infection", "DISEASE", 501, 510], ["JHMV", "GENE_OR_GENE_PRODUCT", 108, 112], ["glial cells", "CELL", 152, 163], ["neural progenitor cells", "CELL", 246, 269], ["cells", "CELL", 281, 286], ["glia", "CELL", 435, 439], ["neural progenitor cells", "CELL", 453, 476], ["JHMV", "CELL", 496, 500], ["JHMV", "PROTEIN", 108, 112], ["glial cells", "CELL_TYPE", 152, 163], ["neural progenitor cells", "CELL_TYPE", 246, 269], ["primary cultures", "CELL_LINE", 415, 431], ["glia", "CELL_TYPE", 435, 439], ["neural progenitor cells", "CELL_TYPE", 453, 476], ["JHMV", "SPECIES", 108, 112], ["JHMV", "SPECIES", 496, 500], ["previous studies", "TEST", 68, 84], ["neural progenitor cells", "PROBLEM", 246, 269], ["viral infection", "PROBLEM", 319, 334], ["the present study", "TEST", 376, 393], ["primary cultures", "TEST", 415, 431], ["neural progenitor cells", "PROBLEM", 453, 476], ["JHMV infection", "PROBLEM", 496, 510], ["support viral replication", "TREATMENT", 515, 540], ["glial cells", "OBSERVATION", 152, 163], ["neural progenitor cells", "OBSERVATION", 246, 269], ["viral", "OBSERVATION_MODIFIER", 319, 324], ["infection", "OBSERVATION", 325, 334], ["well characterized", "OBSERVATION_MODIFIER", 342, 360], ["neural progenitor cells", "OBSERVATION", 453, 476], ["infection", "OBSERVATION", 501, 510]]], ["Additionally, while IFN-\u03b2 production is dampened in response to viral infection, treatment with recombinant mouse IFN-\u03b3 inhibits JHMV replication.", [["viral infection", "DISEASE", 64, 79], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 20, 25], ["mouse", "ORGANISM", 108, 113], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 114, 119], ["JHMV", "CANCER", 129, 133], ["IFN", "PROTEIN", 20, 23], ["\u03b2", "PROTEIN", 24, 25], ["recombinant mouse IFN-\u03b3", "PROTEIN", 96, 119], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["JHMV", "SPECIES", 129, 133], ["dampened", "PROBLEM", 40, 48], ["viral infection", "PROBLEM", 64, 79], ["recombinant mouse IFN", "TREATMENT", 96, 117], ["JHMV replication", "TREATMENT", 129, 145], ["viral infection", "OBSERVATION", 64, 79]]], ["The IFN-\u03b3-mediated antiviral effect is dampened in experiments using cells derived from type I IFN receptor-deficient mice (IFNAR\u2212/\u2212) indicating a role for type I IFN signaling in limiting JHMV replication in glia-committed progenitor cells.", [["cells", "ANATOMY", 69, 74], ["JHMV", "ANATOMY", 189, 193], ["glia-", "ANATOMY", 209, 214], ["progenitor cells", "ANATOMY", 224, 240], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 4, 10], ["cells", "CELL", 69, 74], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 88, 107], ["mice", "ORGANISM", 118, 122], ["IFNAR", "GENE_OR_GENE_PRODUCT", 124, 129], ["type I IFN", "GENE_OR_GENE_PRODUCT", 156, 166], ["JHMV", "CANCER", 189, 193], ["glia-committed progenitor cells", "CELL", 209, 240], ["IFN", "PROTEIN", 4, 7], ["type I IFN receptor", "PROTEIN", 88, 107], ["IFNAR", "PROTEIN", 124, 129], ["IFN", "PROTEIN", 163, 166], ["glia-committed progenitor cells", "CELL_TYPE", 209, 240], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["JHMV", "SPECIES", 189, 193], ["The IFN", "TREATMENT", 0, 7], ["\u03b3-mediated antiviral effect", "TREATMENT", 8, 35], ["type I IFN receptor", "TREATMENT", 88, 107], ["type I IFN signaling", "PROBLEM", 156, 176], ["antiviral effect", "OBSERVATION", 19, 35], ["progenitor cells", "OBSERVATION", 224, 240]]], ["Therefore, these findings provide, to our knowledge, the first demonstration that glia-committed cells derived from neural precursors are susceptible to JHMV infection as well as identify a potential mechanism responsible for controlling viral replication.Neural progenitor cell culturesThe in vitro culture of neural progenitor cells dissected from the striatal region of the brains of day 1 postnatal C57BL/6 mice resulted in the generation of numerous neurospheres (Fig. 1A ) (Hardison et al., 2006; Totoiu et al., 2004) .", [["glia", "ANATOMY", 82, 86], ["cells", "ANATOMY", 97, 102], ["neural precursors", "ANATOMY", 116, 133], ["Neural progenitor cell cultures", "ANATOMY", 256, 287], ["neural progenitor cells", "ANATOMY", 311, 334], ["striatal region", "ANATOMY", 354, 369], ["brains", "ANATOMY", 377, 383], ["neurospheres", "ANATOMY", 455, 467], ["infection", "DISEASE", 158, 167], ["glia", "CELL", 82, 86], ["cells", "CELL", 97, 102], ["neural precursors", "CELL", 116, 133], ["JHMV", "GENE_OR_GENE_PRODUCT", 153, 157], ["Neural progenitor cell cultures", "CELL", 256, 287], ["neural progenitor cells", "CELL", 311, 334], ["striatal region", "MULTI-TISSUE_STRUCTURE", 354, 369], ["brains", "ORGAN", 377, 383], ["C57BL/6 mice", "ORGANISM", 403, 415], ["neurospheres", "CELL", 455, 467], ["glia-committed cells", "CELL_TYPE", 82, 102], ["neural precursors", "CELL_TYPE", 116, 133], ["Neural progenitor cell cultures", "CELL_LINE", 256, 287], ["neural progenitor cells", "CELL_TYPE", 311, 334], ["mice", "SPECIES", 411, 415], ["JHMV", "SPECIES", 153, 157], ["committed cells", "PROBLEM", 87, 102], ["JHMV infection", "PROBLEM", 153, 167], ["viral replication", "TREATMENT", 238, 255], ["Neural progenitor cell cultures", "TEST", 256, 287], ["The in vitro culture", "TEST", 287, 307], ["neural progenitor cells", "PROBLEM", 311, 334], ["glia", "ANATOMY", 82, 86], ["neural precursors", "OBSERVATION", 116, 133], ["infection", "OBSERVATION", 158, 167], ["progenitor cell cultures", "OBSERVATION", 263, 287], ["neural progenitor cells", "OBSERVATION", 311, 334], ["striatal", "ANATOMY_MODIFIER", 354, 362], ["region", "ANATOMY_MODIFIER", 363, 369], ["brains", "ANATOMY", 377, 383]]], ["After the mature neurospheres were plated on an adherent matrix and incubated in growth medium, the majority of the cells exhibited oligodendrocyte morphology characterized by extensive arborization (Fig. 1B) .", [["neurospheres", "ANATOMY", 17, 29], ["matrix", "ANATOMY", 57, 63], ["cells", "ANATOMY", 116, 121], ["oligodendrocyte", "ANATOMY", 132, 147], ["neurospheres", "CELL", 17, 29], ["matrix", "CELLULAR_COMPONENT", 57, 63], ["cells", "CELL", 116, 121], ["oligodendrocyte", "CELL", 132, 147], ["the mature neurospheres", "PROBLEM", 6, 29], ["an adherent matrix", "TREATMENT", 45, 63], ["mature", "OBSERVATION_MODIFIER", 10, 16], ["neurospheres", "OBSERVATION", 17, 29], ["adherent matrix", "OBSERVATION_MODIFIER", 48, 63], ["growth medium", "OBSERVATION_MODIFIER", 81, 94], ["oligodendrocyte morphology", "OBSERVATION", 132, 158], ["extensive", "OBSERVATION_MODIFIER", 176, 185], ["arborization", "OBSERVATION_MODIFIER", 186, 198]]], ["Immunocytochemical staining confirmed the morphology results indicating that \u223c70% of the cells differentiated into oligodendrocytes (determined by GalC staining) (Fig. 1C ).", [["cells", "ANATOMY", 89, 94], ["oligodendrocytes", "ANATOMY", 115, 131], ["cells", "CELL", 89, 94], ["oligodendrocytes", "CELL", 115, 131], ["GalC", "GENE_OR_GENE_PRODUCT", 147, 151], ["oligodendrocytes", "CELL_TYPE", 115, 131], ["Immunocytochemical staining", "TEST", 0, 27], ["GalC staining", "TEST", 147, 160]]], ["The remaining cells had differentiated into either astrocytes (\u223c25%, GFAP-expression) or neurons (b5%, Map2 staining) (Fig. 1D ).", [["cells", "ANATOMY", 14, 19], ["astrocytes", "ANATOMY", 51, 61], ["neurons", "ANATOMY", 89, 96], ["cells", "CELL", 14, 19], ["astrocytes", "CELL", 51, 61], ["GFAP", "GENE_OR_GENE_PRODUCT", 69, 73], ["neurons", "CELL", 89, 96], ["b5", "GENE_OR_GENE_PRODUCT", 98, 100], ["Map2", "GENE_OR_GENE_PRODUCT", 103, 107], ["astrocytes", "CELL_TYPE", 51, 61], ["GFAP", "PROTEIN", 69, 73], ["Map2", "PROTEIN", 103, 107], ["astrocytes", "TEST", 51, 61], ["GFAP", "TEST", 69, 73], ["neurons", "PROBLEM", 89, 96], ["b5", "TEST", 98, 100], ["Map2 staining", "TEST", 103, 116], ["remaining cells", "OBSERVATION", 4, 19], ["astrocytes", "ANATOMY", 51, 61], ["neurons", "ANATOMY", 89, 96]]], ["These differentiated neural progenitor cultures were used for the subsequent studies examining JHMV susceptibility to infection.JHMV infects and replicates in differentiated neural progenitor cell culturesJHMV is able to infect and replicate in differentiated neural progenitor cultures as demonstrated by increasing viral titers measured at 12, 24, and 48 h p.i.", [["neural progenitor cultures", "ANATOMY", 21, 47], ["neural progenitor cell", "ANATOMY", 174, 196], ["neural progenitor cultures", "ANATOMY", 260, 286], ["infection", "DISEASE", 118, 127], ["neural progenitor cultures", "CELL", 21, 47], ["JHMV", "CANCER", 95, 99], ["JHMV", "ORGANISM", 128, 132], ["neural progenitor cell culturesJHMV", "CELL", 174, 209], ["neural progenitor cultures", "CELL", 260, 286], ["differentiated neural progenitor cultures", "CELL_LINE", 6, 47], ["JHMV", "PROTEIN", 128, 132], ["differentiated neural progenitor cell culturesJHMV", "CELL_LINE", 159, 209], ["differentiated neural progenitor cultures", "CELL_LINE", 245, 286], ["JHMV", "SPECIES", 95, 99], ["JHMV", "SPECIES", 128, 132], ["These differentiated neural progenitor cultures", "PROBLEM", 0, 47], ["the subsequent studies", "TEST", 62, 84], ["JHMV susceptibility to infection", "PROBLEM", 95, 127], ["JHMV infects", "PROBLEM", 128, 140], ["neural progenitor cultures", "TEST", 260, 286], ["increasing viral titers", "PROBLEM", 306, 329], ["differentiated", "OBSERVATION_MODIFIER", 6, 20], ["neural progenitor cultures", "OBSERVATION", 21, 47], ["infection", "OBSERVATION", 118, 127], ["infects", "OBSERVATION", 133, 140], ["differentiated", "OBSERVATION_MODIFIER", 159, 173], ["neural progenitor cell culturesJHMV", "OBSERVATION", 174, 209], ["neural progenitor", "OBSERVATION", 260, 277], ["increasing", "OBSERVATION_MODIFIER", 306, 316], ["viral titers", "OBSERVATION", 317, 329]]], ["Immunocytochemistry revealed viral antigen distributed extensively throughout the monolayer (Fig. 2B ).", [["monolayer", "ANATOMY", 82, 91], ["monolayer", "CELL", 82, 91], ["viral antigen", "PROTEIN", 29, 42], ["Immunocytochemistry", "TEST", 0, 19], ["viral antigen", "PROBLEM", 29, 42], ["viral antigen", "OBSERVATION", 29, 42]]], ["In addition, JHMV infection resulted in cytopathic effects by 24 h p.i. characterized by wide-spread syncytia formation (Fig. 2C ).", [["syncytia", "ANATOMY", 101, 109], ["JHMV", "CHEMICAL", 13, 17], ["infection", "DISEASE", 18, 27], ["syncytia", "CELL", 101, 109], ["JHMV", "SPECIES", 13, 17], ["JHMV infection", "PROBLEM", 13, 27], ["cytopathic effects", "PROBLEM", 40, 58], ["wide-spread syncytia formation", "PROBLEM", 89, 119], ["infection", "OBSERVATION", 18, 27], ["cytopathic", "OBSERVATION_MODIFIER", 40, 50], ["wide", "OBSERVATION_MODIFIER", 89, 93], ["spread syncytia", "OBSERVATION", 94, 109]]], ["These findings indicate that differentiated cells derived from neural progenitors are susceptible to JHMV infection and are capable of supporting replicating virus which results in extensive cytopathology.IFN-\u03b3 suppresses JHMV replication in cultured OPCPrevious studies by Parra et al. (1999) demonstrated that IFN-\u03b3 has an important role in controlling JHMV replication within oligodendrocytes of persistently infected mice.", [["cells", "ANATOMY", 44, 49], ["neural progenitors", "ANATOMY", 63, 81], ["JHMV", "ANATOMY", 222, 226], ["JHMV", "ANATOMY", 355, 359], ["oligodendrocytes", "ANATOMY", 379, 395], ["infection", "DISEASE", 106, 115], ["cells", "CELL", 44, 49], ["neural progenitors", "CELL", 63, 81], ["JHMV", "GENE_OR_GENE_PRODUCT", 101, 105], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 205, 210], ["JHMV", "CANCER", 222, 226], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 312, 317], ["JHMV", "GENE_OR_GENE_PRODUCT", 355, 359], ["oligodendrocytes", "CELL", 379, 395], ["mice", "ORGANISM", 421, 425], ["differentiated cells", "CELL_TYPE", 29, 49], ["neural progenitors", "CELL_TYPE", 63, 81], ["IFN", "PROTEIN", 205, 208], ["\u03b3", "PROTEIN", 209, 210], ["IFN-\u03b3", "PROTEIN", 312, 317], ["oligodendrocytes", "CELL_TYPE", 379, 395], ["mice", "SPECIES", 421, 425], ["JHMV", "SPECIES", 101, 105], ["JHMV", "SPECIES", 222, 226], ["JHMV", "SPECIES", 355, 359], ["mice", "SPECIES", 421, 425], ["differentiated cells", "PROBLEM", 29, 49], ["neural progenitors", "PROBLEM", 63, 81], ["JHMV infection", "PROBLEM", 101, 115], ["supporting replicating virus", "PROBLEM", 135, 163], ["extensive cytopathology", "PROBLEM", 181, 204], ["differentiated cells", "OBSERVATION", 29, 49], ["neural progenitors", "OBSERVATION", 63, 81], ["infection", "OBSERVATION", 106, 115], ["extensive", "OBSERVATION_MODIFIER", 181, 190], ["cytopathology", "OBSERVATION", 191, 204], ["persistently", "OBSERVATION_MODIFIER", 399, 411], ["infected mice", "OBSERVATION", 412, 425]]], ["Therefore, we next determined whether IFN-\u03b3 was capable of inhibiting JHMV replication following infection of differentiated neural progenitor cells.", [["neural progenitor cells", "ANATOMY", 125, 148], ["infection", "DISEASE", 97, 106], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 38, 43], ["JHMV", "GENE_OR_GENE_PRODUCT", 70, 74], ["neural progenitor cells", "CELL", 125, 148], ["IFN-\u03b3", "PROTEIN", 38, 43], ["differentiated neural progenitor cells", "CELL_TYPE", 110, 148], ["JHMV", "SPECIES", 70, 74], ["IFN", "TEST", 38, 41], ["JHMV replication", "TREATMENT", 70, 86], ["infection of differentiated neural progenitor cells", "PROBLEM", 97, 148], ["neural progenitor cells", "OBSERVATION", 125, 148]]], ["As shown in Fig. 3A , treatment of JHMV-infected cells with recombinant mouse IFN-\u03b3 inhibited viral replication at 12 (57% reduction, p b 0.05), 24 (56% reduction, p b 0.05), and 48 h p.i.", [["cells", "ANATOMY", 49, 54], ["JHMV", "ORGANISM", 35, 39], ["cells", "CELL", 49, 54], ["mouse", "ORGANISM", 72, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["JHMV-infected cells", "CELL_LINE", 35, 54], ["recombinant mouse IFN-\u03b3", "PROTEIN", 60, 83], ["mouse", "SPECIES", 72, 77], ["JHMV", "SPECIES", 35, 39], ["mouse", "SPECIES", 72, 77], ["JHMV", "PROBLEM", 35, 39], ["infected cells", "PROBLEM", 40, 54], ["recombinant mouse IFN", "TREATMENT", 60, 81], ["viral replication", "TREATMENT", 94, 111], ["infected cells", "OBSERVATION", 40, 54]]], ["(94% reduction, p b 0.05) compared to media-treated controls.", [["media-treated controls", "TREATMENT", 38, 60]]], ["Moreover, the IFN-\u03b3-mediated inhibition of JHMV-replication was concentration-dependent; titration of IFN-\u03b3 resulted in diminished antiviral effects (Fig. 3B ).", [["IFN", "CHEMICAL", 14, 17], ["IFN-\u03b3", "CHEMICAL", 102, 107], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 14, 20], ["JHMV", "SIMPLE_CHEMICAL", 43, 47], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN", "PROTEIN", 14, 17], ["JHMV", "DNA", 43, 47], ["IFN", "PROTEIN", 102, 105], ["\u03b3", "PROTEIN", 106, 107], ["the IFN", "TREATMENT", 10, 17], ["JHMV-replication", "TREATMENT", 43, 59], ["IFN", "TREATMENT", 102, 105], ["diminished antiviral effects", "PROBLEM", 120, 148], ["diminished", "OBSERVATION_MODIFIER", 120, 130], ["antiviral effects", "OBSERVATION", 131, 148]]], ["The pretreatment of cultures with IFN-\u03b3 (100 U/ml) resulted in a significant (p b 0.05) reduction in viral titers at 24 h p.i. when compared to cultures incubated with IFN-\u03b3 following infection (Fig. 3C ).", [["cultures", "ANATOMY", 20, 28], ["cultures", "ANATOMY", 144, 152], ["IFN-\u03b3", "CHEMICAL", 34, 39], ["IFN-\u03b3", "CHEMICAL", 168, 173], ["infection", "DISEASE", 184, 193], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 34, 39], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 168, 173], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 168, 171], ["cultures", "TEST", 20, 28], ["IFN", "TEST", 34, 37], ["viral titers", "PROBLEM", 101, 113], ["cultures", "TEST", 144, 152], ["IFN", "TEST", 168, 171], ["infection", "PROBLEM", 184, 193], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["viral titers", "OBSERVATION", 101, 113], ["infection", "OBSERVATION", 184, 193]]], ["Immunocytochemistry revealed that IFN-\u03b3 treatment of differentiated neural progenitor cultures limited the extensive cytopathic effects (Figs.", [["neural progenitor cultures", "ANATOMY", 68, 94], ["IFN-\u03b3", "CHEMICAL", 34, 39], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 34, 39], ["neural progenitor cultures", "CELL", 68, 94], ["IFN", "PROTEIN", 34, 37], ["differentiated neural progenitor cultures", "CELL_LINE", 53, 94], ["Immunocytochemistry", "TEST", 0, 19], ["IFN", "TEST", 34, 37], ["treatment", "TREATMENT", 40, 49], ["differentiated neural progenitor cultures", "PROBLEM", 53, 94], ["the extensive cytopathic effects", "PROBLEM", 103, 135], ["neural progenitor", "OBSERVATION", 68, 85], ["extensive", "OBSERVATION_MODIFIER", 107, 116], ["cytopathic", "OBSERVATION_MODIFIER", 117, 127]]], ["3D and E) observed in untreated cells (Fig. 3F ) as characterized by diminished syncytium formation.", [["cells", "ANATOMY", 32, 37], ["syncytium", "ANATOMY", 80, 89], ["cells", "CELL", 32, 37], ["Fig. 3F", "CELL", 39, 46], ["syncytium", "CELL", 80, 89], ["untreated cells", "CELL_TYPE", 22, 37], ["diminished syncytium formation", "PROBLEM", 69, 99], ["diminished syncytium formation", "OBSERVATION", 69, 99]]], ["Together these data indicate that IFN-\u03b3 activates differentiated neural progenitors to inhibit JHMV replication, which correlates with muted cytopathology.IFN-\u03b3-mediated suppression of JHMV replication is not dependent on expression of non-ELR chemokinesIt is known that IFN-\u03b3 is capable of inducing expression of the non-ELR chemokines CXCL9 and CXCL10 in numerous cell types including resident cells of the CNS such as astrocytes and microglia (Bhowmick et al., 2007; Majumder et al., 1998; Vanguri and Farber, 1994) .", [["neural progenitors", "ANATOMY", 65, 83], ["JHMV", "ANATOMY", 95, 99], ["cell", "ANATOMY", 366, 370], ["cells", "ANATOMY", 396, 401], ["CNS", "ANATOMY", 409, 412], ["astrocytes", "ANATOMY", 421, 431], ["microglia", "ANATOMY", 436, 445], ["IFN", "CHEMICAL", 155, 158], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 34, 39], ["neural progenitors", "CELL", 65, 83], ["JHMV", "GENE_OR_GENE_PRODUCT", 95, 99], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 155, 161], ["JHMV", "CANCER", 185, 189], ["non-ELR chemokines", "GENE_OR_GENE_PRODUCT", 236, 254], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 271, 276], ["CXCL9", "GENE_OR_GENE_PRODUCT", 337, 342], ["CXCL10", "GENE_OR_GENE_PRODUCT", 347, 353], ["cell", "CELL", 366, 370], ["cells", "CELL", 396, 401], ["CNS", "ANATOMICAL_SYSTEM", 409, 412], ["astrocytes", "CELL", 421, 431], ["microglia", "CELL", 436, 445], ["IFN", "PROTEIN", 34, 37], ["\u03b3", "PROTEIN", 38, 39], ["differentiated neural progenitors", "CELL_TYPE", 50, 83], ["IFN", "PROTEIN", 155, 158], ["non-ELR chemokines", "PROTEIN", 236, 254], ["IFN-\u03b3", "PROTEIN", 271, 276], ["non-ELR chemokines", "PROTEIN", 318, 336], ["CXCL9", "PROTEIN", 337, 342], ["CXCL10", "PROTEIN", 347, 353], ["resident cells", "CELL_TYPE", 387, 401], ["astrocytes", "CELL_TYPE", 421, 431], ["microglia", "CELL_TYPE", 436, 445], ["JHMV", "SPECIES", 95, 99], ["JHMV", "SPECIES", 185, 189], ["these data", "TEST", 9, 19], ["IFN", "PROBLEM", 34, 37], ["JHMV replication", "TREATMENT", 95, 111], ["muted cytopathology", "PROBLEM", 135, 154], ["JHMV replication", "TREATMENT", 185, 201], ["non-ELR chemokines", "TREATMENT", 236, 254], ["IFN", "PROBLEM", 271, 274], ["the non-ELR chemokines CXCL9", "TEST", 314, 342], ["CXCL10", "TEST", 347, 353], ["neural progenitors", "OBSERVATION", 65, 83], ["muted", "OBSERVATION_MODIFIER", 135, 140], ["cytopathology", "OBSERVATION", 141, 154], ["numerous cell types", "OBSERVATION", 357, 376], ["CNS", "ANATOMY", 409, 412]]], ["Moreover, in vivo astrocytes have been shown to express CXCL9 and CXCL10 mRNA transcripts during the acute response to JHMV infection and in vitro cultured astrocytes are capable of expressing CXCL10 mRNA transcripts (Lane et al., 1998; Liu et al., 2000 Liu et al., , 2001 .", [["astrocytes", "ANATOMY", 18, 28], ["astrocytes", "ANATOMY", 156, 166], ["infection", "DISEASE", 124, 133], ["astrocytes", "CELL", 18, 28], ["CXCL9", "GENE_OR_GENE_PRODUCT", 56, 61], ["CXCL10", "GENE_OR_GENE_PRODUCT", 66, 72], ["astrocytes", "CELL", 156, 166], ["CXCL10", "GENE_OR_GENE_PRODUCT", 193, 199], ["astrocytes", "CELL_TYPE", 18, 28], ["CXCL9 and CXCL10 mRNA transcripts", "RNA", 56, 89], ["astrocytes", "CELL_TYPE", 156, 166], ["CXCL10 mRNA transcripts", "RNA", 193, 216], ["JHMV", "SPECIES", 119, 123], ["CXCL9", "TEST", 56, 61], ["CXCL10 mRNA transcripts", "TREATMENT", 66, 89], ["the acute response", "PROBLEM", 97, 115], ["JHMV infection", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 124, 133]]], ["Neither CXCL9 nor CXCL10 are detectable in differentiated neural progenitor cultures in response to JHMV infection at 12 or 24 h p.i.", [["neural progenitor cultures", "ANATOMY", 58, 84], ["infection", "DISEASE", 105, 114], ["CXCL9", "GENE_OR_GENE_PRODUCT", 8, 13], ["CXCL10", "GENE_OR_GENE_PRODUCT", 18, 24], ["neural progenitor cultures", "CELL", 58, 84], ["JHMV", "ORGANISM", 100, 104], ["CXCL9", "PROTEIN", 8, 13], ["CXCL10", "PROTEIN", 18, 24], ["differentiated neural progenitor cultures", "CELL_LINE", 43, 84], ["JHMV", "SPECIES", 100, 104], ["CXCL9 nor CXCL10", "TEST", 8, 24], ["neural progenitor cultures", "TEST", 58, 84], ["JHMV infection", "PROBLEM", 100, 114], ["neural progenitor", "OBSERVATION", 58, 75], ["infection", "OBSERVATION", 105, 114]]], ["4A and B) .", [["B", "GENE_OR_GENE_PRODUCT", 7, 8]]], ["In contrast, IFN-\u03b3 treatment of infected cultures resulted in measurable levels of both CXCL9 and CXCL10 at 12 and 24 h p.i.", [["cultures", "ANATOMY", 41, 49], ["IFN-\u03b3", "CHEMICAL", 13, 18], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 13, 18], ["CXCL9", "GENE_OR_GENE_PRODUCT", 88, 93], ["CXCL10", "GENE_OR_GENE_PRODUCT", 98, 104], ["IFN", "PROTEIN", 13, 16], ["CXCL9", "PROTEIN", 88, 93], ["CXCL10", "PROTEIN", 98, 104], ["IFN", "TREATMENT", 13, 16], ["treatment", "TREATMENT", 19, 28], ["infected cultures", "TEST", 32, 49], ["CXCL9", "TEST", 88, 93], ["CXCL10", "TEST", 98, 104], ["infected", "OBSERVATION", 32, 40], ["both", "ANATOMY_MODIFIER", 83, 87], ["CXCL9", "ANATOMY", 88, 93]]], ["4A and B) .", [["B", "GENE_OR_GENE_PRODUCT", 7, 8]]], ["Levels of CXCL10 were dramatically higher (\u223c 45,000 pg/ml at 12 h) compared to CXCL9 levels (\u223c75 pg/ml at 12 h) suggesting differential promoter sensitivities to IFN-\u03b3 treatment or altered stability at either RNA or protein levels.", [["IFN-\u03b3", "CHEMICAL", 162, 167], ["CXCL10", "GENE_OR_GENE_PRODUCT", 10, 16], ["CXCL9", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 162, 167], ["CXCL10", "PROTEIN", 10, 16], ["CXCL9", "PROTEIN", 79, 84], ["IFN", "PROTEIN", 162, 165], ["Levels of CXCL10", "TEST", 0, 16], ["CXCL9 levels", "TEST", 79, 91], ["IFN", "TREATMENT", 162, 165], ["treatment", "TREATMENT", 168, 177], ["altered stability", "PROBLEM", 181, 198], ["protein levels", "TEST", 216, 230], ["stability", "OBSERVATION_MODIFIER", 189, 198]]], ["To assess the importance of IFN-\u03b3-mediated production of CXCL9 and CXCL10 in the inhibition of JHMV replication, neural progenitor cells were isolated from CXCL10\u2212/\u2212 mice and mice deficient in the signaling receptor for CXCL9 and CXCL10, CXCR3 (CXCR3\u2212/\u2212 mice).", [["JHMV", "ANATOMY", 95, 99], ["neural progenitor cells", "ANATOMY", 113, 136], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 28, 34], ["CXCL9", "GENE_OR_GENE_PRODUCT", 57, 62], ["CXCL10", "GENE_OR_GENE_PRODUCT", 67, 73], ["JHMV", "CELL", 95, 99], ["neural progenitor cells", "CELL", 113, 136], ["CXCL10", "GENE_OR_GENE_PRODUCT", 156, 162], ["mice", "ORGANISM", 175, 179], ["CXCL9", "GENE_OR_GENE_PRODUCT", 220, 225], ["CXCL10", "GENE_OR_GENE_PRODUCT", 230, 236], ["CXCR3", "GENE_OR_GENE_PRODUCT", 238, 243], ["CXCR3\u2212", "GENE_OR_GENE_PRODUCT", 245, 251], ["IFN", "PROTEIN", 28, 31], ["CXCL9", "PROTEIN", 57, 62], ["CXCL10", "PROTEIN", 67, 73], ["neural progenitor cells", "CELL_TYPE", 113, 136], ["CXCL10", "PROTEIN", 156, 162], ["signaling receptor", "PROTEIN", 197, 215], ["CXCL9", "PROTEIN", 220, 225], ["CXCL10", "PROTEIN", 230, 236], ["CXCR3", "PROTEIN", 238, 243], ["CXCR3\u2212", "PROTEIN", 245, 251], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 254, 258], ["JHMV", "SPECIES", 95, 99], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 175, 179], ["IFN", "TREATMENT", 28, 31], ["CXCL9", "TEST", 57, 62], ["CXCL10", "TREATMENT", 67, 73], ["JHMV replication", "TREATMENT", 95, 111], ["neural progenitor cells", "PROBLEM", 113, 136], ["CXCL10", "TEST", 156, 162], ["mice deficient", "PROBLEM", 175, 189], ["CXCL9", "TEST", 220, 225], ["CXCL10", "TEST", 230, 236], ["CXCR3", "TEST", 238, 243], ["CXCR3\u2212", "TEST", 245, 251], ["progenitor cells", "OBSERVATION", 120, 136]]], ["The neural progenitor cells from deficient mice were differentiated in vitro, infected with JHMV and treated with IFN-\u03b3.", [["neural progenitor cells", "ANATOMY", 4, 27], ["neural progenitor cells", "CELL", 4, 27], ["mice", "ORGANISM", 43, 47], ["neural progenitor cells", "CELL_TYPE", 4, 27], ["IFN", "PROTEIN", 114, 117], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["JHMV", "SPECIES", 92, 96], ["deficient mice", "PROBLEM", 33, 47], ["JHMV", "TREATMENT", 92, 96], ["IFN", "TREATMENT", 114, 117], ["neural", "ANATOMY", 4, 10], ["progenitor cells", "OBSERVATION", 11, 27]]], ["As we observed in wildtype mice, such treatment resulted in a significant reduction in viral titers at 24 h p.i. compared to infected cells incubated with medium alone (Figs.", [["cells", "ANATOMY", 134, 139], ["wildtype mice", "ORGANISM", 18, 31], ["cells", "CELL", 134, 139], ["infected cells", "CELL_TYPE", 125, 139], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["such treatment", "TREATMENT", 33, 47], ["a significant reduction in viral titers", "PROBLEM", 60, 99], ["infected cells", "PROBLEM", 125, 139], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["reduction", "OBSERVATION_MODIFIER", 74, 83], ["viral titers", "OBSERVATION", 87, 99]]], ["4C and D).", [["D", "SIMPLE_CHEMICAL", 7, 8]]], ["Therefore, the IFN-\u03b3-mediated anti-viral effect observed occurs independently of either production of CXCL9, and CXCL10 or CXCR3 signaling.IFN-\u03b1/\u03b2 production following IFN-\u03b3-treatmentType I IFN (IFN \u03b1 and \u03b2) exhibit potent antiviral activity and have recently been shown to be important in controlling JHMV replication in vivo (Ireland et al., 2008) .", [["JHMV", "ANATOMY", 302, 306], ["IFN", "CHEMICAL", 168, 171], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 15, 21], ["CXCL9", "GENE_OR_GENE_PRODUCT", 102, 107], ["CXCL10", "GENE_OR_GENE_PRODUCT", 113, 119], ["CXCR3", "GENE_OR_GENE_PRODUCT", 123, 128], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 139, 144], ["\u03b2", "GENE_OR_GENE_PRODUCT", 145, 146], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 168, 174], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 183, 193], ["IFN \u03b1", "GENE_OR_GENE_PRODUCT", 195, 200], ["\u03b2", "GENE_OR_GENE_PRODUCT", 205, 206], ["JHMV", "CELL", 302, 306], ["IFN", "PROTEIN", 15, 18], ["CXCL9", "PROTEIN", 102, 107], ["CXCL10", "PROTEIN", 113, 119], ["CXCR3", "PROTEIN", 123, 128], ["IFN", "PROTEIN", 139, 142], ["\u03b1", "PROTEIN", 143, 144], ["\u03b2", "PROTEIN", 145, 146], ["IFN", "PROTEIN", 168, 171], ["Type I IFN", "PROTEIN", 183, 193], ["IFN", "PROTEIN", 195, 198], ["\u03b1", "PROTEIN", 199, 200], ["\u03b2", "PROTEIN", 205, 206], ["JHMV", "SPECIES", 302, 306], ["the IFN-\u03b3-mediated anti-viral effect", "TREATMENT", 11, 47], ["CXCL9", "TEST", 102, 107], ["CXCL10", "TEST", 113, 119], ["CXCR3 signaling", "TEST", 123, 138], ["IFN-\u03b3-treatment", "TREATMENT", 168, 183], ["Type I IFN", "PROBLEM", 183, 193], ["potent", "OBSERVATION_MODIFIER", 216, 222], ["antiviral activity", "OBSERVATION", 223, 241]]], ["Therefore, we next evaluated production of type I IFN from differentiated progenitor cultures following JHMV infection.", [["progenitor cultures", "ANATOMY", 74, 93], ["infection", "DISEASE", 109, 118], ["type I IFN", "GENE_OR_GENE_PRODUCT", 43, 53], ["progenitor cultures", "CELL", 74, 93], ["JHMV", "ORGANISM", 104, 108], ["type I IFN", "PROTEIN", 43, 53], ["differentiated progenitor cultures", "CELL_LINE", 59, 93], ["JHMV", "SPECIES", 104, 108], ["type I IFN", "PROBLEM", 43, 53], ["progenitor cultures", "TEST", 74, 93], ["JHMV infection", "PROBLEM", 104, 118], ["infection", "OBSERVATION", 109, 118]]], ["As shown in Fig. 5A , JHMV infection did not result in detectable levels of IFN-\u03b1/\u03b2 at either 24 or 48 h p.i.", [["infection", "DISEASE", 27, 36], ["JHMV", "ORGANISM", 22, 26], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 76, 81], ["\u03b2", "GENE_OR_GENE_PRODUCT", 82, 83], ["IFN", "PROTEIN", 76, 79], ["\u03b1", "PROTEIN", 80, 81], ["\u03b2", "PROTEIN", 82, 83], ["JHMV", "SPECIES", 22, 26], ["JHMV infection", "PROBLEM", 22, 36], ["IFN", "TEST", 76, 79], ["infection", "OBSERVATION", 27, 36]]], ["However, IFN-\u03b3 treatment of JHMV-infected cultures resulted in expression of IFN-\u03b1/\u03b2 that was elevated compared to treatment with IFN-\u03b3 alone (Fig. 5A) .", [["cultures", "ANATOMY", 42, 50], ["IFN-\u03b3", "CHEMICAL", 9, 14], ["IFN-\u03b3", "CHEMICAL", 130, 135], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["JHMV", "ORGANISM", 28, 32], ["cultures", "CELL", 42, 50], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 77, 82], ["\u03b2", "GENE_OR_GENE_PRODUCT", 83, 84], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 130, 135], ["IFN", "PROTEIN", 9, 12], ["JHMV-infected cultures", "CELL_LINE", 28, 50], ["IFN", "PROTEIN", 77, 80], ["\u03b1", "PROTEIN", 81, 82], ["\u03b2", "PROTEIN", 83, 84], ["IFN", "PROTEIN", 130, 133], ["\u03b3", "PROTEIN", 134, 135], ["JHMV", "SPECIES", 28, 32], ["IFN", "TREATMENT", 9, 12], ["treatment", "TREATMENT", 15, 24], ["JHMV", "TEST", 28, 32], ["infected cultures", "PROBLEM", 33, 50], ["IFN", "TEST", 77, 80], ["elevated", "PROBLEM", 94, 102], ["IFN", "TREATMENT", 130, 133]]], ["Further, direct treatment with either recombinant mouse IFN-\u03b1 or IFN-\u03b2 of JHMV-infected cultures resulted in a dramatic reduction in viral replication compared to media treatment (Fig. 5B) .", [["cultures", "ANATOMY", 88, 96], ["IFN-\u03b2", "CHEMICAL", 65, 70], ["mouse", "ORGANISM", 50, 55], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 56, 61], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["JHMV", "ORGANISM", 74, 78], ["recombinant mouse IFN-\u03b1 or IFN-\u03b2", "PROTEIN", 38, 70], ["JHMV-infected cultures", "CELL_LINE", 74, 96], ["mouse", "SPECIES", 50, 55], ["mouse", "SPECIES", 50, 55], ["direct treatment", "TREATMENT", 9, 25], ["recombinant mouse IFN", "TREATMENT", 38, 59], ["IFN", "PROBLEM", 65, 68], ["JHMV", "PROBLEM", 74, 78], ["infected cultures", "PROBLEM", 79, 96], ["a dramatic reduction", "TREATMENT", 109, 129], ["viral replication", "TREATMENT", 133, 150], ["media treatment", "TREATMENT", 163, 178], ["infected", "OBSERVATION", 79, 87], ["dramatic", "OBSERVATION_MODIFIER", 111, 119], ["reduction", "OBSERVATION_MODIFIER", 120, 129], ["viral replication", "OBSERVATION", 133, 150]]], ["IFN-\u03b2 exhibited \u223c 90% greater reduction in viral replication compared to IFN-\u03b1 treatment indicating a more potent antiviral activity associated with IFN-\u03b2 signaling (Fig. 5B) .", [["IFN-\u03b2", "CHEMICAL", 0, 5], ["IFN-\u03b1", "CHEMICAL", 73, 78], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 73, 78], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 149, 154], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 73, 76], ["IFN", "PROTEIN", 149, 152], ["\u03b2", "PROTEIN", 153, 154], ["IFN", "TEST", 0, 3], ["\u223c", "PROBLEM", 16, 17], ["viral replication", "TREATMENT", 43, 60], ["IFN-\u03b1 treatment", "TREATMENT", 73, 88], ["a more potent antiviral activity", "PROBLEM", 100, 132], ["IFN", "PROBLEM", 149, 152], ["viral replication", "OBSERVATION", 43, 60], ["more potent", "OBSERVATION_MODIFIER", 102, 113], ["antiviral activity", "OBSERVATION", 114, 132]]], ["Next, progenitor derived glial cultures were generated from type I IFN receptor-deficient mice (IFN-R\u2212/\u2212) mice and treated with IFN-\u03b3 following JHMV infection.", [["progenitor", "ANATOMY", 6, 16], ["glial cultures", "ANATOMY", 25, 39], ["IFN-\u03b3", "CHEMICAL", 128, 133], ["infection", "DISEASE", 149, 158], ["progenitor", "CELL", 6, 16], ["glial cultures", "CELL", 25, 39], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 60, 79], ["mice", "ORGANISM", 90, 94], ["IFN", "GENE_OR_GENE_PRODUCT", 96, 99], ["mice", "ORGANISM", 106, 110], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 128, 133], ["JHMV", "ORGANISM", 144, 148], ["progenitor derived glial cultures", "CELL_LINE", 6, 39], ["type I IFN receptor", "PROTEIN", 60, 79], ["IFN", "PROTEIN", 96, 99], ["IFN", "PROTEIN", 128, 131], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["JHMV", "SPECIES", 144, 148], ["glial cultures", "TEST", 25, 39], ["IFN", "TEST", 96, 99], ["IFN", "TREATMENT", 128, 131], ["JHMV infection", "PROBLEM", 144, 158], ["infection", "OBSERVATION", 149, 158]]], ["As shown in Fig. 5C , such treatment did result in a reduction in viral replication (p b 0.05) compared to media-treated controls by 48 h p.i.", [["such treatment", "TREATMENT", 22, 36], ["a reduction in viral replication", "TREATMENT", 51, 83], ["viral replication", "OBSERVATION", 66, 83]]], ["However, viral replication was reduced, on average, by only 53% in IFN-R\u2212/\u2212 cells compared to N90% reduction in wildtype cells (Figs.", [["IFN-R\u2212/\u2212 cells", "ANATOMY", 67, 81], ["N90", "ANATOMY", 94, 97], ["cells", "ANATOMY", 121, 126], ["IFN-R\u2212", "GENE_OR_GENE_PRODUCT", 67, 73], ["cells", "CELL", 121, 126], ["IFN-R\u2212/\u2212 cells", "CELL_LINE", 67, 81], ["wildtype cells", "CELL_TYPE", 112, 126], ["viral replication", "PROBLEM", 9, 26], ["IFN", "TEST", 67, 70], ["N90% reduction", "TREATMENT", 94, 108], ["wildtype cells", "PROBLEM", 112, 126], ["viral replication", "OBSERVATION", 9, 26], ["wildtype cells", "OBSERVATION", 112, 126]]], ["Therefore, these data indicate that the IFN-\u03b3-mediated antiviral effect is diminished in the absence of type I IFN signaling indicating that one mechanism by which IFN-\u03b3 promotes control of JHMV replication within glial-derived progenitors is through induction of type I IFN.DiscussionThe findings put forth in this paper provide, to our knowledge, the first demonstration that JHMV is capable of infecting and replicating within primary cultures of glia derived from neural progenitor cells.", [["JHMV", "ANATOMY", 190, 194], ["glial-derived progenitors", "ANATOMY", 214, 239], ["primary cultures", "ANATOMY", 430, 446], ["glia", "ANATOMY", 450, 454], ["neural progenitor cells", "ANATOMY", 468, 491], ["JHMV", "CHEMICAL", 378, 382], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 40, 46], ["type I IFN", "GENE_OR_GENE_PRODUCT", 104, 114], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 164, 169], ["JHMV", "GENE_OR_GENE_PRODUCT", 190, 194], ["glial-derived progenitors", "CELL", 214, 239], ["type I IFN", "GENE_OR_GENE_PRODUCT", 264, 274], ["JHMV", "ORGANISM", 378, 382], ["glia", "CELL", 450, 454], ["neural progenitor cells", "CELL", 468, 491], ["IFN", "PROTEIN", 40, 43], ["IFN", "PROTEIN", 111, 114], ["IFN-\u03b3", "PROTEIN", 164, 169], ["glial-derived progenitors", "CELL_TYPE", 214, 239], ["type I IFN", "PROTEIN", 264, 274], ["JHMV", "PROTEIN", 378, 382], ["glia", "CELL_TYPE", 450, 454], ["neural progenitor cells", "CELL_TYPE", 468, 491], ["JHMV", "SPECIES", 190, 194], ["JHMV", "SPECIES", 378, 382], ["these data", "TEST", 11, 21], ["the IFN", "PROBLEM", 36, 43], ["\u03b3-mediated antiviral effect", "PROBLEM", 44, 71], ["diminished", "PROBLEM", 75, 85], ["type I IFN signaling", "PROBLEM", 104, 124], ["JHMV replication", "TREATMENT", 190, 206], ["infecting", "PROBLEM", 397, 406], ["primary cultures", "TEST", 430, 446], ["antiviral effect", "OBSERVATION", 55, 71], ["diminished", "OBSERVATION_MODIFIER", 75, 85], ["neural progenitor cells", "OBSERVATION", 468, 491]]], ["These findings are distinct from earlier studies (Dubois-Dalcq et al., 1982; Lavi et al., 1987; Rempel et al., 2005) showing that primary neural cultures are susceptible to viral infection, as we have allowed for differentiation of glial cells from neural progenitor cells into defined glia populations.", [["neural cultures", "ANATOMY", 138, 153], ["glial cells", "ANATOMY", 232, 243], ["neural progenitor cells", "ANATOMY", 249, 272], ["glia", "ANATOMY", 286, 290], ["viral infection", "DISEASE", 173, 188], ["neural cultures", "CELL", 138, 153], ["glial cells", "CELL", 232, 243], ["neural progenitor cells", "CELL", 249, 272], ["glia populations", "CELL", 286, 302], ["primary neural cultures", "CELL_LINE", 130, 153], ["glial cells", "CELL_TYPE", 232, 243], ["neural progenitor cells", "CELL_TYPE", 249, 272], ["glia populations", "CELL_TYPE", 286, 302], ["earlier studies", "TEST", 33, 48], ["primary neural cultures", "TEST", 130, 153], ["viral infection", "PROBLEM", 173, 188], ["glial cells", "PROBLEM", 232, 243], ["distinct", "OBSERVATION_MODIFIER", 19, 27], ["glial cells", "OBSERVATION", 232, 243], ["neural progenitor cells", "OBSERVATION", 249, 272], ["glia populations", "OBSERVATION", 286, 302]]], ["In addition, we have demonstrated that IFN\u03b3 treatment of JHMV-infected cultures suppresses JHMV replication and this is dependent, in part, on secretion of IFN-I.", [["cultures", "ANATOMY", 71, 79], ["JHMV", "ANATOMY", 91, 95], ["IFN\u03b3", "CHEMICAL", 39, 43], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 39, 43], ["JHMV", "ORGANISM", 57, 61], ["cultures", "CELL", 71, 79], ["JHMV", "CELL", 91, 95], ["IFN-I.", "GENE_OR_GENE_PRODUCT", 156, 162], ["IFN\u03b3", "PROTEIN", 39, 43], ["JHMV-infected cultures", "CELL_LINE", 57, 79], ["IFN", "PROTEIN", 156, 159], ["JHMV", "SPECIES", 57, 61], ["JHMV", "SPECIES", 91, 95], ["IFN\u03b3 treatment", "TREATMENT", 39, 53], ["JHMV", "TREATMENT", 57, 61], ["infected cultures", "TREATMENT", 62, 79], ["JHMV replication", "TREATMENT", 91, 107]]], ["The importance of IFN-I in defense following viral infection of the CNS has been documented in several animal models.", [["CNS", "ANATOMY", 68, 71], ["viral infection", "DISEASE", 45, 60], ["IFN-I", "GENE_OR_GENE_PRODUCT", 18, 23], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["IFN-I", "PROTEIN", 18, 23], ["viral infection of the CNS", "PROBLEM", 45, 71], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["CNS", "ANATOMY", 68, 71]]], ["Infection of mice in which IFN-I is genetically silenced or signaling blocked results in uncontrolled proliferation of West Nile virus (Samuel and Diamond, 2005) , Sindbis virus (Burdeinick-Kerr et al., 2007; Byrnes et al., 2000) , and Semliki forest virus (Fragkoudis et al., 2007) .", [["Sindbis virus", "DISEASE", 164, 177], ["mice", "ORGANISM", 13, 17], ["IFN-I", "GENE_OR_GENE_PRODUCT", 27, 32], ["West Nile virus", "ORGANISM", 119, 134], ["Sindbis virus", "ORGANISM", 164, 177], ["Semliki forest virus", "ORGANISM", 236, 256], ["IFN-I", "PROTEIN", 27, 32], ["mice", "SPECIES", 13, 17], ["West Nile virus", "SPECIES", 119, 134], ["Sindbis virus", "SPECIES", 164, 177], ["Semliki", "SPECIES", 236, 243], ["mice", "SPECIES", 13, 17], ["West Nile virus", "SPECIES", 119, 134], ["Sindbis virus", "SPECIES", 164, 177], ["Semliki forest virus", "SPECIES", 236, 256], ["Infection of mice", "PROBLEM", 0, 17], ["uncontrolled proliferation", "PROBLEM", 89, 115], ["West Nile virus", "PROBLEM", 119, 134], ["Sindbis virus", "PROBLEM", 164, 177], ["Semliki forest virus", "PROBLEM", 236, 256], ["uncontrolled", "OBSERVATION_MODIFIER", 89, 101], ["proliferation", "OBSERVATION_MODIFIER", 102, 115]]], ["The cellular source of IFN-I production is controlled by viral tropism and the model system employed.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["IFN-I", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROBLEM", 23, 26], ["viral tropism", "PROBLEM", 57, 70], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["source", "OBSERVATION_MODIFIER", 13, 19], ["viral tropism", "OBSERVATION", 57, 70]]], ["For example, neurons are a primary source of IFN-I in response to West Nile virus infection and these cells also represent a prominent cellular target for viral infection and replication (Samuel and Diamond, 2005) .", [["neurons", "ANATOMY", 13, 20], ["cells", "ANATOMY", 102, 107], ["cellular", "ANATOMY", 135, 143], ["infection", "DISEASE", 82, 91], ["viral infection", "DISEASE", 155, 170], ["neurons", "CELL", 13, 20], ["IFN-I", "GENE_OR_GENE_PRODUCT", 45, 50], ["West Nile virus", "ORGANISM", 66, 81], ["cells", "CELL", 102, 107], ["cellular", "CELL", 135, 143], ["IFN-I", "PROTEIN", 45, 50], ["Nile virus", "SPECIES", 71, 81], ["West Nile virus", "SPECIES", 66, 81], ["IFN", "PROBLEM", 45, 48], ["West Nile virus infection", "PROBLEM", 66, 91], ["a prominent cellular target", "PROBLEM", 123, 150], ["viral infection", "PROBLEM", 155, 170], ["prominent", "OBSERVATION_MODIFIER", 125, 134], ["cellular target", "OBSERVATION", 135, 150], ["viral", "OBSERVATION_MODIFIER", 155, 160], ["infection", "OBSERVATION", 161, 170]]], ["Similarly, robust cytokine production, including IFN-\u03b2, is observed following infection of astrocyte cultures with Theiler's murine encephalomyelitis virus (TMEV) (Palma et al., 2003) .", [["astrocyte cultures", "ANATOMY", 91, 109], ["infection", "DISEASE", 78, 87], ["Theiler's murine encephalomyelitis", "DISEASE", 115, 149], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 49, 54], ["astrocyte cultures", "CELL", 91, 109], ["Theiler's murine encephalomyelitis virus", "ORGANISM", 115, 155], ["TMEV", "ORGANISM", 157, 161], ["cytokine", "PROTEIN", 18, 26], ["IFN-\u03b2", "PROTEIN", 49, 54], ["astrocyte cultures", "CELL_LINE", 91, 109], ["Theiler", "SPECIES", 115, 122], ["murine encephalomyelitis virus", "SPECIES", 125, 155], ["Theiler's murine encephalomyelitis virus", "SPECIES", 115, 155], ["TMEV", "SPECIES", 157, 161], ["robust cytokine production", "PROBLEM", 11, 37], ["IFN", "TEST", 49, 52], ["infection of astrocyte cultures", "PROBLEM", 78, 109], ["Theiler's murine encephalomyelitis virus", "PROBLEM", 115, 155], ["robust", "OBSERVATION_MODIFIER", 11, 17], ["cytokine production", "OBSERVATION", 18, 37], ["infection", "OBSERVATION", 78, 87]]], ["In the case of JHMV infection, emerging evidence highlights the importance of IFN-I in protection of the CNS in response to infection.", [["CNS", "ANATOMY", 105, 108], ["JHMV infection", "DISEASE", 15, 29], ["infection", "DISEASE", 124, 133], ["JHMV", "CANCER", 15, 19], ["IFN-I", "GENE_OR_GENE_PRODUCT", 78, 83], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["IFN-I", "PROTEIN", 78, 83], ["JHMV", "SPECIES", 15, 19], ["JHMV infection", "PROBLEM", 15, 29], ["infection", "PROBLEM", 124, 133], ["infection", "OBSERVATION", 20, 29], ["CNS", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 124, 133]]], ["Bergmann and colleagues (Ireland et al., 2008) recently demonstrated increased mortality correlating with wide-spread JHMV dissemination throughout the parenchyma including expanded cell tropism with neurons infected in mice deficient in IFN-I receptor (IFNR\u2212/\u2212).", [["parenchyma", "ANATOMY", 152, 162], ["cell", "ANATOMY", 182, 186], ["neurons", "ANATOMY", 200, 207], ["JHMV", "CANCER", 118, 122], ["parenchyma", "TISSUE", 152, 162], ["cell", "CELL", 182, 186], ["neurons", "CELL", 200, 207], ["mice", "ORGANISM", 220, 224], ["IFN-I receptor", "GENE_OR_GENE_PRODUCT", 238, 252], ["IFNR", "GENE_OR_GENE_PRODUCT", 254, 258], ["IFN-I receptor", "PROTEIN", 238, 252], ["IFNR", "PROTEIN", 254, 258], ["\u2212", "PROTEIN", 260, 261], ["mice", "SPECIES", 220, 224], ["JHMV", "SPECIES", 118, 122], ["mice", "SPECIES", 220, 224], ["increased mortality", "PROBLEM", 69, 88], ["wide-spread JHMV dissemination throughout the parenchyma", "PROBLEM", 106, 162], ["expanded cell tropism", "PROBLEM", 173, 194], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["parenchyma", "ANATOMY", 152, 162], ["expanded cell tropism", "OBSERVATION", 173, 194], ["infected", "OBSERVATION_MODIFIER", 208, 216]]], ["Additional support for an important role for IFN-I in host defense in response to infection with mouse coronaviruses are derived from studies that demonstrate increased disease severity following anti-IFN antibody treatment (Lavi and Wang, 1995) and enhanced resistance following treatment with recombinant IFN-\u03b2 (Matsuyama et al., 2000; Smith et al, 1987) .DiscussionFurther support for mouse coronaviruses in initiating IFN-I production following experimental infection of mice are provided by studies from Cervantes- Barragan et al. (2007) indicating that peripheral infection with a hepatotropic strain of MHV (MHV-A59) results in increased IFN-I production by plasmacytoid dendritic cells.", [["plasmacytoid dendritic cells", "ANATOMY", 665, 693], ["infection", "DISEASE", 82, 91], ["infection", "DISEASE", 462, 471], ["peripheral infection", "DISEASE", 559, 579], ["IFN-I", "GENE_OR_GENE_PRODUCT", 45, 50], ["mouse", "ORGANISM", 97, 102], ["coronaviruses", "ORGANISM", 103, 116], ["anti-IFN antibody", "GENE_OR_GENE_PRODUCT", 196, 213], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 307, 312], ["mouse", "ORGANISM", 388, 393], ["coronaviruses", "ORGANISM", 394, 407], ["IFN-I", "GENE_OR_GENE_PRODUCT", 422, 427], ["mice", "ORGANISM", 475, 479], ["MHV (MHV-A59", "ORGANISM", 610, 622], ["IFN-I", "GENE_OR_GENE_PRODUCT", 645, 650], ["plasmacytoid dendritic cells", "CELL", 665, 693], ["IFN-I", "PROTEIN", 45, 50], ["anti-IFN antibody", "PROTEIN", 196, 213], ["IFN", "PROTEIN", 307, 310], ["IFN", "PROTEIN", 422, 425], ["IFN", "PROTEIN", 645, 648], ["plasmacytoid dendritic cells", "CELL_TYPE", 665, 693], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 388, 393], ["mice", "SPECIES", 475, 479], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 388, 393], ["mice", "SPECIES", 475, 479], ["MHV", "SPECIES", 610, 613], ["MHV", "SPECIES", 615, 618], ["Additional support", "TREATMENT", 0, 18], ["infection", "PROBLEM", 82, 91], ["mouse coronaviruses", "PROBLEM", 97, 116], ["increased disease severity", "PROBLEM", 159, 185], ["anti-IFN antibody treatment", "TREATMENT", 196, 223], ["treatment", "TREATMENT", 280, 289], ["DiscussionFurther support", "TREATMENT", 358, 383], ["mouse coronaviruses", "PROBLEM", 388, 407], ["IFN-I production", "TREATMENT", 422, 438], ["experimental infection of mice", "PROBLEM", 449, 479], ["peripheral infection", "PROBLEM", 559, 579], ["a hepatotropic strain of MHV", "PROBLEM", 585, 613], ["increased IFN", "PROBLEM", 635, 648], ["plasmacytoid dendritic cells", "PROBLEM", 665, 693], ["infection", "OBSERVATION", 82, 91], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["disease", "OBSERVATION", 169, 176], ["peripheral", "ANATOMY", 559, 569], ["infection", "OBSERVATION", 570, 579], ["increased", "OBSERVATION_MODIFIER", 635, 644], ["IFN", "OBSERVATION", 645, 648], ["plasmacytoid dendritic cells", "OBSERVATION", 665, 693]]], ["While it is clear that IFN-I is produced in vivo in response to mouse coronavirus infection and participates in effective host defense, the molecular signals regulating expression on a cellular basis are less well characterized.", [["cellular", "ANATOMY", 185, 193], ["coronavirus infection", "DISEASE", 70, 91], ["IFN-I", "GENE_OR_GENE_PRODUCT", 23, 28], ["mouse coronavirus", "ORGANISM", 64, 81], ["cellular", "CELL", 185, 193], ["IFN-I", "PROTEIN", 23, 28], ["mouse", "SPECIES", 64, 69], ["mouse coronavirus", "SPECIES", 64, 81], ["mouse coronavirus infection", "PROBLEM", 64, 91], ["clear", "OBSERVATION", 12, 17], ["coronavirus infection", "OBSERVATION", 70, 91], ["expression", "OBSERVATION_MODIFIER", 169, 179], ["less well characterized", "OBSERVATION_MODIFIER", 204, 227]]], ["Indeed, IFN-\u03b2 is not produced in response to JHMV infection of fibroblasts but this is not dependent on the absence of intracellular double-stranded RNA or deficiencies in IFN-\u03b2 signaling (Roth-Cross et al., 2007) .", [["fibroblasts", "ANATOMY", 63, 74], ["intracellular", "ANATOMY", 119, 132], ["infection", "DISEASE", 50, 59], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 8, 13], ["JHMV", "CELL", 45, 49], ["fibroblasts", "CELL", 63, 74], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 172, 177], ["IFN", "PROTEIN", 8, 11], ["\u03b2", "PROTEIN", 12, 13], ["fibroblasts", "CELL_TYPE", 63, 74], ["intracellular double-stranded RNA", "RNA", 119, 152], ["IFN", "PROTEIN", 172, 175], ["\u03b2", "PROTEIN", 176, 177], ["JHMV", "SPECIES", 45, 49], ["JHMV infection of fibroblasts", "PROBLEM", 45, 74], ["intracellular double-stranded RNA", "PROBLEM", 119, 152], ["deficiencies in IFN", "PROBLEM", 156, 175], ["infection", "OBSERVATION", 50, 59], ["fibroblasts", "OBSERVATION", 63, 74], ["stranded RNA", "OBSERVATION_MODIFIER", 140, 152]]], ["Impaired IFN-\u03b2 production within JHMVinfected cultures correlated with impaired translocation of transcription factors IRF-3 and IRF-7 into the nucleus of infection cells (Versteeg et al., 2007; Zhou and Perlman, 2007) .", [["JHMVinfected cultures", "ANATOMY", 33, 54], ["nucleus", "ANATOMY", 144, 151], ["cells", "ANATOMY", 165, 170], ["infection", "DISEASE", 155, 164], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["JHMVinfected cultures", "CELL", 33, 54], ["IRF-3", "GENE_OR_GENE_PRODUCT", 119, 124], ["IRF-7", "GENE_OR_GENE_PRODUCT", 129, 134], ["nucleus", "CELLULAR_COMPONENT", 144, 151], ["cells", "CELL", 165, 170], ["IFN", "PROTEIN", 9, 12], ["\u03b2", "PROTEIN", 13, 14], ["JHMVinfected cultures", "CELL_LINE", 33, 54], ["transcription factors", "PROTEIN", 97, 118], ["IRF-3", "PROTEIN", 119, 124], ["IRF-7", "PROTEIN", 129, 134], ["infection cells", "CELL_TYPE", 155, 170], ["Impaired IFN-\u03b2 production", "PROBLEM", 0, 25], ["JHMVinfected cultures", "TEST", 33, 54], ["IRF", "TEST", 119, 122], ["IRF", "TEST", 129, 132], ["infection cells", "PROBLEM", 155, 170], ["nucleus", "ANATOMY", 144, 151], ["infection cells", "OBSERVATION", 155, 170]]], ["In addition, it may be possible that double-stranded RNA generated during the course of JHMV infection is not accessible to cellular pattern recognition receptors (PPR) such as RIG-I, Mda-5, and TLR-3 (Zhou and Perlman, 2007) .", [["cellular", "ANATOMY", 124, 132], ["infection", "DISEASE", 93, 102], ["JHMV", "GENE_OR_GENE_PRODUCT", 88, 92], ["cellular", "CELL", 124, 132], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 133, 162], ["PPR", "GENE_OR_GENE_PRODUCT", 164, 167], ["RIG-I", "GENE_OR_GENE_PRODUCT", 177, 182], ["Mda-5", "GENE_OR_GENE_PRODUCT", 184, 189], ["TLR-3", "GENE_OR_GENE_PRODUCT", 195, 200], ["double-stranded RNA", "RNA", 37, 56], ["cellular pattern recognition receptors", "PROTEIN", 124, 162], ["PPR", "PROTEIN", 164, 167], ["RIG", "PROTEIN", 177, 180], ["Mda", "PROTEIN", 184, 187], ["TLR", "PROTEIN", 195, 198], ["JHMV", "SPECIES", 88, 92], ["double-stranded RNA", "PROBLEM", 37, 56], ["JHMV infection", "PROBLEM", 88, 102], ["RIG", "TEST", 177, 180], ["Mda", "TEST", 184, 187], ["TLR", "TEST", 195, 198], ["may be possible", "UNCERTAINTY", 16, 31], ["infection", "OBSERVATION", 93, 102]]], ["While the molecular mechanisms associated with inhibited IFN-\u03b2 production have not been completely defined, the MHV nucleocapsid protein has been suggested to be an IFN-I antagonist (Ye et al., 2007) .DiscussionData provided in the current study demonstrate that JHMV infection of differentiated progenitor cells resulted in muted expression of IFN-I and virus was able to replicate in an unrestricted manner.", [["progenitor cells", "ANATOMY", 296, 312], ["infection", "DISEASE", 268, 277], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 57, 62], ["MHV nucleocapsid", "ORGANISM", 112, 128], ["IFN-I", "GENE_OR_GENE_PRODUCT", 165, 170], ["JHMV", "SIMPLE_CHEMICAL", 263, 267], ["progenitor cells", "CELL", 296, 312], ["IFN-I", "GENE_OR_GENE_PRODUCT", 345, 350], ["IFN", "PROTEIN", 57, 60], ["\u03b2", "PROTEIN", 61, 62], ["MHV nucleocapsid protein", "PROTEIN", 112, 136], ["IFN", "PROTEIN", 165, 168], ["differentiated progenitor cells", "CELL_TYPE", 281, 312], ["IFN", "PROTEIN", 345, 348], ["MHV", "SPECIES", 112, 115], ["JHMV", "SPECIES", 263, 267], ["inhibited IFN-\u03b2 production", "PROBLEM", 47, 73], ["the MHV nucleocapsid protein", "TEST", 108, 136], ["the current study", "TEST", 228, 245], ["JHMV infection of differentiated progenitor cells", "PROBLEM", 263, 312], ["muted expression of IFN-I and virus", "PROBLEM", 325, 360], ["infection", "OBSERVATION", 268, 277], ["progenitor cells", "OBSERVATION", 296, 312]]], ["In addition, secretion of CXCL9 and CXCL10 was also impaired following JHMV infection of differentiated progenitor cultures and this is in contrast to previous findings indicating robust chemokine expression following infection of primary cultures of astrocytes.", [["progenitor cultures", "ANATOMY", 104, 123], ["primary cultures", "ANATOMY", 231, 247], ["astrocytes", "ANATOMY", 251, 261], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 218, 227], ["CXCL9", "GENE_OR_GENE_PRODUCT", 26, 31], ["CXCL10", "GENE_OR_GENE_PRODUCT", 36, 42], ["progenitor cultures", "CELL", 104, 123], ["astrocytes", "CELL", 251, 261], ["CXCL9", "PROTEIN", 26, 31], ["CXCL10", "PROTEIN", 36, 42], ["differentiated progenitor cultures", "CELL_LINE", 89, 123], ["chemokine", "PROTEIN", 187, 196], ["astrocytes", "CELL_TYPE", 251, 261], ["JHMV", "SPECIES", 71, 75], ["CXCL9", "TEST", 26, 31], ["CXCL10", "TEST", 36, 42], ["JHMV infection", "PROBLEM", 71, 85], ["differentiated progenitor cultures", "PROBLEM", 89, 123], ["robust chemokine expression", "PROBLEM", 180, 207], ["infection of primary cultures of astrocytes", "PROBLEM", 218, 261], ["progenitor cultures", "OBSERVATION", 104, 123], ["robust", "OBSERVATION_MODIFIER", 180, 186], ["chemokine expression", "OBSERVATION", 187, 207]]], ["These results support the earlier hypothesis that within certain host cell populations, double-stranded RNA generated during the course of JHMV replication may not be accessible to PPR and this impacts secretion of IFN-I and non-ELR chemokines CXCL9 and CXCL10.", [["cell", "ANATOMY", 70, 74], ["host cell populations", "CELL", 65, 86], ["JHMV", "GENE_OR_GENE_PRODUCT", 139, 143], ["IFN-I", "GENE_OR_GENE_PRODUCT", 215, 220], ["CXCL9", "GENE_OR_GENE_PRODUCT", 244, 249], ["CXCL10", "GENE_OR_GENE_PRODUCT", 254, 260], ["double-stranded RNA", "RNA", 88, 107], ["PPR", "PROTEIN", 181, 184], ["IFN-I", "PROTEIN", 215, 220], ["non-ELR chemokines", "PROTEIN", 225, 243], ["CXCL9", "PROTEIN", 244, 249], ["CXCL10", "PROTEIN", 254, 260], ["JHMV", "SPECIES", 139, 143], ["the earlier hypothesis", "PROBLEM", 22, 44], ["double-stranded RNA", "TREATMENT", 88, 107], ["JHMV replication", "TREATMENT", 139, 155], ["PPR", "TEST", 181, 184], ["IFN", "TEST", 215, 218], ["CXCL9", "TEST", 244, 249], ["CXCL10", "TEST", 254, 260], ["host cell populations", "OBSERVATION", 65, 86]]], ["Moreover, since the majority of progenitor cells (\u223c70-80%) differentiate into oligodendrocyte progenitor cells (OPC), it is possible that oligodendrocytes are unable to synthesize either CXCL9 or CXCL10 in response to JHMV infection.DiscussionTreatment of progenitor cultures with IFN-\u03b3 resulted in reduced JHMV replication and this highlights the importance of this cytokine in host defense following JHMV infection.", [["progenitor cells", "ANATOMY", 32, 48], ["oligodendrocyte progenitor cells", "ANATOMY", 78, 110], ["OPC", "ANATOMY", 112, 115], ["oligodendrocytes", "ANATOMY", 138, 154], ["progenitor cultures", "ANATOMY", 256, 275], ["JHMV", "ANATOMY", 307, 311], ["infection", "DISEASE", 223, 232], ["IFN-\u03b3", "CHEMICAL", 281, 286], ["infection", "DISEASE", 407, 416], ["progenitor cells", "CELL", 32, 48], ["oligodendrocyte progenitor cells", "CELL", 78, 110], ["OPC", "CELL", 112, 115], ["oligodendrocytes", "CELL", 138, 154], ["CXCL9", "GENE_OR_GENE_PRODUCT", 187, 192], ["CXCL10", "GENE_OR_GENE_PRODUCT", 196, 202], ["JHMV", "GENE_OR_GENE_PRODUCT", 218, 222], ["progenitor cultures", "CELL", 256, 275], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 281, 286], ["JHMV", "CANCER", 307, 311], ["JHMV", "ORGANISM", 402, 406], ["progenitor cells", "CELL_TYPE", 32, 48], ["oligodendrocyte progenitor cells", "CELL_TYPE", 78, 110], ["OPC", "CELL_TYPE", 112, 115], ["oligodendrocytes", "CELL_TYPE", 138, 154], ["CXCL9", "PROTEIN", 187, 192], ["CXCL10", "PROTEIN", 196, 202], ["progenitor cultures", "CELL_LINE", 256, 275], ["IFN-\u03b3", "PROTEIN", 281, 286], ["cytokine", "PROTEIN", 367, 375], ["JHMV", "SPECIES", 218, 222], ["JHMV", "SPECIES", 307, 311], ["JHMV", "SPECIES", 402, 406], ["progenitor cells", "TEST", 32, 48], ["\u223c", "TEST", 50, 51], ["oligodendrocytes", "PROBLEM", 138, 154], ["CXCL9", "TEST", 187, 192], ["CXCL10", "TEST", 196, 202], ["JHMV infection", "PROBLEM", 218, 232], ["progenitor cultures", "TEST", 256, 275], ["IFN", "TEST", 281, 284], ["reduced JHMV replication", "PROBLEM", 299, 323], ["this cytokine", "TREATMENT", 362, 375], ["JHMV infection", "PROBLEM", 402, 416], ["oligodendrocyte progenitor cells", "OBSERVATION", 78, 110], ["infection", "OBSERVATION", 223, 232], ["infection", "OBSERVATION", 407, 416]]], ["Additionally, these data support and extend studies by Stohlman and colleagues (Gonzalez et al., 2005 Parra et al., 1999) that have demonstrated IFN-\u03b3 is critical in controlling JHMV replication in oligodendrocytes in vivo.", [["JHMV", "ANATOMY", 178, 182], ["oligodendrocytes", "ANATOMY", 198, 214], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 145, 150], ["JHMV", "GENE_OR_GENE_PRODUCT", 178, 182], ["oligodendrocytes", "CELL", 198, 214], ["IFN", "PROTEIN", 145, 148], ["\u03b3", "PROTEIN", 149, 150], ["oligodendrocytes", "CELL_TYPE", 198, 214], ["JHMV", "SPECIES", 178, 182]]], ["Infection of IFN-\u03b3\u2212/\u2212 mice with JHMV highlighted a critical role for this cytokine in controlling viral replication within oligodendrocytes (Parra et al., 1999) .", [["oligodendrocytes", "ANATOMY", 123, 139], ["IFN", "GENE_OR_GENE_PRODUCT", 13, 16], ["\u03b3\u2212", "GENE_OR_GENE_PRODUCT", 17, 19], ["JHMV", "ORGANISM", 32, 36], ["oligodendrocytes", "CELL", 123, 139], ["IFN", "PROTEIN", 13, 16], ["cytokine", "PROTEIN", 74, 82], ["oligodendrocytes", "CELL_TYPE", 123, 139], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["Infection of IFN", "PROBLEM", 0, 16], ["this cytokine", "TREATMENT", 69, 82]]], ["Additionally, transgenic mice expressing a dominant-negative IFN-\u03b3-receptor specifically on oligodendroglia demonstrated that IFN-\u03b3 is required for inhibiting viral replication (Gonzalez et al., 2005 .", [["oligodendroglia", "ANATOMY", 92, 107], ["transgenic mice", "ORGANISM", 14, 29], ["IFN-\u03b3-receptor", "GENE_OR_GENE_PRODUCT", 61, 75], ["oligodendroglia", "CELL", 92, 107], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 126, 131], ["dominant-negative IFN-\u03b3-receptor", "PROTEIN", 43, 75], ["IFN-\u03b3", "PROTEIN", 126, 131], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["oligodendroglia", "PROBLEM", 92, 107], ["IFN", "TEST", 126, 129]]], ["The findings put forth in the present study clearly indicate that IFN-\u03b3 suppresses JHMV replication in glial-committed progenitor cells derived from neural precursors.", [["glial-committed progenitor cells", "ANATOMY", 103, 135], ["neural precursors", "ANATOMY", 149, 166], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["JHMV", "GENE_OR_GENE_PRODUCT", 83, 87], ["glial-committed progenitor cells", "CELL", 103, 135], ["neural precursors", "MULTI-TISSUE_STRUCTURE", 149, 166], ["IFN", "PROTEIN", 66, 69], ["\u03b3", "PROTEIN", 70, 71], ["glial-committed progenitor cells", "CELL_TYPE", 103, 135], ["neural precursors", "CELL_TYPE", 149, 166], ["JHMV", "SPECIES", 83, 87], ["IFN", "TEST", 66, 69], ["progenitor cells", "OBSERVATION", 119, 135], ["neural precursors", "OBSERVATION", 149, 166]]], ["Moreover, the IFN-\u03b3-mediated antiviral effect is not dependent on secretion of CXCR3-binding chemokines.", [["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 14, 20], ["CXCR3", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN", "PROTEIN", 14, 17], ["CXCR3", "PROTEIN", 79, 84], ["binding chemokines", "PROTEIN", 85, 103], ["the IFN", "TREATMENT", 10, 17], ["\u03b3-mediated antiviral effect", "TREATMENT", 18, 45], ["CXCR3", "TEST", 79, 84]]], ["Although the in vivo mechanism(s) by which IFN-\u03b3 evokes an antiviral response have not yet been defined, our data suggest that production of IFN-I by IFN-\u03b3treated glia may contribute to viral control.", [["glia", "ANATOMY", 163, 167], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 43, 48], ["IFN-I", "GENE_OR_GENE_PRODUCT", 141, 146], ["IFN", "GENE_OR_GENE_PRODUCT", 150, 153], ["glia", "CELL", 163, 167], ["IFN-\u03b3", "PROTEIN", 43, 48], ["IFN-I", "PROTEIN", 141, 146], ["IFN", "PROTEIN", 150, 153], ["IFN", "PROBLEM", 141, 144], ["viral control", "TREATMENT", 186, 199]]], ["Further support for type I IFN in controlling JHMV replication within oligodendrocyteenriched cultures is provided by the demonstration that treatment of JHMV-infected oligodendrocytes with either recombinant IFN-\u03b1 or IFN-\u03b2 resulted in N1 log decrease in viral titers with IFN-\u03b2 having a much greater anti-viral effect compared to IFN-\u03b1 in controlling replication.DiscussionNeurotropic viruses are capable of infecting and replicating within OPC (Dietrich et al., 2004; Levine et al., 1998; Mock et al., 2006) .", [["JHMV", "ANATOMY", 46, 50], ["oligodendrocyteenriched cultures", "ANATOMY", 70, 102], ["oligodendrocytes", "ANATOMY", 168, 184], ["IFN-\u03b2", "CHEMICAL", 218, 223], ["IFN-\u03b1", "CHEMICAL", 331, 336], ["type I IFN", "GENE_OR_GENE_PRODUCT", 20, 30], ["JHMV", "CANCER", 46, 50], ["oligodendrocyteenriched cultures", "CELL", 70, 102], ["JHMV", "GENE_OR_GENE_PRODUCT", 154, 158], ["oligodendrocytes", "CELL", 168, 184], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 209, 214], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 218, 223], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 273, 278], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 331, 336], ["type I IFN", "PROTEIN", 20, 30], ["oligodendrocyteenriched cultures", "CELL_LINE", 70, 102], ["JHMV-infected oligodendrocytes", "CELL_TYPE", 154, 184], ["recombinant IFN-\u03b1 or IFN-\u03b2", "PROTEIN", 197, 223], ["IFN-\u03b2", "PROTEIN", 273, 278], ["IFN", "PROTEIN", 331, 334], ["\u03b1", "PROTEIN", 335, 336], ["JHMV", "SPECIES", 46, 50], ["JHMV", "SPECIES", 154, 158], ["Further support", "TREATMENT", 0, 15], ["type I IFN", "PROBLEM", 20, 30], ["oligodendrocyteenriched cultures", "TEST", 70, 102], ["JHMV", "TEST", 154, 158], ["infected oligodendrocytes", "PROBLEM", 159, 184], ["IFN", "PROBLEM", 218, 221], ["N1 log decrease in viral titers", "PROBLEM", 236, 267], ["IFN", "TREATMENT", 273, 276], ["a much greater anti-viral effect", "PROBLEM", 286, 318], ["IFN", "TREATMENT", 331, 334], ["Neurotropic viruses", "TREATMENT", 374, 393], ["infecting", "PROBLEM", 409, 418], ["infected oligodendrocytes", "OBSERVATION", 159, 184], ["decrease", "OBSERVATION_MODIFIER", 243, 251], ["viral titers", "OBSERVATION", 255, 267]]], ["For example, human herpesvirus 6 (HHV6) is capable of infecting and replicating within the human oligodendrocytes and suggested to be involved in the pathogenesis of both acute and chronic inflammatory demyelinating diseases (Dietrich et al., 2004; Mock et al., 2006) .", [["oligodendrocytes", "ANATOMY", 97, 113], ["demyelinating diseases", "DISEASE", 202, 224], ["human herpesvirus 6", "ORGANISM", 13, 32], ["HHV6", "GENE_OR_GENE_PRODUCT", 34, 38], ["human", "ORGANISM", 91, 96], ["oligodendrocytes", "CELL", 97, 113], ["human oligodendrocytes", "CELL_TYPE", 91, 113], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 91, 96], ["human herpesvirus 6", "SPECIES", 13, 32], ["HHV6", "SPECIES", 34, 38], ["human", "SPECIES", 91, 96], ["human herpesvirus", "PROBLEM", 13, 30], ["HHV6", "TEST", 34, 38], ["infecting", "PROBLEM", 54, 63], ["both acute and chronic inflammatory demyelinating diseases", "PROBLEM", 166, 224], ["infecting", "OBSERVATION", 54, 63], ["both", "OBSERVATION_MODIFIER", 166, 170], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["inflammatory", "OBSERVATION_MODIFIER", 189, 201], ["demyelinating", "OBSERVATION_MODIFIER", 202, 215]]], ["HHV6 infection of human OPC cultures results in formation of multinucleated syncytia and elevated expression of GalC (Dietrich et al., 2004) .", [["OPC cultures", "ANATOMY", 24, 36], ["multinucleated syncytia", "ANATOMY", 61, 84], ["infection", "DISEASE", 5, 14], ["HHV6", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 18, 23], ["OPC cultures", "CELL", 24, 36], ["multinucleated syncytia", "CELL", 61, 84], ["GalC", "GENE_OR_GENE_PRODUCT", 112, 116], ["human OPC cultures", "CELL_LINE", 18, 36], ["GalC", "PROTEIN", 112, 116], ["human", "SPECIES", 18, 23], ["HHV6", "SPECIES", 0, 4], ["human", "SPECIES", 18, 23], ["HHV6 infection", "PROBLEM", 0, 14], ["human OPC cultures", "TEST", 18, 36], ["multinucleated syncytia", "PROBLEM", 61, 84], ["elevated expression of GalC", "PROBLEM", 89, 116], ["infection", "OBSERVATION", 5, 14], ["multinucleated syncytia", "OBSERVATION", 61, 84], ["elevated", "OBSERVATION_MODIFIER", 89, 97], ["expression", "OBSERVATION_MODIFIER", 98, 108]]], ["OPC proliferation was also impaired in HHV6-infected cultures and infected cells and suggests that infection in vivo may have longlasting effects on precursor cell properties.", [["cultures", "ANATOMY", 53, 61], ["cells", "ANATOMY", 75, 80], ["precursor cell", "ANATOMY", 149, 163], ["infection", "DISEASE", 99, 108], ["HHV6-infected cultures", "CELL", 39, 61], ["cells", "CELL", 75, 80], ["precursor cell", "CELL", 149, 163], ["HHV6-infected cultures", "CELL_LINE", 39, 61], ["infected cells", "CELL_TYPE", 66, 80], ["HHV6", "SPECIES", 39, 43], ["OPC proliferation", "PROBLEM", 0, 17], ["HHV6", "PROBLEM", 39, 43], ["infected cultures", "PROBLEM", 44, 61], ["infected cells", "PROBLEM", 66, 80], ["infection", "PROBLEM", 99, 108], ["precursor cell properties", "TREATMENT", 149, 174], ["proliferation", "OBSERVATION", 4, 17], ["impaired", "OBSERVATION_MODIFIER", 27, 35], ["infected cells", "OBSERVATION", 66, 80], ["infection", "OBSERVATION", 99, 108], ["precursor cell properties", "OBSERVATION", 149, 174]]], ["These findings are interesting in that remyelination is relatively slow in JHMV-infected mice yet OPC are present within and surrounding areas of on-going demyelination.", [["demyelination", "DISEASE", 155, 168], ["JHMV", "GENE_OR_GENE_PRODUCT", 75, 79], ["mice", "ORGANISM", 89, 93], ["OPC", "CANCER", 98, 101], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["slow in JHMV", "PROBLEM", 67, 79], ["OPC", "PROBLEM", 98, 101], ["demyelination", "PROBLEM", 155, 168], ["remyelination", "OBSERVATION", 39, 52], ["relatively", "OBSERVATION_MODIFIER", 56, 66], ["slow", "OBSERVATION_MODIFIER", 67, 71], ["infected", "OBSERVATION_MODIFIER", 80, 88], ["areas", "OBSERVATION_MODIFIER", 137, 142], ["demyelination", "OBSERVATION", 155, 168]]], ["This suggests that the ability of OPC to successfully remyelinate axons is impaired and/or an environment that is conducive for promoting remyelination is not available.", [["axons", "ANATOMY", 66, 71], ["OPC", "CELL", 34, 37], ["axons", "MULTI-TISSUE_STRUCTURE", 66, 71], ["promoting remyelination", "PROBLEM", 128, 151]]], ["Having demonstrated that JHMV is capable of infecting and replicating within primary cultures of OPC indicates that these cells are susceptible to infection in vivo.", [["primary cultures", "ANATOMY", 77, 93], ["OPC", "ANATOMY", 97, 100], ["cells", "ANATOMY", 122, 127], ["JHMV", "CHEMICAL", 25, 29], ["infection", "DISEASE", 147, 156], ["OPC", "CELL", 97, 100], ["cells", "CELL", 122, 127], ["primary cultures", "CELL_LINE", 77, 93], ["JHMV", "SPECIES", 25, 29], ["infecting", "PROBLEM", 44, 53], ["primary cultures", "TEST", 77, 93], ["OPC", "PROBLEM", 97, 100], ["these cells", "PROBLEM", 116, 127], ["infection in vivo", "PROBLEM", 147, 164], ["infection", "OBSERVATION", 147, 156]]], ["Therefore, it is interesting to speculate that early infection of neural progenitor cells impacts either generation of OPC and/or the ability of OPC to successfully remyelinate demyelinated axons at later stages of infection.", [["neural progenitor cells", "ANATOMY", 66, 89], ["demyelinated axons", "ANATOMY", 177, 195], ["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 215, 224], ["neural progenitor cells", "CELL", 66, 89], ["OPC", "CELL", 119, 122], ["OPC", "CELL", 145, 148], ["axons", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 195], ["neural progenitor cells", "CELL_TYPE", 66, 89], ["early infection of neural progenitor cells", "PROBLEM", 47, 89], ["OPC", "TREATMENT", 119, 122], ["demyelinated axons", "PROBLEM", 177, 195], ["infection", "PROBLEM", 215, 224], ["early", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62], ["neural progenitor cells", "OBSERVATION", 66, 89], ["infection", "OBSERVATION", 215, 224]]], ["We are currently addressing these possibilities.Virus and miceThe neurotropic strain JHMV (2.2V-1) of mouse hepatitis virus (MHV) was used for all experiments described here (Fleming et al., 1986) .", [["JHMV", "CHEMICAL", 85, 89], ["2.2V-1", "CHEMICAL", 91, 97], ["mouse hepatitis virus", "DISEASE", 102, 123], ["Virus", "ORGANISM", 48, 53], ["mice", "ORGANISM", 58, 62], ["neurotropic strain JHMV", "ORGANISM", 66, 89], ["2.2V-1", "ORGANISM", 91, 97], ["mouse hepatitis virus", "ORGANISM", 102, 123], ["MHV", "ORGANISM", 125, 128], ["mice", "SPECIES", 58, 62], ["mouse", "SPECIES", 102, 107], ["hepatitis virus", "SPECIES", 108, 123], ["mice", "SPECIES", 58, 62], ["JHMV", "SPECIES", 85, 89], ["mouse hepatitis virus", "SPECIES", 102, 123], ["MHV", "SPECIES", 125, 128], ["Virus", "TREATMENT", 48, 53], ["The neurotropic strain JHMV", "TEST", 62, 89], ["mouse hepatitis virus", "PROBLEM", 102, 123]]], ["Wild type mice for progenitor cell isolation, C57BL/6 mice (on the H-2 b background), were purchased from the National Cancer Institute (Frederick, MD).", [["progenitor cell", "ANATOMY", 19, 34], ["Cancer", "DISEASE", 119, 125], ["mice", "ORGANISM", 10, 14], ["progenitor cell", "CELL", 19, 34], ["C57BL/6 mice", "ORGANISM", 46, 58], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 54, 58], ["progenitor cell isolation", "TREATMENT", 19, 44], ["progenitor cell isolation", "OBSERVATION", 19, 44]]], ["Additional mouse strains used for progenitor cultures, CXCL10\u2212/\u2212, CXCR3\u2212/\u2212, and IFN-I receptor deficient (IFNAR\u2212/\u2212) (C57BL/6 H-2 b background), were bred in the University of California, Irvine animal facility.", [["strains", "ANATOMY", 17, 24], ["progenitor cultures", "ANATOMY", 34, 53], ["mouse", "ORGANISM", 11, 16], ["progenitor cultures", "CELL", 34, 53], ["CXCL10", "GENE_OR_GENE_PRODUCT", 55, 61], ["\u2212", "GENE_OR_GENE_PRODUCT", 63, 64], ["CXCR3\u2212", "GENE_OR_GENE_PRODUCT", 66, 72], ["\u2212", "GENE_OR_GENE_PRODUCT", 73, 74], ["IFN-I receptor", "GENE_OR_GENE_PRODUCT", 80, 94], ["IFNAR", "ORGANISM", 106, 111], ["CXCL10", "PROTEIN", 55, 61], ["CXCR3\u2212", "PROTEIN", 66, 72], ["IFN", "PROTEIN", 80, 83], ["IFNAR", "PROTEIN", 106, 111], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["Additional mouse strains", "TREATMENT", 0, 24], ["progenitor cultures", "TEST", 34, 53], ["CXCL10", "TEST", 55, 61], ["\u2212", "TEST", 63, 64], ["CXCR3\u2212", "TEST", 66, 72], ["\u2212", "TEST", 73, 74], ["IFN", "TEST", 80, 83], ["IFNAR", "TEST", 106, 111], ["C57BL", "TEST", 117, 122]]], ["The animal protocols and procedures used for these studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.Neural progenitor culturesNeural progenitor cells were cultured as previously described (Totoiu et al., 2004) .", [["Neural progenitor cultures", "ANATOMY", 177, 203], ["Neural progenitor cells", "ANATOMY", 203, 226], ["Neural progenitor cultures", "CELL", 177, 203], ["Neural progenitor cells", "CELL", 203, 226], ["Neural progenitor cultures", "CELL_LINE", 177, 203], ["Neural progenitor cells", "CELL_TYPE", 203, 226], ["these studies", "TEST", 45, 58], ["Neural progenitor cultures", "TEST", 177, 203], ["Neural progenitor cells", "TEST", 203, 226], ["progenitor cells", "OBSERVATION", 210, 226]]], ["In brief, striata from 5 to 6 postnatal day 1 mice were dissected, triturated and dissociated in 0.05% Trypsin-EDTA.", [["striata", "ANATOMY", 10, 17], ["Trypsin-EDTA", "CHEMICAL", 103, 115], ["EDTA", "CHEMICAL", 111, 115], ["mice", "ORGANISM", 46, 50], ["Trypsin-EDTA", "SIMPLE_CHEMICAL", 103, 115], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50]]], ["The resulting single cell suspension was cultured for 6-7 days in 25 ml serum free media (DMEM:F12 supplemented with B27 supplement, 1\u00d7 Insulin-Transferrin-Selenium-X Supplement, 1\u00d7 Penicillin-Streptomycin and T3) with 20 ng/ml human recombinant epidermal growth factor (EGF; Sigma-Aldrich) (Ben-Hur et al., 1998) .", [["cell", "ANATOMY", 21, 25], ["serum", "ANATOMY", 72, 77], ["Selenium", "CHEMICAL", 156, 164], ["Penicillin", "CHEMICAL", 182, 192], ["Streptomycin", "CHEMICAL", 193, 205], ["T3", "CHEMICAL", 210, 212], ["Selenium", "CHEMICAL", 156, 164], ["Penicillin", "CHEMICAL", 182, 192], ["Streptomycin", "CHEMICAL", 193, 205], ["single cell", "CELL", 14, 25], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["Insulin", "GENE_OR_GENE_PRODUCT", 136, 143], ["Transferrin", "GENE_OR_GENE_PRODUCT", 144, 155], ["Penicillin-Streptomycin", "SIMPLE_CHEMICAL", 182, 205], ["T3", "SIMPLE_CHEMICAL", 210, 212], ["human", "ORGANISM", 228, 233], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 246, 269], ["EGF", "GENE_OR_GENE_PRODUCT", 271, 274], ["human recombinant epidermal growth factor", "PROTEIN", 228, 269], ["EGF", "PROTEIN", 271, 274], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 228, 233], ["The resulting single cell suspension", "TREATMENT", 0, 36], ["B27 supplement", "TREATMENT", 117, 131], ["Insulin-Transferrin-Selenium-X Supplement", "TREATMENT", 136, 177], ["Penicillin", "TREATMENT", 182, 192], ["Streptomycin", "TREATMENT", 193, 205], ["T3", "TREATMENT", 210, 212]]], ["Media was replaced on days 1, 3, and 5; culture supernatant and floating clusters were removed, centrifuged at 300 \u00d7 g for 5 min and resuspended in fresh media with EGF.", [["supernatant", "ANATOMY", 48, 59], ["EGF", "GENE_OR_GENE_PRODUCT", 165, 168], ["EGF", "PROTEIN", 165, 168], ["culture supernatant", "TEST", 40, 59], ["floating clusters", "PROBLEM", 64, 81]]], ["After one week, cells had proliferated into numerous free-floating spheres.Adhesion and differentiation of cell spheresAfter one week, cell spheres were transferred to matrigel (BD Bioscience, Bedford, MA) coated flasks (use thin coat method, 1:30 dilution) at a low density.", [["cells", "ANATOMY", 16, 21], ["cell spheres", "ANATOMY", 107, 119], ["cell spheres", "ANATOMY", 135, 147], ["matrigel", "ANATOMY", 168, 176], ["cells", "CELL", 16, 21], ["cell", "CELL", 107, 111], ["cell spheres", "CELL", 135, 147], ["Adhesion", "PROBLEM", 75, 83], ["cell spheres", "PROBLEM", 107, 119], ["cell spheres", "TREATMENT", 135, 147], ["Bedford, MA) coated flasks", "TREATMENT", 193, 219], ["thin coat method", "TREATMENT", 225, 241], ["numerous", "OBSERVATION_MODIFIER", 44, 52], ["free", "OBSERVATION_MODIFIER", 53, 57], ["floating spheres", "OBSERVATION", 58, 74], ["differentiation of cell spheres", "OBSERVATION", 88, 119], ["cell spheres", "OBSERVATION", 135, 147], ["low density", "OBSERVATION_MODIFIER", 263, 274]]], ["Individual cells spread out from the attached spheres and formed a monolayer with 1 to 2 days.", [["cells", "ANATOMY", 11, 16], ["monolayer", "ANATOMY", 67, 76], ["cells", "CELL", 11, 16], ["monolayer", "CELL", 67, 76], ["Individual cells", "PROBLEM", 0, 16]]], ["Once the monolayer formed, cells were trypsinized, counted and plated into four chamber imaging slides (Nalgene-Nunc International, Rochester, NY), 6-well plates or T25 flask (Costar, Corning, NY) previously coated with matrigel (BD Biosciences).", [["monolayer", "ANATOMY", 9, 18], ["cells", "ANATOMY", 27, 32], ["monolayer", "CELL", 9, 18], ["cells", "CELL", 27, 32], ["matrigel (BD Biosciences", "TREATMENT", 220, 244]]], ["Cells were allowed to equilibrate for an additional 1-2 days before viral infection or staining procedures were done.Viral infection and viral titer assayFor all experiments shown, JHMV was added to cultures at a multiplicity of infection (MOI) of 0.1 pfu/cell.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 256, 260], ["viral infection", "DISEASE", 68, 83], ["Viral infection", "DISEASE", 117, 132], ["JHMV", "CHEMICAL", 181, 185], ["infection", "DISEASE", 229, 238], ["Cells", "CELL", 0, 5], ["Viral", "ORGANISM", 117, 122], ["JHMV", "SIMPLE_CHEMICAL", 181, 185], ["cell", "CELL", 256, 260], ["JHMV", "PROTEIN", 181, 185], ["JHMV", "SPECIES", 181, 185], ["viral infection", "PROBLEM", 68, 83], ["staining procedures", "TEST", 87, 106], ["Viral infection", "PROBLEM", 117, 132], ["viral titer assay", "TEST", 137, 154], ["all experiments", "TEST", 158, 173], ["cultures", "TEST", 199, 207], ["infection", "PROBLEM", 229, 238], ["infection", "OBSERVATION", 74, 83], ["infection", "OBSERVATION", 123, 132], ["viral titer", "OBSERVATION", 137, 148], ["infection", "OBSERVATION", 229, 238]]], ["Virus was allowed to adsorb for 1 h, cultures were washed with PBS and replaced with 4 ml of fresh medium.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5], ["cultures", "TEST", 37, 45], ["PBS", "TREATMENT", 63, 66], ["fresh medium", "TREATMENT", 93, 105]]], ["Recombinant mouse IFN-\u03b3, IFN-\u03b1, and IFN-\u03b2 cytokines were purchased from Cell Sciences (Canton, MA).", [["Cell", "ANATOMY", 72, 76], ["mouse", "ORGANISM", 12, 17], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 18, 23], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 36, 41], ["Cell", "CELL", 72, 76], ["Recombinant mouse IFN-\u03b3, IFN-\u03b1", "PROTEIN", 0, 30], ["IFN-\u03b2 cytokines", "PROTEIN", 36, 51], ["mouse", "SPECIES", 12, 17], ["mouse", "SPECIES", 12, 17], ["Recombinant mouse IFN", "TEST", 0, 21], ["IFN", "TEST", 25, 28], ["IFN", "PROBLEM", 36, 39], ["cytokines", "PROBLEM", 42, 51]]], ["Viral titers in supernatants of infected cultures were determined on DBT astrocytoma cells at defined time points post-infection (p.i.)", [["supernatants", "ANATOMY", 16, 28], ["cultures", "ANATOMY", 41, 49], ["DBT astrocytoma cells", "ANATOMY", 69, 90], ["astrocytoma", "DISEASE", 73, 84], ["Viral", "ORGANISM", 0, 5], ["cultures", "CELL", 41, 49], ["DBT astrocytoma cells", "CELL", 69, 90], ["DBT astrocytoma cells", "CELL_LINE", 69, 90], ["Viral titers", "TEST", 0, 12], ["infected cultures", "PROBLEM", 32, 49], ["DBT astrocytoma cells", "PROBLEM", 69, 90], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["astrocytoma cells", "OBSERVATION", 73, 90]]], ["(Hirano et al., 1978; Lane et al., 2000) .ImmunofluorescenceTo assess differentiation potential, cells were grown on matrigel coated imaging slides for a total of 4 days, fixed in 4% paraformalde-hyde (Fisher Scientific, Fair Lawn, NJ) for 20 min and immunofluorescence staining was performed using standard protocols.", [["cells", "ANATOMY", 97, 102], ["paraformalde-hyde", "CHEMICAL", 183, 200], ["cells", "CELL", 97, 102], ["paraformalde-hyde", "SIMPLE_CHEMICAL", 183, 200], ["matrigel coated imaging slides", "TEST", 117, 147], ["immunofluorescence staining", "TEST", 251, 278], ["standard protocols", "TREATMENT", 299, 317]]], ["Imaging chambers were blocked with 10% normal goat serum (NGS) (Vector Laboratories, Burlingame, CA) for 1 h at room temperature.", [["serum", "ANATOMY", 51, 56], ["goat", "ORGANISM", 46, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["goat", "SPECIES", 46, 50], ["goat", "SPECIES", 46, 50], ["Imaging chambers", "TEST", 0, 16]]], ["Primary antibodies (polyclonal rabbit anti-GalC, Chemicon, 1:100 dilution in 10% NGS; monoclonal mouse anti-Map2, Sigma, 1:750 dilution in 10% NGS; polyclonal rabbit anti-GFAP, Invitrogen, 1:500 dilution in 10% NGS) or blocking solution (negative control, 10% NGS in PBS) were applied to chambers overnight at 4\u00b0C on rocker.", [["rabbit", "ORGANISM", 31, 37], ["anti-GalC", "GENE_OR_GENE_PRODUCT", 38, 47], ["mouse", "ORGANISM", 97, 102], ["Map2", "GENE_OR_GENE_PRODUCT", 108, 112], ["rabbit", "ORGANISM", 159, 165], ["anti-GFAP", "GENE_OR_GENE_PRODUCT", 166, 175], ["Primary antibodies", "PROTEIN", 0, 18], ["polyclonal rabbit anti-GalC", "PROTEIN", 20, 47], ["Chemicon", "PROTEIN", 49, 57], ["Map2", "PROTEIN", 108, 112], ["polyclonal rabbit anti-GFAP", "PROTEIN", 148, 175], ["rabbit", "SPECIES", 31, 37], ["mouse", "SPECIES", 97, 102], ["rabbit", "SPECIES", 159, 165], ["rabbit", "SPECIES", 31, 37], ["mouse", "SPECIES", 97, 102], ["rabbit", "SPECIES", 159, 165], ["Primary antibodies", "TEST", 0, 18], ["polyclonal rabbit anti-GalC", "TREATMENT", 20, 47], ["Chemicon", "TREATMENT", 49, 57], ["monoclonal mouse anti-Map2", "TREATMENT", 86, 112], ["polyclonal rabbit anti-GFAP", "TREATMENT", 148, 175], ["Invitrogen", "TREATMENT", 177, 187], ["dilution", "TREATMENT", 195, 203], ["blocking solution", "TREATMENT", 219, 236], ["10% NGS in PBS", "TREATMENT", 256, 270]]], ["Slides were rinsed three times with PBS and fluorescent-conjugated secondary antibody (Alexa 594, goat anti-rabbit or goat anti-mouse IgG H + L, 1:400 dilution in 10% NGS; Invitrogen) was applied and incubated for 30 min at room temperature.", [["Alexa 594", "CHEMICAL", 87, 96], ["Alexa 594", "SIMPLE_CHEMICAL", 87, 96], ["goat", "ORGANISM", 98, 102], ["goat", "ORGANISM", 118, 122], ["fluorescent-conjugated secondary antibody", "PROTEIN", 44, 85], ["Alexa 594", "PROTEIN", 87, 96], ["goat anti-rabbit", "PROTEIN", 98, 114], ["goat anti-mouse IgG H", "PROTEIN", 118, 139], ["goat", "SPECIES", 98, 102], ["anti-rabbit", "SPECIES", 103, 114], ["goat", "SPECIES", 118, 122], ["anti-mouse", "SPECIES", 123, 133], ["goat", "SPECIES", 98, 102], ["anti-rabbit", "SPECIES", 103, 114], ["goat", "SPECIES", 118, 122], ["Slides", "TEST", 0, 6], ["PBS", "TEST", 36, 39], ["fluorescent-conjugated secondary antibody", "TEST", 44, 85], ["Alexa", "TEST", 87, 92], ["goat anti-rabbit", "TREATMENT", 98, 114], ["goat anti-mouse IgG H", "TREATMENT", 118, 139], ["dilution", "TREATMENT", 151, 159], ["Invitrogen", "TREATMENT", 172, 182]]], ["Slides were rinsed three times in PBS, and nuclear staining was with Hoechst 33342 (1 \u03bcg/ml in PBS, Molecular Probes, Eugene, OR) for 10 min.", [["nuclear", "ANATOMY", 43, 50], ["Hoechst 33342", "CHEMICAL", 69, 82], ["Hoechst 33342", "CHEMICAL", 69, 82], ["nuclear", "CELLULAR_COMPONENT", 43, 50], ["Hoechst 33342", "SIMPLE_CHEMICAL", 69, 82], ["Slides", "TEST", 0, 6], ["nuclear staining", "TEST", 43, 59]]], ["Cell quantification was conducted using an Olympus BX-60 microscope, 200\u00d7 magnification.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell quantification", "TEST", 0, 19], ["an Olympus BX", "TEST", 40, 53]]], ["The percentage of immunopositive cells was determined by dividing the total number of immunopositive cells by the total number of Hoechst-positive cells in five images from each chamber, and averaging the results from three different chambers per marker.", [["cells", "ANATOMY", 33, 38], ["cells", "ANATOMY", 101, 106], ["cells", "ANATOMY", 147, 152], ["cells", "CELL", 33, 38], ["cells", "CELL", 101, 106], ["Hoechst", "SIMPLE_CHEMICAL", 130, 137], ["cells", "CELL", 147, 152], ["immunopositive cells", "CELL_TYPE", 18, 38], ["immunopositive cells", "CELL_TYPE", 86, 106], ["Hoechst-positive cells", "CELL_LINE", 130, 152], ["immunopositive cells", "PROBLEM", 18, 38], ["immunopositive cells", "PROBLEM", 86, 106], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["immunopositive cells", "OBSERVATION", 18, 38], ["immunopositive cells", "OBSERVATION", 86, 106], ["positive cells", "OBSERVATION", 138, 152]]], ["Each 4-chamber imaging slide had one no-primary control chamber and three stained chambers for each of the markers mentioned above.", [["chamber imaging slide", "TEST", 7, 28], ["the markers", "TEST", 103, 114]]], ["Only immunopositive cells with a Hoechst-positive nucleus were counted.ImmunocytochemistryDistribution of viral antigen in cultures was determined by immunoperoxidase staining, as specified by the manufacturer (Vectastain-ABC kit and DAB peroxidase substrate kit; Vector Laboratories).", [["cells", "ANATOMY", 20, 25], ["nucleus", "ANATOMY", 50, 57], ["cultures", "ANATOMY", 123, 131], ["Hoechst", "CHEMICAL", 33, 40], ["cells", "CELL", 20, 25], ["Hoechst", "SIMPLE_CHEMICAL", 33, 40], ["nucleus", "CELLULAR_COMPONENT", 50, 57], ["immunoperoxidase", "GENE_OR_GENE_PRODUCT", 150, 166], ["DAB peroxidase", "GENE_OR_GENE_PRODUCT", 234, 248], ["immunopositive cells", "CELL_TYPE", 5, 25], ["viral antigen", "PROTEIN", 106, 119], ["immunopositive cells", "PROBLEM", 5, 25], ["a Hoechst-positive nucleus", "PROBLEM", 31, 57], ["viral antigen", "PROBLEM", 106, 119], ["cultures", "TEST", 123, 131], ["immunoperoxidase staining", "TEST", 150, 175], ["Vectastain", "TEST", 211, 221], ["immunopositive cells", "OBSERVATION", 5, 25], ["positive nucleus", "OBSERVATION", 41, 57], ["viral antigen", "OBSERVATION", 106, 119]]], ["Imaging chambers were blocked with triton containing blocking buffer (BB), (0.3% Triton X-100 and 10% NGS normal goat serum in PBS), for 1 h at room temperature.", [["serum", "ANATOMY", 118, 123], ["Triton X-100", "CHEMICAL", 81, 93], ["triton", "CHEMICAL", 35, 41], ["triton", "SIMPLE_CHEMICAL", 35, 41], ["BB", "SIMPLE_CHEMICAL", 70, 72], ["Triton X-100", "SIMPLE_CHEMICAL", 81, 93], ["goat", "ORGANISM", 113, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["goat", "SPECIES", 113, 117], ["goat", "SPECIES", 113, 117], ["Imaging chambers", "TEST", 0, 16], ["triton", "TREATMENT", 35, 41], ["blocking buffer (BB)", "TREATMENT", 53, 73]]], ["The anti-JHMV mAb J.3.3 (1:20 dilution in BB) specific for the carboxyl terminus of the viral nucleocapsid (N) protein was applied and incubated overnight at 4\u03d2C.", [["J.3.3", "CHEMICAL", 18, 23], ["carboxyl", "CHEMICAL", 63, 71], ["anti-JHMV mAb J.3.3", "PROTEIN", 4, 23], ["BB", "PROTEIN", 42, 44], ["carboxyl terminus", "PROTEIN", 63, 80], ["viral nucleocapsid (N) protein", "PROTEIN", 88, 118], ["The anti-JHMV mAb", "TEST", 0, 17], ["the carboxyl terminus", "TREATMENT", 59, 80], ["the viral nucleocapsid (N) protein", "TREATMENT", 84, 118]]], ["Slides were rinsed three times in PBS and secondary antibody (biotinylated goat-anti-mouse IgG H + L, Vector Laboratories, 1:750 dilution in BB) was applied and incubated for 1.5 h at room temperature.", [["mouse", "ORGANISM", 85, 90], ["secondary antibody", "PROTEIN", 42, 60], ["biotinylated goat", "PROTEIN", 62, 79], ["goat", "SPECIES", 75, 79], ["mouse", "SPECIES", 85, 90], ["goat", "SPECIES", 75, 79], ["mouse", "SPECIES", 85, 90], ["Slides", "TEST", 0, 6], ["PBS", "TEST", 34, 37], ["secondary antibody", "TEST", 42, 60], ["biotinylated goat", "TEST", 62, 79], ["anti-mouse IgG H", "TEST", 80, 96], ["dilution in BB", "TREATMENT", 129, 143]]], ["Slides were rinsed three times in PBS and counterstained with hematoxylin (Bergmann et al., 2003; Fleming et al., 1983; Walsh et al., 2007) .Interferon bioassayDifferentiated neural progenitor cells were infected with MHV, and levels of IFN were measured using a bioassay based on inhibition of VSV growth in L929 cells.", [["neural progenitor cells", "ANATOMY", 175, 198], ["L929 cells", "ANATOMY", 309, 319], ["hematoxylin", "CHEMICAL", 62, 73], ["hematoxylin", "SIMPLE_CHEMICAL", 62, 73], ["Differentiated neural progenitor cells", "CELL", 160, 198], ["MHV", "ORGANISM", 218, 221], ["IFN", "GENE_OR_GENE_PRODUCT", 237, 240], ["VSV", "ORGANISM", 295, 298], ["L929 cells", "CELL", 309, 319], ["neural progenitor cells", "CELL_TYPE", 175, 198], ["IFN", "PROTEIN", 237, 240], ["L929 cells", "CELL_LINE", 309, 319], ["MHV", "SPECIES", 218, 221], ["VSV", "SPECIES", 295, 298], ["Interferon bioassay", "TREATMENT", 141, 160], ["neural progenitor cells", "PROBLEM", 175, 198], ["MHV", "TREATMENT", 218, 221], ["levels of IFN", "PROBLEM", 227, 240], ["a bioassay", "TEST", 261, 271], ["VSV growth in L929 cells", "PROBLEM", 295, 319], ["neural progenitor cells", "OBSERVATION", 175, 198], ["MHV", "OBSERVATION_MODIFIER", 218, 221], ["L929 cells", "OBSERVATION", 309, 319]]], ["Supernatants were harvested and exposed to UV light to inactivate infectious virus.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["UV light", "TREATMENT", 43, 51], ["infectious virus", "PROBLEM", 66, 82], ["harvested", "OBSERVATION", 18, 27], ["infectious", "OBSERVATION", 66, 76]]], ["L929 cells infected with 1000 pfu VSV were treated with dilutions of supernatants or recombinant murine IFN-\u03b2 (PBL Biomedical Laboratories, Piscataway, NJ) at 30 min post-infection (p.i.).", [["L929 cells", "ANATOMY", 0, 10], ["supernatants", "ANATOMY", 69, 81], ["L929 cells", "CELL", 0, 10], ["VSV", "ORGANISM", 34, 37], ["murine", "ORGANISM", 97, 103], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["L929 cells", "CELL_LINE", 0, 10], ["IFN", "PROTEIN", 104, 107], ["\u03b2", "PROTEIN", 108, 109], ["murine", "SPECIES", 97, 103], ["VSV", "SPECIES", 34, 37], ["L929 cells", "PROBLEM", 0, 10], ["pfu VSV", "TREATMENT", 30, 37], ["dilutions of supernatants", "TREATMENT", 56, 81], ["recombinant murine IFN", "TREATMENT", 85, 107]]], ["Titers of VSV were determined on Vero cells.", [["Vero cells", "ANATOMY", 33, 43], ["VSV", "ORGANISM", 10, 13], ["Vero cells", "CELL", 33, 43], ["Vero cells", "CELL_LINE", 33, 43], ["VSV", "SPECIES", 10, 13], ["VSV", "TREATMENT", 10, 13]]], ["IFN levels were calculated based on standard curves generated with recombinant IFN-\u03b2.ELISAOPC culture supernatants were used to measure chemokines CXCL9 and CXCL10.", [["supernatants", "ANATOMY", 102, 114], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CXCL9", "GENE_OR_GENE_PRODUCT", 147, 152], ["CXCL10", "GENE_OR_GENE_PRODUCT", 157, 163], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 79, 82], ["chemokines", "PROTEIN", 136, 146], ["CXCL9", "PROTEIN", 147, 152], ["CXCL10", "PROTEIN", 157, 163], ["IFN levels", "TEST", 0, 10], ["standard curves", "TEST", 36, 51], ["recombinant IFN", "TREATMENT", 67, 82], ["ELISAOPC culture supernatants", "TEST", 85, 114], ["CXCL9", "TEST", 147, 152], ["CXCL10", "TEST", 157, 163]]], ["ELISAs were performed using the Duoset Mouse CXCL9 and CXCL10 ELISA kit (R & D Systems, Minneapolis, MN), as specified by the manufacturer.Statistical analysisStatistically significant differences between groups of mice were determined by Student's t test and p values of b0.05 were considered significant.", [["Mouse", "ORGANISM", 39, 44], ["CXCL9", "GENE_OR_GENE_PRODUCT", 45, 50], ["CXCL10", "GENE_OR_GENE_PRODUCT", 55, 61], ["mice", "ORGANISM", 215, 219], ["CXCL9", "PROTEIN", 45, 50], ["CXCL10", "PROTEIN", 55, 61], ["Mouse", "SPECIES", 39, 44], ["mice", "SPECIES", 215, 219], ["Mouse", "SPECIES", 39, 44], ["mice", "SPECIES", 215, 219], ["ELISAs", "TEST", 0, 6], ["the Duoset Mouse CXCL9", "TREATMENT", 28, 50], ["CXCL10 ELISA kit", "TEST", 55, 71], ["R & D Systems", "TREATMENT", 73, 86], ["Minneapolis, MN)", "TREATMENT", 88, 104], ["Student's t test", "TEST", 239, 255], ["p values", "TEST", 260, 268], ["significant", "OBSERVATION_MODIFIER", 173, 184]]]], "9a3586e520e44b271573c59c9d79f9eee62afa87": [["IntroductionThe study of epidemics spreading in human populations has a long history both on the mathematical aspects (see e.g. Kermack and McKendrick (1927) ; Bailey (1957) ; Bollob\u00e1s (2013) ), as well as on the modelling of outbreak and control of their evolution (Anderson and May (1991) ; Fraser et al. (2004) ; Fern\u00e1ndez-Villaverde and Jones (2020); Chen et al. (2020) ; Yang et al. (2020) ).", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["The study", "TEST", 12, 21], ["epidemics", "PROBLEM", 25, 34]]], ["Spreading phenomena has been studied extensively also in the realm of statistical physics of disordered systems (e.g. Ben-Avraham and Havlin (2000) ; Bunde and Havlin (2012) ; Stauffer and Aharony (2018) ).IntroductionIn this paper, we introduce a lattice network model for epidemics spreading based in part on concepts taken from percolation theory.", [["Spreading phenomena", "PROBLEM", 0, 19], ["disordered systems", "PROBLEM", 93, 111], ["a lattice network model", "TREATMENT", 246, 269], ["epidemics spreading", "PROBLEM", 274, 293]]], ["Illustrative examples are shown, together with a motivation for the need of going beyond a 'meanfield' approach.", [["a 'meanfield' approach", "TREATMENT", 89, 111]]], ["Extensive (Monte Carlo) simulations are shown to illustrate the advantages and difficulties typically associated with such lattice models.", [["Extensive (Monte Carlo) simulations", "TREATMENT", 0, 35]]], ["5.SIR models with extensions to lockdown effectsInfection spreading is typically modelled by the SIR model, introduced by Kermack and McKendrick (1927) .", [["Infection spreading", "PROBLEM", 48, 67]]], ["To describe the outbreak of an infectious disease, the population can be divided into the following four categories: Susceptible (S), Infected (I), Recovered (R) and Dormant (D).", [["infectious disease", "DISEASE", 31, 49], ["an infectious disease", "PROBLEM", 28, 49], ["infectious", "OBSERVATION", 31, 41]]], ["Susceptible are initially healthy but can become infected; infected people carry the infection and can transmit it to susceptible ones, while recovered people are infected who have healed or have died, thus they do not spread the infection any further.", [["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 230, 239], ["people", "ORGANISM", 68, 74], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 68, 74], ["people", "SPECIES", 152, 158], ["the infection", "PROBLEM", 81, 94], ["the infection", "PROBLEM", 226, 239], ["infected", "OBSERVATION", 49, 57], ["infection", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 230, 239]]], ["The fourth category, D, includes non-susceptible (perhaps immune individuals to the specific disease), and in general healthy subjects who do not get in contact with infected ones during the whole spreading process (Fig. 1) .", [["non-susceptible", "PROBLEM", 33, 48]]], ["(1), read,SIR models with extensions to lockdown effectswhere N eff = N \u2212N 0 = S(t)+I(t)+R(t), is the effective number of individuals taking part in the process, \u03b2 is the infection (or contact) rate between infected and susceptible subjects,\u03b2 = \u03b2N eff /N is the effective infection rate in the presence of dormant, and \u03b3 is the healing (or immunization) rate of infected.", [["infection", "DISEASE", 171, 180], ["infection", "DISEASE", 272, 281], ["N eff = N \u2212N", "CHEMICAL", 62, 74], ["\u03b2", "GENE_OR_GENE_PRODUCT", 162, 163], ["extensions", "TEST", 26, 36], ["lockdown", "TEST", 40, 48], ["effectswhere", "TEST", 49, 61], ["eff", "TEST", 64, 67], ["the infection", "PROBLEM", 167, 180], ["infected and susceptible subjects", "PROBLEM", 207, 240], ["N", "PROBLEM", 253, 254], ["the effective infection rate", "PROBLEM", 258, 286], ["the healing", "PROBLEM", 324, 335], ["immunization", "TREATMENT", 340, 352], ["infected", "PROBLEM", 362, 370], ["infection", "OBSERVATION", 171, 180], ["effective", "OBSERVATION_MODIFIER", 262, 271], ["infection", "OBSERVATION", 272, 281], ["dormant", "OBSERVATION", 306, 313], ["healing", "OBSERVATION_MODIFIER", 328, 335], ["infected", "OBSERVATION", 362, 370]]], ["It is convenient to work with normalized quantities, s(t) = S(t)/N eff , i(t) = I(t)/N eff , and r(t) = R(t)/N eff , so that the SIR equations become, dr dt = \u03b3 i(t).SIR models with extensions to lockdown effectsThe above equations have exactly the same form as in the case N 0 = 0.", [["N", "CHEMICAL", 85, 86], ["N eff", "TEST", 85, 90], ["N eff", "TEST", 109, 114], ["the SIR equations", "TEST", 125, 142], ["dr dt", "TEST", 151, 156]]], ["The idea of considering explicitly a fraction of the whole population not taking part in the spreading phenomenon, f 0 = N 0 /N (0 \u2264 f 0 \u2264 1), allows us to interpret the so-called reproduction number, R 0 , as composed of two factors, a purely 'biological' one, \u223c \u03b2/\u03b3, and a 'structural' one \u223c (1 \u2212 f 0 ), denoted as,R 0 = (\u03b2/\u03b3)(1 \u2212 f 0 ).", [["\u03b2", "PROTEIN", 264, 265], ["\u03b3", "PROTEIN", 266, 267], ["the whole population", "PROBLEM", 49, 69], ["the spreading phenomenon", "TEST", 89, 113], ["\u03b3", "TEST", 266, 267], ["as", "TEST", 314, 316]]], ["The fraction f 0 can change in time, but for simplicity we assume it constant.", [["constant", "OBSERVATION_MODIFIER", 69, 77]]], ["Within the realm of the SIR model dormant people do not seem necessary, however, they play a prominent role within the context of network models of infection spreading, as we will discuss in detail in Sect.", [["infection", "DISEASE", 148, 157], ["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["infection spreading", "PROBLEM", 148, 167], ["infection", "OBSERVATION", 148, 157]]], ["More generally, dormant subjects can be considered as those individuals who interact very weakly with others, thus representing a subset of the population being in a sort of 'quarantine' from others.", [["subjects", "ORGANISM", 24, 32]]], ["(6) admits a partial solution when di/dt = 0, in particular at t = t peak , i.e. at the peak of the infected curve, yielding,SIR models with extensions to lockdown effectsLockdown effects can be modelled using an exponential time dependence of \u03b2 (see e.g. Palladino et al. (2020) ).", [["a partial solution", "TREATMENT", 11, 29], ["di/dt", "PROBLEM", 35, 40], ["infected", "OBSERVATION", 100, 108]]], ["(6), we can obtain the time t lock at which the infected curve displays its new maximum.", [["the time t lock", "TREATMENT", 19, 34], ["infected", "OBSERVATION", 48, 56], ["new", "OBSERVATION_MODIFIER", 76, 79], ["maximum", "OBSERVATION_MODIFIER", 80, 87]]], ["The condition is,R 0 (t lock )s(t lock ) = 1, which, together with Eq.", [["R 0 (t lock )s(t lock )", "TREATMENT", 17, 40]]], ["Illustrative examples are reported in Fig. (2) , forR 0 = 16.5 (with \u03b2 = 1.1 and \u03b3 = 1/30) and f 0 = 1/2.", [["\u03b2", "TEST", 69, 70], ["\u03b3", "TEST", 81, 82]]], ["In the upper panel, we show the standard case, with \u03b3 representing the inverse of a typical COVID-19 healing period.", [["upper panel", "ANATOMY", 7, 18]]], ["(11) predicts s(\u221e) \u223c = 0, clearly consistent with the numerical data.", [["predicts s", "TEST", 5, 15]]], ["As is apparent from the upper panel of Fig. (2) , the effect of f 0 > 0 is to shift the infected peak at longer times by keeping a still high reproduction number.", [["the upper panel", "TEST", 20, 35], ["upper", "ANATOMY_MODIFIER", 24, 29], ["infected", "OBSERVATION", 88, 96], ["peak", "OBSERVATION_MODIFIER", 97, 101], ["high reproduction", "OBSERVATION", 137, 154]]], ["The effects of lockdowns, using relation Eq.", [["lockdowns", "TREATMENT", 15, 24]]], ["(13), are displayed in the lower panel of the figure, for the typical cases \u03c4 0 = 18 days and q = 2.", [["lower", "ANATOMY_MODIFIER", 27, 32]]], ["(14) predicts t lock \u223c = 18 0.66/0.06 \u223c = 60 days, in agreement with the numerical results, and the infected peak is reduced by a factor of about 4.SIR models with extensions to lockdown effectsLet us return to Eq.", [["the infected peak", "PROBLEM", 96, 113], ["infected", "OBSERVATION", 100, 108]]], ["(11) is formally equivalent to the self-consistent relation for the fraction of nodes, P \u221e \u2261 1 \u2212 s(\u221e), belonging to the giant component of random graphs with a finite mean node degree k , given by,SIR models with extensions to lockdown effectswhere 0 < p < 1 is the probability of occupancy of a link between two nodes.", [["random graphs", "TEST", 139, 152], ["a link between two nodes", "PROBLEM", 294, 318], ["nodes", "OBSERVATION", 80, 85], ["occupancy", "OBSERVATION", 281, 290], ["nodes", "OBSERVATION", 313, 318]]], ["It can be shown that a giant cluster exists when k p = c > 1.", [["k p", "TEST", 49, 52], ["giant", "OBSERVATION_MODIFIER", 23, 28]]], ["Using 1 \u2212 s(\u221e) = r(\u221e), we find,SIR models with extensions to lockdown effectsThis correspondence is actually not surprising since the SIR equations are valid in a mean-field sense, where fluctuations and correlations among the categories are neglected.", [["the SIR equations", "TEST", 130, 147]]], ["This analogy suggests us that we should go beyond mean-field theory by studying infectious spreading on a network where correlations can be implemented.", [["infectious", "OBSERVATION", 80, 90]]], ["This is done in the following Section.Spreading phenomena on random graphs: Percolation conceptsTracing infected people in a population and how they move is essential to make an accurate assessment of the extent a virus has spread in a region, country or the whole world, in order to implement effective lockdowns in each particular place (see e.g. Chinazzi et al. (2020) ).", [["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119], ["Spreading phenomena", "PROBLEM", 38, 57], ["an accurate assessment", "TEST", 175, 197], ["a virus", "PROBLEM", 212, 219], ["virus", "OBSERVATION", 214, 219]]], ["Here we discuss a simple network model defined on a two dimensional square lattice.", [["a two dimensional square lattice", "TREATMENT", 50, 82]]], ["The sites of the lattice represent individuals belonging to one of the four categories (S, I, R, D), which we will distinguish with different colours in the plots, i.e. green, red, blue, and yellow, respectively.Spreading phenomena on random graphs: Percolation conceptsTwo individuals are said to be connected, i.e. transmission of the disease can occur, if they are nearest-neighbours (NN) on the lattice, representing a 'short-range' contact interaction.", [["Spreading phenomena", "PROBLEM", 212, 231], ["the disease", "PROBLEM", 333, 344], ["green", "OBSERVATION_MODIFIER", 169, 174], ["yellow", "OBSERVATION_MODIFIER", 191, 197], ["disease", "OBSERVATION", 337, 344]]], ["The NN choice is done just for convenience, and it can be relaxed in other versions of the model.", [["The NN choice", "TREATMENT", 0, 13]]], ["The bonds between sites represent therefore the links in the graph, and the coordination number of 4 gives the maximum node degree, under 'static' conditions.", [["node", "ANATOMY", 119, 123], ["maximum", "OBSERVATION_MODIFIER", 111, 118], ["node", "OBSERVATION", 119, 123]]], ["The latter mean that the individuals are considered to be at rest in their lattice locations, initially, while the virus can move around from site to site if the following rules are obeyed: (1) The virus can cross a bond from an infected site to a susceptible one; (2) no virus transmission occurs otherwise; (3) infected sites heal after \u03c4 H days, becoming recovered sites, so that they can neither infect others nor being infected again (immune sites); and (4) dormant sites do not participate in the spreading process.Spreading phenomena on random graphs: Percolation conceptsIt is essential to consider additional links 'dynamically' as the spreading goes on.", [["site", "ANATOMY", 238, 242], ["sites", "ANATOMY", 322, 327], ["sites", "ANATOMY", 368, 373], ["immune sites", "MULTI-TISSUE_STRUCTURE", 440, 452], ["the virus", "PROBLEM", 111, 120], ["The virus", "PROBLEM", 194, 203], ["an infected site", "PROBLEM", 226, 242], ["virus transmission", "PROBLEM", 272, 290], ["infected sites heal", "PROBLEM", 313, 332], ["dormant sites", "PROBLEM", 463, 476], ["Spreading phenomena", "PROBLEM", 521, 540], ["infected", "OBSERVATION", 229, 237], ["infected", "OBSERVATION_MODIFIER", 313, 321], ["sites", "OBSERVATION_MODIFIER", 322, 327], ["heal", "OBSERVATION_MODIFIER", 328, 332], ["infected", "OBSERVATION", 424, 432]]], ["Thus, any infected site can reach sites that are not NN to it, and the infection can spread according to the above rules.", [["site", "ANATOMY", 19, 23], ["sites", "ANATOMY", 34, 39], ["infection", "DISEASE", 71, 80], ["any infected site", "PROBLEM", 6, 23], ["the infection", "PROBLEM", 67, 80], ["infected", "OBSERVATION", 10, 18], ["infection", "OBSERVATION", 71, 80]]], ["In this case, the infection is transmitted with a probability \u03b2 L = t 0 /\u03c4 L , with \u03c4 L > t 0 , and t 0 = 1 day, provided the target site is a susceptible one.Spreading phenomena on random graphs: Percolation conceptsIn summary, we have taken a two dimensional lattice to facilitate the visualization of the network, and considering both NN transmissions as well as long-range ones, though with a lower probability.", [["infection", "DISEASE", 18, 27], ["the infection", "PROBLEM", 14, 27], ["Spreading phenomena", "PROBLEM", 159, 178], ["a lower probability", "PROBLEM", 395, 414], ["infection", "OBSERVATION", 18, 27]]], ["Another reason for choosing a square lattice is that the percolation threshold for site percolation (in this case the susceptible sites) is about 0.6, meaning that if we take say, f 0 = 1/2, there are not percolating ('infinite') clusters of susceptible subjects on the lattice.", [["the percolation threshold", "TREATMENT", 53, 78], ["site percolation", "PROBLEM", 83, 99]]], ["This 'hindering' effect is useful when implementing lockdowns, since the remaining susceptible clusters (of connected NN sites) are disconnected from each other (they are indeed 'finite').", [["NN sites", "MULTI-TISSUE_STRUCTURE", 118, 126]]], ["The model parameters are: \u03c4 0 = 20 (start of lockdowns) and \u03c4 L = \u221e (no long range transmissions) yielding \u03b2 L = 0.", [["The model parameters", "TEST", 0, 20], ["lockdowns", "TEST", 45, 54]]], ["The average node degree for the starting configuration is k = 2, while additional links are added dynamically until t = \u03c4 0 .", [["node", "ANATOMY", 12, 16], ["node", "MULTI-TISSUE_STRUCTURE", 12, 16], ["average", "OBSERVATION_MODIFIER", 4, 11], ["node", "OBSERVATION", 12, 16], ["degree", "OBSERVATION_MODIFIER", 17, 23]]], ["The newly created links yield an additional mean degree \u2206k = 156/5043 \u223c = 0.03, corresponding to an effective mean node degree k eff = 2.03.Spreading phenomena on random graphs: Percolation conceptsWe show in Fig. 3 and 4 results of simulations for a single configuration, without and with lockdowns, respectively, on a (100x100) lattice for times t \u2264 100 days.", [["node", "ANATOMY", 115, 119], ["an additional mean degree \u2206k", "TEST", 30, 58], ["an effective mean node degree k eff", "PROBLEM", 97, 132], ["Spreading phenomena", "PROBLEM", 140, 159], ["random graphs", "TEST", 163, 176], ["Percolation conceptsWe", "TEST", 178, 200], ["a (100x100) lattice", "TREATMENT", 318, 337], ["mean degree", "OBSERVATION_MODIFIER", 44, 55], ["node", "OBSERVATION", 115, 119]]], ["Fixed boundary conditions are employed.", [["Fixed boundary conditions", "PROBLEM", 0, 25]]], ["The starting con-figuration has a random distribution of either susceptible or dormant sites, chosen with probability f 0 = 1/2.", [["susceptible or dormant sites", "PROBLEM", 64, 92], ["susceptible", "OBSERVATION_MODIFIER", 64, 75], ["dormant", "OBSERVATION_MODIFIER", 79, 86]]], ["The initial conditions include a single infected site right at the centre of the lattice, and no recovered subject.", [["The initial conditions", "PROBLEM", 0, 22], ["a single infected site", "PROBLEM", 31, 53], ["infected", "OBSERVATION", 40, 48], ["right", "ANATOMY_MODIFIER", 54, 59], ["no", "UNCERTAINTY", 94, 96], ["recovered", "OBSERVATION", 97, 106]]], ["We keep track of the existing infected sites, each carrying a clock that starts ticking when the site gets infected.", [["sites", "ANATOMY", 39, 44], ["the existing infected sites", "PROBLEM", 17, 44], ["infected", "PROBLEM", 107, 115], ["infected", "OBSERVATION", 30, 38], ["infected", "OBSERVATION", 107, 115]]], ["Death sites are not implemented, but they can be estimated simply as a fraction of recovered ones.", [["Death", "DISEASE", 0, 5], ["Death sites", "PROBLEM", 0, 11]]], ["(Lower panel) Lockdowns: t \u2265 \u03c4 0 = 20 (Fig. 4) .Spreading phenomena on random graphs: Percolation conceptsWe count the number of dynamical links generated during the spreading, from which we can determine, a posteriori, the effective mean node degree, k eff , in our network.", [["node", "ANATOMY", 239, 243], ["Lower panel", "TEST", 1, 12], ["Spreading phenomena", "PROBLEM", 48, 67], ["node degree", "OBSERVATION", 239, 250]]], ["We find k eff \u223c = 2.22 without lockdowns (Fig. 3) and k eff \u223c = 2.03 with lockdowns (Fig. 4) , indicating an effective reproduction number R eff = k eff \u2212 1 1.", [["k eff", "TEST", 8, 13], ["lockdowns", "PROBLEM", 31, 40], ["Fig.", "TEST", 42, 46], ["k eff \u223c", "TEST", 54, 61], ["k eff", "TEST", 147, 152]]], ["It turns out that the relatively small reduction of the mean node degree in the presence of lockdowns is sufficient to reduce the number of infected subjects considerably, as one can see from the very different structure of recovered clusters from both figures.", [["node", "ANATOMY", 61, 65], ["node", "MULTI-TISSUE_STRUCTURE", 61, 65], ["relatively", "OBSERVATION_MODIFIER", 22, 32], ["small", "OBSERVATION_MODIFIER", 33, 38], ["reduction", "OBSERVATION_MODIFIER", 39, 48], ["mean node degree", "OBSERVATION", 56, 72], ["number", "OBSERVATION_MODIFIER", 130, 136], ["infected", "OBSERVATION", 140, 148], ["recovered clusters", "OBSERVATION", 224, 242], ["both figures", "OBSERVATION", 248, 260]]], ["We should mention that a single lattice simulation takes few seconds on a typical laptop, even for lattices of size (400x400), allowing to obtain accurate mean values by averaging over several configurations if required.Analysis of COVID-19 USA dataAs an application of the present ideas we consider COVID-19 USA data (see also Wu et al. (2020) ; Dong et al. (2020) ; Xu et al. (2020) ), from the point of view of both SIR and network models.", [["COVID", "TEST", 232, 237], ["size", "OBSERVATION_MODIFIER", 111, 115]]], ["In order to do so, and due to the complexity of the data, we need to introduce additional features in particular for the SIR model.Analysis of COVID-19 USA dataFor the USA data (Fig. 6) , the lockdown regime can be described by the Ansatz, similar to Eq.", [["Ansatz", "PROTEIN", 232, 238], ["Analysis", "TEST", 131, 139], ["COVID", "TEST", 143, 148], ["the USA data", "TEST", 164, 176], ["the lockdown regime", "TREATMENT", 188, 207]]], ["(13),Analysis of COVID-19 USA datawhere\u03b2 D = (\u03b2 D /\u03b3)(1\u2212f 0 ), with, in general, a time dependent exponent q(t).Analysis of COVID-19 USA dataLet us consider first the case of the SIR model (upper panel in Fig. 6 ).", [["COVID-19 USA dataLet", "DNA", 124, 144], ["Analysis", "TEST", 5, 13], ["COVID", "TEST", 17, 22], ["Analysis", "TEST", 112, 120], ["COVID", "TEST", 124, 129], ["the SIR model", "TEST", 175, 188], ["upper panel", "TEST", 190, 201]]], ["In addition, a rather complicated form for the factor d(t) determining the time evolution of deaths, Deaths= d(t) \u00d7 R(t), was required.", [["deaths", "DISEASE", 93, 99], ["deaths", "PROBLEM", 93, 99], ["Deaths", "PROBLEM", 101, 107]]], ["We find that the form d(t) = 0.17 [0.3 + 1/(t/60)] reproduces the curve of deaths quite well (black circles in Fig. 6 ), but the results might be improved using more parameters.", [["deaths", "DISEASE", 75, 81]]], ["The whole fitting curves were shifted in time by an amount t Lag = 29 days, that is, the initial data were actually discarded from the fits.", [["The whole fitting curves", "TREATMENT", 0, 24]]], ["In the case of the network model (lower panel in Fig. 6 ), the situation is simpler since all parameters can be taken as constants; the values depending on the regime under consideration.", [["the values", "TEST", 132, 142]]], ["Regarding lockdowns (t \u2265 \u03c4 0 ), the value q = 2.5 works rather well, while we take a finite long-range transmission probability \u03b2 LD = 1/32, i.e. 4 times smaller than its value \u03b2 L = 1/8 (t < \u03c4 0 ), suggesting that indeed the lockdowns are not fully implemented and few additional infected subjects are still moving around.", [["infected", "OBSERVATION", 281, 289]]], ["Also the number of deaths can be estimated from the actual recovered ones using a single value d = 0.06 (6%).", [["deaths", "DISEASE", 19, 25]]], ["As well as in the case of SIR, also here we used times lags for the fits, i.e. t Lag = 45 for the cases and t Lag = 21 for deaths.ConclusionsWe have introduced a network model for the spreading of an infectious disease in a population based on random graph and percolation theory concepts.", [["deaths", "DISEASE", 123, 129], ["infectious disease", "DISEASE", 200, 218], ["t Lag", "TEST", 79, 84], ["t Lag", "TEST", 108, 113], ["deaths", "PROBLEM", 123, 129], ["a network model", "TREATMENT", 160, 175], ["an infectious disease", "PROBLEM", 197, 218], ["random graph", "TEST", 244, 256], ["infectious", "OBSERVATION", 200, 210]]], ["The model is conveniently defined on a square lattice allowing a simple visualization of the four different categories in the problem: Infected, susceptible, recovered and dormant subjects.", [["Infected", "PROBLEM", 135, 143], ["Infected", "OBSERVATION", 135, 143], ["susceptible", "OBSERVATION_MODIFIER", 145, 156]]], ["They do not participate in the spreading phenomena but their presence acts as an effective slowing down of spreading by blocking an otherwise direct transmission between infected and susceptible people.", [["people", "ORGANISM", 195, 201], ["people", "SPECIES", 195, 201], ["the spreading phenomena", "PROBLEM", 27, 50]]], ["To allow the spreading to overcome these 'connection gaps' as the process evolves in time, we allow infected people to reach any other susceptible site in the lattice, and infect it with a relatively lower probability than inside a finite cluster via NN contacts.", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115]]], ["We denote these new links, not present initially in the 'lattice graph', dynamical links.", [["new", "OBSERVATION_MODIFIER", 16, 19]]], ["This dynamical approach allows us to describe lockdown effects in terms of the slowing down or total lacking of the dynamical links.ConclusionsWe have assessed the performance of the network model by fitting COVID-19 USA data and compared the results with predictions using the SIR model.", [["the SIR model", "TREATMENT", 274, 287], ["slowing", "OBSERVATION_MODIFIER", 79, 86]]]], "PMC2770169": [["IntroductionFeline Immunodeficiency Virus (FIV) infects numerous feline species worldwide [1].", [["IntroductionFeline Immunodeficiency Virus (FIV)", "DISEASE", 0, 47], ["IntroductionFeline Immunodeficiency Virus", "ORGANISM", 0, 41], ["FIV", "ORGANISM", 43, 46], ["feline", "ORGANISM", 65, 71], ["feline", "SPECIES", 65, 71], ["IntroductionFeline Immunodeficiency Virus", "SPECIES", 0, 41], ["FIV", "SPECIES", 43, 46], ["IntroductionFeline Immunodeficiency Virus (FIV)", "PROBLEM", 0, 47]]], ["This Lentivirus from Retroviridae family is closely related to Human Immunodeficiency Virus (HIV) and Simian Immunodeficiency Virus (SIV) [2].", [["Human Immunodeficiency Virus (HIV)", "DISEASE", 63, 97], ["Simian Immunodeficiency Virus", "DISEASE", 102, 131], ["Lentivirus", "ORGANISM", 5, 15], ["Retroviridae", "GENE_OR_GENE_PRODUCT", 21, 33], ["Human Immunodeficiency Virus", "ORGANISM", 63, 91], ["HIV", "ORGANISM", 93, 96], ["Simian Immunodeficiency Virus", "ORGANISM", 102, 131], ["SIV", "ORGANISM", 133, 136], ["Human", "SPECIES", 63, 68], ["Immunodeficiency Virus", "SPECIES", 69, 91], ["HIV", "SPECIES", 93, 96], ["Simian Immunodeficiency Virus", "SPECIES", 102, 131], ["Lentivirus", "SPECIES", 5, 15], ["Human Immunodeficiency Virus", "SPECIES", 63, 91], ["HIV", "SPECIES", 93, 96], ["Simian Immunodeficiency Virus", "SPECIES", 102, 131], ["SIV", "SPECIES", 133, 136], ["Human Immunodeficiency Virus (HIV)", "PROBLEM", 63, 97], ["Simian Immunodeficiency Virus", "PROBLEM", 102, 131]]], ["This is a virus of major importance because it is lethal to the domestic cat (Felis silvestris catus) and can affect several other cat species, most of which are threatened or endangered e.g., the European wildcat F. s. silvestris in Europe [3]\u2013[5].", [["cat", "ORGANISM", 73, 76], ["Felis silvestris catus", "ORGANISM", 78, 100], ["cat", "ORGANISM", 131, 134], ["F. s. silvestris", "ORGANISM", 214, 230], ["cat", "SPECIES", 73, 76], ["Felis silvestris", "SPECIES", 78, 94], ["catus", "SPECIES", 95, 100], ["F. s. silvestris", "SPECIES", 214, 230], ["domestic cat", "SPECIES", 64, 76], ["Felis silvestris catus", "SPECIES", 78, 100], ["F. s. silvestris", "SPECIES", 214, 230], ["several other cat species", "PROBLEM", 117, 142]]], ["There is thus a need to better understand the risk factors affecting the spread and patterns of persistence of FIV in natural populations of domestic cats.IntroductionIn natural domestic cat populations, FIV is mainly transmitted through bites arising from aggressive or sexual contacts [3], [6]\u2013[10].", [["FIV", "DISEASE", 111, 114], ["FIV is mainly transmitted through bites", "DISEASE", 204, 243], ["FIV", "ORGANISM", 111, 114], ["cats", "ORGANISM", 150, 154], ["cat", "ORGANISM", 187, 190], ["FIV", "ORGANISM", 204, 207], ["cats", "SPECIES", 150, 154], ["FIV", "SPECIES", 111, 114], ["FIV", "SPECIES", 204, 207], ["the risk factors", "PROBLEM", 42, 58], ["IntroductionIn natural domestic cat populations", "TREATMENT", 155, 202]]], ["As a consequence, the spread of FIV in domestic cat populations is highly influenced by the mating system; a higher FIV prevalence is observed in aggressive and polygynous cat populations that involve more fights and bites than in much less aggressive and promiscuous urban ones [8], [9], where FIV can be absent [11].IntroductionBasically, factors affecting cats\u2019aggressiveness can be divided into two categories.", [["FIV", "DISEASE", 32, 35], ["aggressiveness", "DISEASE", 364, 378], ["FIV", "ORGANISM", 32, 35], ["cat", "ORGANISM", 48, 51], ["FIV", "ORGANISM", 116, 119], ["cat", "ORGANISM", 172, 175], ["FIV", "ORGANISM", 295, 298], ["cats", "ORGANISM", 359, 363], ["cats", "SPECIES", 359, 363], ["FIV", "SPECIES", 32, 35], ["FIV", "SPECIES", 116, 119], ["FIV", "SPECIES", 295, 298], ["aggressive and polygynous cat populations", "TREATMENT", 146, 187], ["spread", "OBSERVATION_MODIFIER", 22, 28], ["FIV", "OBSERVATION", 32, 35], ["aggressive", "OBSERVATION_MODIFIER", 146, 156], ["more fights", "OBSERVATION_MODIFIER", 201, 212]]], ["At the individual level, some cats are more aggressive than others.", [["cats", "ORGANISM", 30, 34], ["cats", "SPECIES", 30, 34], ["more", "OBSERVATION_MODIFIER", 39, 43], ["aggressive", "OBSERVATION_MODIFIER", 44, 54]]], ["Typically, this is the case for dominant males [8], [9] or orange cats [12].", [["cats", "ORGANISM", 66, 70], ["cats", "SPECIES", 66, 70], ["dominant males", "PROBLEM", 32, 46]]], ["In the field, they are generally more often infected than subordinates, females or other colour morphs [8], [12], [13].", [["infected", "OBSERVATION", 44, 52]]], ["At the population level, the overall aggressiveness of cats largely depends on the population social structure.", [["aggressiveness", "DISEASE", 37, 51], ["cats", "ORGANISM", 55, 59], ["cats", "SPECIES", 55, 59], ["overall", "OBSERVATION_MODIFIER", 29, 36], ["aggressiveness", "OBSERVATION_MODIFIER", 37, 51]]], ["A male-biased sex-ratio may make the entire population more aggressive, making virus transmission more efficient and, thus, lead to higher disease prevalence.IntroductionUntil now, to our knowledge, all studies of FIV risk factors have focused on individual risk factors.", [["FIV", "ORGANISM", 214, 217], ["FIV risk factors", "PROTEIN", 214, 230], ["FIV", "SPECIES", 214, 217], ["virus transmission", "PROBLEM", 79, 97], ["higher disease prevalence", "PROBLEM", 132, 157], ["FIV risk factors", "PROBLEM", 214, 230]]], ["Factors that may increase the overall virus transmission rate are at least as important for controlling the disease spread but, paradoxically, have been largely overlooked until now.", [["the disease spread", "PROBLEM", 104, 122], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["disease", "OBSERVATION", 108, 115]]], ["Here, we investigate how some characteristics of cat populations, such as cat density or sex-ratio, e.g., as indicators for aggressiveness in contacts within the population, may act as population risk factors that increase or decrease the virus prevalence within populations.IntroductionUnderstanding the factors that may increase the FIV transmission rate within populations requires the sampling of a set of neighboring cat populations (which, until now, has rarely been done), and then examination of how FIV prevalence correlates with the suspected risk factors.", [["aggressiveness", "DISEASE", 124, 138], ["cat", "ORGANISM", 49, 52], ["cat", "ORGANISM", 74, 77], ["FIV", "ORGANISM", 335, 338], ["cat", "ORGANISM", 422, 425], ["FIV", "ORGANISM", 508, 511], ["FIV", "SPECIES", 335, 338], ["FIV", "SPECIES", 508, 511], ["cat populations", "PROBLEM", 49, 64], ["aggressiveness", "PROBLEM", 124, 138], ["the sampling", "TEST", 385, 397], ["neighboring cat populations", "TREATMENT", 410, 437], ["examination", "TEST", 489, 500]]], ["For that purpose, we sampled 15 cat populations in North-Eastern France and measured, within each population, FIV prevalence in males and females.", [["cat", "ORGANISM", 32, 35], ["FIV", "ORGANISM", 110, 113], ["FIV", "SPECIES", 110, 113], ["FIV prevalence", "OBSERVATION", 110, 124]]], ["We found significant variability in disease prevalence between populations, especially in males.", [["significant variability in disease prevalence between populations", "PROBLEM", 9, 74], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["variability", "OBSERVATION_MODIFIER", 21, 32], ["disease", "OBSERVATION", 36, 43], ["populations", "OBSERVATION_MODIFIER", 63, 74]]], ["We also measured five social indicators in order to measure how they correlated with FIV prevalence.IntroductionCommonly, risk factors are analyzed with logistic regression models.", [["FIV", "ORGANISM", 85, 88], ["FIV", "SPECIES", 85, 88]]], ["However, these models are built on the assumption that individuals become infected independently of each other; a hypothesis that contradicts the fundamental communicable nature of infectious diseases [1], [14], [15].", [["infectious diseases", "DISEASE", 181, 200], ["[14]", "SIMPLE_CHEMICAL", 206, 210], ["infected", "OBSERVATION", 74, 82]]], ["Moreover, as described below, assumptions of independence lead to underestimate the variability in disease prevalence between populations that would be observed in the absence of risk factors.IntroductionOur method is inspired by previous works based on the comparison of stochastic dynamic models of the disease spread within host populations to the data [14], [16]\u2013[20].", [["[16]\u2013[20]", "SIMPLE_CHEMICAL", 362, 371], ["risk factors", "PROTEIN", 179, 191], ["disease prevalence between populations", "PROBLEM", 99, 137], ["the disease spread", "PROBLEM", 301, 319]]], ["The idea is that each combination of population risk factors leads to a different model.", [["population risk factors", "PROBLEM", 37, 60]]], ["Beyond the simple analysis of the risk factors associated with FIV, this work aims to understand why the variability observed in our disease prevalence data is so large - data on disease prevalence in males exhibited significant extra-Binomial variations.", [["FIV", "ORGANISM", 63, 66], ["FIV", "SPECIES", 63, 66], ["the risk factors", "PROBLEM", 30, 46], ["FIV", "TREATMENT", 63, 66], ["significant extra-Binomial variations", "PROBLEM", 217, 254], ["large", "OBSERVATION_MODIFIER", 163, 168], ["significant", "OBSERVATION_MODIFIER", 217, 228], ["extra-Binomial variations", "OBSERVATION", 229, 254]]], ["Can we isolate population risk factors that would explain particularly high disease prevalence in some populations?", [["high disease prevalence", "PROBLEM", 71, 94]]], ["Does the spatial aggregation of populations with high virus prevalence help to explain the variability in disease prevalence?", [["the spatial aggregation of populations", "PROBLEM", 5, 43], ["high virus prevalence", "PROBLEM", 49, 70], ["the variability in disease prevalence", "PROBLEM", 87, 124], ["spatial", "OBSERVATION_MODIFIER", 9, 16], ["aggregation", "OBSERVATION", 17, 28]]], ["Or, in contrast, is the large variability observed in disease prevalence a natural consequence of the transmissible nature of the virus?IntroductionThe work presented here supports this last hypothesis: random fluctuations in the transmission process lead to much greater variation in disease prevalence than with a simple Binomial distribution, underlying classical risk factor analyses.", [["the large variability", "PROBLEM", 20, 41], ["the virus", "PROBLEM", 126, 135], ["random fluctuations", "PROBLEM", 203, 222], ["much greater variation in disease prevalence", "PROBLEM", 259, 303], ["a simple Binomial distribution", "PROBLEM", 314, 344], ["large", "OBSERVATION_MODIFIER", 24, 29], ["variability", "OBSERVATION_MODIFIER", 30, 41], ["disease", "OBSERVATION", 54, 61], ["virus", "OBSERVATION", 130, 135], ["much greater", "OBSERVATION_MODIFIER", 259, 271], ["variation", "OBSERVATION_MODIFIER", 272, 281], ["disease", "OBSERVATION", 285, 292]]], ["So the simplest model describes well the data and explains the large variability observed in disease prevalence between cat populations without invoking any risk factor.", [["cat", "ORGANISM", 120, 123], ["the large variability", "PROBLEM", 59, 80], ["disease prevalence between cat populations", "PROBLEM", 93, 135], ["any risk factor", "PROBLEM", 153, 168], ["large", "OBSERVATION_MODIFIER", 63, 68], ["variability", "OBSERVATION_MODIFIER", 69, 80], ["disease", "OBSERVATION", 93, 100]]], ["Finally, we determine confidence intervals for the model parameters.", [["the model parameters", "TEST", 47, 67]]], ["The model is very simple, explains the data well, and hence constitutes an interesting tool for further understanding and control of the spread of FIV in these cat populations.", [["FIV", "DISEASE", 147, 150], ["FIV", "ORGANISM", 147, 150], ["cat", "ORGANISM", 160, 163], ["FIV", "SPECIES", 147, 150], ["very", "OBSERVATION_MODIFIER", 13, 17], ["simple", "OBSERVATION", 18, 24]]], ["The approach developed here can easily extend to many host-parasite interactions.1.", [["parasite", "CELL", 59, 67]]], ["Data set ::: Materials and MethodsThe field work has been made by qualified people according to current French legislation.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["Methods", "TREATMENT", 27, 34]]], ["Data set ::: Materials and MethodsFifteen spatially separated rural cat populations were sampled during 2007 in North-Eastern France near the city of Nancy (Fig. 1, black rectangles).", [["cat", "ORGANISM", 68, 71]]], ["The distance separating neighboring cat populations varied from 1.2 to 4 km.", [["cat", "ORGANISM", 36, 39], ["The distance separating neighboring cat populations", "PROBLEM", 0, 51], ["distance", "OBSERVATION_MODIFIER", 4, 12], ["neighboring", "OBSERVATION_MODIFIER", 24, 35], ["cat", "OBSERVATION_MODIFIER", 36, 39], ["populations", "OBSERVATION_MODIFIER", 40, 51], ["varied", "OBSERVATION_MODIFIER", 52, 58]]], ["The study zone covers a territory of approximately 250 km2.", [["The study zone", "TEST", 0, 14], ["territory", "OBSERVATION_MODIFIER", 24, 33]]], ["In order to delimit the study area, we considered the geographical characteristics that might limit movements between the studied cat populations and those outside of the studied area.", [["cat", "ORGANISM", 130, 133], ["the study area", "TEST", 20, 34], ["the studied cat populations", "TREATMENT", 118, 145]]], ["The spatial organisation of geographical barriers suggests that the populations may be organized into three distinct metapopulations, with rare contacts between cats of different metapopulations (Fig. 1, grey areas).", [["cats", "ORGANISM", 161, 165], ["cats", "SPECIES", 161, 165], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["distinct", "OBSERVATION_MODIFIER", 108, 116], ["metapopulations", "OBSERVATION", 117, 132]]], ["At a finer scale, behavioral observations reveal that males can disperse between populations along roads.", [["behavioral observations", "TEST", 18, 41]]], ["By adopting a basic assumption that populations are considered connected when they are not too distant from each other (i.e. less than 2 km) and are connected by roads, we propose a connection network between the different populations (see Fig. 1, solid arrows).1.", [["solid arrows", "OBSERVATION", 248, 260]]], ["Data set ::: Materials and MethodsUnfortunately, it was not possible to establish a fully isolated perimeter (at least in relation to spread of FIV), so some populations of the study area are in fact connected to unstudied populations (Fig. 1, white rectangles - the connections to the study populations are represented by dashed arrows).", [["FIV", "ORGANISM", 144, 147], ["FIV", "SPECIES", 144, 147], ["a fully isolated perimeter", "PROBLEM", 82, 108], ["the study area", "TEST", 173, 187], ["white rectangles", "TREATMENT", 244, 260]]], ["In particular, Saulxure-Les-Vannes is connected to several study populations.", [["Saulxure", "TEST", 15, 23], ["Les", "ANATOMY", 24, 27]]], ["However, it was not considered for sampling because of potential bias due to a cat culling programme there.", [["potential bias", "PROBLEM", 55, 69], ["a cat culling programme", "TREATMENT", 77, 100]]], ["Data set ::: Materials and MethodsMost of the cats were captured using baited traps; others being caught directly in their owner\u2019s houses.", [["cats", "ORGANISM", 46, 50], ["cats", "SPECIES", 46, 50], ["Materials", "TREATMENT", 13, 22], ["Methods", "TREATMENT", 27, 34]]], ["Upon capture, cats were anaesthetized with an intramuscular injection of ketamin chlorhydrate (Immalg\u00e8ne 1000 15 mg/kg, Rh\u00f4ne-M\u00e9rieux) and acepromazin (V\u00e9tranquil 5.5% 0.5 mg/kg, Sanofi).", [["intramuscular", "ANATOMY", 46, 59], ["ketamin chlorhydrate", "CHEMICAL", 73, 93], ["Immalg\u00e8ne", "CHEMICAL", 95, 104], ["Rh\u00f4ne-M\u00e9rieux", "CHEMICAL", 120, 133], ["acepromazin", "CHEMICAL", 139, 150], ["V\u00e9tranquil", "CHEMICAL", 152, 162], ["ketamin chlorhydrate", "CHEMICAL", 73, 93], ["Immalg\u00e8ne", "CHEMICAL", 95, 104], ["acepromazin", "CHEMICAL", 139, 150], ["V\u00e9tranquil", "CHEMICAL", 152, 162], ["cats", "ORGANISM", 14, 18], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 59], ["ketamin", "SIMPLE_CHEMICAL", 73, 80], ["chlorhydrate", "SIMPLE_CHEMICAL", 81, 93], ["acepromazin", "SIMPLE_CHEMICAL", 139, 150], ["V\u00e9tranquil", "SIMPLE_CHEMICAL", 152, 162], ["cats", "SPECIES", 14, 18], ["cats", "TREATMENT", 14, 18], ["an intramuscular injection of ketamin chlorhydrate", "TREATMENT", 43, 93], ["Immalg\u00e8ne", "TREATMENT", 95, 104], ["Rh\u00f4ne-M\u00e9rieux)", "TREATMENT", 120, 134], ["acepromazin", "TREATMENT", 139, 150], ["V\u00e9tranquil", "TREATMENT", 152, 162]]], ["They were marked permanently using an electronic passive integrative transponder (pig-tag) to allow all individuals to be identified in case of recapture.", [["pig", "ORGANISM", 82, 85], ["pig-tag", "DNA", 82, 89], ["an electronic passive integrative transponder (pig-tag", "TREATMENT", 35, 89], ["marked", "OBSERVATION_MODIFIER", 10, 16]]], ["For each cat, we have recorded, among other data, information on sex, age and serological status in relation to FIV.", [["cat", "ORGANISM", 9, 12], ["FIV", "ORGANISM", 112, 115], ["FIV", "SPECIES", 112, 115]]], ["Blood samples were taken from the jugular vein and the cats were then released.", [["Blood samples", "ANATOMY", 0, 13], ["jugular vein", "ANATOMY", 34, 46], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 34, 46], ["cats", "ORGANISM", 55, 59], ["cats", "SPECIES", 55, 59], ["Blood samples", "TEST", 0, 13], ["jugular vein", "ANATOMY", 34, 46]]], ["The ELISA method (SNAP Combo +, Idexx) was used to detect the presence of FIV-specific antibodies, which generally identifies virus carriers [6].", [["SNAP", "CHEMICAL", 18, 22], ["FIV", "ORGANISM", 74, 77], ["FIV-specific antibodies", "PROTEIN", 74, 97], ["FIV", "SPECIES", 74, 77], ["The ELISA method (SNAP Combo +, Idexx)", "TREATMENT", 0, 38], ["FIV-specific antibodies", "PROBLEM", 74, 97]]], ["All positive sera for FIV were confirmed by Western blot analysis [21].", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["FIV", "ORGANISM", 22, 25], ["FIV", "SPECIES", 22, 25], ["FIV", "PROBLEM", 22, 25], ["blot analysis", "TEST", 52, 65]]], ["FIV was scored as present or absent for each sampled cat.2.1 General approach ::: 2.", [["FIV", "ORGANISM", 0, 3], ["cat", "ORGANISM", 53, 56], ["FIV", "SPECIES", 0, 3], ["FIV", "PROBLEM", 0, 3]]], ["Statistical analysis ::: Materials and MethodsThe approach we use here is very similar to the classical approach based on multifactorial logistic regression, which consists of:2.1 General approach ::: 2.", [["Methods", "TREATMENT", 39, 46], ["multifactorial logistic regression", "PROBLEM", 122, 156]]], ["Firstly, the expected proportion of infected captured individuals is taken as a function of risk factors plus a random term based on a centered binomial distribution.", [["risk factors", "PROTEIN", 92, 104], ["infected captured individuals", "PROBLEM", 36, 65], ["risk factors", "PROBLEM", 92, 104], ["a random term", "PROBLEM", 110, 123], ["infected", "OBSERVATION", 36, 44], ["binomial distribution", "OBSERVATION", 144, 165]]], ["Secondly, the probability that each captured individual is infected is taken as a function of risk factors, with random fluctuations in expected proportions naturally arising from these probabilities.", [["infected", "PROBLEM", 59, 67], ["risk factors", "PROBLEM", 94, 106], ["random fluctuations in expected proportions", "PROBLEM", 113, 156], ["infected", "OBSERVATION", 59, 67]]], ["Statistical analysis ::: Materials and MethodsThe main difference between our approach and the classical one comes from the model used to describe the data.", [["Methods", "TREATMENT", 39, 46], ["main", "OBSERVATION_MODIFIER", 50, 54], ["difference", "OBSERVATION_MODIFIER", 55, 65]]], ["It is quite obvious that for transmissible diseases the probability of one individual being infected is not independent of the infection status of the other individuals [1], [14], [15].", [["infection", "DISEASE", 127, 136], ["transmissible diseases", "PROBLEM", 29, 51], ["the infection status", "PROBLEM", 123, 143], ["infected", "OBSERVATION", 92, 100], ["infection", "OBSERVATION", 127, 136]]], ["Here we consider the probability of individuals becoming infected as the result of a dynamic process of between-host virus transmission (described in the next section).", [["individuals", "PROBLEM", 36, 47], ["infected", "PROBLEM", 57, 65], ["infected", "OBSERVATION", 57, 65]]], ["These types of models are widely recognized as common tools for representing infectious disease data.2.1 General approach ::: 2.", [["infectious disease data", "PROBLEM", 77, 100], ["widely", "OBSERVATION_MODIFIER", 26, 32], ["infectious", "OBSERVATION", 77, 87]]], ["Statistical analysis ::: Materials and MethodsWe also make some minor changes to steps 2 and 3.", [["MethodsWe", "TREATMENT", 39, 48]]], ["In step 2, the logit function is chosen in the classical approach mainly because the model parameter p is bounded by 0 and 1.", [["the logit function", "TEST", 11, 29]]], ["Lastly, in step 3 for model comparison we use likelihood ratio tests (LRT) rather than AIC.", [["likelihood ratio tests", "TEST", 46, 68], ["AIC", "PROBLEM", 87, 90]]], ["Statistical analysis ::: Materials and MethodsThe aim of this framework is to study population risk factors, i.e. factors that affect the rate at which the virus is transmitted within the population.", [["Methods", "TREATMENT", 39, 46], ["the rate", "TEST", 134, 142], ["the virus", "PROBLEM", 152, 161], ["virus", "OBSERVATION", 156, 161]]], ["Individual risk factors, i.e. factors that make some individuals more prone to infection than others in the same population, are not studied here.2.2.", [["infection", "DISEASE", 79, 88], ["Individual risk factors", "PROBLEM", 0, 23], ["some individuals", "PROBLEM", 48, 64], ["infection", "PROBLEM", 79, 88]]], ["Statistical analysis ::: Materials and MethodsOur mathematical model extends the classical Susceptible-Infected (SI) model (Fig. 2).", [["Materials", "TREATMENT", 25, 34], ["MethodsOur mathematical model", "TREATMENT", 39, 68], ["Susceptible", "OBSERVATION_MODIFIER", 91, 102], ["Infected", "OBSERVATION", 103, 111]]], ["We assume that all individuals of each population are equivalent, apart from their sex, the effect of sex on FIV transmission being too significant to be ignored.", [["FIV", "ORGANISM", 109, 112], ["FIV", "SPECIES", 109, 112], ["FIV transmission", "TREATMENT", 109, 125]]], ["Indeed, of the 250 males captured in the study, 58 were seropositive (23.2%) compared to 22 of 249 (8.8%) females, which is highly significant (\u03c72 = 13.80, 1 df, p<10\u22124).", [["the study", "TEST", 37, 46], ["seropositive", "TEST", 56, 68], ["significant", "OBSERVATION_MODIFIER", 131, 142]]], ["Moreover, males and females play different roles in the transmission of FIV [8], [12].", [["FIV", "ORGANISM", 72, 75]]], ["Since females rarely bite, they can be considered as non-transmitting of the virus.", [["the virus", "PROBLEM", 73, 82]]], ["The sexual structure of the model is simply represented by splitting classes S and I into two sub-classes, one for each sex.2.2.", [["sexual structure", "OBSERVATION", 4, 20]]], ["Statistical analysis ::: Materials and MethodsThe age of individuals is not considered in our model, even though it may affect their behavior and, thus, their risk of becoming infected [3], [8], [13].", [["Methods", "TREATMENT", 39, 46], ["not considered", "UNCERTAINTY", 72, 86], ["infected", "OBSERVATION", 176, 184]]], ["Moreover, due to long FIV infection duration, an accumulation of infected cases develops in older age cohorts.", [["infection", "DISEASE", 26, 35], ["FIV", "ORGANISM", 22, 25], ["FIV", "SPECIES", 22, 25], ["long FIV infection duration", "PROBLEM", 17, 44], ["infected cases", "PROBLEM", 65, 79], ["long FIV", "OBSERVATION_MODIFIER", 17, 25], ["infection", "OBSERVATION", 26, 35], ["accumulation", "OBSERVATION_MODIFIER", 49, 61], ["infected", "OBSERVATION_MODIFIER", 65, 73]]], ["To represent the effects of age in a simplified way, we assume that the mean age of cats in the population may act as a risk factor for FIV transmission.", [["cats", "ORGANISM", 84, 88], ["FIV", "ORGANISM", 136, 139], ["cats", "SPECIES", 84, 88], ["FIV", "SPECIES", 136, 139]]], ["This is justified since, here, we mainly focus on the global prevalence of FIV within populations without reference to the age-distribution of infections.2.2.", [["infections", "DISEASE", 143, 153], ["FIV", "ORGANISM", 75, 78], ["FIV", "SPECIES", 75, 78], ["infections", "PROBLEM", 143, 153], ["infections", "OBSERVATION", 143, 153]]], ["Statistical analysis ::: Materials and MethodsWe assume a proportionate mixing law for the incidence function of FIV between males, which is more appropriate in social species [22], [23].", [["FIV", "ORGANISM", 113, 116], ["FIV", "SPECIES", 113, 116], ["a proportionate mixing law", "TREATMENT", 56, 82]]], ["Transmission between males of the same population occurs at a rate \u03b2M/M, where M is the total number of males in the population, and susceptible females are infected by infected males from their population at a rate \u03b2F/M. The constants \u03b2M and \u03b2F are proportional to the rate at which males are involved in fights and to the rate at which females mate, respectively.", [["\u03b2F", "GENE_OR_GENE_PRODUCT", 243, 245], ["total", "OBSERVATION_MODIFIER", 88, 93], ["number", "OBSERVATION_MODIFIER", 94, 100], ["susceptible", "OBSERVATION_MODIFIER", 133, 144], ["infected", "OBSERVATION_MODIFIER", 169, 177]]], ["We assume constant numbers of males (M) and females (F) within each population, whereby dead cats are instantaneously replaced by newborn cats.", [["cats", "ORGANISM", 93, 97], ["cats", "ORGANISM", 138, 142], ["cats", "SPECIES", 93, 97], ["cats", "SPECIES", 138, 142], ["constant", "OBSERVATION_MODIFIER", 10, 18], ["numbers", "OBSERVATION_MODIFIER", 19, 26]]], ["Since vertical transmission is very unlikely in the field [7], [24]\u2013[26], all newborns are classified as susceptible to infection.", [["infection", "DISEASE", 120, 129], ["newborns", "ORGANISM", 78, 86], ["infection", "PROBLEM", 120, 129], ["very unlikely", "UNCERTAINTY", 31, 44], ["infection", "OBSERVATION", 120, 129]]], ["Infected cats die at a rate a.", [["cats", "ORGANISM", 9, 13], ["cats", "SPECIES", 9, 13], ["Infected cats die", "PROBLEM", 0, 17]]], ["Susceptible cats also die, but since they are instantaneously replaced by susceptible (and thus equivalent) newborn cats, their death is not explicitly modeled.2.2.", [["death", "DISEASE", 128, 133], ["cats", "ORGANISM", 12, 16], ["cats", "ORGANISM", 116, 120], ["cats", "SPECIES", 12, 16], ["cats", "SPECIES", 116, 120], ["susceptible", "OBSERVATION_MODIFIER", 74, 85]]], ["Statistical analysis ::: Materials and MethodsFor the sake of simplicity, we assume that populations are not explicitly connected, such that the numbers of infected cats in the different populations are independent random variables.", [["cats", "ORGANISM", 165, 169], ["cats", "SPECIES", 165, 169], ["Methods", "TREATMENT", 39, 46], ["infected cats", "PROBLEM", 156, 169], ["infected", "OBSERVATION_MODIFIER", 156, 164], ["cats", "OBSERVATION", 165, 169], ["different", "OBSERVATION_MODIFIER", 177, 186], ["populations", "OBSERVATION_MODIFIER", 187, 198]]], ["To avoid the definitive extinction of the virus from the populations we assume regular infections from an external source, e.g. another population.", [["infections", "DISEASE", 87, 97], ["the virus", "PROBLEM", 38, 47], ["regular infections", "PROBLEM", 79, 97], ["infections", "OBSERVATION", 87, 97]]], ["Males and females are infected from external sources at a rate \u03b5M/M and \u03b5F/F, respectively.", [["a rate", "TEST", 56, 62], ["infected", "OBSERVATION", 22, 30]]], ["The rates \u03b5M and \u03b5F are termed the external transmission rates.2.2.", [["\u03b5F", "GENE_OR_GENE_PRODUCT", 17, 19]]], ["Statistical analysis ::: Materials and MethodsThe model is based on a continuous-time Markov process.", [["Methods", "TREATMENT", 39, 46]]], ["Since we consider independent populations and constant numbers of males and females, the following set of (M+1)(F+1) ordinary differential equations describes the model (see [27] for an example of demonstration of differential equations representing continuous-time Markovian processes).2.2.", [["independent populations", "PROBLEM", 18, 41], ["differential equations", "PROBLEM", 214, 236]]]]}